Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31838561,Objective response rates,Objective response rates were 50.0% (95% CI 37.4-62.6%) for Oral-VRL and 53.7% (95% CI 41.1-66.0%) for IV-VRL.,"Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838561/),%,50.0,59,DB00997,Doxorubicin
,31838561,Objective response rates,Objective response rates were 50.0% (95% CI 37.4-62.6%) for Oral-VRL and 53.7% (95% CI 41.1-66.0%) for IV-VRL.,"Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838561/),%,53.7,60,DB00997,Doxorubicin
,8892677,trough,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],461,275,DB00997,Doxorubicin
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],1134,276,DB00997,Doxorubicin
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],821,277,DB00997,Doxorubicin
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],2663,278,DB00997,Doxorubicin
,8892677,plasma AUC 0-->96 h,"With addition of SDZ PSC 833 (5 mg/kg) the mean plasma AUC 0-->96 h of doxorubicin as compared with control patients treated with VAD increased from 779 to 1510 ng/ml/h (P=0.0071), while the doxorubicin clearance was reduced from 47.6 to 27.8 l/h/m2 (P=0.0002).","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [h·ml],77,279,DB00997,Doxorubicin
,8892677,clearance,"With addition of SDZ PSC 833 (5 mg/kg) the mean plasma AUC 0-->96 h of doxorubicin as compared with control patients treated with VAD increased from 779 to 1510 ng/ml/h (P=0.0071), while the doxorubicin clearance was reduced from 47.6 to 27.8 l/h/m2 (P=0.0002).","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[l] / [h·m2],47.6,280,DB00997,Doxorubicin
,16840188,overall response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,85,284,DB00997,Doxorubicin
,16840188,complete response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,38,285,DB00997,Doxorubicin
,26619397,α half-life,"Tc-DOX levels in blood declined in a biphasic manner, with an α half-life of 4.5 min and a β half-life of 277.2 min.",Technetium-99m-labeled doxorubicin as an imaging probe for murine breast tumor (4T1 cell line) identification. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26619397/),min,4.5,529,DB00997,Doxorubicin
,26619397,β half-life,"Tc-DOX levels in blood declined in a biphasic manner, with an α half-life of 4.5 min and a β half-life of 277.2 min.",Technetium-99m-labeled doxorubicin as an imaging probe for murine breast tumor (4T1 cell line) identification. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26619397/),min,277.2,530,DB00997,Doxorubicin
,25562532,half-lives,"Pharmacokinetics of F16-IL2 was dose-dependent over the tested range, with half-lives of ca. 13 and ca. 8 hours for cohorts dosed at lower and higher levels, respectively.",The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562532/),h,13,971,DB00997,Doxorubicin
,25562532,half-lives,"Pharmacokinetics of F16-IL2 was dose-dependent over the tested range, with half-lives of ca. 13 and ca. 8 hours for cohorts dosed at lower and higher levels, respectively.",The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25562532/),h,8,972,DB00997,Doxorubicin
,33669867,T1/2,PK studies showed that ~200 ng/mL (0.43 µM) RIDR-PI-103 is achievable in mice plasma with an initial dose of 20 mg/kg and a 10 h T1/2.,"Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33669867/),[ng] / [m],200,1384,DB00997,Doxorubicin
,33669867,T1/2,PK studies showed that ~200 ng/mL (0.43 µM) RIDR-PI-103 is achievable in mice plasma with an initial dose of 20 mg/kg and a 10 h T1/2.,"Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33669867/),h,10,1385,DB00997,Doxorubicin
,8895673,maximum tolerated dose,The maximum tolerated dose was 80 mg/body.,Intrapleural pirarubicin (4'-O-tetrahydropyranyladriamycin) for treatment of malignant pleural effusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895673/),mg,80,2329,DB00997,Doxorubicin
,8895673,overall response rate,"With regard to clinical efficacy, the overall response rate was 73.7% in 38 evaluable courses (38 patients).",Intrapleural pirarubicin (4'-O-tetrahydropyranyladriamycin) for treatment of malignant pleural effusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895673/),%,73.7,2330,DB00997,Doxorubicin
,8895673,T(1/2),"The mean T(1/2) of pirarubicin concentration in pleural effusion and plasma was 22.1 h and 8.8 h, respectively.",Intrapleural pirarubicin (4'-O-tetrahydropyranyladriamycin) for treatment of malignant pleural effusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895673/),h,22.1,2331,DB00997,Doxorubicin
,8895673,T(1/2),"The mean T(1/2) of pirarubicin concentration in pleural effusion and plasma was 22.1 h and 8.8 h, respectively.",Intrapleural pirarubicin (4'-O-tetrahydropyranyladriamycin) for treatment of malignant pleural effusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895673/),h,8.8,2332,DB00997,Doxorubicin
,12585130,mean residence time,"Further studies on pharmacokinetics showed that the mean residence time of HEPC-SSL in blood is 23.3 h, while that of EPC-SSL is 12.0 h, and the area under the curve (AUC) of concentration of HEPC-SSL is larger than that of EPC-SSL.",[Effects of different phospholipids on the stabilities of doxorubicin liposomes in vitro and in vivo]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12585130/),h,23.3,2539,DB00997,Doxorubicin
,12585130,mean residence time,"Further studies on pharmacokinetics showed that the mean residence time of HEPC-SSL in blood is 23.3 h, while that of EPC-SSL is 12.0 h, and the area under the curve (AUC) of concentration of HEPC-SSL is larger than that of EPC-SSL.",[Effects of different phospholipids on the stabilities of doxorubicin liposomes in vitro and in vivo]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12585130/),h,12.0,2540,DB00997,Doxorubicin
,3370742,peak plasma concentrations,"Verapamil, given according to this treatment schedule, reached peak plasma concentrations of 3 microM.",Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370742/),μM,3,3127,DB00997,Doxorubicin
,3370742,AUC,The resistance of the B16VDXR line was associated with the ability of the tumor to retain less doxorubicin (AUC = 83 micrograms h/g) than the sensitive tumor B16 (AUC = 204 micrograms h/g) in spite of similar initial levels.,Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370742/),[h·μg] / [g],83,3128,DB00997,Doxorubicin
,3370742,AUC,The resistance of the B16VDXR line was associated with the ability of the tumor to retain less doxorubicin (AUC = 83 micrograms h/g) than the sensitive tumor B16 (AUC = 204 micrograms h/g) in spite of similar initial levels.,Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370742/),[h·μg] / [g],204,3129,DB00997,Doxorubicin
,10850372,area under the plasma concentration-time curve,"After pretreatment with SKF-525A, the area under the plasma concentration-time curve of adriamycin from time zero to the last measured time in plasma, 8 h (537 versus 155 microg x min/ml) was significantly greater, and the 24-h urinary excretion of M3 (1.65 versus 23.8 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (33.7 versus 3.38 microg) were significantly smaller than those in control rats suggesting that the formation of M3 and M4 were inhibited by SKF-525A.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),[min·μg] / [ml],537,3215,DB00997,Doxorubicin
,10850372,area under the plasma concentration-time curve,"After pretreatment with SKF-525A, the area under the plasma concentration-time curve of adriamycin from time zero to the last measured time in plasma, 8 h (537 versus 155 microg x min/ml) was significantly greater, and the 24-h urinary excretion of M3 (1.65 versus 23.8 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (33.7 versus 3.38 microg) were significantly smaller than those in control rats suggesting that the formation of M3 and M4 were inhibited by SKF-525A.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),[min·μg] / [ml],155,3216,DB00997,Doxorubicin
,10850372,urinary excretion,"After pretreatment with SKF-525A, the area under the plasma concentration-time curve of adriamycin from time zero to the last measured time in plasma, 8 h (537 versus 155 microg x min/ml) was significantly greater, and the 24-h urinary excretion of M3 (1.65 versus 23.8 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (33.7 versus 3.38 microg) were significantly smaller than those in control rats suggesting that the formation of M3 and M4 were inhibited by SKF-525A.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),μg,1.65,3217,DB00997,Doxorubicin
,10850372,urinary excretion,"After pretreatment with SKF-525A, the area under the plasma concentration-time curve of adriamycin from time zero to the last measured time in plasma, 8 h (537 versus 155 microg x min/ml) was significantly greater, and the 24-h urinary excretion of M3 (1.65 versus 23.8 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (33.7 versus 3.38 microg) were significantly smaller than those in control rats suggesting that the formation of M3 and M4 were inhibited by SKF-525A.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),μg,23.8,3218,DB00997,Doxorubicin
,10850372,urinary excretion,"After pretreatment with SKF-525A, the area under the plasma concentration-time curve of adriamycin from time zero to the last measured time in plasma, 8 h (537 versus 155 microg x min/ml) was significantly greater, and the 24-h urinary excretion of M3 (1.65 versus 23.8 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (33.7 versus 3.38 microg) were significantly smaller than those in control rats suggesting that the formation of M3 and M4 were inhibited by SKF-525A.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),μg,33.7,3219,DB00997,Doxorubicin
,10850372,urinary excretion,"After pretreatment with SKF-525A, the area under the plasma concentration-time curve of adriamycin from time zero to the last measured time in plasma, 8 h (537 versus 155 microg x min/ml) was significantly greater, and the 24-h urinary excretion of M3 (1.65 versus 23.8 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (33.7 versus 3.38 microg) were significantly smaller than those in control rats suggesting that the formation of M3 and M4 were inhibited by SKF-525A.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),μg,3.38,3220,DB00997,Doxorubicin
,10850372,urinary excretion,"After pretreatment with dexamethasone, the 24-h urinary excretion of M3 (94.5 versus 23.8 microg), M4 (8.43 versus 2.78 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (116 versus 33.7 microg) were significantly greater than those in control rats, suggesting that the formation of M3 and M4 seemed to be induced by dexamethasone.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),μg,94.5,3221,DB00997,Doxorubicin
,10850372,urinary excretion,"After pretreatment with dexamethasone, the 24-h urinary excretion of M3 (94.5 versus 23.8 microg), M4 (8.43 versus 2.78 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (116 versus 33.7 microg) were significantly greater than those in control rats, suggesting that the formation of M3 and M4 seemed to be induced by dexamethasone.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),μg,23.8,3222,DB00997,Doxorubicin
,10850372,urinary excretion,"After pretreatment with dexamethasone, the 24-h urinary excretion of M3 (94.5 versus 23.8 microg), M4 (8.43 versus 2.78 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (116 versus 33.7 microg) were significantly greater than those in control rats, suggesting that the formation of M3 and M4 seemed to be induced by dexamethasone.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),μg,8.43,3223,DB00997,Doxorubicin
,10850372,urinary excretion,"After pretreatment with dexamethasone, the 24-h urinary excretion of M3 (94.5 versus 23.8 microg), M4 (8.43 versus 2.78 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (116 versus 33.7 microg) were significantly greater than those in control rats, suggesting that the formation of M3 and M4 seemed to be induced by dexamethasone.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),μg,2.78,3224,DB00997,Doxorubicin
,10850372,urinary excretion,"After pretreatment with dexamethasone, the 24-h urinary excretion of M3 (94.5 versus 23.8 microg), M4 (8.43 versus 2.78 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (116 versus 33.7 microg) were significantly greater than those in control rats, suggesting that the formation of M3 and M4 seemed to be induced by dexamethasone.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),μg,116,3225,DB00997,Doxorubicin
,10850372,urinary excretion,"After pretreatment with dexamethasone, the 24-h urinary excretion of M3 (94.5 versus 23.8 microg), M4 (8.43 versus 2.78 microg), and M3, M4, and their glucuronide and/or sulfate conjugates (116 versus 33.7 microg) were significantly greater than those in control rats, suggesting that the formation of M3 and M4 seemed to be induced by dexamethasone.",Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850372/),μg,33.7,3226,DB00997,Doxorubicin
,8324872,plasma clearance,"In a model-independent framework, mean EPI plasma clearance was identical at the two dose levels of 60 and 120 mg/m2 (65.4 +/- 8.0 vs 65.3 +/- 13.4 l/h, P = 0.92).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [h],65.4,3958,DB00997,Doxorubicin
,8324872,plasma clearance,"In a model-independent framework, mean EPI plasma clearance was identical at the two dose levels of 60 and 120 mg/m2 (65.4 +/- 8.0 vs 65.3 +/- 13.4 l/h, P = 0.92).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [h],65.3,3959,DB00997,Doxorubicin
,8324872,MRT,"Both the mean residence time (MRT) and the volume of distribution at steady-state (VSS) were similar as well (MRT: 22.6 +/- 2.9 vs 24.2 +/- 3.7 h; P = 0.46; VSS: 21.3 +/- 1.5 vs 22.6 +/- 6.5 l/kg, P = 0.46).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),h,22.6,3960,DB00997,Doxorubicin
,8324872,MRT,"Both the mean residence time (MRT) and the volume of distribution at steady-state (VSS) were similar as well (MRT: 22.6 +/- 2.9 vs 24.2 +/- 3.7 h; P = 0.46; VSS: 21.3 +/- 1.5 vs 22.6 +/- 6.5 l/kg, P = 0.46).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),h,24.2,3961,DB00997,Doxorubicin
,8324872,VSS,"Both the mean residence time (MRT) and the volume of distribution at steady-state (VSS) were similar as well (MRT: 22.6 +/- 2.9 vs 24.2 +/- 3.7 h; P = 0.46; VSS: 21.3 +/- 1.5 vs 22.6 +/- 6.5 l/kg, P = 0.46).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [kg],21.3,3962,DB00997,Doxorubicin
,8324872,VSS,"Both the mean residence time (MRT) and the volume of distribution at steady-state (VSS) were similar as well (MRT: 22.6 +/- 2.9 vs 24.2 +/- 3.7 h; P = 0.46; VSS: 21.3 +/- 1.5 vs 22.6 +/- 6.5 l/kg, P = 0.46).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [kg],22.6,3963,DB00997,Doxorubicin
,8324872,"plasma clearance, PlCl","No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [h],83.4,3964,DB00997,Doxorubicin
,8324872,"plasma clearance, PlCl","No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [h],68.5,3965,DB00997,Doxorubicin
,8324872,MRT,"No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),h,22.6,3966,DB00997,Doxorubicin
,8324872,MRT,"No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),h,21.9,3967,DB00997,Doxorubicin
,8324872,VSS,"No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [kg],26.7,3968,DB00997,Doxorubicin
,8324872,VSS,"No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [kg],21.2,3969,DB00997,Doxorubicin
,15640375,binding percentage,The binding percentage of furosemide to albumin was approximately 70% in UPA.,"Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15640375/),%,70,4135,DB00997,Doxorubicin
,12621462,MTD,Mucositis was the dose-limiting toxicity and the MTD was 60 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),mg,60,5056,DB00997,Doxorubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],7.7,5057,DB00997,Doxorubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],26.3,5058,DB00997,Doxorubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],14.8,5059,DB00997,Doxorubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],47.4,5060,DB00997,Doxorubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],423.2,5061,DB00997,Doxorubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],2581,5062,DB00997,Doxorubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],732.8,5063,DB00997,Doxorubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],4590,5064,DB00997,Doxorubicin
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,28.6,5065,DB00997,Doxorubicin
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,38.5,5066,DB00997,Doxorubicin
,24107145,overall response rate,"The overall response rate was 47% (95% CI, 28-65%).",A pilot phase II study of the efficacy and biosafety of doxorubicin chemotherapy in tumor-bearing equidae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107145/),%,47,5847,DB00997,Doxorubicin
,24107145,serum Cmax,"Pooled serum Cmax and half-life of doxorubicin were 121.3 ng/mL and 12.9 hours, respectively.",A pilot phase II study of the efficacy and biosafety of doxorubicin chemotherapy in tumor-bearing equidae. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107145/),[ng] / [ml],121.3,5848,DB00997,Doxorubicin
,24107145,half-life,"Pooled serum Cmax and half-life of doxorubicin were 121.3 ng/mL and 12.9 hours, respectively.",A pilot phase II study of the efficacy and biosafety of doxorubicin chemotherapy in tumor-bearing equidae. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24107145/),h,12.9,5849,DB00997,Doxorubicin
,33063185,Cmax,"Stratified according to Lipiodol distribution, DOX-Cmax increased from 1 segment (DOX-Cmax, 83.94 ± 75.09 ng/mL; DN-DOX-Cmax, 2.67 ± 2.02 ng/mL/mg) to ≥ 2 segments (DOX-Cmax, 139.66 ± 117.73 ng/mL; DN-DOX-Cmax, 3.68 ± 4.20 ng/mL/mg) to lobar distribution (DOX-Cmax, 334.35 ± 215.18 ng/mL; DN-DOX-Cmax, 7.11 ± 4.24 ng/mL/mg; p = 0.036).",Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33063185/),[ng] / [ml],83.94,6929,DB00997,Doxorubicin
,33063185,Cmax,"Stratified according to Lipiodol distribution, DOX-Cmax increased from 1 segment (DOX-Cmax, 83.94 ± 75.09 ng/mL; DN-DOX-Cmax, 2.67 ± 2.02 ng/mL/mg) to ≥ 2 segments (DOX-Cmax, 139.66 ± 117.73 ng/mL; DN-DOX-Cmax, 3.68 ± 4.20 ng/mL/mg) to lobar distribution (DOX-Cmax, 334.35 ± 215.18 ng/mL; DN-DOX-Cmax, 7.11 ± 4.24 ng/mL/mg; p = 0.036).",Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33063185/),[ng] / [mg·ml],2.67,6930,DB00997,Doxorubicin
,33063185,Cmax,"Stratified according to Lipiodol distribution, DOX-Cmax increased from 1 segment (DOX-Cmax, 83.94 ± 75.09 ng/mL; DN-DOX-Cmax, 2.67 ± 2.02 ng/mL/mg) to ≥ 2 segments (DOX-Cmax, 139.66 ± 117.73 ng/mL; DN-DOX-Cmax, 3.68 ± 4.20 ng/mL/mg) to lobar distribution (DOX-Cmax, 334.35 ± 215.18 ng/mL; DN-DOX-Cmax, 7.11 ± 4.24 ng/mL/mg; p = 0.036).",Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33063185/),[ng] / [ml],139.66,6931,DB00997,Doxorubicin
,33063185,Cmax,"Stratified according to Lipiodol distribution, DOX-Cmax increased from 1 segment (DOX-Cmax, 83.94 ± 75.09 ng/mL; DN-DOX-Cmax, 2.67 ± 2.02 ng/mL/mg) to ≥ 2 segments (DOX-Cmax, 139.66 ± 117.73 ng/mL; DN-DOX-Cmax, 3.68 ± 4.20 ng/mL/mg) to lobar distribution (DOX-Cmax, 334.35 ± 215.18 ng/mL; DN-DOX-Cmax, 7.11 ± 4.24 ng/mL/mg; p = 0.036).",Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33063185/),[ng] / [mg·ml],3.68,6932,DB00997,Doxorubicin
,33063185,Cmax,"Stratified according to Lipiodol distribution, DOX-Cmax increased from 1 segment (DOX-Cmax, 83.94 ± 75.09 ng/mL; DN-DOX-Cmax, 2.67 ± 2.02 ng/mL/mg) to ≥ 2 segments (DOX-Cmax, 139.66 ± 117.73 ng/mL; DN-DOX-Cmax, 3.68 ± 4.20 ng/mL/mg) to lobar distribution (DOX-Cmax, 334.35 ± 215.18 ng/mL; DN-DOX-Cmax, 7.11 ± 4.24 ng/mL/mg; p = 0.036).",Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33063185/),[ng] / [ml],334.35,6933,DB00997,Doxorubicin
,33063185,Cmax,"Stratified according to Lipiodol distribution, DOX-Cmax increased from 1 segment (DOX-Cmax, 83.94 ± 75.09 ng/mL; DN-DOX-Cmax, 2.67 ± 2.02 ng/mL/mg) to ≥ 2 segments (DOX-Cmax, 139.66 ± 117.73 ng/mL; DN-DOX-Cmax, 3.68 ± 4.20 ng/mL/mg) to lobar distribution (DOX-Cmax, 334.35 ± 215.18 ng/mL; DN-DOX-Cmax, 7.11 ± 4.24 ng/mL/mg; p = 0.036).",Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33063185/),[ng] / [mg·ml],7.11,6934,DB00997,Doxorubicin
,1453205,half-life at alpha phase [t1/2 alpha],"Leu-Dox was rapidly distributed (half-life at alpha phase [t1/2 alpha] = 2.5 +/- 0.6 minutes) followed by a biphasic elimination (half-life at beta phase [t1/2 beta] = 17.4 +/- 7.3 minutes; half-life at gamma phase [t1/2 gamma] = 1.5 +/- 0.5 hours), as measured over the first 12 hours after administration.",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),min,2.5,7277,DB00997,Doxorubicin
,1453205,half-life at beta phase [t1/2 beta],"Leu-Dox was rapidly distributed (half-life at alpha phase [t1/2 alpha] = 2.5 +/- 0.6 minutes) followed by a biphasic elimination (half-life at beta phase [t1/2 beta] = 17.4 +/- 7.3 minutes; half-life at gamma phase [t1/2 gamma] = 1.5 +/- 0.5 hours), as measured over the first 12 hours after administration.",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),min,17.4,7278,DB00997,Doxorubicin
,1453205,half-life at gamma phase [t1/2 gamma],"Leu-Dox was rapidly distributed (half-life at alpha phase [t1/2 alpha] = 2.5 +/- 0.6 minutes) followed by a biphasic elimination (half-life at beta phase [t1/2 beta] = 17.4 +/- 7.3 minutes; half-life at gamma phase [t1/2 gamma] = 1.5 +/- 0.5 hours), as measured over the first 12 hours after administration.",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),h,1.5,7279,DB00997,Doxorubicin
,1453205,"final elimination half-life (t1/2,elim)","In three patients, in whom Leu-Dox was found in the plasma for up to 48 hours after injection, a final elimination half-life (t1/2,elim) of 16 hours was observed.",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),h,16,7280,DB00997,Doxorubicin
,1453205,"t1/2,elim","The t1/2,elim of Leu-Dox was short (0.6 to 16.5 hours) compared with the t1/2,elim of Dox (38 +/- 11 hours).",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),h,0.6 to 16.5,7281,DB00997,Doxorubicin
,1453205,"t1/2,elim","The t1/2,elim of Leu-Dox was short (0.6 to 16.5 hours) compared with the t1/2,elim of Dox (38 +/- 11 hours).",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),h,38,7282,DB00997,Doxorubicin
,1453205,mean residence time,"The mean residence time and apparent volume of distribution were 23 +/- 5 minutes and 19 +/- 6 L/m2, respectively.",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),min,23,7283,DB00997,Doxorubicin
,1453205,apparent volume of distribution,"The mean residence time and apparent volume of distribution were 23 +/- 5 minutes and 19 +/- 6 L/m2, respectively.",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),[l] / [m2],19,7284,DB00997,Doxorubicin
,1453205,Areas under the plasma concentration versus time curve (AUC infinity,"Areas under the plasma concentration versus time curve (AUC infinity, mean +/- SD, n = 16) of Leu-Dox, Dox, and Dol were 115 +/- 27 mumol.min/L, 41 +/- 12 mumol.min/L, and 33 +/- 14 mumol.",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),[min·μM] / [l],115,7285,DB00997,Doxorubicin
,1453205,Areas under the plasma concentration versus time curve (AUC infinity,"Areas under the plasma concentration versus time curve (AUC infinity, mean +/- SD, n = 16) of Leu-Dox, Dox, and Dol were 115 +/- 27 mumol.min/L, 41 +/- 12 mumol.min/L, and 33 +/- 14 mumol.",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),[min·μM] / [l],41,7286,DB00997,Doxorubicin
,1453205,Areas under the plasma concentration versus time curve (AUC infinity,"Areas under the plasma concentration versus time curve (AUC infinity, mean +/- SD, n = 16) of Leu-Dox, Dox, and Dol were 115 +/- 27 mumol.min/L, 41 +/- 12 mumol.min/L, and 33 +/- 14 mumol.",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),μM,33,7287,DB00997,Doxorubicin
,1453205,AUC infinity,"After the same molar dose of Dox (50 mg/m2 = 86 mumol/m2), the AUC infinity of Dox was 179 mumol.",Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),μM,179,7288,DB00997,Doxorubicin
,1453205,AUCs infinity,The AUCs infinity of Leu-Dox and Dox at the MTD (517 and 145 mumol.,Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),μM,517,7289,DB00997,Doxorubicin
,1453205,AUCs infinity,The AUCs infinity of Leu-Dox and Dox at the MTD (517 and 145 mumol.,Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1453205/),μM,145,7290,DB00997,Doxorubicin
,30587558,circulation half-lives,"This was further confirmed with pharmacokinetic studies in Fischer rats, which showed the PoP and Dox components of the liposomes both had nearly identical, long circulation half-lives (25-26 hours).","Blood Interactions, Pharmacokinetics, and Depth-Dependent Ablation of Rat Mammary Tumors with Photoactivatable, Liposomal Doxorubicin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30587558/),h,25-26,7312,DB00997,Doxorubicin
,26678853,plasma flow,"Over 44 (46)-47(49) h postinfusion, five patients (14 cycles in total) underwent PF using a cascade PF method consisted of plasma separation by centrifugation and plasma treatment using filtration based one volume of plasma treatment, i.e., 3.18 L (±0.6 L) and plasma flow 1.0 L/h (0.91-1.48 L/h).",Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26678853/),[l] / [h],1.0,7350,DB00997,Doxorubicin
,26678853,Total fraction eliminated,Total fraction eliminated attained 81 % (75-86 %).,Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26678853/),%,81,7351,DB00997,Doxorubicin
,4058077,"Cp,max iv/Cp,max ihep","The reduction of maximum plasma concentration (Cp,max) of adriamycin after intrahepatic administration was even more pronounced than the reduction in AUC (mean value Cp,max iv/Cp,max ihep = 1.7).",Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4058077/),,1.7,8103,DB00997,Doxorubicin
,24991836,overall response rate (ORR),"The overall response rate (ORR) for dogs with lymphoma was 93.3%, with median progression-free interval (PFI) of 5 mo.",Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24991836/),%,93.3,8456,DB00997,Doxorubicin
,11335910,steady-state distribution volume (Vss),"This DSPC PLD had a steady-state distribution volume (Vss) of 2.4 +/- 0.9 liters (mean +/- standard deviation), a clearance of 0.027 +/- 0.010 liters per hour, and a beta half-life of 65.0 +/- 17.8 per hour.","Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335910/),l,2.4,8634,DB00997,Doxorubicin
,11335910,clearance,"This DSPC PLD had a steady-state distribution volume (Vss) of 2.4 +/- 0.9 liters (mean +/- standard deviation), a clearance of 0.027 +/- 0.010 liters per hour, and a beta half-life of 65.0 +/- 17.8 per hour.","Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335910/),[l] / [h],0.027,8635,DB00997,Doxorubicin
,11335910,beta half-life,"This DSPC PLD had a steady-state distribution volume (Vss) of 2.4 +/- 0.9 liters (mean +/- standard deviation), a clearance of 0.027 +/- 0.010 liters per hour, and a beta half-life of 65.0 +/- 17.8 per hour.","Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335910/),1/[h],65.0,8636,DB00997,Doxorubicin
,10972478,specific activity,"In an in vivo study female Sprague Dawley rats were pretreated with 100 mg/kg of dexrazoxane by intravenous injection 1 h before the injection of 14C-doxorubicin (specific activity 0.4 microCi/mg, 10 mg/kg).",Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972478/),[μci] / [mg],0.4,8782,DB00997,Doxorubicin
,28660787,Plasma concentration,Plasma concentration of DOX after chemoembolization with lipiodol was 225.91 ± 64.88 ng/mL at 5 min and decreased with time by 24 h to 5.06 ± 0.48 ng/mL.,Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28660787/),[ng] / [ml],225.91,8828,DB00997,Doxorubicin
,28660787,Plasma concentration,Plasma concentration of DOX after chemoembolization with lipiodol was 225.91 ± 64.88 ng/mL at 5 min and decreased with time by 24 h to 5.06 ± 0.48 ng/mL.,Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28660787/),[ng] / [ml],5.06,8829,DB00997,Doxorubicin
,28660787,tissue concentration of doxorubicin (tissCDOX),The tissue concentration of doxorubicin (tissCDOX) ranged from 40.27 μg/mL to 245.70 μg/mL at 1 week and from 5.64 μg/mL to 28.09 μg/mL at 1 month.,Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28660787/),[μg] / [ml],40.27,8830,DB00997,Doxorubicin
,28660787,tissue concentration of doxorubicin (tissCDOX),The tissue concentration of doxorubicin (tissCDOX) ranged from 40.27 μg/mL to 245.70 μg/mL at 1 week and from 5.64 μg/mL to 28.09 μg/mL at 1 month.,Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28660787/),[μg] / [ml],245.70,8831,DB00997,Doxorubicin
,28660787,tissue concentration of doxorubicin (tissCDOX),The tissue concentration of doxorubicin (tissCDOX) ranged from 40.27 μg/mL to 245.70 μg/mL at 1 week and from 5.64 μg/mL to 28.09 μg/mL at 1 month.,Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28660787/),[μg] / [ml],5.64,8832,DB00997,Doxorubicin
,28660787,tissue concentration of doxorubicin (tissCDOX),The tissue concentration of doxorubicin (tissCDOX) ranged from 40.27 μg/mL to 245.70 μg/mL at 1 week and from 5.64 μg/mL to 28.09 μg/mL at 1 month.,Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28660787/),[μg] / [ml],28.09,8833,DB00997,Doxorubicin
,8313389,half-lives,"The plasma elimination of Doxil followed a biexponential curve with half-lives of 2 and 45 h (median values), most of the dose being cleared from plasma under the longer half-life.",Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8313389/),h,2,9111,DB00997,Doxorubicin
,8313389,half-lives,"The plasma elimination of Doxil followed a biexponential curve with half-lives of 2 and 45 h (median values), most of the dose being cleared from plasma under the longer half-life.",Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8313389/),h,45,9112,DB00997,Doxorubicin
,8313389,plasma clearance,A slow plasma clearance (0.1 liter/h for Doxil versus 45 liters/h for free DOX) and a small volume of distribution (4 liters for Doxil versus 254 liters for free DOX) are characteristic of Doxil.,Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8313389/),[l] / [h],0.1,9113,DB00997,Doxorubicin
,8313389,plasma clearance,A slow plasma clearance (0.1 liter/h for Doxil versus 45 liters/h for free DOX) and a small volume of distribution (4 liters for Doxil versus 254 liters for free DOX) are characteristic of Doxil.,Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8313389/),[l] / [h],45,9114,DB00997,Doxorubicin
,8313389,volume of distribution,A slow plasma clearance (0.1 liter/h for Doxil versus 45 liters/h for free DOX) and a small volume of distribution (4 liters for Doxil versus 254 liters for free DOX) are characteristic of Doxil.,Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8313389/),l,4,9115,DB00997,Doxorubicin
,8313389,volume of distribution,A slow plasma clearance (0.1 liter/h for Doxil versus 45 liters/h for free DOX) and a small volume of distribution (4 liters for Doxil versus 254 liters for free DOX) are characteristic of Doxil.,Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8313389/),l,254,9116,DB00997,Doxorubicin
,23618965,area under the curve (AUC(0-∞)),"The area under the curve (AUC(0-∞)) and half-life (t(½)) in the liver of GA-ALG/DOX-ALG NPs were 1156.7 μg h/g and 34.3 h, respectively, which was 11.8- and 3.2-fold higher than that of the DOX·HCl group.",Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618965/),[h·μg] / [g],1156.7,9322,DB00997,Doxorubicin
,23618965,half-life (t(½)),"The area under the curve (AUC(0-∞)) and half-life (t(½)) in the liver of GA-ALG/DOX-ALG NPs were 1156.7 μg h/g and 34.3 h, respectively, which was 11.8- and 3.2-fold higher than that of the DOX·HCl group.",Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618965/),h,34.3,9323,DB00997,Doxorubicin
,23618965,inhibition rate,"Furthermore, the inhibition rate of tumor growth was 79.3% after treatment with GA-ALG/DOX-ALG NPs, which was much higher than that of the DOX·HCl (48.5%) and DOX-ALG NPs groups (62.7%).",Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618965/),%,79.3,9324,DB00997,Doxorubicin
,23618965,inhibition rate,"Furthermore, the inhibition rate of tumor growth was 79.3% after treatment with GA-ALG/DOX-ALG NPs, which was much higher than that of the DOX·HCl (48.5%) and DOX-ALG NPs groups (62.7%).",Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618965/),,48,9325,DB00997,Doxorubicin
,23618965,inhibition rate,"Furthermore, the inhibition rate of tumor growth was 79.3% after treatment with GA-ALG/DOX-ALG NPs, which was much higher than that of the DOX·HCl (48.5%) and DOX-ALG NPs groups (62.7%).",Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618965/),,62,9326,DB00997,Doxorubicin
less,20484616,CL(CR),Modeling study results suggested that equivalent exposure could be achieved if dosing was halved in subjects with CL(CR) less than 40 mL/min compared with controls.,Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484616/),[ml] / [min],40,9704,DB00997,Doxorubicin
,3933285,clearance,"The clearance of the DHP cartridges was relatively high, 82 ml/min for MMC, 76-79 ml/min for ADM, and 78 ml/min for CDDP at the end of the first 30 minutes.",[Fundamental study on intra-arterial chemotherapy with direct hemoperfusion]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3933285/),[ml] / [min],82,10312,DB00997,Doxorubicin
,3933285,clearance,"The clearance of the DHP cartridges was relatively high, 82 ml/min for MMC, 76-79 ml/min for ADM, and 78 ml/min for CDDP at the end of the first 30 minutes.",[Fundamental study on intra-arterial chemotherapy with direct hemoperfusion]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3933285/),[ml] / [min],76-79,10313,DB00997,Doxorubicin
,3933285,clearance,"The clearance of the DHP cartridges was relatively high, 82 ml/min for MMC, 76-79 ml/min for ADM, and 78 ml/min for CDDP at the end of the first 30 minutes.",[Fundamental study on intra-arterial chemotherapy with direct hemoperfusion]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3933285/),[ml] / [min],78,10314,DB00997,Doxorubicin
,3933285,urinary recovery rate,The urinary recovery rate of CDDP was 22.3% in the group with DHP and 41.8% in the group without DHP.,[Fundamental study on intra-arterial chemotherapy with direct hemoperfusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3933285/),%,22.3,10315,DB00997,Doxorubicin
,3933285,urinary recovery rate,The urinary recovery rate of CDDP was 22.3% in the group with DHP and 41.8% in the group without DHP.,[Fundamental study on intra-arterial chemotherapy with direct hemoperfusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3933285/),%,41.8,10316,DB00997,Doxorubicin
,3166400,terminal half-life,"At the end of infusion, plasma decay of esorubicin was rapid initially but slow thereafter, with a terminal half-life of 20 to 54 h.",Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3166400/),h,20 to 54,10766,DB00997,Doxorubicin
,10850343,MTD,The MTD was determined to be 500 mg/m2 although some patients did tolerate 600 mg/m2 with moderate nausea and occasional vomiting.,A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850343/),[mg] / [m2],500,10946,DB00997,Doxorubicin
,6593309,t1/2,4'-epi-DX gave plasma levels constantly lower than those observed after DX; the pharmacokinetic study showed that 4'-epi-DX was eliminated from the body more rapidly (t1/2 30 hours as compared with 43 hours).,Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6593309/),h,30,11038,DB00997,Doxorubicin
,6593309,t1/2,4'-epi-DX gave plasma levels constantly lower than those observed after DX; the pharmacokinetic study showed that 4'-epi-DX was eliminated from the body more rapidly (t1/2 30 hours as compared with 43 hours).,Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6593309/),h,43,11039,DB00997,Doxorubicin
,7452508,Retention half-lives,"Retention half-lives of radioactivity in heart, lung, kidney and small intestine were between 4.5 to 6.5 hr, while in liver, adrenal gland and spleen they were 7 to 13 hr and in skeletal muscle and bone marrow were 17 and 35 hr, respectively.","Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452508/),h,4.5 to 6.5,11127,DB00997,Doxorubicin
,7452508,Retention half-lives,"Retention half-lives of radioactivity in heart, lung, kidney and small intestine were between 4.5 to 6.5 hr, while in liver, adrenal gland and spleen they were 7 to 13 hr and in skeletal muscle and bone marrow were 17 and 35 hr, respectively.","Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452508/),h,7 to 13,11128,DB00997,Doxorubicin
,7452508,Retention half-lives,"Retention half-lives of radioactivity in heart, lung, kidney and small intestine were between 4.5 to 6.5 hr, while in liver, adrenal gland and spleen they were 7 to 13 hr and in skeletal muscle and bone marrow were 17 and 35 hr, respectively.","Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452508/),h,17,11129,DB00997,Doxorubicin
,7452508,Retention half-lives,"Retention half-lives of radioactivity in heart, lung, kidney and small intestine were between 4.5 to 6.5 hr, while in liver, adrenal gland and spleen they were 7 to 13 hr and in skeletal muscle and bone marrow were 17 and 35 hr, respectively.","Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452508/),h,35,11130,DB00997,Doxorubicin
,7452508,binding,"Exhaustive methanol-ether extraction of acid-precipitated homogenates showed covalent binding of radioactivity to lung, liver, kidney and spleen at 40 to 100 pmol/mg of protein, while binding in plasma, small intestine and pancreas ranged from 4 to 30 pmol/mg of protein; heart and skeletal muscle showed 0 to 1.4 pmol/mg of protein at all times examined.","Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452508/),[pM] / [mg],4 to 30,11131,DB00997,Doxorubicin
,7452508,binding,"Exhaustive methanol-ether extraction of acid-precipitated homogenates showed covalent binding of radioactivity to lung, liver, kidney and spleen at 40 to 100 pmol/mg of protein, while binding in plasma, small intestine and pancreas ranged from 4 to 30 pmol/mg of protein; heart and skeletal muscle showed 0 to 1.4 pmol/mg of protein at all times examined.","Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452508/),,0 to 1.4,11132,DB00997,Doxorubicin
,7693418,half-lives,"The pharmacokinetic properties of epirubicin are characterised by a triphasic plasma clearance, with half-lives for the initial (alpha), intermediate (beta) and terminal (gamma) elimination phases of approximately 3 minutes, 1 hour and 30 hours, respectively.",Epirubicin. Clinical pharmacology and dose-effect relationship. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693418/),min,3,11261,DB00997,Doxorubicin
,7693418,half-lives,"The pharmacokinetic properties of epirubicin are characterised by a triphasic plasma clearance, with half-lives for the initial (alpha), intermediate (beta) and terminal (gamma) elimination phases of approximately 3 minutes, 1 hour and 30 hours, respectively.",Epirubicin. Clinical pharmacology and dose-effect relationship. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693418/),h,1,11262,DB00997,Doxorubicin
,7693418,half-lives,"The pharmacokinetic properties of epirubicin are characterised by a triphasic plasma clearance, with half-lives for the initial (alpha), intermediate (beta) and terminal (gamma) elimination phases of approximately 3 minutes, 1 hour and 30 hours, respectively.",Epirubicin. Clinical pharmacology and dose-effect relationship. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693418/),h,30,11263,DB00997,Doxorubicin
,7693418,total plasma clearance,"The total plasma clearance of epirubicin is approximately 50 L/h/m2, which is almost 2-fold higher than that of doxorubicin.",Epirubicin. Clinical pharmacology and dose-effect relationship. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693418/),[l] / [h·m2],50,11264,DB00997,Doxorubicin
,28934281,Area under the plasma concentration time curve (AUC),"Area under the plasma concentration time curve (AUC) of Gem-TSLnps (35.17± 0.04 μghr/mL) was significantly higher than that of free Gem (2.09 ± 0.01 μghr/mL) whereas, AUC of Gd-TSLnps was higher than free Gd by 3.9 fold high.",Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28934281/),[μghr] / [ml],35.17,12054,DB00997,Doxorubicin
,28934281,Area under the plasma concentration time curve (AUC),"Area under the plasma concentration time curve (AUC) of Gem-TSLnps (35.17± 0.04 μghr/mL) was significantly higher than that of free Gem (2.09 ± 0.01 μghr/mL) whereas, AUC of Gd-TSLnps was higher than free Gd by 3.9 fold high.",Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28934281/),[μghr] / [ml],2.09,12055,DB00997,Doxorubicin
,6271847,half-life,CTX half-life was not significantly changed with use of THC (7.7 +/- 3.6 hours without versus 5.25 +/- 2.6 hours with THC).,Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h,7.7,12331,DB00997,Doxorubicin
,6271847,half-life,CTX half-life was not significantly changed with use of THC (7.7 +/- 3.6 hours without versus 5.25 +/- 2.6 hours with THC).,Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h,5.25,12332,DB00997,Doxorubicin
,6271847,half-life,"ADR half-life with THC was greater than without THC (175 +/- 197 hours versus 92 +/- 92 hours, respectively).",Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h,175,12333,DB00997,Doxorubicin
,6271847,half-life,"ADR half-life with THC was greater than without THC (175 +/- 197 hours versus 92 +/- 92 hours, respectively).",Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h,92,12334,DB00997,Doxorubicin
,6271847,areas under the curves,Total drug exposure as determined by areas under the curves were similar (12.4 +/- 6 microM . hr without versus 13.8 +/- 4 microM . hr with THC).,Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h·μM,12.4,12335,DB00997,Doxorubicin
,6271847,areas under the curves,Total drug exposure as determined by areas under the curves were similar (12.4 +/- 6 microM . hr without versus 13.8 +/- 4 microM . hr with THC).,Initial observations on the effects of delta 9-tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6271847/),h·μM,13.8,12336,DB00997,Doxorubicin
,7541151,time to progression,"The median time to progression was 9 months (range, 1 to 20 months).",Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7541151/),month,9,12822,DB00997,Doxorubicin
,7541151,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 125 mg/m2 for paclitaxel and 48 mg/m2 for doxorubicin.,Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7541151/),[mg] / [m2],125,12823,DB00997,Doxorubicin
,7541151,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 125 mg/m2 for paclitaxel and 48 mg/m2 for doxorubicin.,Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7541151/),[mg] / [m2],48,12824,DB00997,Doxorubicin
,7541151,MTDs,"The MTDs of this schedule were 60 mg/m2 and 150 mg/m2 for doxorubicin and paclitaxel, respectively.",Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7541151/),[mg] / [m2],60,12825,DB00997,Doxorubicin
,7541151,MTDs,"The MTDs of this schedule were 60 mg/m2 and 150 mg/m2 for doxorubicin and paclitaxel, respectively.",Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7541151/),[mg] / [m2],150,12826,DB00997,Doxorubicin
,10363621,half-life time,The mean phenazone half-life time was significantly shorter in patients with AML (8.79 (3.01) h) than in control group (11.08 (3.61) h) (p < 0.012).,Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,8.79,14193,DB00997,Doxorubicin
,10363621,half-life time,The mean phenazone half-life time was significantly shorter in patients with AML (8.79 (3.01) h) than in control group (11.08 (3.61) h) (p < 0.012).,Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,11.08,14194,DB00997,Doxorubicin
,10363621,half-life time,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,18.08,14195,DB00997,Doxorubicin
,10363621,metabolic clearance rate,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),[ml] / [min],33.92,14196,DB00997,Doxorubicin
,10363621,metabolic clearance rate,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,10.22,14197,DB00997,Doxorubicin
,10363621,metabolic clearance rate,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),[ml] / [min],50.33,14198,DB00997,Doxorubicin
,24863196,Loading efficiency,Loading efficiency of 84.3±3.1% and 49.3±5.4% was calculated for low-PEGylated and high-PEGylated CNTs respectively.,"Doxorubicin loaded folate-targeted carbon nanotubes: preparation, cellular internalization, in vitro cytotoxicity and disposition kinetic study in the isolated perfused rat liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24863196/),%,84.3,14895,DB00997,Doxorubicin
,24863196,Loading efficiency,Loading efficiency of 84.3±3.1% and 49.3±5.4% was calculated for low-PEGylated and high-PEGylated CNTs respectively.,"Doxorubicin loaded folate-targeted carbon nanotubes: preparation, cellular internalization, in vitro cytotoxicity and disposition kinetic study in the isolated perfused rat liver. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24863196/),%,49.3,14896,DB00997,Doxorubicin
,11038035,time to progression (TTP),"After an overall median follow-up time of 22 months (range 4-39+), the median time to progression (TTP) was 4.5 months and the median duration of response was 8 months (range 3-16).",Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038035/),month,4.5,15145,DB00997,Doxorubicin
,11038035,duration of response,"After an overall median follow-up time of 22 months (range 4-39+), the median time to progression (TTP) was 4.5 months and the median duration of response was 8 months (range 3-16).",Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038035/),month,8,15146,DB00997,Doxorubicin
,18819480,drug loading,"The drug loading and entrapment efficiency of DOX-OSC were (35.8 +/- 0.4)% and (75.3 +/- 1.1)%, respectively.",[Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819480/),%,35.8,15607,DB00997,Doxorubicin
,18819480,entrapment efficiency,"The drug loading and entrapment efficiency of DOX-OSC were (35.8 +/- 0.4)% and (75.3 +/- 1.1)%, respectively.",[Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819480/),%,75.3,15608,DB00997,Doxorubicin
,18819480,diameter,"The diameter and zeta potential of DOX-OSC were (174 +/- 12) nm and (-37.1 +/- 3.0) mV, respectively.",[Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819480/),nm,174,15609,DB00997,Doxorubicin
,18819480,zeta potential,"The diameter and zeta potential of DOX-OSC were (174 +/- 12) nm and (-37.1 +/- 3.0) mV, respectively.",[Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819480/),mv,-,15610,DB00997,Doxorubicin
,18819480,zeta potential,"The diameter and zeta potential of DOX-OSC were (174 +/- 12) nm and (-37.1 +/- 3.0) mV, respectively.",[Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819480/),mv,37.1,15611,DB00997,Doxorubicin
,18025286,half-life,"In athymic mice bearing established human tumor xenografts, pharmacokinetic and biodistribution analysis of SIL-Dox revealed long circulation times in the blood with a half-life of 11 h and effective time-dependent tumor localization, resulting in up to 15% injected dose per gram tissue.",Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18025286/),h,11,15806,DB00997,Doxorubicin
,7574760,drug extraction ratios,The mean drug extraction ratios by the CHP filter averaged 88%.,[Pharmacokinetic evaluation of complete infrarenal inferior vena caval isolation and charcoal hemoperfusion for intra-arterial chemotherapy of pelvic tumors]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574760/),%,88,16183,DB00997,Doxorubicin
,7574760,peak systemic levels,"The peak systemic levels of adriamycin were 0.8 +/- 0.1 and 2.3 +/- 0.8 micrograms/ml, respectively, in IVCI.",[Pharmacokinetic evaluation of complete infrarenal inferior vena caval isolation and charcoal hemoperfusion for intra-arterial chemotherapy of pelvic tumors]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574760/),[μg] / [ml],0.8,16184,DB00997,Doxorubicin
,7574760,peak systemic levels,"The peak systemic levels of adriamycin were 0.8 +/- 0.1 and 2.3 +/- 0.8 micrograms/ml, respectively, in IVCI.",[Pharmacokinetic evaluation of complete infrarenal inferior vena caval isolation and charcoal hemoperfusion for intra-arterial chemotherapy of pelvic tumors]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574760/),[μg] / [ml],2.3,16185,DB00997,Doxorubicin
,7531053,recovery in urinary excretion,"During 6 h after administration, [14C]ADM-OXD was mainly excreted into rat urine at 45.2% of the original dose, but in the [14C]ADM group recovery in urinary excretion was 4.2%.","Tissue distribution of macromolecular conjugate, adriamycin linked to oxidized dextran, in rat and mouse bearing tumor cells. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7531053/),%,4.2,16202,DB00997,Doxorubicin
,10487619,clearance (Q),The final model was: clearance (Q) 0.194 I h(-1); central compartment volume (V1) 4.48 x (1+0.00074 x dose (mg)) I; peripheral compartment volume (V2) 7.94 I; intercompartmental clearance 0.685 I h(-1).,Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),[i] / [h],0.194,16401,DB00997,Doxorubicin
,10487619,central compartment volume (V1),The final model was: clearance (Q) 0.194 I h(-1); central compartment volume (V1) 4.48 x (1+0.00074 x dose (mg)) I; peripheral compartment volume (V2) 7.94 I; intercompartmental clearance 0.685 I h(-1).,Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),,4.48,16402,DB00997,Doxorubicin
,10487619,peripheral compartment volume (V2),The final model was: clearance (Q) 0.194 I h(-1); central compartment volume (V1) 4.48 x (1+0.00074 x dose (mg)) I; peripheral compartment volume (V2) 7.94 I; intercompartmental clearance 0.685 I h(-1).,Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),i,7.94,16403,DB00997,Doxorubicin
,10487619,intercompartmental clearance,The final model was: clearance (Q) 0.194 I h(-1); central compartment volume (V1) 4.48 x (1+0.00074 x dose (mg)) I; peripheral compartment volume (V2) 7.94 I; intercompartmental clearance 0.685 I h(-1).,Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),[i] / [h],0.685,16404,DB00997,Doxorubicin
,10487619,Distribution,Distribution and elimination half-lives had median estimates of 2.7 h and 49 h respectively.,Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),h,2.7,16405,DB00997,Doxorubicin
,10487619,elimination half-lives,Distribution and elimination half-lives had median estimates of 2.7 h and 49 h respectively.,Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),h,49,16406,DB00997,Doxorubicin
,10487619,apparent clearance,"Data were best described using a biexponential model and the following parameters were estimated: apparent clearance 180 I h-(-1); apparent V1 (I) 1450 x (1+0.0013 x dose (mg)), apparent V2 (I) 21 300 x (1-0.0013 x dose (mg)) x (1+2.95 x height (m)) and apparent Q 6950 I h(-1).",Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),[i] / [h-],180,16407,DB00997,Doxorubicin
,10487619,apparent V1 (I),"Data were best described using a biexponential model and the following parameters were estimated: apparent clearance 180 I h-(-1); apparent V1 (I) 1450 x (1+0.0013 x dose (mg)), apparent V2 (I) 21 300 x (1-0.0013 x dose (mg)) x (1+2.95 x height (m)) and apparent Q 6950 I h(-1).",Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),,1450,16408,DB00997,Doxorubicin
,10487619,apparent V2 (I),"Data were best described using a biexponential model and the following parameters were estimated: apparent clearance 180 I h-(-1); apparent V1 (I) 1450 x (1+0.0013 x dose (mg)), apparent V2 (I) 21 300 x (1-0.0013 x dose (mg)) x (1+2.95 x height (m)) and apparent Q 6950 I h(-1).",Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),,21 300,16409,DB00997,Doxorubicin
,10487619,apparent Q,"Data were best described using a biexponential model and the following parameters were estimated: apparent clearance 180 I h-(-1); apparent V1 (I) 1450 x (1+0.0013 x dose (mg)), apparent V2 (I) 21 300 x (1-0.0013 x dose (mg)) x (1+2.95 x height (m)) and apparent Q 6950 I h(-1).",Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),[i] / [h],6950,16410,DB00997,Doxorubicin
,10487619,Distribution,Distribution and elimination half-lives were 0.13 h and 85 h respectively.,Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),h,0.13,16411,DB00997,Doxorubicin
,10487619,elimination half-lives,Distribution and elimination half-lives were 0.13 h and 85 h respectively.,Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10487619/),h,85,16412,DB00997,Doxorubicin
,7543702,overall response,"Among 10 patients, there was one complete response and seven partial responses (overall response, 80%).",Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7543702/),%,80,17829,DB00997,Doxorubicin
,7543702,Response rates,Response rates in both regimens were approximately 20%.,Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7543702/),%,20,17830,DB00997,Doxorubicin
,23650496,survival,"Median survival of PLD-treated animals was 32 days (d, [CI] 31-38), which was significantly longer than controls (26d [CI 25-28]; p = 0.0012) or NonL-doxo treatment (23.5d [CI 18-28], p = 0.0002).",Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23650496/),,32,17887,DB00997,Doxorubicin
,19238629,Objective response rates,"Objective response rates of 65% (95% confidence interval (CI): 43-82), disease stabilisation of 25% (95% CI: 11-47) and a disease control rate (CR + PR + SD) of 90% were achieved overall.","Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238629/),%,65,18433,DB00997,Doxorubicin
,19238629,MTD,"The MTD of matuzumab in combination with ECX was 800 mg weekly, and at this DL it was well-tolerated and showed encouraging antitumour activity.","Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238629/),mg,800,18434,DB00997,Doxorubicin
,11280756,concentration for 50% growth inhibition,"PNU-159548 showed good cytotoxic activity in murine and human cancer cells growing in vitro, with an average concentration for 50% growth inhibition of 15.8 ng/ml.",Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11280756/),[ng] / [ml],15.8,18711,DB00997,Doxorubicin
,11280756,maximum tolerated doses,"In the cyclic studies, the maximum tolerated doses were 0.18 mg/kg/day (cumulative dose/cycle: 0.54 mg/kg) in rats and 0.05 mg/kg/day (cumulative dose/cycle: 0.15 mg/kg) in dogs.",Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11280756/),[mg] / [d·kg],0.18,18712,DB00997,Doxorubicin
,11280756,maximum tolerated doses,"In the cyclic studies, the maximum tolerated doses were 0.18 mg/kg/day (cumulative dose/cycle: 0.54 mg/kg) in rats and 0.05 mg/kg/day (cumulative dose/cycle: 0.15 mg/kg) in dogs.",Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11280756/),[mg] / [d·kg],0.05,18713,DB00997,Doxorubicin
,17579865,peak plasma level,Mean peak plasma level after intravenous etoposide was significantly higher compared to oral administration (16.3+/-3.7 vs. 12.0+/-4.2 microg/ml; P=0.015).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[μg] / [ml],16.3,19185,DB00997,Doxorubicin
,17579865,peak plasma level,Mean peak plasma level after intravenous etoposide was significantly higher compared to oral administration (16.3+/-3.7 vs. 12.0+/-4.2 microg/ml; P=0.015).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[μg] / [ml],12.0,19186,DB00997,Doxorubicin
,17579865,bioavailability,The mean bioavailability of oral etoposide was 58+/-15% with an interpatient variability of 26%.,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,58,19187,DB00997,Doxorubicin
,17579865,AUC,Mean AUC after a 100 mg/m2 intravenous and a 200 mg/m2 oral dose of etoposide were 74.0+/-18.3 and 84.9+/-29.6 microg h/ml (P=0.481).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[h·μg] / [ml],74.0,19188,DB00997,Doxorubicin
,17579865,AUC,Mean AUC after a 100 mg/m2 intravenous and a 200 mg/m2 oral dose of etoposide were 74.0+/-18.3 and 84.9+/-29.6 microg h/ml (P=0.481).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[h·μg] / [ml],84.9,19189,DB00997,Doxorubicin
,17579865,excretion,Urinary etoposide excretion as percentage of administered dose was 39.4+/-10.6% after intravenous infusion versus 35.4+/-9.4% after oral intake (P=0.422).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,39.4,19190,DB00997,Doxorubicin
,17579865,excretion,Urinary etoposide excretion as percentage of administered dose was 39.4+/-10.6% after intravenous infusion versus 35.4+/-9.4% after oral intake (P=0.422).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,35.4,19191,DB00997,Doxorubicin
,17579865,Renal clearance,Renal clearance was also very similar with intravenous and oral route (18.5+/-7.4 vs. 16.7+/-6.6 ml/min; P=0.546).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[ml] / [min],18.5,19192,DB00997,Doxorubicin
,17579865,Renal clearance,Renal clearance was also very similar with intravenous and oral route (18.5+/-7.4 vs. 16.7+/-6.6 ml/min; P=0.546).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[ml] / [min],16.7,19193,DB00997,Doxorubicin
,10990195,encapsulation efficiency,"The average diameter of SRP-L-DXR in pure water was 112.9 +/- 8.6 (nm) and the encapsulation efficiency of SRP-L-DXR was 96.5 +/- 0.2% in pure water, 95.5 +/- 0.1% in 5% glucose and 98.01 +/- 0.6% in 0.9% NaCl.",Pharmacokinetics and antitumor effect of doxorubicin carried by stealth and remote loading proliposome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10990195/),%,96.5,19278,DB00997,Doxorubicin
,10990195,encapsulation efficiency,"The average diameter of SRP-L-DXR in pure water was 112.9 +/- 8.6 (nm) and the encapsulation efficiency of SRP-L-DXR was 96.5 +/- 0.2% in pure water, 95.5 +/- 0.1% in 5% glucose and 98.01 +/- 0.6% in 0.9% NaCl.",Pharmacokinetics and antitumor effect of doxorubicin carried by stealth and remote loading proliposome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10990195/),%,95.5,19279,DB00997,Doxorubicin
,10990195,encapsulation efficiency,"The average diameter of SRP-L-DXR in pure water was 112.9 +/- 8.6 (nm) and the encapsulation efficiency of SRP-L-DXR was 96.5 +/- 0.2% in pure water, 95.5 +/- 0.1% in 5% glucose and 98.01 +/- 0.6% in 0.9% NaCl.",Pharmacokinetics and antitumor effect of doxorubicin carried by stealth and remote loading proliposome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10990195/),%,98.01,19280,DB00997,Doxorubicin
,11592781,t(1/2alpha),HPMA copolymer-cathespin B exhibited a longer plasma half-life (free cathepsin B t(1/2alpha)= 2.8 h; bound cathepsin B t(1/2alpha)= 3.2 h) and a 4.2-fold increase in tumour accumulation compared to the free enzyme.,PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592781/),h,2.8,19292,DB00997,Doxorubicin
,11592781,t(1/2alpha),HPMA copolymer-cathespin B exhibited a longer plasma half-life (free cathepsin B t(1/2alpha)= 2.8 h; bound cathepsin B t(1/2alpha)= 3.2 h) and a 4.2-fold increase in tumour accumulation compared to the free enzyme.,PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592781/),h,3.2,19293,DB00997,Doxorubicin
,11592781,T/C%),"When PK1 and the PDEPT combination were used to treat established B16F10 melanoma tumour (single dose; 10 mg kg(-1)dox-equiv.), the antitumour activity (T/C%) seen for the combination PDEPT was 168% compared to 152% seen for PK1 alone, and 144% for free dox.",PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592781/),%,168,19294,DB00997,Doxorubicin
,11592781,T/C%),"When PK1 and the PDEPT combination were used to treat established B16F10 melanoma tumour (single dose; 10 mg kg(-1)dox-equiv.), the antitumour activity (T/C%) seen for the combination PDEPT was 168% compared to 152% seen for PK1 alone, and 144% for free dox.",PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592781/),%,152,19295,DB00997,Doxorubicin
,11592781,T/C%),"When PK1 and the PDEPT combination were used to treat established B16F10 melanoma tumour (single dose; 10 mg kg(-1)dox-equiv.), the antitumour activity (T/C%) seen for the combination PDEPT was 168% compared to 152% seen for PK1 alone, and 144% for free dox.",PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11592781/),%,144,19296,DB00997,Doxorubicin
,10850396,elimination half-life,The Rituximab elimination half-life of approximately 20 days accounts for the demonstrated accumulation of MAb in serum samples.,Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850396/),d,20,19743,DB00997,Doxorubicin
,29175695,extraction recovery,The extraction recovery was about 97% for L-DOX and about 65% for NL-DOX.,Determination of non-liposomal and liposomal doxorubicin in plasma by LC-MS/MS coupled with an effective solid phase extraction: In comparison with ultrafiltration technique and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175695/),%,97,20002,DB00997,Doxorubicin
,29175695,extraction recovery,The extraction recovery was about 97% for L-DOX and about 65% for NL-DOX.,Determination of non-liposomal and liposomal doxorubicin in plasma by LC-MS/MS coupled with an effective solid phase extraction: In comparison with ultrafiltration technique and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29175695/),%,65,20003,DB00997,Doxorubicin
,1451235,Detection,Detection limits ranged from 0.01 nmol/g tissue for the aglycons to 0.06 nmol/g for Dox.,Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),,0.01,20108,DB00997,Doxorubicin
,1451235,Detection,Detection limits ranged from 0.01 nmol/g tissue for the aglycons to 0.06 nmol/g for Dox.,Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),,0.06,20109,DB00997,Doxorubicin
,1451235,Recoveries,"Recoveries were in the range of 82%-110%, and calibration curves were linear over the concentration range tested (0.1-10 nmol/g tissue, r > or = 0.998).",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),%,82,20110,DB00997,Doxorubicin
,1451235,final half-lives,"The elimination of Leu-Dox was also fast as illustrated by final half-lives of 1.1, 0.8, and 0.9 h in the plasma, heart, and tumor, respectively.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),h,1.1,20111,DB00997,Doxorubicin
,1451235,final half-lives,"The elimination of Leu-Dox was also fast as illustrated by final half-lives of 1.1, 0.8, and 0.9 h in the plasma, heart, and tumor, respectively.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),h,0.8,20112,DB00997,Doxorubicin
,1451235,final half-lives,"The elimination of Leu-Dox was also fast as illustrated by final half-lives of 1.1, 0.8, and 0.9 h in the plasma, heart, and tumor, respectively.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),h,0.9,20113,DB00997,Doxorubicin
,1451235,final half-lives,"For Dox, the final half-lives were 16.7 h in plasma, 15.3 h in heart tissues, and 27.4 h in tumor tissues.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),h,16.7,20114,DB00997,Doxorubicin
,1451235,final half-lives,"For Dox, the final half-lives were 16.7 h in plasma, 15.3 h in heart tissues, and 27.4 h in tumor tissues.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),h,15.3,20115,DB00997,Doxorubicin
,1451235,final half-lives,"For Dox, the final half-lives were 16.7 h in plasma, 15.3 h in heart tissues, and 27.4 h in tumor tissues.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),h,27.4,20116,DB00997,Doxorubicin
,1451235,AUC,"AUC values determined for Leu-Dox and Dox were 221 and 51 nmol ml-1 min, 443 and 4,262 nmol g-1 min, and 153 and 1,466 nmol g-1 min in the plasma, heart, and tumor, respectively.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),[min·nM] / [ml],221,20117,DB00997,Doxorubicin
,1451235,AUC,"AUC values determined for Leu-Dox and Dox were 221 and 51 nmol ml-1 min, 443 and 4,262 nmol g-1 min, and 153 and 1,466 nmol g-1 min in the plasma, heart, and tumor, respectively.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),[min·nM] / [ml],51,20118,DB00997,Doxorubicin
,1451235,AUC,"AUC values determined for Leu-Dox and Dox were 221 and 51 nmol ml-1 min, 443 and 4,262 nmol g-1 min, and 153 and 1,466 nmol g-1 min in the plasma, heart, and tumor, respectively.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),[min·nM] / [g],443,20119,DB00997,Doxorubicin
,1451235,AUC,"AUC values determined for Leu-Dox and Dox were 221 and 51 nmol ml-1 min, 443 and 4,262 nmol g-1 min, and 153 and 1,466 nmol g-1 min in the plasma, heart, and tumor, respectively.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),[min·nM] / [g],"4,262",20120,DB00997,Doxorubicin
,1451235,AUC,"AUC values determined for Leu-Dox and Dox were 221 and 51 nmol ml-1 min, 443 and 4,262 nmol g-1 min, and 153 and 1,466 nmol g-1 min in the plasma, heart, and tumor, respectively.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),[min·nM] / [g],153,20121,DB00997,Doxorubicin
,1451235,AUC,"AUC values determined for Leu-Dox and Dox were 221 and 51 nmol ml-1 min, 443 and 4,262 nmol g-1 min, and 153 and 1,466 nmol g-1 min in the plasma, heart, and tumor, respectively.",Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451235/),[min·nM] / [g],"1,466",20122,DB00997,Doxorubicin
up,30276137,entrapment,"The entrapment and loading efficiency of Dox were up to 40% and 23%, respectively.",Enhanced Intestinal Permeation of Doxorubicin Using Chitosan Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30276137/),%,40,20198,DB00997,Doxorubicin
up,30276137,loading efficiency,"The entrapment and loading efficiency of Dox were up to 40% and 23%, respectively.",Enhanced Intestinal Permeation of Doxorubicin Using Chitosan Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30276137/),%,40,20199,DB00997,Doxorubicin
,30276137,loading efficiency,"The entrapment and loading efficiency of Dox were up to 40% and 23%, respectively.",Enhanced Intestinal Permeation of Doxorubicin Using Chitosan Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30276137/),%,23,20200,DB00997,Doxorubicin
below,22759979,MWs,"Only star conjugates with MWs below 50,000g.",HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22759979/),g,"50,000",20282,DB00997,Doxorubicin
,22759979,MWs,"mo(-1) were removed by kidney filtration, while linear polymer conjugates with MWs near 70,000g.mol(-1), exceeding the generally accepted limit for renal elimination, were detected in the urine 36-96h after injection.",HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22759979/),[g] / [mol],"70,000",20283,DB00997,Doxorubicin
,856462,half-life,It disappeared according to a triphasic pattern with a mean half-life of 30 hr.,Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/856462/),h,30,20310,DB00997,Doxorubicin
,17239825,clearance in the distribution phase of drug disposition (CL(d)),"Upon i.v. injection of 4 microg kg(-1) (tracer), 2 and 20 mg kg(-1), the clearance in the distribution phase of drug disposition (CL(d)) significantly decreased from 9.7+/-0.7 to 4.7+/-2.3 and 1.0+/-0.1 ml kg(-1)min(-1), respectively.",Pharmacokinetics of a hepatic stellate cell-targeted doxorubicin construct in bile duct-ligated rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239825/),[ml] / [kg],9.7,20774,DB00997,Doxorubicin
,17239825,clearance in the distribution phase of drug disposition (CL(d)),"Upon i.v. injection of 4 microg kg(-1) (tracer), 2 and 20 mg kg(-1), the clearance in the distribution phase of drug disposition (CL(d)) significantly decreased from 9.7+/-0.7 to 4.7+/-2.3 and 1.0+/-0.1 ml kg(-1)min(-1), respectively.",Pharmacokinetics of a hepatic stellate cell-targeted doxorubicin construct in bile duct-ligated rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239825/),[ml] / [kg],4.7,20775,DB00997,Doxorubicin
,17239825,clearance in the distribution phase of drug disposition (CL(d)),"Upon i.v. injection of 4 microg kg(-1) (tracer), 2 and 20 mg kg(-1), the clearance in the distribution phase of drug disposition (CL(d)) significantly decreased from 9.7+/-0.7 to 4.7+/-2.3 and 1.0+/-0.1 ml kg(-1)min(-1), respectively.",Pharmacokinetics of a hepatic stellate cell-targeted doxorubicin construct in bile duct-ligated rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239825/),[ml] / [kg],1.0,20776,DB00997,Doxorubicin
,3978646,t1/2 alpha,Disappearance of 4'-DXDX from plasma was triphasic with a rapid initial phase clearance showing a t1/2 alpha of 1 to 2 min and a prolonged terminal phase with a median t1/2 gamma in excess of 90 h in patients receiving 30 mg/sq m.,Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978646/),min,1 to 2,21014,DB00997,Doxorubicin
excess,3978646,t1/2 gamma,Disappearance of 4'-DXDX from plasma was triphasic with a rapid initial phase clearance showing a t1/2 alpha of 1 to 2 min and a prolonged terminal phase with a median t1/2 gamma in excess of 90 h in patients receiving 30 mg/sq m.,Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3978646/),h,90,21015,DB00997,Doxorubicin
,27022865,tumor inhibitory rate,"The tumor inhibitory rate after IT administration of DH700kMF-13.5/M-DocLF was 92.4%, followed by 85.8%, 75.6%, 62.9%, 50.6%, and 49.5% for DH700kMF-15, free DOX, F-13.5/M-DocLF, Tynen (DOC solution), and M-DocLF, respectively.",Codelivery of doxorubicin-containing thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles enhances local cancer therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27022865/),%,92.4,21366,DB00997,Doxorubicin
,27022865,tumor inhibitory rate,"The tumor inhibitory rate after IT administration of DH700kMF-13.5/M-DocLF was 92.4%, followed by 85.8%, 75.6%, 62.9%, 50.6%, and 49.5% for DH700kMF-15, free DOX, F-13.5/M-DocLF, Tynen (DOC solution), and M-DocLF, respectively.",Codelivery of doxorubicin-containing thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles enhances local cancer therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27022865/),%,85.8,21367,DB00997,Doxorubicin
,27022865,tumor inhibitory rate,"The tumor inhibitory rate after IT administration of DH700kMF-13.5/M-DocLF was 92.4%, followed by 85.8%, 75.6%, 62.9%, 50.6%, and 49.5% for DH700kMF-15, free DOX, F-13.5/M-DocLF, Tynen (DOC solution), and M-DocLF, respectively.",Codelivery of doxorubicin-containing thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles enhances local cancer therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27022865/),%,75.6,21368,DB00997,Doxorubicin
,27022865,tumor inhibitory rate,"The tumor inhibitory rate after IT administration of DH700kMF-13.5/M-DocLF was 92.4%, followed by 85.8%, 75.6%, 62.9%, 50.6%, and 49.5% for DH700kMF-15, free DOX, F-13.5/M-DocLF, Tynen (DOC solution), and M-DocLF, respectively.",Codelivery of doxorubicin-containing thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles enhances local cancer therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27022865/),%,62.9,21369,DB00997,Doxorubicin
,27022865,tumor inhibitory rate,"The tumor inhibitory rate after IT administration of DH700kMF-13.5/M-DocLF was 92.4%, followed by 85.8%, 75.6%, 62.9%, 50.6%, and 49.5% for DH700kMF-15, free DOX, F-13.5/M-DocLF, Tynen (DOC solution), and M-DocLF, respectively.",Codelivery of doxorubicin-containing thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles enhances local cancer therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27022865/),%,50.6,21370,DB00997,Doxorubicin
,27022865,tumor inhibitory rate,"The tumor inhibitory rate after IT administration of DH700kMF-13.5/M-DocLF was 92.4%, followed by 85.8%, 75.6%, 62.9%, 50.6%, and 49.5% for DH700kMF-15, free DOX, F-13.5/M-DocLF, Tynen (DOC solution), and M-DocLF, respectively.",Codelivery of doxorubicin-containing thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles enhances local cancer therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27022865/),%,49.5,21371,DB00997,Doxorubicin
,19588140,time to progression survival,"Median time to progression survival and overall survival were 8.7 and 21.5 months, respectively.",Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19588140/),month,8.7,22331,DB00997,Doxorubicin
,19588140,overall survival,"Median time to progression survival and overall survival were 8.7 and 21.5 months, respectively.",Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19588140/),month,21.5,22332,DB00997,Doxorubicin
,11852999,absolute gran,"The median absolute granulocyte count nadir for all courses was 200 mm(-3) (range, 0.1-7700 mm(-3)), and the median time to this nadir was 9 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),1/[(mm)^3],200,22892,DB00997,Doxorubicin
,11852999,time to this nadir,"The median absolute granulocyte count nadir for all courses was 200 mm(-3) (range, 0.1-7700 mm(-3)), and the median time to this nadir was 9 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),d,9,22893,DB00997,Doxorubicin
,11852999,platelet nadir,"The median platelet nadir was 163 (range, 27-401 k), and the median time to this nadir was 8 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),k,163,22894,DB00997,Doxorubicin
,11852999,time to this nadir,"The median platelet nadir was 163 (range, 27-401 k), and the median time to this nadir was 8 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),d,8,22895,DB00997,Doxorubicin
,10789595,half-lives,"Pharmacokinetic analysis shows a proportional increase of plasma drug levels with dose and the characteristic long circulation time of Doxil with half-lives in the range of 3 days, somewhat longer than previously reported.",Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10789595/),d,3,23516,DB00997,Doxorubicin
,3712761,plasma half-lives,"The plasma half-lives of THP in alpha, beta and gamma-phases were 0.25 minute, 0.241 hour and 5.11 hours, respectively.",[Pharmacokinetics and disposition of a new anticancer antibiotic (2''R)-4'-O-tetrahydropyranyladriamycin in rats. Distribution and excretion after a single administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712761/),min,0.25,23557,DB00997,Doxorubicin
,3712761,plasma half-lives,"The plasma half-lives of THP in alpha, beta and gamma-phases were 0.25 minute, 0.241 hour and 5.11 hours, respectively.",[Pharmacokinetics and disposition of a new anticancer antibiotic (2''R)-4'-O-tetrahydropyranyladriamycin in rats. Distribution and excretion after a single administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712761/),h,0.241,23558,DB00997,Doxorubicin
,3712761,plasma half-lives,"The plasma half-lives of THP in alpha, beta and gamma-phases were 0.25 minute, 0.241 hour and 5.11 hours, respectively.",[Pharmacokinetics and disposition of a new anticancer antibiotic (2''R)-4'-O-tetrahydropyranyladriamycin in rats. Distribution and excretion after a single administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712761/),h,5.11,23559,DB00997,Doxorubicin
,3712761,Ratios of excretion,"Ratios of excretion of the radioactivity in the feces, urine and expired air were 80.3, 5.6 and 9.7% of the dose, respectively, 168 hours after an injection of 14C-THP.",[Pharmacokinetics and disposition of a new anticancer antibiotic (2''R)-4'-O-tetrahydropyranyladriamycin in rats. Distribution and excretion after a single administration]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712761/),%,80.3,23560,DB00997,Doxorubicin
,3712761,Ratios of excretion,"Ratios of excretion of the radioactivity in the feces, urine and expired air were 80.3, 5.6 and 9.7% of the dose, respectively, 168 hours after an injection of 14C-THP.",[Pharmacokinetics and disposition of a new anticancer antibiotic (2''R)-4'-O-tetrahydropyranyladriamycin in rats. Distribution and excretion after a single administration]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712761/),%,5.6,23561,DB00997,Doxorubicin
,3712761,Ratios of excretion,"Ratios of excretion of the radioactivity in the feces, urine and expired air were 80.3, 5.6 and 9.7% of the dose, respectively, 168 hours after an injection of 14C-THP.",[Pharmacokinetics and disposition of a new anticancer antibiotic (2''R)-4'-O-tetrahydropyranyladriamycin in rats. Distribution and excretion after a single administration]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712761/),%,9.7,23562,DB00997,Doxorubicin
,27789365,zeta potential,"The PSA-BS18 modified liposomal epirubicin (EPI-SL), had a particle size of 133.63±0.92nm, a zeta potential of -26.23±1.50mV and an encapsulation efficiency (%EE) of 96.23±1.16%.","Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789365/),mv,-,23796,DB00997,Doxorubicin
,27789365,zeta potential,"The PSA-BS18 modified liposomal epirubicin (EPI-SL), had a particle size of 133.63±0.92nm, a zeta potential of -26.23±1.50mV and an encapsulation efficiency (%EE) of 96.23±1.16%.","Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789365/),mv,26.23,23797,DB00997,Doxorubicin
,27789365,encapsulation efficiency (%EE),"The PSA-BS18 modified liposomal epirubicin (EPI-SL), had a particle size of 133.63±0.92nm, a zeta potential of -26.23±1.50mV and an encapsulation efficiency (%EE) of 96.23±1.16%.","Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789365/),%,96.23,23798,DB00997,Doxorubicin
,11103239,index,"However, the dialysis index was about 75 and 85% in the 3rd and 4th cycles, respectively.","[Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103239/),,75,24119,DB00997,Doxorubicin
,11103239,index,"However, the dialysis index was about 75 and 85% in the 3rd and 4th cycles, respectively.","[Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103239/),,85,24120,DB00997,Doxorubicin
,31526064,drug loading capacity,"The BSA-IrO2 NPs exhibits uniform size (40 nm), superb biocompatibility and high drug loading capacity for doxorubicin (27.4 wt%).",Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31526064/),w,27.4,24301,DB00997,Doxorubicin
,7505268,maximum peak plasma concentration (ppc),The maximum peak plasma concentration (ppc) for total DOX was 12.3 micrograms/ml at 40 mg/m2 DOXeq.,"Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7505268/),[μg] / [ml],12.3,24396,DB00997,Doxorubicin
,7505268,area under the plasma concentration time curve (AUC),The area under the plasma concentration time curve (AUC) ranged from 28.83-80.21 micrograms/ml*h with dose-dependent elimination half lives (t1/2 alpha: 0.02-0.87 h; t1/2 beta: 2.69-11.58 h; t1/2 gamma: 41.44-136.58 h).,"Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7505268/),[μg] / [h·ml],28.83-80.21,24397,DB00997,Doxorubicin
,7505268,elimination half lives (t1/2 alpha,The area under the plasma concentration time curve (AUC) ranged from 28.83-80.21 micrograms/ml*h with dose-dependent elimination half lives (t1/2 alpha: 0.02-0.87 h; t1/2 beta: 2.69-11.58 h; t1/2 gamma: 41.44-136.58 h).,"Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7505268/),h,0.02-0.87,24398,DB00997,Doxorubicin
,7505268,t1/2 beta,The area under the plasma concentration time curve (AUC) ranged from 28.83-80.21 micrograms/ml*h with dose-dependent elimination half lives (t1/2 alpha: 0.02-0.87 h; t1/2 beta: 2.69-11.58 h; t1/2 gamma: 41.44-136.58 h).,"Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7505268/),h,2.69-11.58,24399,DB00997,Doxorubicin
,7505268,t1/2 gamma,The area under the plasma concentration time curve (AUC) ranged from 28.83-80.21 micrograms/ml*h with dose-dependent elimination half lives (t1/2 alpha: 0.02-0.87 h; t1/2 beta: 2.69-11.58 h; t1/2 gamma: 41.44-136.58 h).,"Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7505268/),h,41.44-136.58,24400,DB00997,Doxorubicin
,3365351,urine pH,"Median urine pH was 5.0 or 8.0, and median arterial blood pH 7.30 or 7.43 respectively.",Pharmacokinetics of doxorubicin in man with induced acid or alkaline urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365351/),,5.0,24533,DB00997,Doxorubicin
,3365351,urine pH,"Median urine pH was 5.0 or 8.0, and median arterial blood pH 7.30 or 7.43 respectively.",Pharmacokinetics of doxorubicin in man with induced acid or alkaline urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365351/),,8.0,24534,DB00997,Doxorubicin
,3365351,arterial blood pH,"Median urine pH was 5.0 or 8.0, and median arterial blood pH 7.30 or 7.43 respectively.",Pharmacokinetics of doxorubicin in man with induced acid or alkaline urine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365351/),,7.30,24535,DB00997,Doxorubicin
,3365351,arterial blood pH,"Median urine pH was 5.0 or 8.0, and median arterial blood pH 7.30 or 7.43 respectively.",Pharmacokinetics of doxorubicin in man with induced acid or alkaline urine. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365351/),,7.43,24536,DB00997,Doxorubicin
,14610219,Labeling efficiency,Labeling efficiency of (99m)Tc-Doxil was 70.6 +/- 0.8% (n = 3).,Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14610219/),%,70.6,25080,DB00997,Doxorubicin
,14610219,half-clearance times,There was a two-phase blood clearance with half-clearance times of 2.2 and 26.2 h after bolus intravenous injection in normal rats.,Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14610219/),h,2.2,25081,DB00997,Doxorubicin
,14610219,half-clearance times,There was a two-phase blood clearance with half-clearance times of 2.2 and 26.2 h after bolus intravenous injection in normal rats.,Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14610219/),h,26.2,25082,DB00997,Doxorubicin
,14610219,half-clearance time,Unencapsulated (99m)Tc-BMEDA had a very rapid blood clearance with a half-clearance time of only 0.12 h (n = 4).,Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14610219/),h,0.12,25083,DB00997,Doxorubicin
,12228205,area under the concentration-time curve (AUC),"One hundred patients with ABC received paclitaxel 135 mg/m(2) (group 1, n = 20) and carboplatin area under the concentration-time curve (AUC) of 2.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),,2,25349,DB00997,Doxorubicin
,12228205,overall response rate (ORR),"The overall response rate (ORR) among 95 assessable patients was 62%, including 8% complete responses and 54% partial responses.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),%,62,25350,DB00997,Doxorubicin
,12228205,time to response,"The median time to response was 1.8 months, and the median duration of response was 13.3 months.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),month,1.8,25351,DB00997,Doxorubicin
,12228205,duration of response,"The median time to response was 1.8 months, and the median duration of response was 13.3 months.",Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),month,13.3,25352,DB00997,Doxorubicin
,12228205,time to progression,The median time to progression was 4.8 months.,Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12228205/),month,4.8,25353,DB00997,Doxorubicin
,12172704,AUC (0-24 h,"Following administration of 210+/-29, 278+/-41, 1143+/-79 and 1143+/-79 mg ETO, the AUC (0-24 h, normalized to 150 mg/m(2)) was 123+/-23, 113+/-22, 92+/-11 and 100+/-22 microgxh/ml.",Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172704/),[h·μg] / [ml],123,25813,DB00997,Doxorubicin
,12172704,AUC (0-24 h,"Following administration of 210+/-29, 278+/-41, 1143+/-79 and 1143+/-79 mg ETO, the AUC (0-24 h, normalized to 150 mg/m(2)) was 123+/-23, 113+/-22, 92+/-11 and 100+/-22 microgxh/ml.",Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172704/),[h·μg] / [ml],113,25814,DB00997,Doxorubicin
,12172704,AUC (0-24 h,"Following administration of 210+/-29, 278+/-41, 1143+/-79 and 1143+/-79 mg ETO, the AUC (0-24 h, normalized to 150 mg/m(2)) was 123+/-23, 113+/-22, 92+/-11 and 100+/-22 microgxh/ml.",Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172704/),[h·μg] / [ml],92,25815,DB00997,Doxorubicin
,12172704,AUC (0-24 h,"Following administration of 210+/-29, 278+/-41, 1143+/-79 and 1143+/-79 mg ETO, the AUC (0-24 h, normalized to 150 mg/m(2)) was 123+/-23, 113+/-22, 92+/-11 and 100+/-22 microgxh/ml.",Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172704/),[h·μg] / [ml],100,25816,DB00997,Doxorubicin
,28444427,cumulative prior dose,"Eleven patients had received previous doses of anthracyclines, with a median cumulative prior dose of 90 mg/m2 (range 0-225 mg/m2).",Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444427/),,90,25873,DB00997,Doxorubicin
,28444427,CL,"Body surface area was related to all clearance and distribution parameters and age further influenced clearance (CL, 58.7 L/h/1.8 m2 for an average 8.4-year-old patient).",Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444427/),[l] / [1.8·h·m2],58.7,25874,DB00997,Doxorubicin
,24481679,intra-abdominal fat volume,"Higher intra-abdominal fat volume and fat ratio (intra-abdominal:total abdominal fat volume) correlated with greater incidence of grade 4 leukopenia on cycle 1 day 15 (mean intra-abdominal fat volume: 97.4 ± 46.5 cm(3) vs 63.4 ± 30.9 cm(3), p = 0.014; mean fat ratio: 0.43 ± 0.11 vs 0.33 ± 0.09, p = 0.012, grade 4 vs grade 0-3 leukopenia).",Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24481679/),cm(3),97.4,26945,DB00997,Doxorubicin
,24481679,intra-abdominal fat volume,"Higher intra-abdominal fat volume and fat ratio (intra-abdominal:total abdominal fat volume) correlated with greater incidence of grade 4 leukopenia on cycle 1 day 15 (mean intra-abdominal fat volume: 97.4 ± 46.5 cm(3) vs 63.4 ± 30.9 cm(3), p = 0.014; mean fat ratio: 0.43 ± 0.11 vs 0.33 ± 0.09, p = 0.012, grade 4 vs grade 0-3 leukopenia).",Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24481679/),cm(3),63.4,26946,DB00997,Doxorubicin
,24481679,fat ratio,"Higher intra-abdominal fat volume and fat ratio (intra-abdominal:total abdominal fat volume) correlated with greater incidence of grade 4 leukopenia on cycle 1 day 15 (mean intra-abdominal fat volume: 97.4 ± 46.5 cm(3) vs 63.4 ± 30.9 cm(3), p = 0.014; mean fat ratio: 0.43 ± 0.11 vs 0.33 ± 0.09, p = 0.012, grade 4 vs grade 0-3 leukopenia).",Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24481679/),,0.43,26947,DB00997,Doxorubicin
,24481679,fat ratio,"Higher intra-abdominal fat volume and fat ratio (intra-abdominal:total abdominal fat volume) correlated with greater incidence of grade 4 leukopenia on cycle 1 day 15 (mean intra-abdominal fat volume: 97.4 ± 46.5 cm(3) vs 63.4 ± 30.9 cm(3), p = 0.014; mean fat ratio: 0.43 ± 0.11 vs 0.33 ± 0.09, p = 0.012, grade 4 vs grade 0-3 leukopenia).",Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24481679/),,0.33,26948,DB00997,Doxorubicin
,9421103,alpha,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),1/[hr],4.06,27469,DB00997,Doxorubicin
,9421103,mean residence time,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),[h·μg] / [l],1145,27470,DB00997,Doxorubicin
,9421103,mean residence time,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),[l] / [h·m2],49.3,27471,DB00997,Doxorubicin
,9421103,mean residence time,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),h,26.8,27472,DB00997,Doxorubicin
less,1990216,overall response rate,"The treatment of pulmonary metastases from soft tissue sarcomas with chemotherapy has an overall response rate of less than 30%, and the majority of these responses are short lived.",Pharmacokinetics and toxicity of isolated perfusion of lung with doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990216/),%,30,27521,DB00997,Doxorubicin
,4058012,half-lives,"The plasma disappearance curves were triphasic with mean half-lives of 2 min, 18 min and 15 h for the alpha-, beta- and gamma-phases, respectively.",Doxorubicin pharmacokinetics in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4058012/),min,2,27662,DB00997,Doxorubicin
,4058012,half-lives,"The plasma disappearance curves were triphasic with mean half-lives of 2 min, 18 min and 15 h for the alpha-, beta- and gamma-phases, respectively.",Doxorubicin pharmacokinetics in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4058012/),min,18,27663,DB00997,Doxorubicin
,4058012,half-lives,"The plasma disappearance curves were triphasic with mean half-lives of 2 min, 18 min and 15 h for the alpha-, beta- and gamma-phases, respectively.",Doxorubicin pharmacokinetics in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4058012/),h,15,27664,DB00997,Doxorubicin
,2703005,plasma clearance,The mean plasma clearance of doxorubicin was 25.2 l/h/m2 and the mean terminal half-lives of doxorubicin and doxorubicinol were respectively 43.6 and 66.2 h.,Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2703005/),[l] / [h·m2],25.2,27689,DB00997,Doxorubicin
,2703005,terminal half-lives,The mean plasma clearance of doxorubicin was 25.2 l/h/m2 and the mean terminal half-lives of doxorubicin and doxorubicinol were respectively 43.6 and 66.2 h.,Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2703005/),h,43.6,27690,DB00997,Doxorubicin
,2703005,terminal half-lives,The mean plasma clearance of doxorubicin was 25.2 l/h/m2 and the mean terminal half-lives of doxorubicin and doxorubicinol were respectively 43.6 and 66.2 h.,Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2703005/),h,66.2,27691,DB00997,Doxorubicin
,3315280,plasma elimination half-lives,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),min,457,28030,DB00997,Doxorubicin
,3315280,apparent volume of distribution,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),1,36.1,28031,DB00997,Doxorubicin
,3315280,plasma clearance,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),[ml] / [min],25.9 and 166.6,28032,DB00997,Doxorubicin
,3315280,plasma clearance,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),[ml] / [min],69.5,28033,DB00997,Doxorubicin
,25019569,objective response rates,"Confirmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1), and 0.0% (B3).",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),%,36.0,28079,DB00997,Doxorubicin
,25019569,objective response rates,"Confirmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1), and 0.0% (B3).",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),%,34.8,28080,DB00997,Doxorubicin
,25019569,objective response rates,"Confirmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1), and 0.0% (B3).",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),%,16.7,28081,DB00997,Doxorubicin
,25019569,objective response rates,"Confirmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1), and 0.0% (B3).",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),%,0.0,28082,DB00997,Doxorubicin
,25019569,progression-free survival duration,"Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1 (B3), respectively.",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),month,7.4,28083,DB00997,Doxorubicin
,25019569,progression-free survival duration,"Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1 (B3), respectively.",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),month,7.1,28084,DB00997,Doxorubicin
,25019569,progression-free survival duration,"Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1 (B3), respectively.",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),month,3.5,28085,DB00997,Doxorubicin
,25019569,progression-free survival duration,"Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1 (B3), respectively.",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),month,3.1,28086,DB00997,Doxorubicin
,11223552,IC(50),Ex-vivo bioassay revealed that activity in serum for reversing multidrug resistance was achieved in all patients; IC(50) of P-glycoprotein expressing 8226 / Dox(6) in patients' serum was decreased from 5.9 to 1.3 microg / ml (P < 0.0001) by PSC-833 administration.,Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11223552/),[μg] / [ml],5.9,28087,DB00997,Doxorubicin
,11223552,IC(50),Ex-vivo bioassay revealed that activity in serum for reversing multidrug resistance was achieved in all patients; IC(50) of P-glycoprotein expressing 8226 / Dox(6) in patients' serum was decreased from 5.9 to 1.3 microg / ml (P < 0.0001) by PSC-833 administration.,Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11223552/),[μg] / [ml],1.3,28088,DB00997,Doxorubicin
,11223552,clearance,"Doxorubicin clearance was 24.3 +/- 13.7 (mean +/- SD) liter / h/m(2), which was lower than the 49.0 +/- 16.9 liter / h/m(2) without PSC-833 (P < 0.0001).",Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11223552/),[h·l] / [m(2],24.3,28089,DB00997,Doxorubicin
,11223552,clearance,"Doxorubicin clearance was 24.3 +/- 13.7 (mean +/- SD) liter / h/m(2), which was lower than the 49.0 +/- 16.9 liter / h/m(2) without PSC-833 (P < 0.0001).",Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11223552/),[h·l] / [m(2],49.0,28090,DB00997,Doxorubicin
,11855753,Cmax,"G3139 administered i.v. at 5 mg/kg revealed a biexponential plasma concentration-time curve with a Cmax of 99.9 microg/ml and elimination half-lives of 0.03 h and 9.8 h, respectively, which resulted in an area under the concentration-time curve (AUC) of 15.9 microg x h/ml.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),[μg] / [ml],99.9,28509,DB00997,Doxorubicin
,11855753,elimination half-lives,"G3139 administered i.v. at 5 mg/kg revealed a biexponential plasma concentration-time curve with a Cmax of 99.9 microg/ml and elimination half-lives of 0.03 h and 9.8 h, respectively, which resulted in an area under the concentration-time curve (AUC) of 15.9 microg x h/ml.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),h,0.03,28510,DB00997,Doxorubicin
,11855753,elimination half-lives,"G3139 administered i.v. at 5 mg/kg revealed a biexponential plasma concentration-time curve with a Cmax of 99.9 microg/ml and elimination half-lives of 0.03 h and 9.8 h, respectively, which resulted in an area under the concentration-time curve (AUC) of 15.9 microg x h/ml.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),h,9.8,28511,DB00997,Doxorubicin
,11855753,area under the concentration-time curve (AUC),"G3139 administered i.v. at 5 mg/kg revealed a biexponential plasma concentration-time curve with a Cmax of 99.9 microg/ml and elimination half-lives of 0.03 h and 9.8 h, respectively, which resulted in an area under the concentration-time curve (AUC) of 15.9 microg x h/ml.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),[h·μg] / [ml],15.9,28512,DB00997,Doxorubicin
,11855753,half-lives,"G3139 administered i.p. showed a plasma absorption, distribution and elimination profile typical of this route of administration, characterized by half-lives of 0.03 h, 0.2 h and 8.9 h, respectively and a Cmax of 8.6 microg/ml.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),h,0.03,28513,DB00997,Doxorubicin
,11855753,half-lives,"G3139 administered i.p. showed a plasma absorption, distribution and elimination profile typical of this route of administration, characterized by half-lives of 0.03 h, 0.2 h and 8.9 h, respectively and a Cmax of 8.6 microg/ml.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),h,0.2,28514,DB00997,Doxorubicin
,11855753,half-lives,"G3139 administered i.p. showed a plasma absorption, distribution and elimination profile typical of this route of administration, characterized by half-lives of 0.03 h, 0.2 h and 8.9 h, respectively and a Cmax of 8.6 microg/ml.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),h,8.9,28515,DB00997,Doxorubicin
,11855753,Cmax,"G3139 administered i.p. showed a plasma absorption, distribution and elimination profile typical of this route of administration, characterized by half-lives of 0.03 h, 0.2 h and 8.9 h, respectively and a Cmax of 8.6 microg/ml.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),[μg] / [ml],8.6,28516,DB00997,Doxorubicin
,11855753,bioavailability,"Based on AUC comparisons, the bioavailability of G3139 injected i.p. was 84% compared to i.v. administration.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),%,84,28517,DB00997,Doxorubicin
,11855753,Cmax,"Specifically, a six-fold slower absorption rate, lower Cmax (6.9 microg/ml), increased Tmax (0.2 h), and an AUC of 17.4 microg x h/ml were observed, consistent with concentrations approaching saturation levels in tissue sites to which G3139 distributes.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),[μg] / [ml],6.9,28518,DB00997,Doxorubicin
,11855753,Tmax,"Specifically, a six-fold slower absorption rate, lower Cmax (6.9 microg/ml), increased Tmax (0.2 h), and an AUC of 17.4 microg x h/ml were observed, consistent with concentrations approaching saturation levels in tissue sites to which G3139 distributes.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),h,0.2,28519,DB00997,Doxorubicin
,11855753,AUC,"Specifically, a six-fold slower absorption rate, lower Cmax (6.9 microg/ml), increased Tmax (0.2 h), and an AUC of 17.4 microg x h/ml were observed, consistent with concentrations approaching saturation levels in tissue sites to which G3139 distributes.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),[h·μg] / [ml],17.4,28520,DB00997,Doxorubicin
,11855753,Cmax,"Coadministration of DOX had significant effects on the PK properties of G3139, manifested by an increased Cmax (11.2 microg/ml), higher AUC (19.7 microg x h/ml), and ninefold lower plasma clearance for single-dose G3139 administration.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),[μg] / [ml],11.2,28521,DB00997,Doxorubicin
,11855753,AUC,"Coadministration of DOX had significant effects on the PK properties of G3139, manifested by an increased Cmax (11.2 microg/ml), higher AUC (19.7 microg x h/ml), and ninefold lower plasma clearance for single-dose G3139 administration.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),[h·μg] / [ml],19.7,28522,DB00997,Doxorubicin
,11855753,peak levels,"Significant accumulation of G3139 was observed in solid tumors, with peak levels of approximately 5 microg G3139/g tumor, and approximately a two-to threefold tumor/muscle AUC ratio.",Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855753/),μg,5,28523,DB00997,Doxorubicin
,2076745,ratio AUCI-AOL/AOL/AUCI-,The ratio AUCI-AOL/AOL/AUCI-DOX/DOX was 27 in the case of I-DOX and 0.4 after DOX.,Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076745/),,27,29102,DB00997,Doxorubicin
,2076745,ratio AUCI-AOL/AOL/AUCI-,The ratio AUCI-AOL/AOL/AUCI-DOX/DOX was 27 in the case of I-DOX and 0.4 after DOX.,Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076745/),,0.4,29103,DB00997,Doxorubicin
,2220657,oral bioavailability,The oral bioavailability of etoposide was 21% and 36% in the two patients who had had prior gastrectomy.,"Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2220657/),%,21,30030,DB00997,Doxorubicin
,2220657,oral bioavailability,The oral bioavailability of etoposide was 21% and 36% in the two patients who had had prior gastrectomy.,"Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2220657/),%,36,30031,DB00997,Doxorubicin
,24902790,elimination half-life t1/2,"The effective elimination half-life t1/2 of the pH-sensitive, pH-insensitive polymeric micelles and DOX-PBS in rats were 11.3 h, 9.4 h, and 2.1 h, respectively.",Evaluation of doxorubicin-loaded pH-sensitive polymeric micelle release from tumor blood vessels and anticancer efficacy using a dorsal skin-fold window chamber model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24902790/),h,11.3,30370,DB00997,Doxorubicin
,24902790,elimination half-life t1/2,"The effective elimination half-life t1/2 of the pH-sensitive, pH-insensitive polymeric micelles and DOX-PBS in rats were 11.3 h, 9.4 h, and 2.1 h, respectively.",Evaluation of doxorubicin-loaded pH-sensitive polymeric micelle release from tumor blood vessels and anticancer efficacy using a dorsal skin-fold window chamber model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24902790/),h,9.4,30371,DB00997,Doxorubicin
,24902790,elimination half-life t1/2,"The effective elimination half-life t1/2 of the pH-sensitive, pH-insensitive polymeric micelles and DOX-PBS in rats were 11.3 h, 9.4 h, and 2.1 h, respectively.",Evaluation of doxorubicin-loaded pH-sensitive polymeric micelle release from tumor blood vessels and anticancer efficacy using a dorsal skin-fold window chamber model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24902790/),h,2.1,30372,DB00997,Doxorubicin
,14962724,MTD,The MTD of 3-weekly BMS-184476 was 30 mg/m(2).,Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14962724/),[mg] / [m(2],30,30788,DB00997,Doxorubicin
,14962724,objective response rate,The objective response rate in 17 previously untreated or minimally pretreated patients with breast cancer treated at 35 mg/m(2)/week of BMS-184476 was 59% (95% Confidence Interval (CI): 33-82%).,Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14962724/),%,59,30789,DB00997,Doxorubicin
,8932544,Clearance,"Clearance of PEG-liposomal doxorubicin was 0.034 L/h/m2 to 0.108 L/h/m2, volume of distribution (Vd) was 2.2 L/m2 to 4.4 L/m2, and half-lives (t1/2) of the initial decline in the plasma concentration-time curve and of the terminal decline were 3.77 hours and 41.3 hours, respectively.","Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932544/),[l] / [h·m2],0.034,30932,DB00997,Doxorubicin
,8932544,Clearance,"Clearance of PEG-liposomal doxorubicin was 0.034 L/h/m2 to 0.108 L/h/m2, volume of distribution (Vd) was 2.2 L/m2 to 4.4 L/m2, and half-lives (t1/2) of the initial decline in the plasma concentration-time curve and of the terminal decline were 3.77 hours and 41.3 hours, respectively.","Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932544/),[l] / [h·m2],0.108,30933,DB00997,Doxorubicin
,8932544,volume of distribution (Vd),"Clearance of PEG-liposomal doxorubicin was 0.034 L/h/m2 to 0.108 L/h/m2, volume of distribution (Vd) was 2.2 L/m2 to 4.4 L/m2, and half-lives (t1/2) of the initial decline in the plasma concentration-time curve and of the terminal decline were 3.77 hours and 41.3 hours, respectively.","Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932544/),[l] / [m2],2.2,30934,DB00997,Doxorubicin
,8932544,volume of distribution (Vd),"Clearance of PEG-liposomal doxorubicin was 0.034 L/h/m2 to 0.108 L/h/m2, volume of distribution (Vd) was 2.2 L/m2 to 4.4 L/m2, and half-lives (t1/2) of the initial decline in the plasma concentration-time curve and of the terminal decline were 3.77 hours and 41.3 hours, respectively.","Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932544/),[l] / [m2],4.4,30935,DB00997,Doxorubicin
,8932544,half-lives (t1/2),"Clearance of PEG-liposomal doxorubicin was 0.034 L/h/m2 to 0.108 L/h/m2, volume of distribution (Vd) was 2.2 L/m2 to 4.4 L/m2, and half-lives (t1/2) of the initial decline in the plasma concentration-time curve and of the terminal decline were 3.77 hours and 41.3 hours, respectively.","Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932544/),h,3.77,30936,DB00997,Doxorubicin
,8932544,half-lives (t1/2),"Clearance of PEG-liposomal doxorubicin was 0.034 L/h/m2 to 0.108 L/h/m2, volume of distribution (Vd) was 2.2 L/m2 to 4.4 L/m2, and half-lives (t1/2) of the initial decline in the plasma concentration-time curve and of the terminal decline were 3.77 hours and 41.3 hours, respectively.","Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8932544/),h,41.3,30937,DB00997,Doxorubicin
,9459159,AUC0-infinity,"Mean (+/- s.d.) MMRDX AUC0-infinity calculated up to 24 h after dosing was 20.4 +/- 6.2 microg h l(-1) (n = 11) and t(1/2, gamma) was 44.2 h.","Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459159/),[h·μg] / [l],20.4,31169,DB00997,Doxorubicin
,9459159,"t(1/2, gamma)","Mean (+/- s.d.) MMRDX AUC0-infinity calculated up to 24 h after dosing was 20.4 +/- 6.2 microg h l(-1) (n = 11) and t(1/2, gamma) was 44.2 h.","Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459159/),h,44.2,31170,DB00997,Doxorubicin
,9459159,plasma clearance,Mean plasma clearance (+/- s.d.) was 37.2 +/- 7.3 l h(-1) m(-2) and volume of distribution 1982 +/- 64 l m(-2).,"Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459159/),[l] / [(m)^2·h],37.2,31171,DB00997,Doxorubicin
,9459159,volume of distribution,Mean plasma clearance (+/- s.d.) was 37.2 +/- 7.3 l h(-1) m(-2) and volume of distribution 1982 +/- 64 l m(-2).,"Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459159/),[l] / [(m)^2],1982,31172,DB00997,Doxorubicin
,10025364,CLt,"Vss (ml/kg), CLt (ml/hr/kg) and half-life (h) were 44.1, 1.39 and 23.1, respectively.",Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10025364/),h,44.1,31204,DB00997,Doxorubicin
,10025364,CLt,"Vss (ml/kg), CLt (ml/hr/kg) and half-life (h) were 44.1, 1.39 and 23.1, respectively.",Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10025364/),h,1.39,31205,DB00997,Doxorubicin
,10025364,half-life,"Vss (ml/kg), CLt (ml/hr/kg) and half-life (h) were 44.1, 1.39 and 23.1, respectively.",Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10025364/),h,1.39,31206,DB00997,Doxorubicin
,10025364,half-life,"Vss (ml/kg), CLt (ml/hr/kg) and half-life (h) were 44.1, 1.39 and 23.1, respectively.",Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10025364/),h,23.1,31207,DB00997,Doxorubicin
,8070217,half-life,"Epirubicin pharmacokinetics may be described by a 3-compartment model, with median half-life values of 3.2 minutes, 1.2 and 32 hours for each phase.",Clinical pharmacokinetics of epirubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070217/),min,3.2,31951,DB00997,Doxorubicin
,8070217,half-life,"Epirubicin pharmacokinetics may be described by a 3-compartment model, with median half-life values of 3.2 minutes, 1.2 and 32 hours for each phase.",Clinical pharmacokinetics of epirubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070217/),h,1.2,31952,DB00997,Doxorubicin
,8070217,half-life,"Epirubicin pharmacokinetics may be described by a 3-compartment model, with median half-life values of 3.2 minutes, 1.2 and 32 hours for each phase.",Clinical pharmacokinetics of epirubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070217/),h,32,31953,DB00997,Doxorubicin
,8070217,Total plasma clearance,Total plasma clearance is 46 L/h/m2 and volume of distribution at steady-state is 1000 L/m2.,Clinical pharmacokinetics of epirubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070217/),[l] / [h·m2],46,31954,DB00997,Doxorubicin
,8070217,volume of distribution at steady-state,Total plasma clearance is 46 L/h/m2 and volume of distribution at steady-state is 1000 L/m2.,Clinical pharmacokinetics of epirubicin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070217/),[l] / [m2],1000,31955,DB00997,Doxorubicin
,6141919,limit of,"The limit of detection for 4'-epidoxorubicin and 4'-epidoxorubicinol was 1 ng/injection, and concentrations as low as 5 ng/ml could be analyzed in plasma and urine.",Sensitive and specific determination of the new anthracycline analog 4'-epidoxorubicin and its metabolites by high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141919/),[ng] / [injection],1,32217,DB00997,Doxorubicin
≥,31534507,separation time,"Those prepared using iodinated DEBs, which are more hydrophobic, were able to form stable Pickering-like emulsions (separation time ≥ 20 minutes) and demonstrated handling, administration and imaging observations more akin to Lipiodol™ TACE emulsions in both embolization models.",Evaluation of novel formulations for transarterial chemoembolization: combining elements of Lipiodol emulsions with Drug-eluting Beads. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31534507/),min,20,32229,DB00997,Doxorubicin
,16419071,progression-free survival,Median progression-free survival was 7 months with VAD alone and 4.9 months with valspodar (P = 0.50).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,7,32967,DB00997,Doxorubicin
,16419071,progression-free survival,Median progression-free survival was 7 months with VAD alone and 4.9 months with valspodar (P = 0.50).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,4.9,32968,DB00997,Doxorubicin
,16419071,Subjective response,Subjective response was 19% with VAD alone and 17% with valspodar (P = 1.0).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),,19,32969,DB00997,Doxorubicin
,16419071,survival,Median survival with VAD alone was 18.5 months and 15.3 with the addition of valspodar (P = 0.055).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,18.,32970,DB00997,Doxorubicin
,16419071,Toxicity,Toxicity of Grade 3 or greater was higher (P < 0.0001) in the valspodar arm (89%) compared with the VAD-alone arm (58%).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),%,89,32971,DB00997,Doxorubicin
,16419071,Toxicity,Toxicity of Grade 3 or greater was higher (P < 0.0001) in the valspodar arm (89%) compared with the VAD-alone arm (58%).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),%,58,32972,DB00997,Doxorubicin
,2029805,peak plasma concentration,After an oral dose of N-acetylcysteine 200 to 400 mg the peak plasma concentration of 0.35 to 4 mg/L is achieved within 1 to 2 hours.,Clinical pharmacokinetics of N-acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[mg] / [l],0.35 to 4,33002,DB00997,Doxorubicin
,2029805,volume of distribution,"The volume of distribution ranges from 0.33 to 0.47 L/kg and protein binding is significant, reaching approximately 50% 4 hours after the dose.",Clinical pharmacokinetics of N-acetylcysteine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[l] / [kg],0.33 to 0.47,33003,DB00997,Doxorubicin
,2029805,Renal clearance,Renal clearance has been reported as 0.190 to 0.211 L/h/kg and approximately 70% of the total body clearance is nonrenal.,Clinical pharmacokinetics of N-acetylcysteine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),[l] / [h·kg],0.190 to 0.211,33004,DB00997,Doxorubicin
,2029805,terminal half-life,"Following oral administration, reduced N-acetylcysteine has a terminal half-life of 6.25h.",Clinical pharmacokinetics of N-acetylcysteine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029805/),h,6.25,33005,DB00997,Doxorubicin
,30851393,zeta potential,"Dynamic light scattering and transmission electron microscopy analysis confirmed the physicochemical characterizations of PSO-PLNs, which had an average size of 93.44 ± 2.39 nm and a zeta potential of -27.63 ± 0.31 mV.",Polymer-lipid hybrid nanoparticles: A novel drug delivery system for enhancing the activity of Psoralen against breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30851393/),mv,-27.63,34017,DB00997,Doxorubicin
,8015074,maximal concentrations,The maximal concentrations ranged from 0.5 to 4.5 ng./ml. (mean 1.4).,Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8015074/),[ng] / [ml],1.4,34159,DB00997,Doxorubicin
,8015074,recovery,"The recovery of doxorubicin at the end of treatment averaged 88.3%, with an additional recovery of 3.7% during the subsequent 4 hours.",Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8015074/),%,88.3,34160,DB00997,Doxorubicin
,11127946,AUC,The initial carboplatin dose was AUC 4.0 mg/ml per min.,A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127946/),[mg] / [min·ml],4.0,34248,DB00997,Doxorubicin
,11127946,AUC,We conclude that carboplatin dose intensification beyond an AUC of 4.0 mg/ml per min is not made feasible by the addition of G-CSF to infusional doxorubicin and ifosfamide in patients with advanced gynecologic cancer.,A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127946/),[mg] / [min·ml],4.0,34249,DB00997,Doxorubicin
,24381947,t₁/₂β,"The two polyethylene glycol (PEG) conjugates slowly released DOX, and t₁/₂β for total DOX from DOX-LNA, PEG-ami-DOX, and PEG-hyd-DOX was 5.79, 10.22, and 15.18 h, respectively.",Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24381947/),h,5.79,35100,DB00997,Doxorubicin
,24381947,t₁/₂β,"The two polyethylene glycol (PEG) conjugates slowly released DOX, and t₁/₂β for total DOX from DOX-LNA, PEG-ami-DOX, and PEG-hyd-DOX was 5.79, 10.22, and 15.18 h, respectively.",Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24381947/),h,10.22,35101,DB00997,Doxorubicin
,24381947,t₁/₂β,"The two polyethylene glycol (PEG) conjugates slowly released DOX, and t₁/₂β for total DOX from DOX-LNA, PEG-ami-DOX, and PEG-hyd-DOX was 5.79, 10.22, and 15.18 h, respectively.",Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24381947/),h,15.18,35102,DB00997,Doxorubicin
,24381947,C(max),"All three conjugates also deposited less DOX into normal organs than did an equivalent dose of free DOX, and the C(max) value of free DOX released by DOX-LNA, PEG-ami-DOX, and PEG-hyd-DOX was 32.5, 9.5, and 4.7 μg/g, respectively.",Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24381947/),[μg] / [g],32.5,35103,DB00997,Doxorubicin
,24381947,C(max),"All three conjugates also deposited less DOX into normal organs than did an equivalent dose of free DOX, and the C(max) value of free DOX released by DOX-LNA, PEG-ami-DOX, and PEG-hyd-DOX was 32.5, 9.5, and 4.7 μg/g, respectively.",Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24381947/),[μg] / [g],9.5,35104,DB00997,Doxorubicin
,24381947,C(max),"All three conjugates also deposited less DOX into normal organs than did an equivalent dose of free DOX, and the C(max) value of free DOX released by DOX-LNA, PEG-ami-DOX, and PEG-hyd-DOX was 32.5, 9.5, and 4.7 μg/g, respectively.",Deposition of doxorubicin in rats following administration of three newly synthesized doxorubicin conjugates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24381947/),[μg] / [g],4.7,35105,DB00997,Doxorubicin
more,25759584,Accumulative drug release,Accumulative drug release was more than 56% within 24 hours.,"Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759584/),%,56,35222,DB00997,Doxorubicin
,15565444,steady state plasma level,The starting daily dose of GF120918 was 50 mg and was to be increased in subsequent cohorts until a steady state plasma level of 100 ng/ml was reached.,A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15565444/),[ng] / [ml],100,36512,DB00997,Doxorubicin
>,26231452,extraction recoveries,"The extraction recoveries of morroniside, loganin and internal standard (IS) were all >67.62% and the matrix effects ranged from 95.07% to 102.75%.",Comparative pharmacokinetics of the main compounds of Shanzhuyu extract after oral administration in normal and chronic kidney disease rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26231452/),%,67.62,37431,DB00997,Doxorubicin
,3652044,terminal half-life,"4'-Deoxy-4'-I-DX disappears from plasma with a terminal half-life of 5 h, which is half the terminal half-life of doxorubicin (11 h), and its efficiency of absorption after oral administration is 27%.",Pharmacokinetics of 4'-deoxy-4'-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3652044/),h,5,37620,DB00997,Doxorubicin
,3652044,terminal half-life,"4'-Deoxy-4'-I-DX disappears from plasma with a terminal half-life of 5 h, which is half the terminal half-life of doxorubicin (11 h), and its efficiency of absorption after oral administration is 27%.",Pharmacokinetics of 4'-deoxy-4'-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3652044/),h,11,37621,DB00997,Doxorubicin
,3652044,efficiency of absorption,"4'-Deoxy-4'-I-DX disappears from plasma with a terminal half-life of 5 h, which is half the terminal half-life of doxorubicin (11 h), and its efficiency of absorption after oral administration is 27%.",Pharmacokinetics of 4'-deoxy-4'-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3652044/),%,27,37622,DB00997,Doxorubicin
,18269776,time to progression,"Median time to progression was 5.3 months (95% CI, 3.1-8.9 months), and median time to treatment failure was 3.5 months (95% CI, 2.6-5.9 months).",Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18269776/),month,5.3,37883,DB00997,Doxorubicin
,18269776,time to treatment failure,"Median time to progression was 5.3 months (95% CI, 3.1-8.9 months), and median time to treatment failure was 3.5 months (95% CI, 2.6-5.9 months).",Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18269776/),month,3.5,37884,DB00997,Doxorubicin
,9533107,AUC0-8 h,The AUC0-8 h of M1 (47.1 versus 7.85 micrograms min mL-1) and M2 (20.7 versus 44.3 micrograms min mL-1) decreased significantly in the PBT group compared to those in the PBC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],47.1,38103,DB00997,Doxorubicin
,9533107,AUC0-8 h,The AUC0-8 h of M1 (47.1 versus 7.85 micrograms min mL-1) and M2 (20.7 versus 44.3 micrograms min mL-1) decreased significantly in the PBT group compared to those in the PBC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],7.85,38104,DB00997,Doxorubicin
,9533107,AUC0-8 h,The AUC0-8 h of M1 (47.1 versus 7.85 micrograms min mL-1) and M2 (20.7 versus 44.3 micrograms min mL-1) decreased significantly in the PBT group compared to those in the PBC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],20.7,38105,DB00997,Doxorubicin
,9533107,AUC0-8 h,The AUC0-8 h of M1 (47.1 versus 7.85 micrograms min mL-1) and M2 (20.7 versus 44.3 micrograms min mL-1) decreased significantly in the PBT group compared to those in the PBC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],44.3,38106,DB00997,Doxorubicin
,9533107,M1,"However, the corresponding value of only M1 (74.6 versus 89.9 micrograms min mL-1) decreased significantly in the MCT group.","Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],74.6,38107,DB00997,Doxorubicin
,9533107,M1,"However, the corresponding value of only M1 (74.6 versus 89.9 micrograms min mL-1) decreased significantly in the MCT group.","Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],89.9,38108,DB00997,Doxorubicin
,9533107,AUC0-8 h,The AUC0-8 h of both M1 (126 versus 78.5 micrograms min mL-1) and M2 (69.2 versus 44.3 micrograms min mL-1) increased significantly in the SKT group compared to the SKC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],126,38109,DB00997,Doxorubicin
,9533107,AUC0-8 h,The AUC0-8 h of both M1 (126 versus 78.5 micrograms min mL-1) and M2 (69.2 versus 44.3 micrograms min mL-1) increased significantly in the SKT group compared to the SKC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],78.5,38110,DB00997,Doxorubicin
,9533107,AUC0-8 h,The AUC0-8 h of both M1 (126 versus 78.5 micrograms min mL-1) and M2 (69.2 versus 44.3 micrograms min mL-1) increased significantly in the SKT group compared to the SKC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],69.2,38111,DB00997,Doxorubicin
,9533107,AUC0-8 h,The AUC0-8 h of both M1 (126 versus 78.5 micrograms min mL-1) and M2 (69.2 versus 44.3 micrograms min mL-1) increased significantly in the SKT group compared to the SKC group.,"Pharmacokinetic changes of M1, M2, M3 and M4 after intravenous administration of a new anthracycline, DA-125, to rats pretreated with phenobarbital, 3-methylcholanthrene, chloramphenicol, or SKF-525A. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533107/),[min·μg] / [ml],44.3,38112,DB00997,Doxorubicin
,6228294,dwell time,"Cisplatin (120-270 mg in 2 L of Ringer's lactate) was administered via Tenckhoff catheter, with a dwell time of 15-20 mins.",Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228294/),min,15-20,38879,DB00997,Doxorubicin
,6228294,dwell time,"With a dwell time of 20 mins, 75% +/- 5% (mean +/- SD) of platinum was recovered.",Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228294/),min,20,38880,DB00997,Doxorubicin
,6228294,dwell time,"With 120 mg of cisplatin and a dwell time of 20 mins, total plasma platinum peaked at 1.23 +/- 0.42 microgram/ml and by 8 hrs decreased to 0.67 +/- 0.12 microgram/ml.",Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228294/),min,20,38881,DB00997,Doxorubicin
,6228294,total plasma platinum,"With 120 mg of cisplatin and a dwell time of 20 mins, total plasma platinum peaked at 1.23 +/- 0.42 microgram/ml and by 8 hrs decreased to 0.67 +/- 0.12 microgram/ml.",Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228294/),[μg] / [ml],1.23,38882,DB00997,Doxorubicin
,6228294,total plasma platinum,"With 120 mg of cisplatin and a dwell time of 20 mins, total plasma platinum peaked at 1.23 +/- 0.42 microgram/ml and by 8 hrs decreased to 0.67 +/- 0.12 microgram/ml.",Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228294/),[μg] / [ml],0.67,38883,DB00997,Doxorubicin
,6228294,Excretion rate,"Excretion rate paralleled the filterable plasma curve, peaking at 40 mins; 30% +/- 7% of absorbed drug was recovered in urine within 24 hrs.",Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228294/),min,40,38884,DB00997,Doxorubicin
,6228294,Excretion rate,"Excretion rate paralleled the filterable plasma curve, peaking at 40 mins; 30% +/- 7% of absorbed drug was recovered in urine within 24 hrs.",Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228294/),%,30,38885,DB00997,Doxorubicin
,6228294,Renal clearance,Renal clearance of filterable platinum was 106 +/- 20 ml/min.,Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228294/),[ml] / [min],106,38886,DB00997,Doxorubicin
,2265458,ratio of the AUCs,The ratio of the AUCs for doxorubicinol: doxorubicin averaged 0.514.,Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265458/),,0.514,39311,DB00997,Doxorubicin
,7710452,gamma-HL,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),h,18.18,39426,DB00997,Doxorubicin
,7710452,gamma-HL,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),h,8.47,39427,DB00997,Doxorubicin
,7710452,total clearance,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ml] / [min],72.33,39428,DB00997,Doxorubicin
,7710452,total clearance,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ml] / [min],48.41,39429,DB00997,Doxorubicin
,7710452,area under the concentration-time curve (AUC,"The area under the concentration-time curve (AUC, according to the 3-compartment model) increases under the influence of IFN from 2004 +/- 1105 ng/ml.h for EPR up to 2582 +/- 1024 ng/ml.h for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ng] / [h·ml],2004,39430,DB00997,Doxorubicin
,7710452,area under the concentration-time curve (AUC,"The area under the concentration-time curve (AUC, according to the 3-compartment model) increases under the influence of IFN from 2004 +/- 1105 ng/ml.h for EPR up to 2582 +/- 1024 ng/ml.h for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ng] / [h·ml],2582,39431,DB00997,Doxorubicin
>,11165404,AUC,"In patients with etoposide AUC>254.8 mg h/l, 1-year survival was 50.0 vs.",The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165404/),[h·mg] / [l],254.8,39599,DB00997,Doxorubicin
,11165404,survival,"In patients with extensive disease only (n=15), 1-year survival was 42.9 vs. 0% (median 11.3 vs. 5.3 months, P=0.01).",The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165404/),%,42,39600,DB00997,Doxorubicin
,11165404,survival,"In patients with extensive disease only (n=15), 1-year survival was 42.9 vs. 0% (median 11.3 vs. 5.3 months, P=0.01).",The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165404/),%,0,39601,DB00997,Doxorubicin
,11165404,survival,"In patients with extensive disease only (n=15), 1-year survival was 42.9 vs. 0% (median 11.3 vs. 5.3 months, P=0.01).",The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165404/),month,11,39602,DB00997,Doxorubicin
,11165404,survival,"In patients with extensive disease only (n=15), 1-year survival was 42.9 vs. 0% (median 11.3 vs. 5.3 months, P=0.01).",The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165404/),month,5.3,39603,DB00997,Doxorubicin
,25189481,Objective response rates,"Objective response rates in thymoma and thymic carcinoma were 64% (95% confidence interval, 30.8%-89.1%) and 21% (4.7%-50.8%), respectively.","A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25189481/),%,64,40050,DB00997,Doxorubicin
,25189481,Objective response rates,"Objective response rates in thymoma and thymic carcinoma were 64% (95% confidence interval, 30.8%-89.1%) and 21% (4.7%-50.8%), respectively.","A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25189481/),%,21,40051,DB00997,Doxorubicin
below,17490879,IC(50),Bis-substitution at both the 6- and 7-positions led to inhibitors with IC(50) values below 0.3nM.,"1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17490879/),nM,0.3,40115,DB00997,Doxorubicin
,11688520,overall response rate,"The overall response rate to GET was 92% (95% CI, 77.53%-98.25%); CR 31% and PR 61%.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),%,92,40254,DB00997,Doxorubicin
,11688520,overall response rate,"After six courses of GET, 25 patients received HDCT, leading to an overall response rate of 96% with 58% CR.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),%,96,40255,DB00997,Doxorubicin
,11688520,progression free survival,"Median progression free survival is 21 months, while median overall survival has not yet been reached.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),month,21,40256,DB00997,Doxorubicin
,3463434,Biliary clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],32.5,40362,DB00997,Doxorubicin
,3463434,Biliary clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],8.1,40363,DB00997,Doxorubicin
,3463434,Biliary clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],21.6,40364,DB00997,Doxorubicin
,3463434,renal clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],15.2,40365,DB00997,Doxorubicin
,3463434,renal clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],3.3,40366,DB00997,Doxorubicin
,3463434,renal clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],9.41,40367,DB00997,Doxorubicin
,15942626,total doxorubicin clearance,The mean (range) total doxorubicin clearance decreased from 27 (10-73) ml h(-1) m(-2) in cycle 1 to 18 (3-37) ml h(-1) m(-2) with the addition of valspodar in cycle 2 (P=0.009).,"Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15942626/),[ml] / [(m)^2·h],27,40557,DB00997,Doxorubicin
,15942626,total doxorubicin clearance,The mean (range) total doxorubicin clearance decreased from 27 (10-73) ml h(-1) m(-2) in cycle 1 to 18 (3-37) ml h(-1) m(-2) with the addition of valspodar in cycle 2 (P=0.009).,"Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15942626/),[ml] / [(m)^2·h],18,40558,DB00997,Doxorubicin
,30171978,en,The prepared system was loaded with PNIPAM-DOX conjugate with encapsulation efficiency of 30.80%.,Encapsulation of Thermo-responsive Gel in pH-sensitive Polymersomes as Dual-Responsive Smart carriers for Controlled Release of Doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30171978/),,30,41199,DB00997,Doxorubicin
,17627902,peak plasma doxorubicin concentration,"The pharmacokinetic study showed a low peak plasma doxorubicin concentration (49.4 +/- 23.7 ng/mL), and no systemic toxicity was observed.",A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17627902/),[ng] / [ml],49.4,41330,DB00997,Doxorubicin
,17627902,treatment-related complication rate,The treatment-related complication rate was 11.4%.,A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17627902/),%,11.4,41331,DB00997,Doxorubicin
,17627902,partial response rate,"Among 30 patients who completed 2 courses of TACE, the partial response rate and the complete response rates were 50% and 0%, respectively, by response evaluation criteria in solid tumors (RECIST) criteria at computerized tomography scan 1 month after the second TACE.",A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17627902/),%,50,41332,DB00997,Doxorubicin
,17627902,complete response rates,"Among 30 patients who completed 2 courses of TACE, the partial response rate and the complete response rates were 50% and 0%, respectively, by response evaluation criteria in solid tumors (RECIST) criteria at computerized tomography scan 1 month after the second TACE.",A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17627902/),%,0,41333,DB00997,Doxorubicin
,25646154,AUC0- ∞,"Mean (SD) AUC0- ∞ for DOX and doxorubicinol with enalapril exposure was 1185.56 (44.64) hr*ng/ml and 1040 (80.6) hr*ng/ml, respectively.",Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25646154/),[h·ng] / [ml],1185.56,41595,DB00997,Doxorubicin
,25646154,AUC0- ∞,"Mean (SD) AUC0- ∞ for DOX and doxorubicinol with enalapril exposure was 1185.56 (44.64) hr*ng/ml and 1040 (80.6) hr*ng/ml, respectively.",Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25646154/),[h·ng] / [ml],1040,41596,DB00997,Doxorubicin
,25646154,AUC0- ∞,"AUC0- ∞ for DOX and doxobubicinol without enalapril was 1167.73 (45.26) hr*ng/ml and 1056.32 (92.03) hr*ng/ml, respectively.",Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25646154/),[h·ng] / [ml],1167.73,41597,DB00997,Doxorubicin
,25646154,AUC0- ∞,"AUC0- ∞ for DOX and doxobubicinol without enalapril was 1167.73 (45.26) hr*ng/ml and 1056.32 (92.03) hr*ng/ml, respectively.",Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25646154/),[h·ng] / [ml],1056.32,41598,DB00997,Doxorubicin
,34080039,area under the concentration-time curve [AUC] ratio,"Extrapolation of the vincristine mechanistic PBPK model to other P-gp substrates further suggested DDI risk when ibrutinib (area under the concentration-time curve [AUC] ratio: 1.8), but not acalabrutinib (AUC ratio: 0.92), was given orally with venetoclax or digoxin.",Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080039/),,1.8,41785,DB00997,Doxorubicin
,34080039,AUC ratio,"Extrapolation of the vincristine mechanistic PBPK model to other P-gp substrates further suggested DDI risk when ibrutinib (area under the concentration-time curve [AUC] ratio: 1.8), but not acalabrutinib (AUC ratio: 0.92), was given orally with venetoclax or digoxin.",Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080039/),,0.92,41786,DB00997,Doxorubicin
,9895415,half-lives,"Gradient high performance liquid chromatography (HPLC) evaluation of plasma and urine has been combined with 123I-based imaging to show biphasic clearance of the drug from the plasma (half-lives of 78+/-1 and 990+/-15), and approximately 30% delivery of the drug to the hepatic region, as determined by planar whole body imaging at 24 h.",Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9895415/),,78,42405,DB00997,Doxorubicin
,9895415,half-lives,"Gradient high performance liquid chromatography (HPLC) evaluation of plasma and urine has been combined with 123I-based imaging to show biphasic clearance of the drug from the plasma (half-lives of 78+/-1 and 990+/-15), and approximately 30% delivery of the drug to the hepatic region, as determined by planar whole body imaging at 24 h.",Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9895415/),,990,42406,DB00997,Doxorubicin
,9895415,ratio of tumour tissue to normal liver uptake,"This patient has a multifocal hepatoma, and single photon emission computed tomography (SPECT) analysis showed a ratio of tumour tissue to normal liver uptake of approximately 1:3, at 24 h.",Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9895415/),,1:3,42407,DB00997,Doxorubicin
,9918206,maximum tolerated dose,"The maximum tolerated dose was 320 mg/m2, and the dose-limiting toxicities were febrile neutropenia and mucositis.",Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918206/),mg,320,43635,DB00997,Doxorubicin
,9918206,distribution t(1/2),"Pharmacokinetically, PK1 has a distribution t(1/2) of 1.8 h and an elimination t(1/2) averaging 93 h.",Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918206/),h,1.8,43636,DB00997,Doxorubicin
,9918206,elimination t(1/2),"Pharmacokinetically, PK1 has a distribution t(1/2) of 1.8 h and an elimination t(1/2) averaging 93 h.",Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918206/),h,93,43637,DB00997,Doxorubicin
,11583191,MTD,At the second step (75 mg/m2 of epirubicin) the MTD of docetaxel was 80 mg/m2.,Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583191/),[mg] / [m2],80,43811,DB00997,Doxorubicin
,11583191,Overall response rate,"Overall response rate was 73% in 42 out of 58 patients, with no apparent epirubicin dose-related effect.",Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583191/),%,73,43812,DB00997,Doxorubicin
,7379023,uptake,"Normal liver showed the highest levels of adriamycin uptake (2.3--19.8 micrograms/g); lymph nodes were second; muscle and bone marrow, next; fat and skin had the lowest adriamycin uptake (0.04--0.40 microgram/g).","Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379023/),[μg] / [g],2.3,45432,DB00997,Doxorubicin
,7379023,uptake,"Normal liver showed the highest levels of adriamycin uptake (2.3--19.8 micrograms/g); lymph nodes were second; muscle and bone marrow, next; fat and skin had the lowest adriamycin uptake (0.04--0.40 microgram/g).","Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379023/),[μg] / [g],0.04,45433,DB00997,Doxorubicin
,12759776,area under the curve ratio,Mitomycin C area under the curve ratio in total peritonectomy patients was 20.5 and 25.7 in patients with less-extensive peritonectomy.,Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12759776/),,20.5,45981,DB00997,Doxorubicin
,12759776,area under the curve ratio,Mitomycin C area under the curve ratio in total peritonectomy patients was 20.5 and 25.7 in patients with less-extensive peritonectomy.,Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12759776/),,25.7,45982,DB00997,Doxorubicin
,8462124,Peak plasma concentrations,Peak plasma concentrations of doxorubicin (1739 +/- 265 vs 100 +/- 10 ng.ml-1) and doxorubicinol (78 +/- 3 vs 16 +/- 3 ng.ml-1) were significantly higher following bolus than infusion dosing.,Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462124/),[ng] / [ml],1739,46233,DB00997,Doxorubicin
,8462124,Peak plasma concentrations,Peak plasma concentrations of doxorubicin (1739 +/- 265 vs 100 +/- 10 ng.ml-1) and doxorubicinol (78 +/- 3 vs 16 +/- 3 ng.ml-1) were significantly higher following bolus than infusion dosing.,Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462124/),[ng] / [ml],100,46234,DB00997,Doxorubicin
,8462124,Peak plasma concentrations,Peak plasma concentrations of doxorubicin (1739 +/- 265 vs 100 +/- 10 ng.ml-1) and doxorubicinol (78 +/- 3 vs 16 +/- 3 ng.ml-1) were significantly higher following bolus than infusion dosing.,Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462124/),[ng] / [ml],78,46235,DB00997,Doxorubicin
,8462124,Peak plasma concentrations,Peak plasma concentrations of doxorubicin (1739 +/- 265 vs 100 +/- 10 ng.ml-1) and doxorubicinol (78 +/- 3 vs 16 +/- 3 ng.ml-1) were significantly higher following bolus than infusion dosing.,Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462124/),[ng] / [ml],16,46236,DB00997,Doxorubicin
,8462124,Peak left ventricular tissue concentrations,Peak left ventricular tissue concentrations of doxorubicin (16.92 +/- 0.9 vs 3.59 +/- 0.72 micrograms.g-1 tissue; P < 0.001) and doxorubicinol (0.24 +/- 0.02 vs 0.09 +/- 0.01 micrograms.g-1 tissue; P < 0.01) following bolus injection of doxorubicin were significantly higher than those following infusion administration.,Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462124/),[tissue·μg] / [g],16.92,46237,DB00997,Doxorubicin
,8462124,Peak left ventricular tissue concentrations,Peak left ventricular tissue concentrations of doxorubicin (16.92 +/- 0.9 vs 3.59 +/- 0.72 micrograms.g-1 tissue; P < 0.001) and doxorubicinol (0.24 +/- 0.02 vs 0.09 +/- 0.01 micrograms.g-1 tissue; P < 0.01) following bolus injection of doxorubicin were significantly higher than those following infusion administration.,Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462124/),[tissue·μg] / [g],3.59,46238,DB00997,Doxorubicin
,8462124,Peak left ventricular tissue concentrations,Peak left ventricular tissue concentrations of doxorubicin (16.92 +/- 0.9 vs 3.59 +/- 0.72 micrograms.g-1 tissue; P < 0.001) and doxorubicinol (0.24 +/- 0.02 vs 0.09 +/- 0.01 micrograms.g-1 tissue; P < 0.01) following bolus injection of doxorubicin were significantly higher than those following infusion administration.,Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462124/),[tissue·μg] / [g],0.24,46239,DB00997,Doxorubicin
,8462124,Peak left ventricular tissue concentrations,Peak left ventricular tissue concentrations of doxorubicin (16.92 +/- 0.9 vs 3.59 +/- 0.72 micrograms.g-1 tissue; P < 0.001) and doxorubicinol (0.24 +/- 0.02 vs 0.09 +/- 0.01 micrograms.g-1 tissue; P < 0.01) following bolus injection of doxorubicin were significantly higher than those following infusion administration.,Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462124/),[tissue·μg] / [g],0.09,46240,DB00997,Doxorubicin
,10561171,AUC,"The EOL AUC after paclitaxel treatment (1,521 +/- 150 ng/mL*h) was significantly higher (P <.01) than the corresponding values after epirubicin administered either as a single agent (692 +/- 46 ng/mL*h) or in combination with docetaxel (848 +/- 237 ng/mL*h).",Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561171/),[ng] / [h·ml],"1,521",46568,DB00997,Doxorubicin
,10561171,AUC,"The EOL AUC after paclitaxel treatment (1,521 +/- 150 ng/mL*h) was significantly higher (P <.01) than the corresponding values after epirubicin administered either as a single agent (692 +/- 46 ng/mL*h) or in combination with docetaxel (848 +/- 237 ng/mL*h).",Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561171/),[ng] / [h·ml],692,46569,DB00997,Doxorubicin
,10561171,AUC,"The EOL AUC after paclitaxel treatment (1,521 +/- 150 ng/mL*h) was significantly higher (P <.01) than the corresponding values after epirubicin administered either as a single agent (692 +/- 46 ng/mL*h) or in combination with docetaxel (848 +/- 237 ng/mL*h).",Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561171/),[ng] / [h·ml],848,46570,DB00997,Doxorubicin
,11839653,maximum tolerated dose,"Myelosuppression was the dose-limiting toxicity with 75 and then 67.5 mg/m(2) doxorubicin, and the maximum tolerated dose was established at 60 mg/m(2) with VX-710, 120 mg/m(2)/h, 72-h CIV.",Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839653/),mg,60,46654,DB00997,Doxorubicin
,11839653,progression-free interval,"Among 26 evaluable patients, minimal activity was noted among 11 patients with gastrointestinal stromal tumors (GISTs); however, in 15 patients with anthracycline-resistant sarcomas of other histologies, 2 achieved partial responses and 7 patients had disease stabilization with an overall median progression-free interval of 3.4 months.",Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839653/),month,3.4,46655,DB00997,Doxorubicin
,7554038,clearance,"The 6 men had a significantly higher doxorubicin clearance than did the 21 women (median values, 59 and 27 lh-1 m-2, respectively; P = 0.002).",Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554038/),1/[(m)^2·lh],59,46886,DB00997,Doxorubicin
,7554038,clearance,"The 6 men had a significantly higher doxorubicin clearance than did the 21 women (median values, 59 and 27 lh-1 m-2, respectively; P = 0.002).",Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554038/),1/[(m)^2·lh],27,46887,DB00997,Doxorubicin
,7554038,clearance,"Doxorubicin clearance was significantly lower in patients with breast cancer than in those with other tumours (median values, 26 and 53 lh-1 m-2, respectively; P = 0.0008).",Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554038/),1/[(m)^2·lh],26,46888,DB00997,Doxorubicin
,7554038,clearance,"Doxorubicin clearance was significantly lower in patients with breast cancer than in those with other tumours (median values, 26 and 53 lh-1 m-2, respectively; P = 0.0008).",Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554038/),1/[(m)^2·lh],53,46889,DB00997,Doxorubicin
,4086243,peak plasma concentration,The peak plasma concentration of esorubicin was 0.74 +/- 0.57 microM (mean +/- SE).,Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086243/),μM,0.74,46909,DB00997,Doxorubicin
,4086243,terminal half-life,Esorubicin disappeared from plasma according to a tri-exponential pattern with a terminal half-life of 20.4 +/- 7.3 hr.,Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086243/),h,20.4,46910,DB00997,Doxorubicin
,4086243,area under the plasma concentration versus time curve,The area under the plasma concentration versus time curve was 0.64 +/- 0.31 microM x hr.,Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086243/),h·μM,0.64,46911,DB00997,Doxorubicin
,4086243,Total body plasma clearance,"Total body plasma clearance was 45.5 +/- 26.8 liter/min/m2 and the apparent volume of the central compartment, 41.0 +/- 24.8 L.",Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086243/),[l] / [m2·min],45.5,46912,DB00997,Doxorubicin
,4086243,apparent volume of the central compartment,"Total body plasma clearance was 45.5 +/- 26.8 liter/min/m2 and the apparent volume of the central compartment, 41.0 +/- 24.8 L.",Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086243/),l,41.0,46913,DB00997,Doxorubicin
,4086243,peak concentration,This metabolite was observed in 5 patients only and its mean peak concentration was 0.029 +/- 0.017 microM.,Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086243/),μM,0.029,46914,DB00997,Doxorubicin
,4086243,area under the plasma versus concentration time curve,The area under the plasma versus concentration time curve for 4'-deoxydoxorubicinol was 0.02 +/- 0.014 microM xhr.,Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086243/),h·μM,0.02,46915,DB00997,Doxorubicin
,4086243,urinary excretion,The urinary excretion of total fluorescence within 5 days of therapy was 7.3 +/- 1.3% of the administered dose.,Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086243/),%,7.3,46916,DB00997,Doxorubicin
,11979457,dose normalized plasma concentration,"There was a more than 10-fold difference between patients in dose normalized plasma concentration of doxorubicin, median 62.8 ng/ml, range 22.6-334 ng/ml.",Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11979457/),[ng] / [ml],62.8,47397,DB00997,Doxorubicin
,11979457,concentrations,"Children aged 4-6 years had the highest doxorubicin concentrations, median 77.9 ng/ml, followed by 2-4-year-old children, median 64.3 ng/ml.",Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11979457/),ng,77,47398,DB00997,Doxorubicin
,11979457,plasma clearance,"Four infants, 7-9 months old, had plasma clearance between 350-431 ml/min/m(2), which is in the same range as in older children.",Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11979457/),[min·ml] / [m(2],350-431,47399,DB00997,Doxorubicin
,11979457,clearance,A 3-month-old infant had a clearance of 181 ml/min/m(2).,Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11979457/),[min·ml] / [m(2],181,47400,DB00997,Doxorubicin
,21351514,extract recovery,"The average extract recovery was 89.3% and 92.1%, respectively.",[Pharmacokinetics of epirubicin hydrochloride long-circulating thermosensitive liposomes in rat plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351514/),%,89.3,48249,DB00997,Doxorubicin
,21351514,extract recovery,"The average extract recovery was 89.3% and 92.1%, respectively.",[Pharmacokinetics of epirubicin hydrochloride long-circulating thermosensitive liposomes in rat plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351514/),%,92.1,48250,DB00997,Doxorubicin
,10073147,duration of response,"The median duration of response was 5.8 months (range, 1-23+) and median survival was 25.3 months (range, 6.2-54.7+).",A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073147/),month,5.8,48689,DB00997,Doxorubicin
,10073147,survival,"The median duration of response was 5.8 months (range, 1-23+) and median survival was 25.3 months (range, 6.2-54.7+).",A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073147/),month,25.3,48690,DB00997,Doxorubicin
,2909292,LD10,"Lethality studies in female Balb-c mice resulted in an LD10 value of 20 mg/kg (95% confidence limits; range, 19-21 mg/kg) and an LD50 value of 22 mg/kg (95% confidence limits; range, 21-23 mg/kg).",The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2909292/),[mg] / [kg],20,48909,DB00997,Doxorubicin
,2909292,LD50,"Lethality studies in female Balb-c mice resulted in an LD10 value of 20 mg/kg (95% confidence limits; range, 19-21 mg/kg) and an LD50 value of 22 mg/kg (95% confidence limits; range, 21-23 mg/kg).",The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2909292/),[mg] / [kg],22,48910,DB00997,Doxorubicin
,2909292,cleared,"The drug was rapidly cleared from the plasma (250-400 ml/min per kg) at a rate approaching the cardiac output of mice, displaying triphasic plasma pharmacokinetics.",The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2909292/),[ml] / [kg·min],250-400,48911,DB00997,Doxorubicin
,2909292,AUC,"The area under the plasma CI-941 concentration vs time curve (AUC) was linear with respect to the dose, up to and including 15 mg/kg (AUC = 110 microM x min at 15 mg/kg), but became non-linear at 20 mg/kg (AUC = 277 microM x min).",The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2909292/),min·μM,110,48912,DB00997,Doxorubicin
,2909292,AUC,"The area under the plasma CI-941 concentration vs time curve (AUC) was linear with respect to the dose, up to and including 15 mg/kg (AUC = 110 microM x min at 15 mg/kg), but became non-linear at 20 mg/kg (AUC = 277 microM x min).",The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2909292/),min·μM,277,48913,DB00997,Doxorubicin
,2909292,AUC,"In addition, a pharmacokinetically guided dose-escalation strategy, based on achieving a target AUC of 110 microM x min, is proposed.",The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2909292/),min·μM,110,48914,DB00997,Doxorubicin
,7494796,clearance,"The clearance of doxorubicin released from the niosomes was about 10 fold greater than the clearance of niosomal doxorubicin (176.5 mL h-1 and 16.2 mL h-1, respectively).","Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494796/),[ml] / [h],176.5,49054,DB00997,Doxorubicin
,7494796,clearance,"The clearance of doxorubicin released from the niosomes was about 10 fold greater than the clearance of niosomal doxorubicin (176.5 mL h-1 and 16.2 mL h-1, respectively).","Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494796/),[ml] / [h],16.2,49055,DB00997,Doxorubicin
,7494796,area under the plasma level-time curve,"The area under the plasma level-time curve increased 6 fold when doxorubicin was administered in niosomes, compared to doxorubicin solution (66.0 micrograms.h mL-1 and 10.3 micrograms. h mL-1, respectively).","Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494796/),[h·μg] / [ml],66.0,49056,DB00997,Doxorubicin
,7494796,area under the plasma level-time curve,"The area under the plasma level-time curve increased 6 fold when doxorubicin was administered in niosomes, compared to doxorubicin solution (66.0 micrograms.h mL-1 and 10.3 micrograms. h mL-1, respectively).","Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494796/),[h·μg] / [ml],10.3,49057,DB00997,Doxorubicin
,7494796,area under the tumour level time curve,"The area under the tumour level time curve was increased by over 50% by the administration of doxorubicin in niosomes when compared to the drug administered in solution (58.6 micrograms.h mL-1 and 34.3 micrograms.h mL-1, respectively).","Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494796/),[h·μg] / [ml],58.6,49058,DB00997,Doxorubicin
,7494796,area under the tumour level time curve,"The area under the tumour level time curve was increased by over 50% by the administration of doxorubicin in niosomes when compared to the drug administered in solution (58.6 micrograms.h mL-1 and 34.3 micrograms.h mL-1, respectively).","Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494796/),[h·μg] / [ml],34.3,49059,DB00997,Doxorubicin
,7494796,tumour to heart AUC0-24 ratio,"Modest tumour targeting was achieved by the delivery of doxorubicin in sorbitan monostearate niosomes, increasing the tumour to heart AUC0-24 ratio from 0.27 to 0.36 and a doubling of tumoricidal activity.","Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494796/),,0.27,49060,DB00997,Doxorubicin
,7494796,tumour to heart AUC0-24 ratio,"Modest tumour targeting was achieved by the delivery of doxorubicin in sorbitan monostearate niosomes, increasing the tumour to heart AUC0-24 ratio from 0.27 to 0.36 and a doubling of tumoricidal activity.","Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494796/),,0.36,49061,DB00997,Doxorubicin
,8765434,AUC ratio,M3 (aglycone-type metabolite) showed a very high AUC ratio in the liver (34%).,"Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765434/),%,34,49407,DB00997,Doxorubicin
,11408511,half-life,VX-710 exhibited linear pharmacokinetics with a harmonic mean half-life of 1.1 hours.,Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408511/),h,1.1,49653,DB00997,Doxorubicin
,10501914,maximum tolerated dose (MTD),"Neutropenia was the main hematologic toxic effect and the maximum tolerated dose (MTD) for myelotoxicity was 940 microg/m(2), with neutropenia grade 3-4 in two of three patients.",Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501914/),[μg] / [m(2],940,49751,DB00997,Doxorubicin
,10501914,MTD,"Dose-dependent nausea and vomiting were dose-limiting and the MTD for gastrointestinal toxicity was fixed at 820 microg/m(2), with grade 4 vomiting in one of two patients.",Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10501914/),[μg] / [m(2],820,49752,DB00997,Doxorubicin
,9626462,trough,"The median trough dexverapamil plus norverapamil level on day 3 was 1110 ng/ml (range, 186-3385 ng/ml), and the median peak level was 2164 ng/ml (range, 964-8382 ng/ml).",Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626462/),[ng] / [ml],1110,50015,DB00997,Doxorubicin
,9626462,peak level,"The median trough dexverapamil plus norverapamil level on day 3 was 1110 ng/ml (range, 186-3385 ng/ml), and the median peak level was 2164 ng/ml (range, 964-8382 ng/ml).",Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626462/),[ng] / [ml],2164,50016,DB00997,Doxorubicin
,10630779,elimination half-life,"Mean elimination half-life was 54 minutes, half-life of distribution was 3.5 minutes, and volume of distribution was 2,038 ml/kg.",Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630779/),min,54,50507,DB00997,Doxorubicin
,10630779,half-life of distribution,"Mean elimination half-life was 54 minutes, half-life of distribution was 3.5 minutes, and volume of distribution was 2,038 ml/kg.",Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630779/),min,3.5,50508,DB00997,Doxorubicin
,10630779,volume of distribution,"Mean elimination half-life was 54 minutes, half-life of distribution was 3.5 minutes, and volume of distribution was 2,038 ml/kg.",Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630779/),[ml] / [kg],"2,038",50509,DB00997,Doxorubicin
,26812610,hydrodynamic particle size,"Average hydrodynamic particle size of EPI-PNPs and EPI-MNPs was found 248.63 ± 12.36 and 254.23 ± 15.16 nm, respectively.",Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26812610/),nm,248.63,50518,DB00997,Doxorubicin
,26812610,hydrodynamic particle size,"Average hydrodynamic particle size of EPI-PNPs and EPI-MNPs was found 248.63 ± 12.36 and 254.23 ± 15.16 nm, respectively.",Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26812610/),nm,254.23,50519,DB00997,Doxorubicin
,19016765,CL/BSA,"Patients in the CBR1 D1 diplotype group had significantly higher clearance (CL) normalized to body surface area (BSA) (CL/BSA[L/h/m(2)]: median 25.09; range 16.44-55.66) and significantly lower exposure levels; area under curve (AUC(0-infinity)/dose/BSA [h/m(5)]; median 15.08; range 6.18-38.03) of doxorubicin compared with patients belonging to the CBR1 D2 diplotype group (CL/BSA[L/h/m(2)]; median 20.88; range 8.68-31.79, P = 0.014; and AUC(0-infinity)/dose/BSA[h/m(5)]; median 21.35; range 9.82-67.17, P = 0.007 respectively).",CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19016765/),[h·l] / [m(2],25.09,51047,DB00997,Doxorubicin
,19016765,area under curve (AUC(0-infinity),"Patients in the CBR1 D1 diplotype group had significantly higher clearance (CL) normalized to body surface area (BSA) (CL/BSA[L/h/m(2)]: median 25.09; range 16.44-55.66) and significantly lower exposure levels; area under curve (AUC(0-infinity)/dose/BSA [h/m(5)]; median 15.08; range 6.18-38.03) of doxorubicin compared with patients belonging to the CBR1 D2 diplotype group (CL/BSA[L/h/m(2)]; median 20.88; range 8.68-31.79, P = 0.014; and AUC(0-infinity)/dose/BSA[h/m(5)]; median 21.35; range 9.82-67.17, P = 0.007 respectively).",CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19016765/),[h] / [m(5],15.08,51048,DB00997,Doxorubicin
,19016765,CL/BSA,"Patients in the CBR1 D1 diplotype group had significantly higher clearance (CL) normalized to body surface area (BSA) (CL/BSA[L/h/m(2)]: median 25.09; range 16.44-55.66) and significantly lower exposure levels; area under curve (AUC(0-infinity)/dose/BSA [h/m(5)]; median 15.08; range 6.18-38.03) of doxorubicin compared with patients belonging to the CBR1 D2 diplotype group (CL/BSA[L/h/m(2)]; median 20.88; range 8.68-31.79, P = 0.014; and AUC(0-infinity)/dose/BSA[h/m(5)]; median 21.35; range 9.82-67.17, P = 0.007 respectively).",CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19016765/),[h·l] / [m(2],20.88,51049,DB00997,Doxorubicin
,19016765,AUC(0-infinity),"Patients in the CBR1 D1 diplotype group had significantly higher clearance (CL) normalized to body surface area (BSA) (CL/BSA[L/h/m(2)]: median 25.09; range 16.44-55.66) and significantly lower exposure levels; area under curve (AUC(0-infinity)/dose/BSA [h/m(5)]; median 15.08; range 6.18-38.03) of doxorubicin compared with patients belonging to the CBR1 D2 diplotype group (CL/BSA[L/h/m(2)]; median 20.88; range 8.68-31.79, P = 0.014; and AUC(0-infinity)/dose/BSA[h/m(5)]; median 21.35; range 9.82-67.17, P = 0.007 respectively).",CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19016765/),[h] / [m(5],21.35,51050,DB00997,Doxorubicin
,942583,initial,"Pharmacokinetic data, collected in 25 patients by fluorometric and chromatographic assay, suggested a biphasic plasma clearance of drug with initial and secondary half-lives of about 1.5 and 14 to 21 hr, respectively.",Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/942583/),h,1.5,51910,DB00997,Doxorubicin
,942583,secondary half-lives,"Pharmacokinetic data, collected in 25 patients by fluorometric and chromatographic assay, suggested a biphasic plasma clearance of drug with initial and secondary half-lives of about 1.5 and 14 to 21 hr, respectively.",Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/942583/),h,1.5,51911,DB00997,Doxorubicin
,942583,secondary half-lives,"Pharmacokinetic data, collected in 25 patients by fluorometric and chromatographic assay, suggested a biphasic plasma clearance of drug with initial and secondary half-lives of about 1.5 and 14 to 21 hr, respectively.",Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/942583/),h,14 to 21,51912,DB00997,Doxorubicin
,8431970,Maximal concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],705,51952,DB00997,Doxorubicin
,8431970,Maximal concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],308,51953,DB00997,Doxorubicin
,8431970,steady-state concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],265,51954,DB00997,Doxorubicin
,8431970,steady-state concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],180,51955,DB00997,Doxorubicin
,3457647,Peak levels,Plasma levels of the reduced metabolite DMDRol were higher than those of the parent compound: Peak levels were 4-10 ng/ml for DMDR and 15-40 ng/ml for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [ml],4-10,51995,DB00997,Doxorubicin
,3457647,Peak levels,Plasma levels of the reduced metabolite DMDRol were higher than those of the parent compound: Peak levels were 4-10 ng/ml for DMDR and 15-40 ng/ml for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [ml],15-40,51996,DB00997,Doxorubicin
,3457647,area under the time-concentration curve (AUC),"The dose-corrected area under the time-concentration curve (AUC) was consequently higher for DMDRol (12.3-74.7, mean 32.6 vs 2.4-7.4, mean 4.6 ng/ml.mg for DMDR).",Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [mg·ml],32.6,51997,DB00997,Doxorubicin
,3457647,area under the time-concentration curve (AUC),"The dose-corrected area under the time-concentration curve (AUC) was consequently higher for DMDRol (12.3-74.7, mean 32.6 vs 2.4-7.4, mean 4.6 ng/ml.mg for DMDR).",Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [mg·ml],4.6,51998,DB00997,Doxorubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,13-36,51999,DB00997,Doxorubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,23.7,52000,DB00997,Doxorubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,30-81,52001,DB00997,Doxorubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,58.9,52002,DB00997,Doxorubicin
,2291452,maximal tolerated dose (MTD),The limiting toxicity was neutropenia and the maximal tolerated dose (MTD) ranged from 50 to 110 mg/m2.,Intra-arterial hepatic chemotherapy with pirarubicin. Preclinical and clinical studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291452/),[mg] / [m2],50 to 110,52376,DB00997,Doxorubicin
,2291452,MTD,"The median MTD was 85 mg/m2 (range of 60-120 mg/m2), and the median number of cycles was 7 (range of 2-11) with cumulated doses from 180 to 1,030 mg/m2.",Intra-arterial hepatic chemotherapy with pirarubicin. Preclinical and clinical studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291452/),[mg] / [m2],85,52377,DB00997,Doxorubicin
,2556012,cumulative dose,"The median cumulative dose was 110 mg/m2 (range: 50-1,100).",Phase II study of idarubicin in extensive-disease non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556012/),[mg] / [m2],110,52723,DB00997,Doxorubicin
≤,30580500,Time to serum methotrexate level,Time to serum methotrexate level ≤0.1 µmol/L was the primary outcome.,Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580500/),[μM] / [l],0.1,54137,DB00997,Doxorubicin
,30580500,time to clearance,Median time to clearance for patients ≤18 years was 79 hours (range 63-116) compared to 120 hours (range 77-315) for patients >18 years (P < 0.001).,Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580500/),h,79,54138,DB00997,Doxorubicin
,30580500,time to clearance,Median time to clearance for patients ≤18 years was 79 hours (range 63-116) compared to 120 hours (range 77-315) for patients >18 years (P < 0.001).,Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30580500/),h,120,54139,DB00997,Doxorubicin
,28054329,objective response rate,"Partial response was observed in one patient with breast cancer treated at 100 mg/m2, yielding an objective response rate of 5% (1/19).",A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28054329/),%,5,54338,DB00997,Doxorubicin
,27243582,recovery,"The mean recovery for Sabarubicin was 62.4%, 71.9% for M3, and 58.8% for IS.",Development and validation of a UHPLC-MS/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27243582/),%,62.4,54618,DB00997,Doxorubicin
,27243582,recovery,"The mean recovery for Sabarubicin was 62.4%, 71.9% for M3, and 58.8% for IS.",Development and validation of a UHPLC-MS/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27243582/),%,71.9,54619,DB00997,Doxorubicin
,27243582,recovery,"The mean recovery for Sabarubicin was 62.4%, 71.9% for M3, and 58.8% for IS.",Development and validation of a UHPLC-MS/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27243582/),%,58.8,54620,DB00997,Doxorubicin
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),min,4.75,55225,DB00997,Doxorubicin
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),h,0.822,55226,DB00997,Doxorubicin
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),h,18.9,55227,DB00997,Doxorubicin
,6891324,total plasma clearance,The total plasma clearance of the parent drug ranged from 28.3 to 98.7 1/hr.,Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),[1] / [h],28.3 to 98.7,55228,DB00997,Doxorubicin
,10550567,Clearance (CL),"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],3. 57,55584,DB00997,Doxorubicin
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55585,DB00997,Doxorubicin
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55586,DB00997,Doxorubicin
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55587,DB00997,Doxorubicin
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],3.67,55588,DB00997,Doxorubicin
,10550567,Q2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55589,DB00997,Doxorubicin
,10550567,Q2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55590,DB00997,Doxorubicin
,10550567,Q2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55591,DB00997,Doxorubicin
,10550567,Q3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55592,DB00997,Doxorubicin
,10550567,Q3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55593,DB00997,Doxorubicin
,10550567,Q3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55594,DB00997,Doxorubicin
,10550567,central (,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55595,DB00997,Doxorubicin
,10550567,central (,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55596,DB00997,Doxorubicin
,10550567,V1,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55597,DB00997,Doxorubicin
,10550567,V1,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55598,DB00997,Doxorubicin
,10550567,V1,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55599,DB00997,Doxorubicin
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55600,DB00997,Doxorubicin
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55601,DB00997,Doxorubicin
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55602,DB00997,Doxorubicin
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],3.67,55603,DB00997,Doxorubicin
,10550567,V3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55604,DB00997,Doxorubicin
,10550567,V3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55605,DB00997,Doxorubicin
,10550567,V3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55606,DB00997,Doxorubicin
,10550567,volumes of distribution,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],158,55607,DB00997,Doxorubicin
,10550567,CL,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],7.3,55608,DB00997,Doxorubicin
,10550567,intercompartmental clearance (Q),"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],4. 6,55609,DB00997,Doxorubicin
,10550567,intercompartmental clearance (Q),"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.69,55610,DB00997,Doxorubicin
,10550567,V1,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],4. 6,55611,DB00997,Doxorubicin
,10550567,V1,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.69,55612,DB00997,Doxorubicin
,10550567,V2,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],2.6,55613,DB00997,Doxorubicin
,1742849,t1/2 elimination,"The mean errors were -0.0315 x 10(-4) l-1 for A3/V1, 0.0839 h for t1/2 elimination, and -0.22 ng/ml for c(48 h).",Bayesian estimation of doxorubicin pharmacokinetic parameters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742849/),h,0.0839,55732,DB00997,Doxorubicin
,26711181,overall,"The overall and complete response rates were 68% and 37%, respectively.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),%,68,56026,DB00997,Doxorubicin
,26711181,complete response rates,"The overall and complete response rates were 68% and 37%, respectively.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),%,37,56027,DB00997,Doxorubicin
,26711181,trough levels,"Highest day 1 alemtuzumab trough levels were achieved at 60 mg (1973 ng/mL), but with significant inter- and intradose variability.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),[ng] / [ml],1973,56028,DB00997,Doxorubicin
,3579988,AUC0-48 h,"Both drugs produced toxicity of equal severity to hearts after 24 hr, associated with high cardiac levels of 7-deoxyaglycones in the case of ADR (AUC0-48 hr, micrograms/g X hr: ADR, 47; ADR 7-deoxyaglycone (ADR-DONE), 24; and adriamycinol 7-deoxyaglycone (AOL-DONE), 35) compared to low cardiac levels of 7-deoxyaglycones but a times five higher peak cardiac concentration of parent drug in the case of 4'-DOX (AUC0-48 hr, micrograms/g X hr: 4'-DOX, 68; 4'-DOX-DONE, 3.8; and 4'-DOL-DONE, 0.8).",Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3579988/),[μg] / [g·h],3,56761,DB00997,Doxorubicin
,7546045,t(1/2),"Within the first 15 min after administration, EPR was distributed from the central compartment distinctly faster in compare to the control, when QUI was preadministered (t(1/2) = 6 min for the control group and t(1/2) = 3 min with QUI; -46%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),min,6,56863,DB00997,Doxorubicin
,7546045,t(1/2),"Within the first 15 min after administration, EPR was distributed from the central compartment distinctly faster in compare to the control, when QUI was preadministered (t(1/2) = 6 min for the control group and t(1/2) = 3 min with QUI; -46%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),min,3,56864,DB00997,Doxorubicin
,7546045,Half-life of elimination,Half-life of elimination was 0.5 h for the control group and 8.6 h for the QUI group (-10%).,Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),h,0.5,56865,DB00997,Doxorubicin
,7546045,Half-life of elimination,Half-life of elimination was 0.5 h for the control group and 8.6 h for the QUI group (-10%).,Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),h,8.6,56866,DB00997,Doxorubicin
,7546045,initial serum concentration (co),"The mean initial serum concentration (co) was reduced significantly by QUI from 7359 +/- 506 ng/ml to 4351 +/- 1682 ng/ml (-42%, p < 0.005).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [ml],7359,56867,DB00997,Doxorubicin
,7546045,initial serum concentration (co),"The mean initial serum concentration (co) was reduced significantly by QUI from 7359 +/- 506 ng/ml to 4351 +/- 1682 ng/ml (-42%, p < 0.005).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [ml],4351,56868,DB00997,Doxorubicin
,7546045,serum bioavailability,"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [h·ml],3404,56869,DB00997,Doxorubicin
,7546045,serum bioavailability,"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[h·ml·ng] / [-],2359,56870,DB00997,Doxorubicin
,7546045,AUC(o-24),"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [h·ml],3404,56871,DB00997,Doxorubicin
,7546045,AUC(o-24),"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[h·ml·ng] / [-],2359,56872,DB00997,Doxorubicin
,7546045,total body clearance,"Vd and Vdbeta were increased at about 90% and the mean total body clearance was accelerated from 45.3 to 1487 ml/min, but due to the large standard deviations the calculated difference for these parameters was not statistically significant.",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ml] / [min],45,56873,DB00997,Doxorubicin
,7546045,k(rbc),"In the observed time interval of 24 h, the red blood cell coefficient of distribution k(rbc) of EPR was lower if QUI was coadministered (k(rbc) = 1.25 +/- 0.12 for the control group k(rbc) = 1.15 +/- 0.13 under QUI; p < 0.04).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),,1.25,56874,DB00997,Doxorubicin
,7546045,k(rbc),"In the observed time interval of 24 h, the red blood cell coefficient of distribution k(rbc) of EPR was lower if QUI was coadministered (k(rbc) = 1.25 +/- 0.12 for the control group k(rbc) = 1.15 +/- 0.13 under QUI; p < 0.04).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),,1.15,56875,DB00997,Doxorubicin
,15110880,clearance,The mean (+/-S.D.) clearance was 63.6+/-22.7 L/h for doxorubicin and 42.8+/-14.9 L/h for docetaxel.,Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15110880/),[l] / [h],63.6,57079,DB00997,Doxorubicin
,15110880,clearance,The mean (+/-S.D.) clearance was 63.6+/-22.7 L/h for doxorubicin and 42.8+/-14.9 L/h for docetaxel.,Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15110880/),[l] / [h],42.8,57080,DB00997,Doxorubicin
,2824523,t1/2term,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),h,60.5,57138,DB00997,Doxorubicin
,2824523,t1/2term,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),h,28.3,57139,DB00997,Doxorubicin
,2824523,AUC,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),[h] / [ml·ug],3.00,57140,DB00997,Doxorubicin
,2824523,AUC,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),[h] / [ml·ug],1.43,57141,DB00997,Doxorubicin
,2824523,AUCadriamycinol/AUCadriamycin ratio,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),,0.94,57142,DB00997,Doxorubicin
,2824523,AUCadriamycinol/AUCadriamycin ratio,"Unlike adriamycin and antipyrine, adriamycinol was found to have a significantly longer t1/2term (60.5 vs 28.3 h, P less than 0.001), an increased AUC (3.00 vs 1.43 h/ug per ml, P less than 0.02), and a higher AUCadriamycinol/AUCadriamycin ratio (0.94 vs 0.52, P less than 0.02) in patients with moderate tumor involvement of the liver.","Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2824523/),,0.52,57143,DB00997,Doxorubicin
,25230100,transfer constant Ktrans,"By examining several clinical treatment aspects (e.g. sonication scheme, permeability enhancement, injection mode), our simulation results support the experimental findings of optimal interval delay between two consecutive sonications and therapeutically-sufficient intracellular concentration with respect to transfer constant Ktrans range of 0.01-0.03 min(-1).",Modeling localized delivery of Doxorubicin to the brain following focused ultrasound enhanced blood-brain barrier permeability. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25230100/),1/[min],0.01-0.03,57364,DB00997,Doxorubicin
,21380815,50% inhibition concentration,Myricetin inhibited CYP3A4 enzyme activity with 50% inhibition concentration of 7.8 μM.,Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21380815/),μM,7.8,57390,DB00997,Doxorubicin
,1530304,hepatic extraction,"The hepatic extraction calculated from the areas under the plasma concentration time curve of both administrations was 40% in ADM, 60% in ERB, and 0% in MMC.",[A pharmacokinetic study of intra-arterial chemotherapy for prophylactic treatment of liver metastasis after hepatectomy for liver cancer]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530304/),%,40,57794,DB00997,Doxorubicin
,1530304,hepatic extraction,"The hepatic extraction calculated from the areas under the plasma concentration time curve of both administrations was 40% in ADM, 60% in ERB, and 0% in MMC.",[A pharmacokinetic study of intra-arterial chemotherapy for prophylactic treatment of liver metastasis after hepatectomy for liver cancer]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530304/),%,60,57795,DB00997,Doxorubicin
,1530304,hepatic extraction,"The hepatic extraction calculated from the areas under the plasma concentration time curve of both administrations was 40% in ADM, 60% in ERB, and 0% in MMC.",[A pharmacokinetic study of intra-arterial chemotherapy for prophylactic treatment of liver metastasis after hepatectomy for liver cancer]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530304/),%,0,57796,DB00997,Doxorubicin
,2758564,terminal plasma half-life,Plasma levels of the compound were fitted to a three-compartment open model; a triexponential decrease in plasma concentrations with a long terminal plasma half-life (44.8 +/- 21.2 h) was observed in 27 patients.,Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),h,44.8,58272,DB00997,Doxorubicin
,2758564,serum,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[ng] / [ml],7.67,58273,DB00997,Doxorubicin
,2758564,AUC,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[ng] / [ml],7.67,58274,DB00997,Doxorubicin
,2758564,plasma clearance,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[h·ng] / [ml],"4,002",58275,DB00997,Doxorubicin
,2758564,plasma clearance,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[l] / [h·m2],26.6,58276,DB00997,Doxorubicin
,2758564,plasma clearance,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[ng] / [ml],4.96,58277,DB00997,Doxorubicin
,2758564,plasma clearance,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[h·ng] / [ml],1.88,58278,DB00997,Doxorubicin
,2758564,terminal elimination rate constant,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[l] / [h],0.009,58279,DB00997,Doxorubicin
,2758564,terminal elimination rate constant,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[l] / [h],0.017,58280,DB00997,Doxorubicin
,15948037,survival time,"The mean survival time of the mice treated with RGD-SSL-DOX, RGDm-SSL-DOX, and SSL-DOX was 55, 49, and 44 days, respectively.",Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948037/),d,55,58538,DB00997,Doxorubicin
,15948037,survival time,"The mean survival time of the mice treated with RGD-SSL-DOX, RGDm-SSL-DOX, and SSL-DOX was 55, 49, and 44 days, respectively.",Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948037/),d,49,58539,DB00997,Doxorubicin
,15948037,survival time,"The mean survival time of the mice treated with RGD-SSL-DOX, RGDm-SSL-DOX, and SSL-DOX was 55, 49, and 44 days, respectively.",Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15948037/),d,44,58540,DB00997,Doxorubicin
,24754897,aspect ratio,"Mean particle diameter of the disk was 80.14 nm, and the disk height was about 6 nm with aspect ratio about 12.",PEG-stabilized bilayer nanodisks as carriers for doxorubicin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24754897/),,12,58633,DB00997,Doxorubicin
,24754897,Encapsulation efficiency,"Encapsulation efficiency of DOX-Disks was as high as 96.1%, and DOX release from DOX-Disks was pH-dependent (25.6% of total DOX released at 24 h in pH 7.4).",PEG-stabilized bilayer nanodisks as carriers for doxorubicin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24754897/),%,96.1,58634,DB00997,Doxorubicin
,24754897,IC50,"In addition, DOX-Disks exhibited much effectiveness in inhibiting tumor cell growth, and the IC50 values were 2.03, 0.85, and 0.86 μg/mL for DOX-Sol and 0.23, 0.24, and 0.20 μg/mL for DOX-Disks after treatment for 48, 72, and 96 h against MCF-7/Adr cells, respectively.",PEG-stabilized bilayer nanodisks as carriers for doxorubicin delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24754897/),[μg] / [ml],2.03,58635,DB00997,Doxorubicin
,24754897,IC50,"In addition, DOX-Disks exhibited much effectiveness in inhibiting tumor cell growth, and the IC50 values were 2.03, 0.85, and 0.86 μg/mL for DOX-Sol and 0.23, 0.24, and 0.20 μg/mL for DOX-Disks after treatment for 48, 72, and 96 h against MCF-7/Adr cells, respectively.",PEG-stabilized bilayer nanodisks as carriers for doxorubicin delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24754897/),[μg] / [ml],0.85,58636,DB00997,Doxorubicin
,24754897,IC50,"In addition, DOX-Disks exhibited much effectiveness in inhibiting tumor cell growth, and the IC50 values were 2.03, 0.85, and 0.86 μg/mL for DOX-Sol and 0.23, 0.24, and 0.20 μg/mL for DOX-Disks after treatment for 48, 72, and 96 h against MCF-7/Adr cells, respectively.",PEG-stabilized bilayer nanodisks as carriers for doxorubicin delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24754897/),[μg] / [ml],0.86,58637,DB00997,Doxorubicin
,24754897,IC50,"In addition, DOX-Disks exhibited much effectiveness in inhibiting tumor cell growth, and the IC50 values were 2.03, 0.85, and 0.86 μg/mL for DOX-Sol and 0.23, 0.24, and 0.20 μg/mL for DOX-Disks after treatment for 48, 72, and 96 h against MCF-7/Adr cells, respectively.",PEG-stabilized bilayer nanodisks as carriers for doxorubicin delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24754897/),[μg] / [ml],0.23,58638,DB00997,Doxorubicin
,24754897,IC50,"In addition, DOX-Disks exhibited much effectiveness in inhibiting tumor cell growth, and the IC50 values were 2.03, 0.85, and 0.86 μg/mL for DOX-Sol and 0.23, 0.24, and 0.20 μg/mL for DOX-Disks after treatment for 48, 72, and 96 h against MCF-7/Adr cells, respectively.",PEG-stabilized bilayer nanodisks as carriers for doxorubicin delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24754897/),[μg] / [ml],0.24,58639,DB00997,Doxorubicin
,24754897,IC50,"In addition, DOX-Disks exhibited much effectiveness in inhibiting tumor cell growth, and the IC50 values were 2.03, 0.85, and 0.86 μg/mL for DOX-Sol and 0.23, 0.24, and 0.20 μg/mL for DOX-Disks after treatment for 48, 72, and 96 h against MCF-7/Adr cells, respectively.",PEG-stabilized bilayer nanodisks as carriers for doxorubicin delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24754897/),[μg] / [ml],0.20,58640,DB00997,Doxorubicin
,9796961,area under the concentration versus time curve (AUC),"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],1448,59876,DB00997,Doxorubicin
,9796961,area under the concentration versus time curve (AUC),"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],1786,59877,DB00997,Doxorubicin
,9796961,AUC,"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],252,59878,DB00997,Doxorubicin
,9796961,AUC,"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],486,59879,DB00997,Doxorubicin
,6492776,concentration multiplied by time (area under curve),Plasma MTX concentration multiplied by time (area under curve) was 131 g . hr/liter in 43 degrees C dogs compared with 73 g . hr/liter in 37 degrees C dogs (P less than 0.001).,Systemic thermochemotherapy: toxicity and plasma pharmacokinetics of methotrexate and doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492776/),[g·h] / [l],131,60455,DB00997,Doxorubicin
,6492776,concentration multiplied by time (area under curve),Plasma MTX concentration multiplied by time (area under curve) was 131 g . hr/liter in 43 degrees C dogs compared with 73 g . hr/liter in 37 degrees C dogs (P less than 0.001).,Systemic thermochemotherapy: toxicity and plasma pharmacokinetics of methotrexate and doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6492776/),[g·h] / [l],73,60456,DB00997,Doxorubicin
,15907579,D:L,"Regardless of the initial drug-to-lipid ratios (D:L), the final D:L reached a maximum of 0.05 (w/w) when doxorubicin was encapsulated via a pH gradient for both thermosensitive liposome formulations.",Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907579/),,0.05,60494,DB00997,Doxorubicin
,15907579,D:L,"In contrast, the final maximum D:L achieved through manganese complexation was 0.2 (w/w), and this loading method did not affect temperature-induced drug release, with 85% of drug released from MSPC-containing liposomes within 10 min at 42 degrees C but <5% released over 60 min at 37 degrees C.",Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907579/),,0.2,60495,DB00997,Doxorubicin
,15907579,D:L ratio,"Following acidification of the liposomal interior and establishment of an apparent new D:L equilibrium, the measured D:L ratio was 0.05 (w/w).",Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907579/),,0.05,60496,DB00997,Doxorubicin
,1433357,terminal half-life,Doxorubicin's estimated terminal half-life was 39.5 +/- 18.3 (mean +/- SD) hours; the area under the curve for plasma concentration of drug x time (AUC) was 1.74 +/- 0.40 (micrograms/microL) x hour.,Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),h,39.5,61210,DB00997,Doxorubicin
,1433357,area under the curve for plasma concentration of drug x time (AUC),Doxorubicin's estimated terminal half-life was 39.5 +/- 18.3 (mean +/- SD) hours; the area under the curve for plasma concentration of drug x time (AUC) was 1.74 +/- 0.40 (micrograms/microL) x hour.,Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),[μg] / [h·μl)],1.74,61211,DB00997,Doxorubicin
,1433357,Total-body clearance,"Total-body clearance was 598 +/- 142 microL/m2 per minute (N = 20), and it did not vary with ADR-529 dose.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),[μl] / [m2·min],598,61212,DB00997,Doxorubicin
,1433357,distribution,"Estimated distribution and elimination phase half-lives for plasma ADR-529 were 0.46 +/- 0.30 hours and 4.16 +/- 2.94 hours, respectively.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),h,0.46,61213,DB00997,Doxorubicin
,1433357,elimination phase half-lives,"Estimated distribution and elimination phase half-lives for plasma ADR-529 were 0.46 +/- 0.30 hours and 4.16 +/- 2.94 hours, respectively.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),h,4.16,61214,DB00997,Doxorubicin
,1433357,Total-body clearance,"Total-body clearance was 111 +/- 87 microL/m2 per minute (N = 18); AUC was linear (r2 = .92), and the clearance rate was constant (r2 = .18) from 60 to 900 mg/m2.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),[μl] / [m2·min],111,61215,DB00997,Doxorubicin
,884924,plasma elimination half-life,"The pharmacokinetics of adriamycin and metabolites in plasma urine resembled those of previous patients, with a plasma elimination half-life for adriamycin of 25.2 hr.",Bilary disposition of adriamycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/884924/),h,25.2,61784,DB00997,Doxorubicin
,8722343,clearance rate,The mean VP-16 clearance rate was 17.3 ml/min/m2 with continuous infusion.,Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[ml] / [m2·min],17.3,62274,DB00997,Doxorubicin
,8722343,steady-state plasma concentration,"A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM.",Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[μg] / [ml],24.2,62275,DB00997,Doxorubicin
,8722343,steady-state plasma concentration,"A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM.",Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[μg] / [ml],28.3,62276,DB00997,Doxorubicin
,6322986,terminal half-life,"In African patients with hepatocellular carcinoma, terminal half-life of doxorubicin was prolonged at 39.8 +/- 15.9 hours.",Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6322986/),h,39.8,62564,DB00997,Doxorubicin
,8402670,MTD,"The MTD of CsA was 6 micrograms/kg/min, and for dox it was 45 mg/m2.",Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),[μg] / [kg·min],6,62794,DB00997,Doxorubicin
,8402670,MTD,"The MTD of CsA was 6 micrograms/kg/min, and for dox it was 45 mg/m2.",Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),[mg] / [m],45,62795,DB00997,Doxorubicin
,8402670,whole blood steady state concentrations,Mean whole blood steady state concentrations of CsA were 2210 ng/ml during the infusion with total body clearance of 0.177 liter/h/kg.,Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),[ng] / [ml],2210,62796,DB00997,Doxorubicin
,8402670,total body clearance,Mean whole blood steady state concentrations of CsA were 2210 ng/ml during the infusion with total body clearance of 0.177 liter/h/kg.,Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),[l] / [h·kg],0.177,62797,DB00997,Doxorubicin
,8402670,total body clearance,"The mean total body clearance was 2.46 liters/h/m2, and terminal half-life was 49.6 h.",Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),[l] / [h·m2],2.46,62798,DB00997,Doxorubicin
,8402670,terminal half-life,"The mean total body clearance was 2.46 liters/h/m2, and terminal half-life was 49.6 h.",Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),h,49.6,62799,DB00997,Doxorubicin
,24171458,liver extraction,"Following i.v. infusion (55 min), DOX had a liver extraction of 41 (28-53)%, and the fraction of the dose eliminated in bile of DOX and DOXol was 20 (15-22)% and 4.2 (3.2-5.2)%, respectively.",Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24171458/),%,41,64086,DB00997,Doxorubicin
,24171458,fraction of the dose eliminated,"Following i.v. infusion (55 min), DOX had a liver extraction of 41 (28-53)%, and the fraction of the dose eliminated in bile of DOX and DOXol was 20 (15-22)% and 4.2 (3.2-5.2)%, respectively.",Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24171458/),%,20,64087,DB00997,Doxorubicin
,24171458,fraction of the dose eliminated,"Following i.v. infusion (55 min), DOX had a liver extraction of 41 (28-53)%, and the fraction of the dose eliminated in bile of DOX and DOXol was 20 (15-22)% and 4.2 (3.2-5.2)%, respectively.",Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24171458/),%,4.2,64088,DB00997,Doxorubicin
,24171458,AUCbile/AUCVP,"The AUCbile/AUCVP for DOX and DOXol was 640 (580-660) and 5000 (3900-5400), respectively.",Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24171458/),,640,64089,DB00997,Doxorubicin
,24171458,AUCbile/AUCVP,"The AUCbile/AUCVP for DOX and DOXol was 640 (580-660) and 5000 (3900-5400), respectively.",Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24171458/),,5000,64090,DB00997,Doxorubicin
,7636539,MTD,"The MTD of dexverapamil was 150 mg/m2 every 4 hours (900 mg/m2/d), and hypotension was the principal dose-limiting toxicity.",Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636539/),[mg] / [m2],150,64149,DB00997,Doxorubicin
,30518853,relative bioavailability,"In a pharmacokinetics study compared to free QUE, intravenous and oral administration of QUE-loaded LsbPMs was found to have significantly increased the relative bioavailability to 158% and 360%, respectively, and the absolute bioavailability to 5.13%.",Lecithin-Stabilized Polymeric Micelles (LsbPMs) for Delivering Quercetin: Pharmacokinetic Studies and Therapeutic Effects of Quercetin Alone and in Combination with Doxorubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30518853/),%,158,64163,DB00997,Doxorubicin
,30518853,relative bioavailability,"In a pharmacokinetics study compared to free QUE, intravenous and oral administration of QUE-loaded LsbPMs was found to have significantly increased the relative bioavailability to 158% and 360%, respectively, and the absolute bioavailability to 5.13%.",Lecithin-Stabilized Polymeric Micelles (LsbPMs) for Delivering Quercetin: Pharmacokinetic Studies and Therapeutic Effects of Quercetin Alone and in Combination with Doxorubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30518853/),%,360,64164,DB00997,Doxorubicin
,30518853,absolute bioavailability,"In a pharmacokinetics study compared to free QUE, intravenous and oral administration of QUE-loaded LsbPMs was found to have significantly increased the relative bioavailability to 158% and 360%, respectively, and the absolute bioavailability to 5.13%.",Lecithin-Stabilized Polymeric Micelles (LsbPMs) for Delivering Quercetin: Pharmacokinetic Studies and Therapeutic Effects of Quercetin Alone and in Combination with Doxorubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30518853/),%,5.13,64165,DB00997,Doxorubicin
,30607545,Cmax,Values for aprepitant group vs. control group were as follows: geometric mean of Cmax was 119 vs.,"Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,119,64315,DB00997,Doxorubicin
,30607545,AUC0-last,"120 ng/mL, AUC0-last was 648 vs.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,648,64316,DB00997,Doxorubicin
,30607545,AUC0-inf,"635 ng h/mL, AUC0-inf was 681 vs.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,681,64317,DB00997,Doxorubicin
,30607545,plasma clearance,"668 ng h/mL, plasma clearance was 4.40 vs.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),,4.40,64318,DB00997,Doxorubicin
,30607545,t1/2,"4.49 (L/h/m2), respectively; harmonic means of t1/2 was 2.11 vs. 2.25 h.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),h,2.11,64319,DB00997,Doxorubicin
,30607545,t1/2,"4.49 (L/h/m2), respectively; harmonic means of t1/2 was 2.11 vs. 2.25 h.","Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30607545/),h,2.25,64320,DB00997,Doxorubicin
,7579031,AUAt,"The amount of M1 in the lung was significantly greater in the tumour-bearing mice than in the control mice, resulting in a greater AUAt in the tumour-bearing mice (18,600 against 8940 micrograms min g-1), and vice versa in the liver (962 against 3840 micrograms min g-1).","Pharmacokinetics and antitumour activity of a new anthracycline, DA-125, after intravenous administration to subcutaneously implanted Lewis-lung-carcinoma-bearing mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579031/),[min·μg] / [g],"18,600",64384,DB00997,Doxorubicin
,7579031,AUAt,"The amount of M1 in the lung was significantly greater in the tumour-bearing mice than in the control mice, resulting in a greater AUAt in the tumour-bearing mice (18,600 against 8940 micrograms min g-1), and vice versa in the liver (962 against 3840 micrograms min g-1).","Pharmacokinetics and antitumour activity of a new anthracycline, DA-125, after intravenous administration to subcutaneously implanted Lewis-lung-carcinoma-bearing mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579031/),[min·μg] / [g],8940,64385,DB00997,Doxorubicin
,7579031,AUAt,"The amount of M1 in the lung was significantly greater in the tumour-bearing mice than in the control mice, resulting in a greater AUAt in the tumour-bearing mice (18,600 against 8940 micrograms min g-1), and vice versa in the liver (962 against 3840 micrograms min g-1).","Pharmacokinetics and antitumour activity of a new anthracycline, DA-125, after intravenous administration to subcutaneously implanted Lewis-lung-carcinoma-bearing mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579031/),[min·μg] / [g],962,64386,DB00997,Doxorubicin
,7579031,AUAt,"The amount of M1 in the lung was significantly greater in the tumour-bearing mice than in the control mice, resulting in a greater AUAt in the tumour-bearing mice (18,600 against 8940 micrograms min g-1), and vice versa in the liver (962 against 3840 micrograms min g-1).","Pharmacokinetics and antitumour activity of a new anthracycline, DA-125, after intravenous administration to subcutaneously implanted Lewis-lung-carcinoma-bearing mice. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579031/),[min·μg] / [g],3840,64387,DB00997,Doxorubicin
,7579031,Cmax,"The amount of M1 in the tumour mass reached a mean Cmax of 3.75 micrograms g-1 immediately after i.v. administration of DA-125 to the tumour-bearing mice, then declined very slowly to an amount that remained almost constant for up to 24 h.","Pharmacokinetics and antitumour activity of a new anthracycline, DA-125, after intravenous administration to subcutaneously implanted Lewis-lung-carcinoma-bearing mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7579031/),[μg] / [g],3.75,64388,DB00997,Doxorubicin
,12628836,areas under the concentration-time curve (AUCs),We first identified target areas under the concentration-time curve (AUCs) of 2400 and 1600 ng/ml.h from pharmacokinetic studies in 15 women with normal liver tests.,Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12628836/),[ng] / [h·ml],2400,65723,DB00997,Doxorubicin
,12628836,areas under the concentration-time curve (AUCs),We first identified target areas under the concentration-time curve (AUCs) of 2400 and 1600 ng/ml.h from pharmacokinetic studies in 15 women with normal liver tests.,Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12628836/),[ng] / [h·ml],1600,65724,DB00997,Doxorubicin
,12628836,AUCs,"The median AUCs were 2444 and 1608 ng/ml.h, close to the high and low target AUCs, respectively.",Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12628836/),[ng] / [h·ml],2444,65725,DB00997,Doxorubicin
,12628836,AUCs,"The median AUCs were 2444 and 1608 ng/ml.h, close to the high and low target AUCs, respectively.",Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12628836/),[ng] / [h·ml],1608,65726,DB00997,Doxorubicin
,12881383,area under the plasma concentration-time curve (AUC(0-24 h)),The area under the plasma concentration-time curve (AUC(0-24 h)) was 1230 +/- 318 [mean +/- standard deviation (SD)] at the first cycle and 1287 +/- 385 h.,Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),,1230,66532,DB00997,Doxorubicin
,12881383,area under the plasma concentration-time curve (AUC(0-24 h)),The area under the plasma concentration-time curve (AUC(0-24 h)) was 1230 +/- 318 [mean +/- standard deviation (SD)] at the first cycle and 1287 +/- 385 h.,Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),,1287,66533,DB00997,Doxorubicin
,12881383,maximum plasma concentration (C(max)),"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),[μg] / [l],1303,66534,DB00997,Doxorubicin
,12881383,maximum plasma concentration (C(max)),"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),[μg] / [l],1229,66535,DB00997,Doxorubicin
,12881383,terminal elimination half-life,"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),h,12.5,66536,DB00997,Doxorubicin
,12881383,terminal elimination half-life,"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),h,11.5,66537,DB00997,Doxorubicin
,16846074,[deltaB],A non-uniform stationary magnetic field B of 210 mT and [deltaB] of 200 mT/cm was found to be efficient in increasing DOX conjugate bioavailability in the target site.,Pharmacokinetics of the doxorubicin magnetic nanoconjugate in mice. Effects of the nonuniform stationary magnetic field. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16846074/),[mt] / [cm],200,66555,DB00997,Doxorubicin
,3162516,cumulative urinary excretion,"The cumulative urinary excretion appeared to be 10.5% for EPI and its metabolites, and 6.9% for DOX and its metabolite.",Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162516/),%,10.5,67145,DB00997,Doxorubicin
,3162516,cumulative urinary excretion,"The cumulative urinary excretion appeared to be 10.5% for EPI and its metabolites, and 6.9% for DOX and its metabolite.",Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162516/),%,6.9,67146,DB00997,Doxorubicin
,9862055,alpha half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),min,11.3,67530,DB00997,Doxorubicin
,9862055,alpha half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),min,13.2,67531,DB00997,Doxorubicin
,9862055,terminal half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),h,13.5,67532,DB00997,Doxorubicin
,9862055,terminal half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),h,15,67533,DB00997,Doxorubicin
over,1568796,distribution half-life,"In contrast, when administered in the S-EPI formulation, the distribution half-life of the drug was over 22 hr.",Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568796/),h,22,68107,DB00997,Doxorubicin
,1568796,clearance,"S-EPI also exhibited a reduced clearance compared to F-EPI, from 111 to less than 1.0 ml/hr.",Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568796/),[ml] / [h],111,68108,DB00997,Doxorubicin
less,1568796,clearance,"S-EPI also exhibited a reduced clearance compared to F-EPI, from 111 to less than 1.0 ml/hr.",Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568796/),[ml] / [h],1.0,68109,DB00997,Doxorubicin
,28239897,specific clearance,"The data were best described by a two-compartment model comprising linear nonspecific clearance of 0.252 [95% confidence interval (CI): 0.227-0.279] l day-1 and time-varying specific clearance of 0.278 (95% CI: 0.181-0.390) l day-1 , corresponding to target-mediated drug disposition of rituximab.",Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28239897/),[l] / [d],0.278,68234,DB00997,Doxorubicin
,28239897,Rate constant of specific clearance decay,"Rate constant of specific clearance decay was 0.143 day-1 (95% CI: 0.0478-0.418) in patients with no disease progression, while in patients with disease progression it was 82.2% lower (95% CI: 33.4-95.0).",Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28239897/),1/[d],0.143,68235,DB00997,Doxorubicin
,3162849,t/2 alpha,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),min,4.8,68595,DB00997,Doxorubicin
,3162849,t/2 alpha,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),min,3,68596,DB00997,Doxorubicin
,3162849,t/2 beta,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,2.57,68597,DB00997,Doxorubicin
,3162849,t/2 beta,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,1.09,68598,DB00997,Doxorubicin
,3162849,t/2 gamma,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,48.4,68599,DB00997,Doxorubicin
,3162849,t/2 gamma,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,31.2,68600,DB00997,Doxorubicin
,3162849,PlCl,"According to a model-independent analysis, the different plasma disposition kinetics of the two compounds appears to be related to a higher plasma clearance (PlCl) and to a lower mean residence time (MRT) of epiDX (PlCl: 75.0 l/h, range: 35.6-133.4 l/h; MRT: 31.6 h, range: 7.0-41.5 h;) compared to DX (PlCl: 56.8 l/h, range: 24.4-119.5; MRT: 45.6 h, range: 26.0-83.1 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],75.0,68601,DB00997,Doxorubicin
,3162849,MRT,"According to a model-independent analysis, the different plasma disposition kinetics of the two compounds appears to be related to a higher plasma clearance (PlCl) and to a lower mean residence time (MRT) of epiDX (PlCl: 75.0 l/h, range: 35.6-133.4 l/h; MRT: 31.6 h, range: 7.0-41.5 h;) compared to DX (PlCl: 56.8 l/h, range: 24.4-119.5; MRT: 45.6 h, range: 26.0-83.1 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,31.6,68602,DB00997,Doxorubicin
,3162849,PlCl,"According to a model-independent analysis, the different plasma disposition kinetics of the two compounds appears to be related to a higher plasma clearance (PlCl) and to a lower mean residence time (MRT) of epiDX (PlCl: 75.0 l/h, range: 35.6-133.4 l/h; MRT: 31.6 h, range: 7.0-41.5 h;) compared to DX (PlCl: 56.8 l/h, range: 24.4-119.5; MRT: 45.6 h, range: 26.0-83.1 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],56.8,68603,DB00997,Doxorubicin
,3162849,MRT,"According to a model-independent analysis, the different plasma disposition kinetics of the two compounds appears to be related to a higher plasma clearance (PlCl) and to a lower mean residence time (MRT) of epiDX (PlCl: 75.0 l/h, range: 35.6-133.4 l/h; MRT: 31.6 h, range: 7.0-41.5 h;) compared to DX (PlCl: 56.8 l/h, range: 24.4-119.5; MRT: 45.6 h, range: 26.0-83.1 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,45.6,68604,DB00997,Doxorubicin
,3162849,volume of distribution at steady state (Vss),"No statistically significant differences could be detected for the volume of distribution at steady state (Vss) (epiDX, 31.8 l/kg; DX, 33.3 l/kg).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [kg],31.8,68605,DB00997,Doxorubicin
,3162849,volume of distribution at steady state (Vss),"No statistically significant differences could be detected for the volume of distribution at steady state (Vss) (epiDX, 31.8 l/kg; DX, 33.3 l/kg).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [kg],33.3,68606,DB00997,Doxorubicin
,3162849,renal clearance,"A comparable renal clearance was calculated for DX (4.7 l/h, range 1.4-7.0 l/h) and epiDX (4.4 l/h, range 1.7-7.0 l/h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],4.7,68607,DB00997,Doxorubicin
,3162849,renal clearance,"A comparable renal clearance was calculated for DX (4.7 l/h, range 1.4-7.0 l/h) and epiDX (4.4 l/h, range 1.7-7.0 l/h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],4.4,68608,DB00997,Doxorubicin
,3162849,PlCl,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],35.6,68609,DB00997,Doxorubicin
,3162849,PlCl,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],24.4,68610,DB00997,Doxorubicin
,3162849,MRT,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,39.0,68611,DB00997,Doxorubicin
,3162849,MRT,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,83.1,68612,DB00997,Doxorubicin
,3162849,t/2 gamma,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,47,68613,DB00997,Doxorubicin
,3162849,t/2 gamma,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,74,68614,DB00997,Doxorubicin
,11907177,Extracellular pH,"Extracellular pH was lower in tumors than in healthy tissue (6.46 +/- 0.35, n = 8 versus 7.30 +/- 0.33, n = 10; p < 0.001).",Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907177/),,6.46,68912,DB00997,Doxorubicin
,11907177,Extracellular pH,"Extracellular pH was lower in tumors than in healthy tissue (6.46 +/- 0.35, n = 8 versus 7.30 +/- 0.33, n = 10; p < 0.001).",Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907177/),,7.30,68913,DB00997,Doxorubicin
,9768830,steady-state DEX plasma concentrations,Results of pharmacokinetic studies in support of the trial have found that steady-state DEX plasma concentrations in the range of 4 to 5 micromol/L can be achieved safely.,Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768830/),[μM] / [l],4 to 5,69641,DB00997,Doxorubicin
,8406379,peak plasma levels,The plasma pharmacokinetics were described by a one-compartment open model with peak plasma levels of 6.9 +/- 2.5 micrograms/ml.,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),[μg] / [ml],6.9,69689,DB00997,Doxorubicin
,8406379,relative oral bioavailability,Mean relative oral bioavailability was generally high (91 +/- 27 per cent).,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),%,91,69690,DB00997,Doxorubicin
,9923536,AUC,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[min·μg] / [ml],2227,69829,DB00997,Doxorubicin
,9923536,AUC,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[min·μg] / [ml],245,69830,DB00997,Doxorubicin
,9923536,total clearance,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[ml] / [min],0.8,69831,DB00997,Doxorubicin
,9923536,total clearance,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),[ml] / [min],7.0,69832,DB00997,Doxorubicin
,9923536,elimination half-life,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),min,92,69833,DB00997,Doxorubicin
,9923536,elimination half-life,"Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value +/-SD, n=3; (P < 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227+/-106 versus 245+/-40 microg ml(-1) min), 9-fold decrease in total clearance (0.8+/-0.1 versus 7.0+/-1.1 ml/min), and 5-fold increase in elimination half-life (92+/-14 versus 18+/-4 min) being observed after a dose of 800 microl Cremophor.",Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923536/),min,18,69834,DB00997,Doxorubicin
,1428729,maximum tolerated dose,The maximum tolerated dose was 90 mg/m2 and the recommended phase II dose was 75 mg/m2.,Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1428729/),[mg] / [m2],90,70331,DB00997,Doxorubicin
,26356793,area under the plasma concentration-time curve (AUC0-t),"Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively.",Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356793/),[mg] / [h·l],1336.58,70484,DB00997,Doxorubicin
,26356793,area under the plasma concentration-time curve (AUC0-t),"Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively.",Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356793/),[mg] / [l],96.35,70485,DB00997,Doxorubicin
,26356793,Cmax,"Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively.",Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356793/),[mg] / [l],96.35,70486,DB00997,Doxorubicin
,26356793,Cmax,"Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively.",Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356793/),[mg] / [h·l],1.40,70487,DB00997,Doxorubicin
,26356793,Cmax,"Pharmacokinetic study showed area under the plasma concentration-time curve (AUC0-t) and Cmax for 20% CD-PEG-DOX8 micelles and DOX solution were 1336.58 ± 179.43 mg/L·h, 96.35 ± 3.32 mg/L and 1.40 ± 0.19 mg/L·h, 1.15 ± 0.25 mg/L, respectively.",Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26356793/),[mg] / [l],1.15,70488,DB00997,Doxorubicin
,28528285,LD50,"However, the LD50 value of LINEAR was slightly higher than that of DIBLOCK (50mg/kg vs 37.5mg/kg, respectively).",Comparison of the pharmacological and biological properties of HPMA copolymer-pirarubicin conjugates: A single-chain copolymer conjugate and its biodegradable tandem-diblock copolymer conjugate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528285/),[mg] / [kg],50,70842,DB00997,Doxorubicin
,28528285,LD50,"However, the LD50 value of LINEAR was slightly higher than that of DIBLOCK (50mg/kg vs 37.5mg/kg, respectively).",Comparison of the pharmacological and biological properties of HPMA copolymer-pirarubicin conjugates: A single-chain copolymer conjugate and its biodegradable tandem-diblock copolymer conjugate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528285/),[mg] / [kg],37.5,70843,DB00997,Doxorubicin
,209882,survival,"Mean survival was 21 weeks for nonresponders, and 43 weeks for responders.",Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/209882/),weeks,21,71676,DB00997,Doxorubicin
,209882,survival,"Mean survival was 21 weeks for nonresponders, and 43 weeks for responders.",Intraaterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/209882/),weeks,43,71677,DB00997,Doxorubicin
,17559346,AUC(0 negative infinity),"Breast cancer patients harboring the 146GG genotype showed a trend towards higher exposure levels to doxorubicin (AUC(0 negative infinity)/dose/body surface area [BSA] [hm(-5)]: 21.6; range: 18.8-27.7) compared with patients with either the reference genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 17.4; range: 8.2-26.3, p = 0.066) or heterozygotes (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 15.4; range: 6.2-38.0, p = 0.055).",Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559346/),1/[(hm)^5],21.6,71793,DB00997,Doxorubicin
,17559346,AUC(0 negative infinity),"Breast cancer patients harboring the 146GG genotype showed a trend towards higher exposure levels to doxorubicin (AUC(0 negative infinity)/dose/body surface area [BSA] [hm(-5)]: 21.6; range: 18.8-27.7) compared with patients with either the reference genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 17.4; range: 8.2-26.3, p = 0.066) or heterozygotes (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 15.4; range: 6.2-38.0, p = 0.055).",Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559346/),1/[(hm)^5],17.4,71794,DB00997,Doxorubicin
,17559346,AUC(0 negative infinity)/,"Breast cancer patients harboring the 146GG genotype showed a trend towards higher exposure levels to doxorubicin (AUC(0 negative infinity)/dose/body surface area [BSA] [hm(-5)]: 21.6; range: 18.8-27.7) compared with patients with either the reference genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 17.4; range: 8.2-26.3, p = 0.066) or heterozygotes (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 15.4; range: 6.2-38.0, p = 0.055).",Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559346/),1/[(hm)^5],15.4,71795,DB00997,Doxorubicin
,17559346,AUC(0 negative infinity),"The exposure levels of doxorubicinol were also higher in patients harboring the variant 146GG genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 13.3; range: 8.8-21.7) when compared with patients harboring the reference genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]): 9.8; range: 6.1-24.3, p = 0.137) or heterozygotes (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 8.98; range: 3.7-20.6, p = 0.047).",Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559346/),1/[(hm)^5],13.3,71796,DB00997,Doxorubicin
,17559346,AUC(0 negative infinity)/,"The exposure levels of doxorubicinol were also higher in patients harboring the variant 146GG genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 13.3; range: 8.8-21.7) when compared with patients harboring the reference genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]): 9.8; range: 6.1-24.3, p = 0.137) or heterozygotes (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 8.98; range: 3.7-20.6, p = 0.047).",Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559346/),1/[(hm)^5],9.8,71797,DB00997,Doxorubicin
,17559346,AUC(0 negative infinity)/dose/BSA,"The exposure levels of doxorubicinol were also higher in patients harboring the variant 146GG genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 13.3; range: 8.8-21.7) when compared with patients harboring the reference genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]): 9.8; range: 6.1-24.3, p = 0.137) or heterozygotes (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 8.98; range: 3.7-20.6, p = 0.047).",Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559346/),1/[(hm)^5],8.98,71798,DB00997,Doxorubicin
,12065559,overall response rate,"Among 34 patients, complete response was observed in three patients and partial response in 15, for an overall response rate of 53% (95% confidence interval, 35% to 70%).",Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065559/),%,53,72501,DB00997,Doxorubicin
,12065559,time to progression,"The median time to progression was 5.6 months (range, 4 to 10 months).",Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12065559/),month,5.6,72502,DB00997,Doxorubicin
,33628047,Imax,The drug concentrations producing 50% of Imax for DOX and ABE were 0.565 and 2.31 μM (MDA-MB-231) and 0.121 and 1.61 μM (MDA-MB-468).,In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),μ,0.,72587,DB00997,Doxorubicin
,33628047,Imax,The drug concentrations producing 50% of Imax for DOX and ABE were 0.565 and 2.31 μM (MDA-MB-231) and 0.121 and 1.61 μM (MDA-MB-468).,In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),μ,2.31,72588,DB00997,Doxorubicin
,33628047,Imax,The drug concentrations producing 50% of Imax for DOX and ABE were 0.565 and 2.31 μM (MDA-MB-231) and 0.121 and 1.61 μM (MDA-MB-468).,In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),μ,0.121,72589,DB00997,Doxorubicin
,33628047,Imax,The drug concentrations producing 50% of Imax for DOX and ABE were 0.565 and 2.31 μM (MDA-MB-231) and 0.121 and 1.61 μM (MDA-MB-468).,In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),μ,1.61,72590,DB00997,Doxorubicin
,33628047,first-orders rate constant,The first-orders rate constants of abemaciclib absorption (ka) and doxorubicin release from L_DOX (kRel) were estimated at 0.31 and 0.013 h-1.,In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),1/[h],0.31,72591,DB00997,Doxorubicin
,33628047,ka,The first-orders rate constants of abemaciclib absorption (ka) and doxorubicin release from L_DOX (kRel) were estimated at 0.31 and 0.013 h-1.,In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),1/[h],0.31,72592,DB00997,Doxorubicin
,33628047,kRel,The first-orders rate constants of abemaciclib absorption (ka) and doxorubicin release from L_DOX (kRel) were estimated at 0.31 and 0.013 h-1.,In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),1/[h],0.31,72593,DB00997,Doxorubicin
,33628047,kRel,The first-orders rate constants of abemaciclib absorption (ka) and doxorubicin release from L_DOX (kRel) were estimated at 0.31 and 0.013 h-1.,In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),1/[h],0.013,72594,DB00997,Doxorubicin
,33628047,linear clearances,Their linear clearances were 21.7 (ABE) and 32.1 L/h (DOX).,In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),[l] / [h],21.7,72595,DB00997,Doxorubicin
,33628047,linear clearances,Their linear clearances were 21.7 (ABE) and 32.1 L/h (DOX).,In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),[l] / [h],32.1,72596,DB00997,Doxorubicin
,33628047,TTP,"The estimated TTP for intravenous DOX (75 mg/m2 every 21 days), intravenous L_DOX (50 mg/m2 every 28 days), and oral ABE (200 mg twice a day) were 125, 31.2, and 8.6 days shorter than drug-free control.",In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),d,125,72597,DB00997,Doxorubicin
,33628047,TTP,"The estimated TTP for intravenous DOX (75 mg/m2 every 21 days), intravenous L_DOX (50 mg/m2 every 28 days), and oral ABE (200 mg twice a day) were 125, 31.2, and 8.6 days shorter than drug-free control.",In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),d,31.2,72598,DB00997,Doxorubicin
,33628047,TTP,"The estimated TTP for intravenous DOX (75 mg/m2 every 21 days), intravenous L_DOX (50 mg/m2 every 28 days), and oral ABE (200 mg twice a day) were 125, 31.2, and 8.6 days shorter than drug-free control.",In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),d,8.6,72599,DB00997,Doxorubicin
,33628047,TTP,"The TTP for DOX+ABE and L_DOX+ABE were 312 days and 47.5 days shorter than control, both larger than single-agent DOX, suggesting improved activity with the DOX+ABE combination.",In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),d,312,72600,DB00997,Doxorubicin
,33628047,TTP,"The TTP for DOX+ABE and L_DOX+ABE were 312 days and 47.5 days shorter than control, both larger than single-agent DOX, suggesting improved activity with the DOX+ABE combination.",In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33628047/),d,47.5,72601,DB00997,Doxorubicin
,21590446,clearance,"The mean ± SD clearance for patients <60 years old and ≥60 years old were 54.6 ± 28.5 and 23.3 ± 10.8 mL/h/m(2), respectively (P < 0.0001), and for female and male patients were 23.7 ± 18.8 and 55.6 ± 26.8 mL/h/m(2), respectively (P < 0.0001).",Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590446/),[h·ml] / [m(2],54.6,73037,DB00997,Doxorubicin
,21590446,clearance,"The mean ± SD clearance for patients <60 years old and ≥60 years old were 54.6 ± 28.5 and 23.3 ± 10.8 mL/h/m(2), respectively (P < 0.0001), and for female and male patients were 23.7 ± 18.8 and 55.6 ± 26.8 mL/h/m(2), respectively (P < 0.0001).",Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590446/),[h·ml] / [m(2],23.3,73038,DB00997,Doxorubicin
,21590446,clearance,"The mean ± SD clearance for patients <60 years old and ≥60 years old were 54.6 ± 28.5 and 23.3 ± 10.8 mL/h/m(2), respectively (P < 0.0001), and for female and male patients were 23.7 ± 18.8 and 55.6 ± 26.8 mL/h/m(2), respectively (P < 0.0001).",Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590446/),[h·ml] / [m(2],23.7,73039,DB00997,Doxorubicin
,21590446,clearance,"The mean ± SD clearance for patients <60 years old and ≥60 years old were 54.6 ± 28.5 and 23.3 ± 10.8 mL/h/m(2), respectively (P < 0.0001), and for female and male patients were 23.7 ± 18.8 and 55.6 ± 26.8 mL/h/m(2), respectively (P < 0.0001).",Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590446/),[h·ml] / [m(2],55.6,73040,DB00997,Doxorubicin
,7989950,extraction efficiencies,"The system functioned efficiently throughout the dose range, with extraction efficiencies ranging from 64% to 91% (P < .001).",Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7989950/),%,64,73203,DB00997,Doxorubicin
,7989950,extraction efficiencies,"The system functioned efficiently throughout the dose range, with extraction efficiencies ranging from 64% to 91% (P < .001).",Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7989950/),%,91,73204,DB00997,Doxorubicin
,29032193,accumulative,The accumulative Dox release from Dox-SeLPs was 46.5% and it was 64.9% for Dox-LPs within 84 h.,Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032193/),%,46.5,73428,DB00997,Doxorubicin
,29032193,accumulative,The accumulative Dox release from Dox-SeLPs was 46.5% and it was 64.9% for Dox-LPs within 84 h.,Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032193/),%,64.9,73429,DB00997,Doxorubicin
,29032193,IC50,"Dox-SeLPs showed a IC50 of 0.92 ± 0.16 μg/mL on A549 cells, far lower than that of free Dox (4.40 ± 0.58 μg/mL) and Dox-LPs (5.68 ± 0.73 μg/mL).",Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032193/),[μg] / [ml],0.92,73430,DB00997,Doxorubicin
,29032193,IC50,"Dox-SeLPs showed a IC50 of 0.92 ± 0.16 μg/mL on A549 cells, far lower than that of free Dox (4.40 ± 0.58 μg/mL) and Dox-LPs (5.68 ± 0.73 μg/mL).",Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032193/),[μg] / [ml],4.40,73431,DB00997,Doxorubicin
,29032193,IC50,"Dox-SeLPs showed a IC50 of 0.92 ± 0.16 μg/mL on A549 cells, far lower than that of free Dox (4.40 ± 0.58 μg/mL) and Dox-LPs (5.68 ± 0.73 μg/mL).",Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29032193/),[μg] / [ml],5.68,73432,DB00997,Doxorubicin
,19087684,peak content,Adriamycin content could be detected 30 min after the injection and lasted for 72 h at high levels with the peak content of (84.6 +/- 2.0) microg per gram tissue at 60 min in the perilymph node of gastroepiploic artery.,[Intralymphatic chemotherapy with adriamycin-adsorbing nanometric activated carbon:pharmacokinetic experiment with dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19087684/),[μg] / [gram·tissue],84.6,73480,DB00997,Doxorubicin
,1576324,half-life,The estimated half-life for this process was 20 min.,Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats: I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576324/),min,20,73718,DB00997,Doxorubicin
,1576324,half-life,The half-life for the degradation of liposomes in blood circulation was also estimated at 20 min from data on the urinary excretion of released 3H-inulin.,Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats: I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576324/),min,20,73719,DB00997,Doxorubicin
,3168142,total plasma concentrations,Phenytoin infusion was guided by plasma phenytoin estimation to maintain total plasma concentrations between 20 and 30 micrograms/ml.,Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),[μg] / [ml],20 and 30,74278,DB00997,Doxorubicin
,3168142,Clearance,"Clearance of doxorubicin during phenytoin administration (60.9 +/- 5.8 ml/min per kg, mean +/- SE) was similar to that during vehicle infusion (67.5 +/- 5.4 ml/min per kg).",Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),[ml] / [kg·min],60.9,74279,DB00997,Doxorubicin
,3168142,Clearance,"Clearance of doxorubicin during phenytoin administration (60.9 +/- 5.8 ml/min per kg, mean +/- SE) was similar to that during vehicle infusion (67.5 +/- 5.4 ml/min per kg).",Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),[ml] / [kg·min],67.5,74280,DB00997,Doxorubicin
,3168142,elimination half-life,Phenytoin administration was associated with a significant decrease in doxorubicinol elimination half-life from 41.0 +/- 4.8 to 25.6 +/- 2.8 h.,Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),h,41.0,74281,DB00997,Doxorubicin
,3168142,elimination half-life,Phenytoin administration was associated with a significant decrease in doxorubicinol elimination half-life from 41.0 +/- 4.8 to 25.6 +/- 2.8 h.,Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),h,25.6,74282,DB00997,Doxorubicin
,3168142,area under the plasma concentration/time curve (AUC),The area under the plasma concentration/time curve (AUC) for doxorubicinol decreased significantly from 666.8 +/- 100.4 to 491.5 +/- 65.7 n.h.ml-1.,Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),[h·n] / [ml],666.8,74283,DB00997,Doxorubicin
,3168142,area under the plasma concentration/time curve (AUC),The area under the plasma concentration/time curve (AUC) for doxorubicinol decreased significantly from 666.8 +/- 100.4 to 491.5 +/- 65.7 n.h.ml-1.,Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3168142/),[h·n] / [ml],491.5,74284,DB00997,Doxorubicin
,3411343,area under the curve (AUC),"Doxorubicin area under the curve (AUC) was greater in obese than in normal patients (2,209 v 1,190 ng h/mL; P less than .05), yielding correspondingly reduced systemic clearance of the agent in obese patients (891 v 1,569 mL/min; P less than .001).",Doxorubicin clearance in the obese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411343/),[h·ng] / [ml],"2,209",74359,DB00997,Doxorubicin
,3411343,area under the curve (AUC),"Doxorubicin area under the curve (AUC) was greater in obese than in normal patients (2,209 v 1,190 ng h/mL; P less than .05), yielding correspondingly reduced systemic clearance of the agent in obese patients (891 v 1,569 mL/min; P less than .001).",Doxorubicin clearance in the obese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411343/),[h·ng] / [ml],"1,190",74360,DB00997,Doxorubicin
,3411343,systemic clearance,"Doxorubicin area under the curve (AUC) was greater in obese than in normal patients (2,209 v 1,190 ng h/mL; P less than .05), yielding correspondingly reduced systemic clearance of the agent in obese patients (891 v 1,569 mL/min; P less than .001).",Doxorubicin clearance in the obese. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411343/),[ml] / [min],891,74361,DB00997,Doxorubicin
,3411343,systemic clearance,"Doxorubicin area under the curve (AUC) was greater in obese than in normal patients (2,209 v 1,190 ng h/mL; P less than .05), yielding correspondingly reduced systemic clearance of the agent in obese patients (891 v 1,569 mL/min; P less than .001).",Doxorubicin clearance in the obese. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411343/),[ml] / [min],"1,569",74362,DB00997,Doxorubicin
,3411343,elimination half-life (T1/2),The mean elimination half-life (T1/2) was 20.4 hours in the obese patients and 13.0 hours in the normal patients.,Doxorubicin clearance in the obese. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411343/),h,20.4,74363,DB00997,Doxorubicin
,3411343,elimination half-life (T1/2),The mean elimination half-life (T1/2) was 20.4 hours in the obese patients and 13.0 hours in the normal patients.,Doxorubicin clearance in the obese. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3411343/),h,13.0,74364,DB00997,Doxorubicin
,1829915,steady state plasma concentration,"Bepridil was administered in a continuous 36 h infusion at 22 mg/kg/36 h, with a dose scheme which should result in a steady state plasma concentration of approximately 5 mumol/l, able to reverse anthracycline resistance in vitro.",Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829915/),[μM] / [l],5,74555,DB00997,Doxorubicin
,1829915,plasma concentration,"Pharmacokinetic studies demonstrated a median bepridil plasma concentration of 5.3 mumol/l (range 2.6-19.3 mumol/l), at the time of administration of the anthracycline.",Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829915/),[μM] / [l],5.3,74556,DB00997,Doxorubicin
,2322293,peak concentrations,"However, in microspherical form both drugs were extensively metabolized (peak concentrations: 3.6 micrograms/g doxorubicin 7-deoxyaglycone; 2.5 micrograms/g 4'-deoxydoxorubicin 7-deoxyaglycone).",Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2322293/),[μg] / [g],3.6,74952,DB00997,Doxorubicin
,2322293,peak concentrations,"However, in microspherical form both drugs were extensively metabolized (peak concentrations: 3.6 micrograms/g doxorubicin 7-deoxyaglycone; 2.5 micrograms/g 4'-deoxydoxorubicin 7-deoxyaglycone).",Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2322293/),[μg] / [g],2.5,74953,DB00997,Doxorubicin
,3712763,half-lives,"The plasma level of THP was lowered in a triphasic pattern up to 24 hours and was simulated by a three-compartment open model in which the half-lives of alpha-, beta- and gamma-phase were calculated to be 0.0116 hour, 0.152 hour and 7.02 hours, respectively.",Pharmacokinetics and disposition of (2''R)-4'-O-tetrahydropyranyladriamycin in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712763/),h,0.0116,75348,DB00997,Doxorubicin
,3712763,half-lives,"The plasma level of THP was lowered in a triphasic pattern up to 24 hours and was simulated by a three-compartment open model in which the half-lives of alpha-, beta- and gamma-phase were calculated to be 0.0116 hour, 0.152 hour and 7.02 hours, respectively.",Pharmacokinetics and disposition of (2''R)-4'-O-tetrahydropyranyladriamycin in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712763/),h,0.152,75349,DB00997,Doxorubicin
,3712763,half-lives,"The plasma level of THP was lowered in a triphasic pattern up to 24 hours and was simulated by a three-compartment open model in which the half-lives of alpha-, beta- and gamma-phase were calculated to be 0.0116 hour, 0.152 hour and 7.02 hours, respectively.",Pharmacokinetics and disposition of (2''R)-4'-O-tetrahydropyranyladriamycin in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3712763/),h,7.02,75350,DB00997,Doxorubicin
,16923981,Maximum plasma concentrations,"Maximum plasma concentrations were 651 ng/mL and 42.8 ng/mL for the 100- to 300-microm and 700- to 900-microm DEB groups, respectively, observed at 1 minute for both groups.",Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16923981/),[ng] / [ml],651,75730,DB00997,Doxorubicin
,16923981,Maximum plasma concentrations,"Maximum plasma concentrations were 651 ng/mL and 42.8 ng/mL for the 100- to 300-microm and 700- to 900-microm DEB groups, respectively, observed at 1 minute for both groups.",Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16923981/),[ng] / [ml],42.8,75731,DB00997,Doxorubicin
,20678033,en,"Spray-drying produced a dispersed powder with a mean particle size of 4.91 ± 1.2 µm, 60% product yield, and encapsulation efficiency of 85% and a ζ potential range of 37 to -40 mV.",Spray-dried doxorubicin-albumin microparticulate systems for treatment of multidrug resistant melanomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678033/),,85,76263,DB00997,Doxorubicin
,20678033,ζ potential,"Spray-drying produced a dispersed powder with a mean particle size of 4.91 ± 1.2 µm, 60% product yield, and encapsulation efficiency of 85% and a ζ potential range of 37 to -40 mV.",Spray-dried doxorubicin-albumin microparticulate systems for treatment of multidrug resistant melanomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678033/),mv,37 to -40,76264,DB00997,Doxorubicin
,19927044,area under the curve,"Patients with successful remission (n = 14) had a trend toward a higher median area under the curve than those who failed remission (n = 4; 36,390 versus 19,350 ng/mL x minute, P = 0.08, respectively).",Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927044/),[ng] / [min·ml],"36,390",76453,DB00997,Doxorubicin
,19927044,area under the curve,"Patients with successful remission (n = 14) had a trend toward a higher median area under the curve than those who failed remission (n = 4; 36,390 versus 19,350 ng/mL x minute, P = 0.08, respectively).",Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927044/),[ng] / [min·ml],"19,350",76454,DB00997,Doxorubicin
,19927044,peak serum concentrations,Median peak serum concentrations were 73 ng/mL among failures and 280 ng/mL in those who achieved remission (P = 0.06).,Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927044/),[ng] / [ml],73,76455,DB00997,Doxorubicin
,19927044,peak serum concentrations,Median peak serum concentrations were 73 ng/mL among failures and 280 ng/mL in those who achieved remission (P = 0.06).,Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927044/),[ng] / [ml],280,76456,DB00997,Doxorubicin
,9649122,t(1/2),"Both 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP) rapidly penetrated DLD-1 multicell layers (50.9 +/- 12.1 microm thick) with t(1/2) values of 1.36 and 2.38 h respectively, whereas the rate of penetration of 5-aziridino-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-beta-en-alpha-ol (EO9) and doxorubicin through multicell layers was significantly slower (t(1/2) = 4.62 and 13.1 h respectively).",Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649122/),h,1.36,76623,DB00997,Doxorubicin
,9649122,t(1/2),"Both 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP) rapidly penetrated DLD-1 multicell layers (50.9 +/- 12.1 microm thick) with t(1/2) values of 1.36 and 2.38 h respectively, whereas the rate of penetration of 5-aziridino-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-beta-en-alpha-ol (EO9) and doxorubicin through multicell layers was significantly slower (t(1/2) = 4.62 and 13.1 h respectively).",Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649122/),h,2.38,76624,DB00997,Doxorubicin
,9649122,t(1/2),"Both 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP) rapidly penetrated DLD-1 multicell layers (50.9 +/- 12.1 microm thick) with t(1/2) values of 1.36 and 2.38 h respectively, whereas the rate of penetration of 5-aziridino-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-beta-en-alpha-ol (EO9) and doxorubicin through multicell layers was significantly slower (t(1/2) = 4.62 and 13.1 h respectively).",Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649122/),h,4.62,76625,DB00997,Doxorubicin
,9649122,t(1/2),"Both 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine) and 7-[4'-(2-nitroimidazol-1-yl)-butyl]-theophylline (NITP) rapidly penetrated DLD-1 multicell layers (50.9 +/- 12.1 microm thick) with t(1/2) values of 1.36 and 2.38 h respectively, whereas the rate of penetration of 5-aziridino-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-beta-en-alpha-ol (EO9) and doxorubicin through multicell layers was significantly slower (t(1/2) = 4.62 and 13.1 h respectively).",Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649122/),h,13.1,76626,DB00997,Doxorubicin
<,9649122,t(1/2),"The fact that EO9 does not readily penetrate a multicell layer, in conjunction with its rapid elimination in vivo (t(1/2) < 10 min), suggests that EO9 is unlikely to penetrate more than a few microm from a blood vessel within its pharmacokinetic lifespan.",Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649122/),min,10,76627,DB00997,Doxorubicin
,15813033,Mw,In vitro drug release experiments were carried out with a dialysis bag (Mw cut-off 12000 - 14000).,[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),,12000 - 14000,76690,DB00997,Doxorubicin
,15813033,particle size,"The particle size of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were (103 +/- 8), (102 +/- 12) and (97 +/- 8) nm.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),,103,76691,DB00997,Doxorubicin
,15813033,particle size,"The particle size of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were (103 +/- 8), (102 +/- 12) and (97 +/- 8) nm.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),,102,76692,DB00997,Doxorubicin
,15813033,particle size,"The particle size of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were (103 +/- 8), (102 +/- 12) and (97 +/- 8) nm.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),,97,76693,DB00997,Doxorubicin
,15813033,zeta potential,"The zeta potential and the encapsulation ratio were (-21.3 +/- 0.5), (-21.7 +/- 0.4), (-20.9 +/- 0.7) mV and 47.8%, 96.7%, 98.6%, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),m,21.3,76694,DB00997,Doxorubicin
,15813033,encapsulation ratio,"The zeta potential and the encapsulation ratio were (-21.3 +/- 0.5), (-21.7 +/- 0.4), (-20.9 +/- 0.7) mV and 47.8%, 96.7%, 98.6%, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),m,21.7,76695,DB00997,Doxorubicin
,15813033,encapsulation ratio,"The zeta potential and the encapsulation ratio were (-21.3 +/- 0.5), (-21.7 +/- 0.4), (-20.9 +/- 0.7) mV and 47.8%, 96.7%, 98.6%, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),m,20.9,76696,DB00997,Doxorubicin
,15813033,encapsulation ratio,"The zeta potential and the encapsulation ratio were (-21.3 +/- 0.5), (-21.7 +/- 0.4), (-20.9 +/- 0.7) mV and 47.8%, 96.7%, 98.6%, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),%,47.8,76697,DB00997,Doxorubicin
,15813033,encapsulation ratio,"The zeta potential and the encapsulation ratio were (-21.3 +/- 0.5), (-21.7 +/- 0.4), (-20.9 +/- 0.7) mV and 47.8%, 96.7%, 98.6%, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),,96,76698,DB00997,Doxorubicin
,15813033,MRT (mean retention time),"Pharmacokinetic study showed that the MRT (mean retention time) of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were 12.13, 23.31 and 29.79 h, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),h,12.13,76699,DB00997,Doxorubicin
,15813033,MRT (mean retention time),"Pharmacokinetic study showed that the MRT (mean retention time) of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were 12.13, 23.31 and 29.79 h, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),h,23.31,76700,DB00997,Doxorubicin
,15813033,MRT (mean retention time),"Pharmacokinetic study showed that the MRT (mean retention time) of liposomes with glycinate buffer, citrate buffer and ammonium sulfate as the inner water phase were 12.13, 23.31 and 29.79 h, respectively.",[Influence of different doxorubicin-salt aggregates on the leakage of liposomal doxorubicin in vitro and long circulation in vivo]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813033/),h,29.79,76701,DB00997,Doxorubicin
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,21,77038,DB00997,Doxorubicin
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,35,77039,DB00997,Doxorubicin
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,56,77040,DB00997,Doxorubicin
,17453364,time to progression,"At median follow-up of 113 months, the median time to progression and median overall survival were 14 and 36 months, respectively.","Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17453364/),month,14,78618,DB00997,Doxorubicin
,17453364,overall survival,"At median follow-up of 113 months, the median time to progression and median overall survival were 14 and 36 months, respectively.","Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17453364/),month,36,78619,DB00997,Doxorubicin
,15778066,terminal half-life,"The PK of total, unconjugated and metabolized doxorubicin was examined for 5 days following intravenous (i.v.) administration of the NP formulation (250 microg doxorubicin equiv.), revealing a bi-exponential fix with a terminal half-life of 5.99 h.",Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778066/),h,5.99,79510,DB00997,Doxorubicin
,1544285,total body clearance,The pharmacokinetics of N-L-leucyl-doxorubicin was linear with a total body clearance of 41.3 +/- 25.7 L/hr/m2.,"Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544285/),[l] / [h·m2],41.3,79641,DB00997,Doxorubicin
,1544285,m,The mean molar doxorubicin/N-L-leucyl-doxorubicin area under the curve (AUC) ratio was 0.49 +/- 0.22 and was independent of the administered dose.,"Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544285/),,0.49,79642,DB00997,Doxorubicin
,1544285,area under the curve (AUC) ratio,The mean molar doxorubicin/N-L-leucyl-doxorubicin area under the curve (AUC) ratio was 0.49 +/- 0.22 and was independent of the administered dose.,"Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544285/),,0.49,79643,DB00997,Doxorubicin
,30690115,zeta potential,"A particle size (198.3 ± 9.21 nm), drug content (47.06 ± 1.16 mg/mg) and zeta potential (11.3 ± 0.98 mV), consisting of smooth and spherical shape was observed for developed formulation.",Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30690115/),mv,11.3,79833,DB00997,Doxorubicin
,30690115,el,"With regard to bioanalytical method, easy as well as a rapid method for DAUN-plasma quantification was developed as; 2.75 min and 528.49/321.54 m/z for DAUN along with 1.94 min and 544.36/397.41 m/z for IS i.e. Doxorubicin, for elution time and transition, respectively.",Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30690115/),min,1.94,79834,DB00997,Doxorubicin
,30690115,el,"With regard to bioanalytical method, easy as well as a rapid method for DAUN-plasma quantification was developed as; 2.75 min and 528.49/321.54 m/z for DAUN along with 1.94 min and 544.36/397.41 m/z for IS i.e. Doxorubicin, for elution time and transition, respectively.",Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30690115/),[m] / [z],544.36,79835,DB00997,Doxorubicin
,2383143,half-life,"Artificial hyperglycemia was found to change the doxorubicin pharmacokinetics in the experimental animals evident from increased in antibiotic half-life to 42.3 min against 26.5 min in the controls, the apparent initial concentration of doxorubicin being increased 1.6 times.",[Modification of doxorubicin action with artificial hyperglycemia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2383143/),min,42.3,80898,DB00997,Doxorubicin
,2383143,half-life,"Artificial hyperglycemia was found to change the doxorubicin pharmacokinetics in the experimental animals evident from increased in antibiotic half-life to 42.3 min against 26.5 min in the controls, the apparent initial concentration of doxorubicin being increased 1.6 times.",[Modification of doxorubicin action with artificial hyperglycemia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2383143/),min,26.5,80899,DB00997,Doxorubicin
,17907289,response rate,"One patient showed complete response (CR) with disappearance of HCC and PVTT after treatment, and the two patients showed partial response (PR), response rate (CR + PR/All cases 30%).","Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17907289/),%,30,81438,DB00997,Doxorubicin
,17907289,survival time,The median survival time after the therapy was 457.2 d.,"Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17907289/),d,457.2,81439,DB00997,Doxorubicin
,9717822,area under the plasma concentration versus time curves,"The area under the plasma concentration versus time curves and the peak plasma levels of CrEL increased from 253+/-36.8 (mean+/-SD) to 680+/- 180 microl.h/ml, and from 3.40+/-0.10 to 6.58+/-0.52 microl/ml, respectively, consistent with linear pharmacokinetics.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[h·μl] / [ml],253,82062,DB00997,Doxorubicin
,9717822,area under the plasma concentration versus time curves,"The area under the plasma concentration versus time curves and the peak plasma levels of CrEL increased from 253+/-36.8 (mean+/-SD) to 680+/- 180 microl.h/ml, and from 3.40+/-0.10 to 6.58+/-0.52 microl/ml, respectively, consistent with linear pharmacokinetics.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[h·μl] / [ml],680,82063,DB00997,Doxorubicin
,9717822,peak plasma levels,"The area under the plasma concentration versus time curves and the peak plasma levels of CrEL increased from 253+/-36.8 (mean+/-SD) to 680+/- 180 microl.h/ml, and from 3.40+/-0.10 to 6.58+/-0.52 microl/ml, respectively, consistent with linear pharmacokinetics.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[h·μl] / [ml],680,82064,DB00997,Doxorubicin
,9717822,peak plasma levels,"The area under the plasma concentration versus time curves and the peak plasma levels of CrEL increased from 253+/-36.8 (mean+/-SD) to 680+/- 180 microl.h/ml, and from 3.40+/-0.10 to 6.58+/-0.52 microl/ml, respectively, consistent with linear pharmacokinetics.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[μl] / [ml],3.40,82065,DB00997,Doxorubicin
,9717822,peak plasma levels,"The area under the plasma concentration versus time curves and the peak plasma levels of CrEL increased from 253+/-36.8 (mean+/-SD) to 680+/- 180 microl.h/ml, and from 3.40+/-0.10 to 6.58+/-0.52 microl/ml, respectively, consistent with linear pharmacokinetics.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[μl] / [ml],6.58,82066,DB00997,Doxorubicin
,9717822,terminal elimination half-life,"Disappearance of CrEL from the central plasma compartment was characterized by a terminal elimination half-life of 84.1+/-20.4 h, resulting in extended persistence of substantial levels even at 1 week after paclitaxel treatment.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),h,84.1,82067,DB00997,Doxorubicin
,9717822,volume of distribution,"The observed volume of distribution was extremely low and averaged 3.70+/-0.49 liters/m2, implying that the tumor delivery of CrEL is insignificant.",Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717822/),[l] / [m2],3.70,82068,DB00997,Doxorubicin
,9703908,cavity/blood ratios,"The cavity/blood ratios of the area under the concentration curve (AUC), of smancs, bovine serum albumin (BSA), DOX, and MMC were 9.69, 7.06, 1.38, 1.15, respectively.",Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9703908/),,9,82322,DB00997,Doxorubicin
,9703908,cavity/blood ratios,"The cavity/blood ratios of the area under the concentration curve (AUC), of smancs, bovine serum albumin (BSA), DOX, and MMC were 9.69, 7.06, 1.38, 1.15, respectively.",Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9703908/),,7,82323,DB00997,Doxorubicin
,9703908,cavity/blood ratios,"The cavity/blood ratios of the area under the concentration curve (AUC), of smancs, bovine serum albumin (BSA), DOX, and MMC were 9.69, 7.06, 1.38, 1.15, respectively.",Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9703908/),,1,82324,DB00997,Doxorubicin
,10967428,encapsulation efficiency,The average diameter of the liposomal DXR in saline was 129.0+/-1.9 nm and the encapsulation efficiency was 98.1+/-0.6%.,In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967428/),%,98.1,82719,DB00997,Doxorubicin
,25213162,maximum serum concentration,Median maximum serum concentration of pantoprazole was 84.3 μM at 1-2 h after injection of pantoprazole 240 mg.,A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25213162/),μM,84.3,82784,DB00997,Doxorubicin
,22669705,AUC,"This study demonstrates that PolyDoxSome has higher AUC (569 vs. 4 h*μg/mL), longer plasma circulation half life (21.9 vs. 0.49 h), decreased clearance (10.5 vs.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),[h·μg] / [ml],569,82978,DB00997,Doxorubicin
,22669705,AUC,"This study demonstrates that PolyDoxSome has higher AUC (569 vs. 4 h*μg/mL), longer plasma circulation half life (21.9 vs. 0.49 h), decreased clearance (10.5 vs.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),[h·μg] / [ml],4,82979,DB00997,Doxorubicin
,22669705,plasma circulation half life,"This study demonstrates that PolyDoxSome has higher AUC (569 vs. 4 h*μg/mL), longer plasma circulation half life (21.9 vs. 0.49 h), decreased clearance (10.5 vs.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),h,21.9,82980,DB00997,Doxorubicin
,22669705,plasma circulation half life,"This study demonstrates that PolyDoxSome has higher AUC (569 vs. 4 h*μg/mL), longer plasma circulation half life (21.9 vs. 0.49 h), decreased clearance (10.5 vs.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),h,0.49,82981,DB00997,Doxorubicin
,22669705,clearance,"This study demonstrates that PolyDoxSome has higher AUC (569 vs. 4 h*μg/mL), longer plasma circulation half life (21.9 vs. 0.49 h), decreased clearance (10.5 vs.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),,10.5,82982,DB00997,Doxorubicin
,22669705,volume of distribution,1579 mL/h/kg) and volume of distribution (137.7 vs. 1091 mL/kg) as compared to free doxorubicin.,In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),[ml] / [kg],137.7,82983,DB00997,Doxorubicin
,22669705,volume of distribution,1579 mL/h/kg) and volume of distribution (137.7 vs. 1091 mL/kg) as compared to free doxorubicin.,In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),[ml] / [kg],1091,82984,DB00997,Doxorubicin
,22669705,plasma circulation half life,"When PolyDoxSome was compared with LipoDox™, it differs in size (171 vs. <100 nm), plasma circulation half life (22 vs. 35 h), C(max) (34 vs. 67 μg/mL), and AUC (568 vs. 2291 h*μg/mL), however PolyDoxSome was comparable on efficacy and toxicity profile of LipoDox™.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),h,22,82985,DB00997,Doxorubicin
,22669705,plasma circulation half life,"When PolyDoxSome was compared with LipoDox™, it differs in size (171 vs. <100 nm), plasma circulation half life (22 vs. 35 h), C(max) (34 vs. 67 μg/mL), and AUC (568 vs. 2291 h*μg/mL), however PolyDoxSome was comparable on efficacy and toxicity profile of LipoDox™.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),h,35,82986,DB00997,Doxorubicin
,22669705,C(max),"When PolyDoxSome was compared with LipoDox™, it differs in size (171 vs. <100 nm), plasma circulation half life (22 vs. 35 h), C(max) (34 vs. 67 μg/mL), and AUC (568 vs. 2291 h*μg/mL), however PolyDoxSome was comparable on efficacy and toxicity profile of LipoDox™.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),[μg] / [ml],34,82987,DB00997,Doxorubicin
,22669705,C(max),"When PolyDoxSome was compared with LipoDox™, it differs in size (171 vs. <100 nm), plasma circulation half life (22 vs. 35 h), C(max) (34 vs. 67 μg/mL), and AUC (568 vs. 2291 h*μg/mL), however PolyDoxSome was comparable on efficacy and toxicity profile of LipoDox™.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),[μg] / [ml],67,82988,DB00997,Doxorubicin
,22669705,AUC,"When PolyDoxSome was compared with LipoDox™, it differs in size (171 vs. <100 nm), plasma circulation half life (22 vs. 35 h), C(max) (34 vs. 67 μg/mL), and AUC (568 vs. 2291 h*μg/mL), however PolyDoxSome was comparable on efficacy and toxicity profile of LipoDox™.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),[h·μg] / [ml],568,82989,DB00997,Doxorubicin
,22669705,AUC,"When PolyDoxSome was compared with LipoDox™, it differs in size (171 vs. <100 nm), plasma circulation half life (22 vs. 35 h), C(max) (34 vs. 67 μg/mL), and AUC (568 vs. 2291 h*μg/mL), however PolyDoxSome was comparable on efficacy and toxicity profile of LipoDox™.",In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22669705/),[h·μg] / [ml],2291,82990,DB00997,Doxorubicin
>,11585754,tumor,"Under all of the conditions, ST1481 exhibited an impressive efficacy in terms of tumor growth inhibition (tumor volume inhibition percentage > 99%), log(10) cell kill, rate of complete responses (including ""cures""), and an improvement of the therapeutic index compared with topotecan (used as the reference drug).","Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11585754/),,99,83093,DB00997,Doxorubicin
,3282579,elimination half-life,The elimination half-life of epirubicin or esorubicin is similar to that of doxorubicin (30 h) and the elimination half-life of unchanged idarubicin or pirarubicin is shorter (15-20 h).,[Pharmacokinetics of new anthracyclines]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282579/),h,30,83802,DB00997,Doxorubicin
,3282579,elimination half-life,The elimination half-life of epirubicin or esorubicin is similar to that of doxorubicin (30 h) and the elimination half-life of unchanged idarubicin or pirarubicin is shorter (15-20 h).,[Pharmacokinetics of new anthracyclines]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282579/),h,15-20,83803,DB00997,Doxorubicin
,10389912,MTD,"Anemia, neutropenia, thrombocytopenia, and mucositis became dose limiting at the fourth dose level, defining the MTD of doxorubicin in this regimen as 50 mg/m2.",A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389912/),,50,83820,DB00997,Doxorubicin
,10389912,Apparent steady-state plasma concentrations,"Apparent steady-state plasma concentrations (mean +/- SD) of paclitaxel and doxorubicin in the three patients treated at the MTD were 33.9 +/- 12.5 nM and 15.7 +/- 1.3 nM, respectively.",A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389912/),nM,33.9,83821,DB00997,Doxorubicin
,10389912,Apparent steady-state plasma concentrations,"Apparent steady-state plasma concentrations (mean +/- SD) of paclitaxel and doxorubicin in the three patients treated at the MTD were 33.9 +/- 12.5 nM and 15.7 +/- 1.3 nM, respectively.",A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389912/),nM,15.7,83822,DB00997,Doxorubicin
,7945673,encapsulation rate,The in vitro encapsulation rate in isolated erythrocytes amounts to 52.9 +/- 2.8% and remains constant within the range of studied concentrations (2.5-20 micrograms/ml).,In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,52.9,84025,DB00997,Doxorubicin
,7945673,Binding,"Binding to alpha-HSA amounted up to 51.0 +/- 7.10%, to alpha+beta-HSG 79.45 +/- 2.7%, to gamma-HSG 57.1 +/- 2.8%.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,51,84026,DB00997,Doxorubicin
,7945673,Binding,"Binding to alpha-HSA amounted up to 51.0 +/- 7.10%, to alpha+beta-HSG 79.45 +/- 2.7%, to gamma-HSG 57.1 +/- 2.8%.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,79.45,84027,DB00997,Doxorubicin
,7945673,Binding,"Binding to alpha-HSA amounted up to 51.0 +/- 7.10%, to alpha+beta-HSG 79.45 +/- 2.7%, to gamma-HSG 57.1 +/- 2.8%.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,57.1,84028,DB00997,Doxorubicin
,7945673,in vivo-binding rate,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,32,84029,DB00997,Doxorubicin
,7945673,in vivo-binding rate,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,11.6,84030,DB00997,Doxorubicin
,7945673,in vivo-binding rate,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,10.05,84031,DB00997,Doxorubicin
,7945673,availability in serum,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,42.6,84032,DB00997,Doxorubicin
,7945673,availability in serum,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,2.4,84033,DB00997,Doxorubicin
,7945673,availability in serum,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,1.2,84034,DB00997,Doxorubicin
,10789596,Cmax ratio Dox/Epi,The Cmax ratio Dox/Epi was 1.39+/-0.19 (mean +/- SD).,A comparative pharmacokinetic study of doxorubicin and 4'-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10789596/),,1.39,84340,DB00997,Doxorubicin
,4063148,LD50,"The fluorescent stain Hoechst 33342, when injected i.v. into mice, has an LD50 of 300 micrograms g-1.","Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4063148/),[μg] / [g],300,84341,DB00997,Doxorubicin
,4063148,half-life,"The stain exits rapidly from the blood, with a half-life of 110 sec following an injection of 10 micrograms g-1, but remains bound within target cells, redistributing with a half-life longer than 2 h.","Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4063148/),s,110,84342,DB00997,Doxorubicin
longer,4063148,half-life,"The stain exits rapidly from the blood, with a half-life of 110 sec following an injection of 10 micrograms g-1, but remains bound within target cells, redistributing with a half-life longer than 2 h.","Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4063148/),h,2,84343,DB00997,Doxorubicin
,11387367,clearance,"The clearance and terminal elimination half-lives for NSC 655649 averaged 7.57 (SD = 4.2) L/h/m(2) and 48.85 (SD = 23.65) hours, respectively.","Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11387367/),[h·l] / [m(2],7.57,84419,DB00997,Doxorubicin
,11387367,terminal elimination half-lives,"The clearance and terminal elimination half-lives for NSC 655649 averaged 7.57 (SD = 4.2) L/h/m(2) and 48.85 (SD = 23.65) hours, respectively.","Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11387367/),h,48.85,84420,DB00997,Doxorubicin
,9569055,area under the plasma concentration-time curve (AUC),"In nine intrapatient comparisons, the area under the plasma concentration-time curve (AUC) of epirubicin was significantly reduced by dexverapamil (mean 2968 vs 1901 microg ml[-1] h[-1], P= 0.02).",Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),[μg] / [h·ml],2968,84831,DB00997,Doxorubicin
,9569055,area under the plasma concentration-time curve (AUC),"In nine intrapatient comparisons, the area under the plasma concentration-time curve (AUC) of epirubicin was significantly reduced by dexverapamil (mean 2968 vs 1901 microg ml[-1] h[-1], P= 0.02).",Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),[μg] / [h·ml],1901,84832,DB00997,Doxorubicin
,9569055,trough plasma levels,The mean trough plasma levels of dexverapamil and its major metabolite nor-dexverapamil were 1.2 and 1.5 microM respectively.,Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),μM,1.2,84833,DB00997,Doxorubicin
,9569055,trough plasma levels,The mean trough plasma levels of dexverapamil and its major metabolite nor-dexverapamil were 1.2 and 1.5 microM respectively.,Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),μM,1.5,84834,DB00997,Doxorubicin
,23153506,maximum tolerated dose,"Of the 26 patients assessed for the primary endpoint, two who received a dose of 60 mg/m(2) had dose-limiting toxicities (one had neutropenia and the other had anaemia); therefore, the maximum tolerated dose was defined as 50 mg/m(2).","Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153506/),[mg] / [m],50,85121,DB00997,Doxorubicin
,12183668,clearance,"The clearance (0.51 versus 0.33 l/h/kg) and V(d) (1.25 versus 0.93 l/kg) of DM5 were found to be higher (p < 0.05), however the area under the curve (26.1 versus 38.2 microg/ml.",Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183668/),[l] / [h·kg],0.51,85333,DB00997,Doxorubicin
,12183668,clearance,"The clearance (0.51 versus 0.33 l/h/kg) and V(d) (1.25 versus 0.93 l/kg) of DM5 were found to be higher (p < 0.05), however the area under the curve (26.1 versus 38.2 microg/ml.",Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183668/),[l] / [h·kg],0.33,85334,DB00997,Doxorubicin
,12183668,V(d),"The clearance (0.51 versus 0.33 l/h/kg) and V(d) (1.25 versus 0.93 l/kg) of DM5 were found to be higher (p < 0.05), however the area under the curve (26.1 versus 38.2 microg/ml.",Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183668/),[l] / [kg],1.25,85335,DB00997,Doxorubicin
,12183668,V(d),"The clearance (0.51 versus 0.33 l/h/kg) and V(d) (1.25 versus 0.93 l/kg) of DM5 were found to be higher (p < 0.05), however the area under the curve (26.1 versus 38.2 microg/ml.",Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183668/),[l] / [kg],0.93,85336,DB00997,Doxorubicin
,12183668,area under the curve,"The clearance (0.51 versus 0.33 l/h/kg) and V(d) (1.25 versus 0.93 l/kg) of DM5 were found to be higher (p < 0.05), however the area under the curve (26.1 versus 38.2 microg/ml.",Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183668/),[μg] / [ml],26.1,85337,DB00997,Doxorubicin
,12183668,area under the curve,"The clearance (0.51 versus 0.33 l/h/kg) and V(d) (1.25 versus 0.93 l/kg) of DM5 were found to be higher (p < 0.05), however the area under the curve (26.1 versus 38.2 microg/ml.",Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183668/),[μg] / [ml],38.2,85338,DB00997,Doxorubicin
,23082168,Maximum intracellular tumor drug concentrations,"Maximum intracellular tumor drug concentrations for Free-DOX, Stealth-DOX, TSL-i, and TSL-e were 3.4, 0.4, 100.6, and 15.9 µg/g, respectively.","Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23082168/),[μg] / [g],3.4,85447,DB00997,Doxorubicin
,23082168,Maximum intracellular tumor drug concentrations,"Maximum intracellular tumor drug concentrations for Free-DOX, Stealth-DOX, TSL-i, and TSL-e were 3.4, 0.4, 100.6, and 15.9 µg/g, respectively.","Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23082168/),[μg] / [g],0.4,85448,DB00997,Doxorubicin
,23082168,Maximum intracellular tumor drug concentrations,"Maximum intracellular tumor drug concentrations for Free-DOX, Stealth-DOX, TSL-i, and TSL-e were 3.4, 0.4, 100.6, and 15.9 µg/g, respectively.","Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23082168/),[μg] / [g],100.6,85449,DB00997,Doxorubicin
,23082168,Maximum intracellular tumor drug concentrations,"Maximum intracellular tumor drug concentrations for Free-DOX, Stealth-DOX, TSL-i, and TSL-e were 3.4, 0.4, 100.6, and 15.9 µg/g, respectively.","Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23082168/),[μg] / [g],15.9,85450,DB00997,Doxorubicin
,22341684,recovery,"The recovery of total Dox (i.e. free Dox and Dox associated with nanoparticles) from plasma and tissues (liver, spleen and heart) spiked with Dox-PACA were 71 and 78% for 0.05 and 1 μg/mL in rat plasma, respectively, and 73% and 80% for 0.5 and 10 μg/g in tissues, respectively.",HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341684/),%,71,85979,DB00997,Doxorubicin
,22341684,recovery,"The recovery of total Dox (i.e. free Dox and Dox associated with nanoparticles) from plasma and tissues (liver, spleen and heart) spiked with Dox-PACA were 71 and 78% for 0.05 and 1 μg/mL in rat plasma, respectively, and 73% and 80% for 0.5 and 10 μg/g in tissues, respectively.",HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341684/),%,78,85980,DB00997,Doxorubicin
,22341684,recovery,"The recovery of total Dox (i.e. free Dox and Dox associated with nanoparticles) from plasma and tissues (liver, spleen and heart) spiked with Dox-PACA were 71 and 78% for 0.05 and 1 μg/mL in rat plasma, respectively, and 73% and 80% for 0.5 and 10 μg/g in tissues, respectively.",HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341684/),%,73,85981,DB00997,Doxorubicin
,22341684,recovery,"The recovery of total Dox (i.e. free Dox and Dox associated with nanoparticles) from plasma and tissues (liver, spleen and heart) spiked with Dox-PACA were 71 and 78% for 0.05 and 1 μg/mL in rat plasma, respectively, and 73% and 80% for 0.5 and 10 μg/g in tissues, respectively.",HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341684/),%,80,85982,DB00997,Doxorubicin
,22341684,limit of detection,The limit of detection of the method is 0.5 ng of Dox per injection (50 μL).,HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22341684/),ng,0.5,85983,DB00997,Doxorubicin
,11304769,complete response rates,"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively.",Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304769/),%,30,86057,DB00997,Doxorubicin
,11304769,complete response rates,"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively.",Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304769/),%,48,86058,DB00997,Doxorubicin
,2529962,terminal disposition half-life (t1/2),"Upon i.v. administration, menogaril plasma concentration-time curves declined in a biexponential (dog) or triexponential (mouse and monkey) manner, with the terminal disposition half-life (t1/2) being considerably shorter in the dog (2.86 +/- 0.47 h) than in the mouse and monkey (21.6 and 19.0 +/- 3.7 h, respectively).","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),h,2.86,86474,DB00997,Doxorubicin
,2529962,terminal disposition half-life (t1/2),"Upon i.v. administration, menogaril plasma concentration-time curves declined in a biexponential (dog) or triexponential (mouse and monkey) manner, with the terminal disposition half-life (t1/2) being considerably shorter in the dog (2.86 +/- 0.47 h) than in the mouse and monkey (21.6 and 19.0 +/- 3.7 h, respectively).","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),h,21.6,86475,DB00997,Doxorubicin
,2529962,terminal disposition half-life (t1/2),"Upon i.v. administration, menogaril plasma concentration-time curves declined in a biexponential (dog) or triexponential (mouse and monkey) manner, with the terminal disposition half-life (t1/2) being considerably shorter in the dog (2.86 +/- 0.47 h) than in the mouse and monkey (21.6 and 19.0 +/- 3.7 h, respectively).","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),h,19.0,86476,DB00997,Doxorubicin
,2529962,systemic clearance (CL,"The systemic clearance (CL, in liters/h/kg) was highest in mouse (6.2), followed by dog (2.9) and then monkey (1.4).","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),[l] / [h·kg],6.2,86477,DB00997,Doxorubicin
,2529962,systemic clearance (CL,"The systemic clearance (CL, in liters/h/kg) was highest in mouse (6.2), followed by dog (2.9) and then monkey (1.4).","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),[l] / [h·kg],2.9,86478,DB00997,Doxorubicin
,2529962,systemic clearance (CL,"The systemic clearance (CL, in liters/h/kg) was highest in mouse (6.2), followed by dog (2.9) and then monkey (1.4).","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),[l] / [h·kg],1.4,86479,DB00997,Doxorubicin
,2529962,steady state volumes of distribution,"The drug was extensively distributed in all three species, with steady state volumes of distribution being 88.5, 9.8, and 27.9 liters/kg in the mouse, dog, and monkey, respectively.","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),[l] / [kg],88.5,86480,DB00997,Doxorubicin
,2529962,steady state volumes of distribution,"The drug was extensively distributed in all three species, with steady state volumes of distribution being 88.5, 9.8, and 27.9 liters/kg in the mouse, dog, and monkey, respectively.","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),[l] / [kg],9.8,86481,DB00997,Doxorubicin
,2529962,steady state volumes of distribution,"The drug was extensively distributed in all three species, with steady state volumes of distribution being 88.5, 9.8, and 27.9 liters/kg in the mouse, dog, and monkey, respectively.","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),[l] / [kg],27.9,86482,DB00997,Doxorubicin
,2529962,systemic bioavailability,"Upon p.o. treatment, first-pass metabolism or incomplete absorption reduced the systemic bioavailability to 12% in the dog and 33% in the mouse and monkey.","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),%,12,86483,DB00997,Doxorubicin
,2529962,systemic bioavailability,"Upon p.o. treatment, first-pass metabolism or incomplete absorption reduced the systemic bioavailability to 12% in the dog and 33% in the mouse and monkey.","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),%,33,86484,DB00997,Doxorubicin
,2529962,systemic bioavailability,"Interspecies comparison of menogaril pharmacokinetic parameters in mice, dogs, monkeys, and humans using allometric techniques indicated that the parameters for mice, monkeys, and humans were highly correlated; in each of these species presystemic metabolism of p.o. administered menogaril reduced its systemic bioavailability to an equivalent extent (30-35%).","Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529962/),%,30-35,86485,DB00997,Doxorubicin
,33046971,area under the concentration curve in,"The area under the concentration curve in PerC cells AUC0-10d was 8.2±0.57 µg/g x h, 4.6±0.27 µg/g x h and 1.6±0.02 µg/g x h in ""cure"", ""relapse"" and ""resistance"" TBM respectively (p<0.05 ""relapse"" vs ""cure"" and p<0.001 ""resistance"" vs ""cure"").",Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046971/),[μg] / [g·h],8.2,87257,DB00997,Doxorubicin
,33046971,area under the concentration curve in,"The area under the concentration curve in PerC cells AUC0-10d was 8.2±0.57 µg/g x h, 4.6±0.27 µg/g x h and 1.6±0.02 µg/g x h in ""cure"", ""relapse"" and ""resistance"" TBM respectively (p<0.05 ""relapse"" vs ""cure"" and p<0.001 ""resistance"" vs ""cure"").",Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046971/),[μg] / [g·h],4.6,87258,DB00997,Doxorubicin
,33046971,area under the concentration curve in,"The area under the concentration curve in PerC cells AUC0-10d was 8.2±0.57 µg/g x h, 4.6±0.27 µg/g x h and 1.6±0.02 µg/g x h in ""cure"", ""relapse"" and ""resistance"" TBM respectively (p<0.05 ""relapse"" vs ""cure"" and p<0.001 ""resistance"" vs ""cure"").",Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046971/),[μg] / [g·h],1.6,87259,DB00997,Doxorubicin
,33046971,AUC0-10d,"The area under the concentration curve in PerC cells AUC0-10d was 8.2±0.57 µg/g x h, 4.6±0.27 µg/g x h and 1.6±0.02 µg/g x h in ""cure"", ""relapse"" and ""resistance"" TBM respectively (p<0.05 ""relapse"" vs ""cure"" and p<0.001 ""resistance"" vs ""cure"").",Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046971/),[μg] / [g·h],8.2,87260,DB00997,Doxorubicin
,33046971,AUC0-10d,"The area under the concentration curve in PerC cells AUC0-10d was 8.2±0.57 µg/g x h, 4.6±0.27 µg/g x h and 1.6±0.02 µg/g x h in ""cure"", ""relapse"" and ""resistance"" TBM respectively (p<0.05 ""relapse"" vs ""cure"" and p<0.001 ""resistance"" vs ""cure"").",Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046971/),[μg] / [g·h],4.6,87261,DB00997,Doxorubicin
,33046971,AUC0-10d,"The area under the concentration curve in PerC cells AUC0-10d was 8.2±0.57 µg/g x h, 4.6±0.27 µg/g x h and 1.6±0.02 µg/g x h in ""cure"", ""relapse"" and ""resistance"" TBM respectively (p<0.05 ""relapse"" vs ""cure"" and p<0.001 ""resistance"" vs ""cure"").",Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33046971/),[μg] / [g·h],1.6,87262,DB00997,Doxorubicin
,9212807,EH,"The EH value of ADR in rats at each infusion rate of 2, 10 and 50 micrograms/kg/min, was 0.290, 0.286 and 0.251, respectively.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),,0.290,88030,DB00997,Doxorubicin
,9212807,EH,"The EH value of ADR in rats at each infusion rate of 2, 10 and 50 micrograms/kg/min, was 0.290, 0.286 and 0.251, respectively.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),,0.286,88031,DB00997,Doxorubicin
,9212807,EH,"The EH value of ADR in rats at each infusion rate of 2, 10 and 50 micrograms/kg/min, was 0.290, 0.286 and 0.251, respectively.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),,0.251,88032,DB00997,Doxorubicin
,9212807,systemic clearance (CLtot),"The systemic clearance (CLtot) at each infusion rate was 108, 77.6 and 72.9 ml/min/kg, respectively.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),[ml] / [kg·min],108,88033,DB00997,Doxorubicin
,9212807,systemic clearance (CLtot),"The systemic clearance (CLtot) at each infusion rate was 108, 77.6 and 72.9 ml/min/kg, respectively.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),[ml] / [kg·min],77.6,88034,DB00997,Doxorubicin
,9212807,systemic clearance (CLtot),"The systemic clearance (CLtot) at each infusion rate was 108, 77.6 and 72.9 ml/min/kg, respectively.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),[ml] / [kg·min],72.9,88035,DB00997,Doxorubicin
,9212807,EH,"The EH value of MMC in rats at each infusion rate of 2.5, 7.5 and 25 micrograms/kg/min, was 0.332, 0.358 and 0.360, respectively.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),,0.332,88036,DB00997,Doxorubicin
,9212807,EH,"The EH value of MMC in rats at each infusion rate of 2.5, 7.5 and 25 micrograms/kg/min, was 0.332, 0.358 and 0.360, respectively.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),,0.358,88037,DB00997,Doxorubicin
,9212807,EH,"The EH value of MMC in rats at each infusion rate of 2.5, 7.5 and 25 micrograms/kg/min, was 0.332, 0.358 and 0.360, respectively.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),,0.360,88038,DB00997,Doxorubicin
,9212807,systemic clearance (CLtot),"The systemic clearance (CLtot) at each infusion rate was 38.3, 36.1 and 35.3 ml/min/kg.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),[ml] / [kg·min],38.3,88039,DB00997,Doxorubicin
,9212807,systemic clearance (CLtot),"The systemic clearance (CLtot) at each infusion rate was 38.3, 36.1 and 35.3 ml/min/kg.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),[ml] / [kg·min],36.1,88040,DB00997,Doxorubicin
,9212807,systemic clearance (CLtot),"The systemic clearance (CLtot) at each infusion rate was 38.3, 36.1 and 35.3 ml/min/kg.",[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9212807/),[ml] / [kg·min],35.3,88041,DB00997,Doxorubicin
,32737470,minimum optimal C1-trough,"The first cycle trough concentration (C1-trough) of rituximab was a significant independent risk factor for achieving CR in matched-pair logistic regression analysis, rather than the concentrations in later cycles; the recommendatory minimum optimal C1-trough was 13.60 μg/mL.",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],13.60,88213,DB00997,Doxorubicin
,32737470,C1-trough,"Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P < 0.001), only 30% patients with grade 1/2 could reach 13.60 μg/mL, compared with 91.67% in patients with grade 3, which was in accord with its unsatisfactory CR rates (43.33% vs. 76.32%).",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],12.21,88214,DB00997,Doxorubicin
,32737470,C1-trough,"Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P < 0.001), only 30% patients with grade 1/2 could reach 13.60 μg/mL, compared with 91.67% in patients with grade 3, which was in accord with its unsatisfactory CR rates (43.33% vs. 76.32%).",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],23.45,88215,DB00997,Doxorubicin
,7993646,distribution half-life,"In contrast, recent tests of a doxorubicin formulation of polyethyleneglycol-coated liposomes (Doxil) in cancer patients indicate that the drug pharmacokinetic properties are significantly altered, with a prolonged distribution half-life of approximately 2 days.",Clinical studies of liposome-encapsulated doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993646/),d,2,88691,DB00997,Doxorubicin
,9816034,response rate,"Among 40 evaluable patients treated on this protocol, a major response (partial or complete remission) was observed in 26 patients (response rate, 62%; 95% confidence interval, 46-77).",Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816034/),%,62,89354,DB00997,Doxorubicin
,9816034,alpha,"Pharmacokinetic studies revealed a triphasic elimination of pirarubicin with alpha, beta and gamma half-lives of 0.12, 1.44, and 33.9 h, respectively.",Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816034/),h,0.12,89355,DB00997,Doxorubicin
,9816034,beta,"Pharmacokinetic studies revealed a triphasic elimination of pirarubicin with alpha, beta and gamma half-lives of 0.12, 1.44, and 33.9 h, respectively.",Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816034/),h,1.44,89356,DB00997,Doxorubicin
,9816034,gamma half-lives,"Pharmacokinetic studies revealed a triphasic elimination of pirarubicin with alpha, beta and gamma half-lives of 0.12, 1.44, and 33.9 h, respectively.",Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816034/),h,33.9,89357,DB00997,Doxorubicin
,9816034,Total clearance of drug,Total clearance of drug was 4.2 liters.,Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816034/),l,4.2,89358,DB00997,Doxorubicin
,10893285,overall response rate,"There were three complete and 20 partial responses, for an overall response rate of 55% (95% confidence interval [CI], 40% to 70%) and a complete response rate of 7%.",Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10893285/),%,55,90122,DB00997,Doxorubicin
,10893285,complete response rate,"There were three complete and 20 partial responses, for an overall response rate of 55% (95% confidence interval [CI], 40% to 70%) and a complete response rate of 7%.",Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10893285/),%,7,90123,DB00997,Doxorubicin
,10893285,survival time,"The median survival time for all 42 patients was 27 months (95% CI, 13.4 to 30.0 months) and the 1-year survival rate was 80%.",Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10893285/),month,27,90124,DB00997,Doxorubicin
,4017162,t1/2(alpha),"The plasma level of 4'-O-tetrahydropyranyladriamycin (THP) declined rapidly after IV injection to mice, with a t1/2(alpha) of 0.453 min.",Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017162/),min,0.453,90662,DB00997,Doxorubicin
,23822734,loading efficiency,The loading efficiency was determined to be 92.0 ± 0.92 (DOX/FA-PEG-MWCNTs) in phosphate buffer solution (pH 7.4) ascribed to π-π stacking interaction.,"Development, characterization and cancer targeting potential of surface engineered carbon nanotubes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23822734/),,92.0,91050,DB00997,Doxorubicin
,23822734,survival time,The median survival time for tumor bearing rats treated with DOX/FA-PEG-MWCNTs (30 d) was extended very significantly as compared to free DOX (p < 0.001).,"Development, characterization and cancer targeting potential of surface engineered carbon nanotubes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23822734/),d,30,91051,DB00997,Doxorubicin
,25787324,zeta potential,"PF-NPs had an average hydrodynamic diameter and zeta potential of 137 ± 3 nm and -38 ± 1 mV, respectively.",Evaluation of new bi-functional terpolymeric nanoparticles for simultaneous in vivo optical imaging and chemotherapy of breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25787324/),mv,-,91099,DB00997,Doxorubicin
,25787324,zeta potential,"PF-NPs had an average hydrodynamic diameter and zeta potential of 137 ± 3 nm and -38 ± 1 mV, respectively.",Evaluation of new bi-functional terpolymeric nanoparticles for simultaneous in vivo optical imaging and chemotherapy of breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25787324/),mv,38,91100,DB00997,Doxorubicin
,7710633,absolute bioavailability,"Cinchonine demonstrates a greater absolute bioavailability than quinine (44% versus 30%, respectively).",Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710633/),%,44,91127,DB00997,Doxorubicin
,7710633,absolute bioavailability,"Cinchonine demonstrates a greater absolute bioavailability than quinine (44% versus 30%, respectively).",Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710633/),%,30,91128,DB00997,Doxorubicin
,27628785,en,"By incorporation of the negative polymer of enoxaparin sodium (ES), DOX was highly encapsulated into EPNs with an encapsulation efficiency of 92.49%, and ES effectively inhibited the proliferation of HUVEC cell lines.",Novel nanostructured enoxaparin sodium-PLGA hybrid carriers overcome tumor multidrug resistance of doxorubicin hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27628785/),,92,91236,DB00997,Doxorubicin
,19568235,shedding,There was no apparent PK interaction and the shedding of soluble TNF-receptors did not increase to 0.8 microg m(-2).,"Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19568235/),[μg] / [(m)^2],0.8,91527,DB00997,Doxorubicin
,7665004,Cmax,"No evidence of adverse systemic toxicity was seen up to 20 mg/kg in either species [for rats: Cmax = 12,600 (males) or 17,133 (females) ng/ml, AUC = 3853 (males) or 4365 (females) ng x hr/ml; for dogs: Cmax = 2533 ng/ml, AUC = 2851 ng x hr/ml (no sex differences)].",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[ng] / [ml],"12,600",91678,DB00997,Doxorubicin
,7665004,Cmax,"No evidence of adverse systemic toxicity was seen up to 20 mg/kg in either species [for rats: Cmax = 12,600 (males) or 17,133 (females) ng/ml, AUC = 3853 (males) or 4365 (females) ng x hr/ml; for dogs: Cmax = 2533 ng/ml, AUC = 2851 ng x hr/ml (no sex differences)].",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[ng] / [ml],"17,133",91679,DB00997,Doxorubicin
,7665004,AUC,"No evidence of adverse systemic toxicity was seen up to 20 mg/kg in either species [for rats: Cmax = 12,600 (males) or 17,133 (females) ng/ml, AUC = 3853 (males) or 4365 (females) ng x hr/ml; for dogs: Cmax = 2533 ng/ml, AUC = 2851 ng x hr/ml (no sex differences)].",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[h·ng] / [ml],3853,91680,DB00997,Doxorubicin
,7665004,AUC,"No evidence of adverse systemic toxicity was seen up to 20 mg/kg in either species [for rats: Cmax = 12,600 (males) or 17,133 (females) ng/ml, AUC = 3853 (males) or 4365 (females) ng x hr/ml; for dogs: Cmax = 2533 ng/ml, AUC = 2851 ng x hr/ml (no sex differences)].",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[h·ng] / [ml],4365,91681,DB00997,Doxorubicin
,7665004,Cmax,"No evidence of adverse systemic toxicity was seen up to 20 mg/kg in either species [for rats: Cmax = 12,600 (males) or 17,133 (females) ng/ml, AUC = 3853 (males) or 4365 (females) ng x hr/ml; for dogs: Cmax = 2533 ng/ml, AUC = 2851 ng x hr/ml (no sex differences)].",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[ng] / [ml],2533,91682,DB00997,Doxorubicin
,7665004,AUC,"No evidence of adverse systemic toxicity was seen up to 20 mg/kg in either species [for rats: Cmax = 12,600 (males) or 17,133 (females) ng/ml, AUC = 3853 (males) or 4365 (females) ng x hr/ml; for dogs: Cmax = 2533 ng/ml, AUC = 2851 ng x hr/ml (no sex differences)].",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[h·ng] / [ml],2851,91683,DB00997,Doxorubicin
,7665004,Cmax,"A dose of 40 mg/kg [for rats: Cmax = 31,233 (males) or 91,300 (females) ng/ml, AUC = 11,519 (males) or 18,620 (females) ng x hr/ml; for dogs: Cmax = 9033 ng/ml, AUC = 11,094 ng x hr/ml (combined sex)] was associated with clinical pathologic and renal histomorphologic changes considered consequent to intravascular hemolysis in both species, lethality and testicular toxicity in rats, and clinical biochemical changes indicative of hepatobiliary injury in dogs.",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[ng] / [ml],"31,233",91684,DB00997,Doxorubicin
,7665004,Cmax,"A dose of 40 mg/kg [for rats: Cmax = 31,233 (males) or 91,300 (females) ng/ml, AUC = 11,519 (males) or 18,620 (females) ng x hr/ml; for dogs: Cmax = 9033 ng/ml, AUC = 11,094 ng x hr/ml (combined sex)] was associated with clinical pathologic and renal histomorphologic changes considered consequent to intravascular hemolysis in both species, lethality and testicular toxicity in rats, and clinical biochemical changes indicative of hepatobiliary injury in dogs.",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[ng] / [ml],"91,300",91685,DB00997,Doxorubicin
,7665004,AUC,"A dose of 40 mg/kg [for rats: Cmax = 31,233 (males) or 91,300 (females) ng/ml, AUC = 11,519 (males) or 18,620 (females) ng x hr/ml; for dogs: Cmax = 9033 ng/ml, AUC = 11,094 ng x hr/ml (combined sex)] was associated with clinical pathologic and renal histomorphologic changes considered consequent to intravascular hemolysis in both species, lethality and testicular toxicity in rats, and clinical biochemical changes indicative of hepatobiliary injury in dogs.",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[h·ng] / [ml],"11,519",91686,DB00997,Doxorubicin
,7665004,AUC,"A dose of 40 mg/kg [for rats: Cmax = 31,233 (males) or 91,300 (females) ng/ml, AUC = 11,519 (males) or 18,620 (females) ng x hr/ml; for dogs: Cmax = 9033 ng/ml, AUC = 11,094 ng x hr/ml (combined sex)] was associated with clinical pathologic and renal histomorphologic changes considered consequent to intravascular hemolysis in both species, lethality and testicular toxicity in rats, and clinical biochemical changes indicative of hepatobiliary injury in dogs.",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[h·ng] / [ml],"18,620",91687,DB00997,Doxorubicin
,7665004,Cmax,"A dose of 40 mg/kg [for rats: Cmax = 31,233 (males) or 91,300 (females) ng/ml, AUC = 11,519 (males) or 18,620 (females) ng x hr/ml; for dogs: Cmax = 9033 ng/ml, AUC = 11,094 ng x hr/ml (combined sex)] was associated with clinical pathologic and renal histomorphologic changes considered consequent to intravascular hemolysis in both species, lethality and testicular toxicity in rats, and clinical biochemical changes indicative of hepatobiliary injury in dogs.",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[ng] / [ml],9033,91688,DB00997,Doxorubicin
,7665004,AUC,"A dose of 40 mg/kg [for rats: Cmax = 31,233 (males) or 91,300 (females) ng/ml, AUC = 11,519 (males) or 18,620 (females) ng x hr/ml; for dogs: Cmax = 9033 ng/ml, AUC = 11,094 ng x hr/ml (combined sex)] was associated with clinical pathologic and renal histomorphologic changes considered consequent to intravascular hemolysis in both species, lethality and testicular toxicity in rats, and clinical biochemical changes indicative of hepatobiliary injury in dogs.",Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7665004/),[h·ng] / [ml],"11,094",91689,DB00997,Doxorubicin
,16884884,extraction recoveries,The extraction recoveries of doxorubicin in all of the ocular tissues were between 83.47% and 96.33%.,Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-beta-hydroxybutyrate microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16884884/),%,83.47,91847,DB00997,Doxorubicin
,16884884,extraction recoveries,The extraction recoveries of doxorubicin in all of the ocular tissues were between 83.47% and 96.33%.,Determination of doxorubicin in rabbit ocular tissues and pharmacokinetics after intravitreal injection of a single dose of doxorubicin-loaded poly-beta-hydroxybutyrate microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16884884/),%,96.33,91848,DB00997,Doxorubicin
,25698442,AUC,"Pharmacokinetic analysis revealed an AUC of 8.0 (±2.6) μg · h/mL, a clearance of 607 (±210) mL/min/m(2) and a t1/2β of 13.8 (±4.6) hours.",Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25698442/),[h·μg] / [ml],8.0,92057,DB00997,Doxorubicin
,25698442,clearance,"Pharmacokinetic analysis revealed an AUC of 8.0 (±2.6) μg · h/mL, a clearance of 607 (±210) mL/min/m(2) and a t1/2β of 13.8 (±4.6) hours.",Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25698442/),[min·ml] / [m(2],607,92058,DB00997,Doxorubicin
,25698442,t1/2β,"Pharmacokinetic analysis revealed an AUC of 8.0 (±2.6) μg · h/mL, a clearance of 607 (±210) mL/min/m(2) and a t1/2β of 13.8 (±4.6) hours.",Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25698442/),h,13.8,92059,DB00997,Doxorubicin
,3777957,overall survival,The overall survival from the beginning of treatment was 6.0 months (2.6+ -21.4 months).,[Intrapleural chemotherapy with cisplatin and adriamycin in lung cancer with carcinomatous pleuritis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777957/),month,6.0,92859,DB00997,Doxorubicin
,3777957,overall survival,The overall survival from the beginning of treatment was 6.0 months (2.6+ -21.4 months).,[Intrapleural chemotherapy with cisplatin and adriamycin in lung cancer with carcinomatous pleuritis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777957/),month,2.6,92860,DB00997,Doxorubicin
,3777957,half-life,The pharmacokinetics of intrapleural non-protein-bound platinum showed a mean half-life of 20.45 hours.,[Intrapleural chemotherapy with cisplatin and adriamycin in lung cancer with carcinomatous pleuritis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777957/),h,20.45,92861,DB00997,Doxorubicin
,1742853,AUC ratios,"Pirarubicin's pharmacokinetics and metabolism were linear within this dose range; the metabolites identified were pirarubicinol, doxorubicin and doxorubicinol (AUC ratios of metabolite/pirarubicin were 0.6, 0.64 and 0.57 respectively).",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),,0.6,94338,DB00997,Doxorubicin
,1742853,AUC ratios,"Pirarubicin's pharmacokinetics and metabolism were linear within this dose range; the metabolites identified were pirarubicinol, doxorubicin and doxorubicinol (AUC ratios of metabolite/pirarubicin were 0.6, 0.64 and 0.57 respectively).",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),,0.64,94339,DB00997,Doxorubicin
,1742853,AUC ratios,"Pirarubicin's pharmacokinetics and metabolism were linear within this dose range; the metabolites identified were pirarubicinol, doxorubicin and doxorubicinol (AUC ratios of metabolite/pirarubicin were 0.6, 0.64 and 0.57 respectively).",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),,0.57,94340,DB00997,Doxorubicin
,1742853,half-lives,"Pirarubicin's decay from plasma followed a two-compartmental pattern, showing half-lives of 15.6 min and 16.6 h; the total plasma clearance of the drug was 140 l/h-1/m-2, and the total volume of distribution was 2,830 l/m2.",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),min,15.6,94341,DB00997,Doxorubicin
,1742853,half-lives,"Pirarubicin's decay from plasma followed a two-compartmental pattern, showing half-lives of 15.6 min and 16.6 h; the total plasma clearance of the drug was 140 l/h-1/m-2, and the total volume of distribution was 2,830 l/m2.",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),h,16.6,94342,DB00997,Doxorubicin
,1742853,total plasma clearance,"Pirarubicin's decay from plasma followed a two-compartmental pattern, showing half-lives of 15.6 min and 16.6 h; the total plasma clearance of the drug was 140 l/h-1/m-2, and the total volume of distribution was 2,830 l/m2.",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),[l] / [h],140,94343,DB00997,Doxorubicin
,1742853,total volume of distribution,"Pirarubicin's decay from plasma followed a two-compartmental pattern, showing half-lives of 15.6 min and 16.6 h; the total plasma clearance of the drug was 140 l/h-1/m-2, and the total volume of distribution was 2,830 l/m2.",A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742853/),[l] / [m2],"2,830",94344,DB00997,Doxorubicin
,19666094,zeta potential,The cationic liposomes had approximately 98.6+/-1.0 nm of mean particle diameter and 45.5+/-1.1 mV of zeta potential value.,Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19666094/),m,45.5,94427,DB00997,Doxorubicin
,19666094,zeta potential,"While, the PCL had 110.1+/-1.2 nm of mean particle diameter and 18.4+/-0.8 mV of zeta potential value as a result of the ionic complex of mPEG-COOH with cationic liposomes.",Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19666094/),m,18.4,94428,DB00997,Doxorubicin
,19666094,Loading efficiency,"Loading efficiency of model drug, doxorubicin, into cationic liposomes or PCL was about 96.0+/-0.7%.",Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19666094/),%,96.0,94429,DB00997,Doxorubicin
,33555226,zeta electrical potential,The two drugs were co-encapsulated into the distearoyl phosphatidylethanolamine-polyethylene glycol (DSPE-mPEG2000) liposome and the liposome had an average particle size of (100 ± 3.5) nm and zeta electrical potential of (-31.3 ± 0.5) mV.,"Long-circulating doxorubicin and schizandrin A liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33555226/),mv,-,94679,DB00997,Doxorubicin
,33555226,zeta electrical potential,The two drugs were co-encapsulated into the distearoyl phosphatidylethanolamine-polyethylene glycol (DSPE-mPEG2000) liposome and the liposome had an average particle size of (100 ± 3.5) nm and zeta electrical potential of (-31.3 ± 0.5) mV.,"Long-circulating doxorubicin and schizandrin A liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33555226/),mv,31.3,94680,DB00997,Doxorubicin
,33555226,encapsulation rate,The average encapsulation rate of DOX was 97.98% and that of SchA was 86.94%.,"Long-circulating doxorubicin and schizandrin A liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33555226/),%,97.98,94681,DB00997,Doxorubicin
,33555226,encapsulation rate,The average encapsulation rate of DOX was 97.98% and that of SchA was 86.94%.,"Long-circulating doxorubicin and schizandrin A liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33555226/),%,86.94,94682,DB00997,Doxorubicin
,33555226,IC50,"The IC50 of compound liposome to HepG2 and HepG2/ADR were 0.55 μmol/L and 1.38 μmol/L, respectively, which could significantly reverse the resistance of HepG2/ADR and the reversion multiple was 30.28.","Long-circulating doxorubicin and schizandrin A liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33555226/),[μM] / [l],0.55,94683,DB00997,Doxorubicin
,33555226,IC50,"The IC50 of compound liposome to HepG2 and HepG2/ADR were 0.55 μmol/L and 1.38 μmol/L, respectively, which could significantly reverse the resistance of HepG2/ADR and the reversion multiple was 30.28.","Long-circulating doxorubicin and schizandrin A liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33555226/),[μM] / [l],1.38,94684,DB00997,Doxorubicin
,33555226,reversion multiple,"The IC50 of compound liposome to HepG2 and HepG2/ADR were 0.55 μmol/L and 1.38 μmol/L, respectively, which could significantly reverse the resistance of HepG2/ADR and the reversion multiple was 30.28.","Long-circulating doxorubicin and schizandrin A liposome with drug-resistant liver cancer activity: preparation, characterization, and pharmacokinetic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33555226/),,30.28,94685,DB00997,Doxorubicin
,11919247,area under the concentration-time profiles,"PK were linear; after administration of single doses of 225 mg/m(2), the mean area under the concentration-time profiles of L-377202, Leu-Dox, and Dox were 6 micromol x L/h, 4 micromol x L/h, and 1 micromol x L/h, and peak concentrations were 14 micromol/L, 5 micromol/L, and 120 nmol/L, respectively.",Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11919247/),[l·μM] / [h],6,95024,DB00997,Doxorubicin
,11919247,area under the concentration-time profiles,"PK were linear; after administration of single doses of 225 mg/m(2), the mean area under the concentration-time profiles of L-377202, Leu-Dox, and Dox were 6 micromol x L/h, 4 micromol x L/h, and 1 micromol x L/h, and peak concentrations were 14 micromol/L, 5 micromol/L, and 120 nmol/L, respectively.",Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11919247/),[l·μM] / [h],4,95025,DB00997,Doxorubicin
,11919247,area under the concentration-time profiles,"PK were linear; after administration of single doses of 225 mg/m(2), the mean area under the concentration-time profiles of L-377202, Leu-Dox, and Dox were 6 micromol x L/h, 4 micromol x L/h, and 1 micromol x L/h, and peak concentrations were 14 micromol/L, 5 micromol/L, and 120 nmol/L, respectively.",Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11919247/),[l·μM] / [h],1,95026,DB00997,Doxorubicin
,11919247,peak concentrations,"PK were linear; after administration of single doses of 225 mg/m(2), the mean area under the concentration-time profiles of L-377202, Leu-Dox, and Dox were 6 micromol x L/h, 4 micromol x L/h, and 1 micromol x L/h, and peak concentrations were 14 micromol/L, 5 micromol/L, and 120 nmol/L, respectively.",Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11919247/),[μM] / [l],14,95027,DB00997,Doxorubicin
,11919247,peak concentrations,"PK were linear; after administration of single doses of 225 mg/m(2), the mean area under the concentration-time profiles of L-377202, Leu-Dox, and Dox were 6 micromol x L/h, 4 micromol x L/h, and 1 micromol x L/h, and peak concentrations were 14 micromol/L, 5 micromol/L, and 120 nmol/L, respectively.",Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11919247/),[μM] / [l],5,95028,DB00997,Doxorubicin
,11919247,peak concentrations,"PK were linear; after administration of single doses of 225 mg/m(2), the mean area under the concentration-time profiles of L-377202, Leu-Dox, and Dox were 6 micromol x L/h, 4 micromol x L/h, and 1 micromol x L/h, and peak concentrations were 14 micromol/L, 5 micromol/L, and 120 nmol/L, respectively.",Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11919247/),[nM] / [l],120,95029,DB00997,Doxorubicin
,9771949,terminal half-life of elimination,"Prior to toremifene dosing, baseline doxorubicin pharmacokinetic studies showed an average terminal half-life of elimination of 40.04+/-7.86 h in 4 patients, and an average AUC of 135 600+/-67 600 microg/ml.h in 11 patients.",Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9771949/),h,40.04,95180,DB00997,Doxorubicin
,9771949,AUC,"Prior to toremifene dosing, baseline doxorubicin pharmacokinetic studies showed an average terminal half-life of elimination of 40.04+/-7.86 h in 4 patients, and an average AUC of 135 600+/-67 600 microg/ml.h in 11 patients.",Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9771949/),[μg] / [h·ml],135 600,95181,DB00997,Doxorubicin
,9771949,terminal half-life of elimination,"In 4 of the patients receiving 600 mg/day toremifene for 5 days, the average terminal half-life of elimination was 38.12+/-7.81 h, and the average AUC was 141 900+/-62 900 microg/ml.h in 6 patients, i.e. a slight increase of 4.6%.",Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9771949/),h,38.12,95182,DB00997,Doxorubicin
,9771949,AUC,"In 4 of the patients receiving 600 mg/day toremifene for 5 days, the average terminal half-life of elimination was 38.12+/-7.81 h, and the average AUC was 141 900+/-62 900 microg/ml.h in 6 patients, i.e. a slight increase of 4.6%.",Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9771949/),[μg] / [h·ml],141 900,95183,DB00997,Doxorubicin
,9556164,maximum CSF concentration,The maximum CSF concentration of THP was 0.97% of plasma in patient A and 0.89% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),,0,95277,DB00997,Doxorubicin
,9556164,AUC,The CSF AUC of THP was 28.4% of plasma in patient A and 13.1% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),%,28.4,95278,DB00997,Doxorubicin
,9556164,AUC,The CSF AUC of THP was 28.4% of plasma in patient A and 13.1% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),%,13.1,95279,DB00997,Doxorubicin
,8690750,concentrations,In vivo concentrations of dexniguldipine 5 h after a single oral dose of 30 mg/kg were 72 (+/- 19 SD) ng/ml in plasma and 925 (+/- 495 SD) ng/g in tumour tissue.,Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690750/),[ng] / [g],92,95951,DB00997,Doxorubicin
,16282248,MTD,The MTD for PLD when administered in combination with carboplatin is 40 mg/m2.,Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16282248/),[mg] / [m2],40,96235,DB00997,Doxorubicin
,17197005,peak concentration,"The mean (+/- SD) peak concentration was 8341 +/- 3132 microg/L at 17.5 +/- 5.0 min after the start of the infusion, and doxorubicinol concentrations declined biexponentially to 154.3 +/- 34.5 microg/L, 40 min after the end of the infusion.","Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17197005/),[μg] / [l],8341,96417,DB00997,Doxorubicin
,17197005,Systemic clearance,"Systemic clearance was 0.940 +/- 0.473 L/h/kg, mean residence time was 0.165 +/- 0.133 h, and steady-state volume of distribution was 0.123 +/- 0.0526 L/kg.","Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17197005/),[l] / [h·kg],0.940,96418,DB00997,Doxorubicin
,17197005,mean residence time,"Systemic clearance was 0.940 +/- 0.473 L/h/kg, mean residence time was 0.165 +/- 0.133 h, and steady-state volume of distribution was 0.123 +/- 0.0526 L/kg.","Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17197005/),h,0.165,96419,DB00997,Doxorubicin
,17197005,steady-state volume of distribution,"Systemic clearance was 0.940 +/- 0.473 L/h/kg, mean residence time was 0.165 +/- 0.133 h, and steady-state volume of distribution was 0.123 +/- 0.0526 L/kg.","Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita). ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17197005/),[l] / [kg],0.123,96420,DB00997,Doxorubicin
,17197005,terminal half-life,The terminal half-life was 0.660 +/- 0.611 h.,"Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17197005/),h,0.660,96421,DB00997,Doxorubicin
,8826613,peak plasma concentrations (Cmax),Pharmacokinetic evaluations performed i.v. at the highest non-toxic dosage in mice bearing P03 tumors revealed CPT-11 peak plasma concentrations (Cmax) of 8.9 micrograms/ml and a terminal half-life of 0.6 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),[μg] / [ml],8.9,96648,DB00997,Doxorubicin
,8826613,terminal half-life,Pharmacokinetic evaluations performed i.v. at the highest non-toxic dosage in mice bearing P03 tumors revealed CPT-11 peak plasma concentrations (Cmax) of 8.9 micrograms/ml and a terminal half-life of 0.6 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,0.6,96649,DB00997,Doxorubicin
,8826613,Cmax,The metabolite SN-38 plasma concentrations presented a Cmax of 1.6 micrograms/ml and a terminal half-life of 7.4 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),[μg] / [ml],1.6,96650,DB00997,Doxorubicin
,8826613,terminal half-life,The metabolite SN-38 plasma concentrations presented a Cmax of 1.6 micrograms/ml and a terminal half-life of 7.4 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,7.4,96651,DB00997,Doxorubicin
,8826613,half-life,"Although the CPT-11 tumor levels were similar to the plasma concentrations for early time points, drug levels decreased more slowly in the tumor compared to plasma (half-life, 5.0 h).",Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,5.0,96652,DB00997,Doxorubicin
,8826613,half-life,SN-38 tumor levels reached concentrations in the range of 0.32-0.34 micrograms/g and decayed with a half-life of 6.9 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,6.9,96653,DB00997,Doxorubicin
,10506711,overall response rate,The overall response rate was 16% (2 patients achieved a complete response and 5 patients achieved a partial response).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),%,16,97318,DB00997,Doxorubicin
,10506711,duration of response,The median duration of response was 4.3 months and the median overall survival was 8.6 months.,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,4.3,97319,DB00997,Doxorubicin
,10506711,overall survival,The median duration of response was 4.3 months and the median overall survival was 8.6 months.,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,8.6,97320,DB00997,Doxorubicin
,10506711,durations of response,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,3.1,97321,DB00997,Doxorubicin
,10506711,durations of response,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,4. 9,97322,DB00997,Doxorubicin
,10506711,overall survival,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,8.1,97323,DB00997,Doxorubicin
,10506711,overall survival,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,12,97324,DB00997,Doxorubicin
,19342996,concentration,The median TGN concentration in non-DS children above 2 years of age was 2.30 micromol/mmol Hb (range 0.57-25.3).,Thioguanine pharmacokinetics in induction therapy of children with acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19342996/),[μM] / [hb·mM],2.30,97683,DB00997,Doxorubicin
,20087738,percentage tumor cell death,Mean percentage tumor cell death in the doxorubicin QSM group was 90% at 7 days and 60% in the bland QSM embolization group.,Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20087738/),%,90,97768,DB00997,Doxorubicin
,20087738,percentage tumor cell death,Mean percentage tumor cell death in the doxorubicin QSM group was 90% at 7 days and 60% in the bland QSM embolization group.,Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20087738/),%,60,97769,DB00997,Doxorubicin
less,3770056,apparent half-life,Its apparent half-life was normally less than 30 min.,Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770056/),min,30,97966,DB00997,Doxorubicin
,3770056,apparent half-lives,"Its pharmacokinetics exhibited marked inter-patient variations, with apparent half-lives ranging from 0.1 to 24 hr.",Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770056/),h,0.1 to 24,97967,DB00997,Doxorubicin
above,8402633,tissue level/blood level ratio,"After i.v. administration to mice, GF120918 penetrates thoroughly various organs that have a tissue level/blood level ratio above 10.","In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402633/),,10,98460,DB00997,Doxorubicin
,8402633,half-time,It is eliminated from organs and blood with a half-time of approximately 2.7 h.,"In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402633/),h,2.7,98461,DB00997,Doxorubicin
,19920107,apparent clearance,Pegfilgrastim apparent clearance (11 mL/h/kg) was similar to that reported in adults.,Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19920107/),[ml] / [h·kg],11,98475,DB00997,Doxorubicin
,11254185,retention time,The retention time of monoHER was about 5.2 min.,High-performance liquid chromatography with electrochemical detection for the determination of 7-monohydroxyethylrutoside in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254185/),min,5.2,98864,DB00997,Doxorubicin
,11254185,recovery,"The recovery of monoHER (using quality control concentrations) was concentration independent and ranged from 90.5 to 95.3% except for the lowest quality control, 0.45 microM, of which the recovery was 85%.",High-performance liquid chromatography with electrochemical detection for the determination of 7-monohydroxyethylrutoside in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254185/),%,90.5 to 95.3,98865,DB00997,Doxorubicin
,11254185,recovery,"The recovery of monoHER (using quality control concentrations) was concentration independent and ranged from 90.5 to 95.3% except for the lowest quality control, 0.45 microM, of which the recovery was 85%.",High-performance liquid chromatography with electrochemical detection for the determination of 7-monohydroxyethylrutoside in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254185/),%,85,98866,DB00997,Doxorubicin
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,85,99063,DB00997,Doxorubicin
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,90,99064,DB00997,Doxorubicin
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,81,99065,DB00997,Doxorubicin
,1607922,half-lives,"Plasma concentrations were best fitted to a three-compartment model with half-lives of 5.2 minutes, 0.79 hours, and 10.3 hours.",Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607922/),min,5.2,99890,DB00997,Doxorubicin
,1607922,half-lives,"Plasma concentrations were best fitted to a three-compartment model with half-lives of 5.2 minutes, 0.79 hours, and 10.3 hours.",Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607922/),h,0.79,99891,DB00997,Doxorubicin
,1607922,half-lives,"Plasma concentrations were best fitted to a three-compartment model with half-lives of 5.2 minutes, 0.79 hours, and 10.3 hours.",Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607922/),h,10.3,99892,DB00997,Doxorubicin
,1607922,total body clearance,"The total body clearance and volume of distribution at steady state were high (350 L/h/m2 and 2,065 L/m2).",Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607922/),[l] / [h·m2],350,99893,DB00997,Doxorubicin
,1607922,volume of distribution at steady state,"The total body clearance and volume of distribution at steady state were high (350 L/h/m2 and 2,065 L/m2).",Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607922/),[l] / [m2],"2,065",99894,DB00997,Doxorubicin
,1607922,area under the curve (AUC) ratio,"The drug was metabolized extensively to a 13-dihydroderivative, 4'-iodo-4'-deoxy-doxorubicinol; the mean area under the curve (AUC) ratio metabolite/parent drug was the highest observed ever for an anthracycline (12.1 +/- 7.4); the metabolite was cleared from the plasma with an elimination half-life of 15.3 hours.",Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607922/),,12.1,99895,DB00997,Doxorubicin
,1607922,elimination half-life,"The drug was metabolized extensively to a 13-dihydroderivative, 4'-iodo-4'-deoxy-doxorubicinol; the mean area under the curve (AUC) ratio metabolite/parent drug was the highest observed ever for an anthracycline (12.1 +/- 7.4); the metabolite was cleared from the plasma with an elimination half-life of 15.3 hours.",Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607922/),h,15.3,99896,DB00997,Doxorubicin
,15867261,t1/2,"The rate of clearance of the liposomal lipid was similar for all formulations (average t1/2, 18 hours), but the rate of clearance of doxorubicin was dependent on the release rate of the formulation (t1/2, 2-315 hours).",Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15867261/),h,18,100663,DB00997,Doxorubicin
,15867261,t1/2,"The rate of clearance of the liposomal lipid was similar for all formulations (average t1/2, 18 hours), but the rate of clearance of doxorubicin was dependent on the release rate of the formulation (t1/2, 2-315 hours).",Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15867261/),h,2-315,100664,DB00997,Doxorubicin
,20828803,half-life,The half-life of AESZ-108 was estimated to be about 2h.,"Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828803/),h,2,100942,DB00997,Doxorubicin
,20828803,maximum tolerated dose,The maximum tolerated dose of AESZ-108 in the absence of supportive medication is 267 mg/m² and this dose is recommended as starting dose for therapeutic Phase II studies.,"Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20828803/),[mg] / [m²],267,100943,DB00997,Doxorubicin
,10370192,t1/2 alpha,MEBCD pharmacokinetic profile was consistent with a two-compartment model (t1/2 alpha: 30 min; t1/2 beta: 7 h).,Methyl-beta-cyclodextrin and doxorubicin pharmacokinetics and tissue concentrations following bolus injection of these drugs alone or together in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10370192/),min,30,101376,DB00997,Doxorubicin
,10370192,t1/2 beta,MEBCD pharmacokinetic profile was consistent with a two-compartment model (t1/2 alpha: 30 min; t1/2 beta: 7 h).,Methyl-beta-cyclodextrin and doxorubicin pharmacokinetics and tissue concentrations following bolus injection of these drugs alone or together in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10370192/),h,7,101377,DB00997,Doxorubicin
,15567504,half-life,"The results suggest that half-life of P85 varies from 60 to 90 h, depending on its aggregation state.",Distribution kinetics of a micelle-forming block copolymer Pluronic P85. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15567504/),h,60 to 90,101892,DB00997,Doxorubicin
,11695718,tmax,"Peak serum concentrations occurred from 0.04 to 4.0 days after infusion (mean tmax = 1.79 +/- 1.55 d) with a mean cmax of 4,595 +/- 2,849 ng/ml.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,1.79,102175,DB00997,Doxorubicin
,11695718,cmax,"Peak serum concentrations occurred from 0.04 to 4.0 days after infusion (mean tmax = 1.79 +/- 1.55 d) with a mean cmax of 4,595 +/- 2,849 ng/ml.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [ml],"4,595",102176,DB00997,Doxorubicin
,11695718,Vp,"A total amount of 12.84 +/- 2.47 mg liposomal DOXO in the plasma volume (Vp = 2,794 + 537 ml) could be estimated at tmax (= 27 % of the mean dose of 47.6 mg).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),ml,"2,794",102177,DB00997,Doxorubicin
,11695718,t 1/2el,Stealth liposomes were eliminated slowly from the blood with a mean t 1/2el of 1.9 + 0.5 days (MRT was 4.6 + 2.5 days).,"Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,1.9,102178,DB00997,Doxorubicin
,11695718,MRT,Stealth liposomes were eliminated slowly from the blood with a mean t 1/2el of 1.9 + 0.5 days (MRT was 4.6 + 2.5 days).,"Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,4.6,102179,DB00997,Doxorubicin
,11695718,AUClast,"AUClast values ranged from 8,070 to 33,446 ng/ml*d (mean 10,987 +/- 9,339 ng/ml*d).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [d·ml],"8,070 to 33,446",102180,DB00997,Doxorubicin
,11695718,AUClast,"AUClast values ranged from 8,070 to 33,446 ng/ml*d (mean 10,987 +/- 9,339 ng/ml*d).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [d·ml],"10,987",102181,DB00997,Doxorubicin
,11695718,plasma clearance (Cltot,"The low plasma clearance (Cltot = 4,681 +/- 2,835 ml/day) and the small volume of distribution (Vz = 11.7 +/- 6.31) suggested that stealth-liposomes were stable in the blood at least for 14 days.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ml] / [d],"4,681",102182,DB00997,Doxorubicin
,11695718,volume of distribution (Vz,"The low plasma clearance (Cltot = 4,681 +/- 2,835 ml/day) and the small volume of distribution (Vz = 11.7 +/- 6.31) suggested that stealth-liposomes were stable in the blood at least for 14 days.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),,11.7,102183,DB00997,Doxorubicin
,3552542,terminal half-life,Intravenously administered mitoxantrone disappears from the plasma of man and laboratory animals with multiexponential kinetics and with the terminal half-life ranging from 38 h to several days.,Pharmacokinetics of mitoxantrone in man and laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552542/),h,38,102508,DB00997,Doxorubicin
,3552542,terminal half-life,Intravenously administered mitoxantrone disappears from the plasma of man and laboratory animals with multiexponential kinetics and with the terminal half-life ranging from 38 h to several days.,Pharmacokinetics of mitoxantrone in man and laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552542/),d,several,102509,DB00997,Doxorubicin
more,28081674,lifetime,"The in vivo lifetime of the nanogel in the blood circulation system of hairless mouse was determined by fluorescence imaging method using rhodamine B isothiocyanate as a fluorescence probe, and it was more than 192 h.",In vivo lifetime and anti-cancer efficacy of doxorubicin-loaded nanogels composed of cinnamoyl poly (β-cyclodextrin) and cinnamoyl Pluronic F127. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28081674/),h,192,102551,DB00997,Doxorubicin
,8869103,AUC,"For each of the anthracyclines, the sum of the corrected AUC values (nmol/g/min) of the active compounds was calculated as 8812 for Dauno; 9320 for Epi-Dox; 10 986 for Dox and 15 163 for Leu-Dox.",Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8869103/),[nM] / [g·min],8812,102579,DB00997,Doxorubicin
,8869103,AUC,"For each of the anthracyclines, the sum of the corrected AUC values (nmol/g/min) of the active compounds was calculated as 8812 for Dauno; 9320 for Epi-Dox; 10 986 for Dox and 15 163 for Leu-Dox.",Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8869103/),[nM] / [g·min],9320,102580,DB00997,Doxorubicin
,8869103,AUC,"For each of the anthracyclines, the sum of the corrected AUC values (nmol/g/min) of the active compounds was calculated as 8812 for Dauno; 9320 for Epi-Dox; 10 986 for Dox and 15 163 for Leu-Dox.",Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8869103/),[nM] / [g·min],10 986,102581,DB00997,Doxorubicin
,8869103,AUC,"For each of the anthracyclines, the sum of the corrected AUC values (nmol/g/min) of the active compounds was calculated as 8812 for Dauno; 9320 for Epi-Dox; 10 986 for Dox and 15 163 for Leu-Dox.",Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8869103/),[nM] / [g·min],15 163,102582,DB00997,Doxorubicin
,15498517,t(1/2),"We showed that DOX-mGA3 was enzymatically converted to DOX-GA3 with a t(1/2) of approximately 0.5 min in mouse plasma to 2.5 h in human plasma, which was in agreement with differences in esterase activity between species.",A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15498517/),min,0.5,103006,DB00997,Doxorubicin
,15498517,t(1/2),"We showed that DOX-mGA3 was enzymatically converted to DOX-GA3 with a t(1/2) of approximately 0.5 min in mouse plasma to 2.5 h in human plasma, which was in agreement with differences in esterase activity between species.",A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15498517/),h,2.5,103007,DB00997,Doxorubicin
,9768822,alpha half-life,Pharmacologic studies of single agent dexrazoxane (originally studied as an antineoplastic agent) demonstrates an alpha half-life of approximately 30 minutes and a beta half-life of 2 to 4 hours.,Clinical pharmacology of dexrazoxane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768822/),min,30,103351,DB00997,Doxorubicin
,9768822,beta half-life,Pharmacologic studies of single agent dexrazoxane (originally studied as an antineoplastic agent) demonstrates an alpha half-life of approximately 30 minutes and a beta half-life of 2 to 4 hours.,Clinical pharmacology of dexrazoxane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768822/),h,2 to 4,103352,DB00997,Doxorubicin
,15272215,"Elimination half-time (T(1/2,gamma))","Elimination half-time (T(1/2,gamma)) of pegylated, regular liposomal doxorubicin and free doxorubicin were 46.09 +/- 14.44, 26.04 +/- 3.34, and 23.72 +/- 5.13 h, respectively.","A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15272215/),h,46.09,103535,DB00997,Doxorubicin
,15272215,"Elimination half-time (T(1/2,gamma))","Elimination half-time (T(1/2,gamma)) of pegylated, regular liposomal doxorubicin and free doxorubicin were 46.09 +/- 14.44, 26.04 +/- 3.34, and 23.72 +/- 5.13 h, respectively.","A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15272215/),h,26.04,103536,DB00997,Doxorubicin
,15272215,"Elimination half-time (T(1/2,gamma))","Elimination half-time (T(1/2,gamma)) of pegylated, regular liposomal doxorubicin and free doxorubicin were 46.09 +/- 14.44, 26.04 +/- 3.34, and 23.72 +/- 5.13 h, respectively.","A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15272215/),h,23.72,103537,DB00997,Doxorubicin
,33650286,half-life,The half-life of the nanodrug reached almost two days and the corresponding bioavailability increased by 17-fold.,Improving Bioavailability of Hydrophobic Prodrugs through Supramolecular Nanocarriers Based on Recombinant Proteins for Osteosarcoma Treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33650286/),d,two,103949,DB00997,Doxorubicin
,23093902,blood circulation time (t(1/2),"Lac-L-DOX exhibited enhanced in vivo cytotoxicity compared with the nontargeted liposomal doxorubicin (L-DOX), and its pharmacokinetic parameters indicate that Lac-L-DOX has a long blood circulation time (t(1/2) 8.73 hours).",Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093902/),h,8.73,104357,DB00997,Doxorubicin
,7917909,area under the concentration-time curve (0-48 h; AUC),"Doxorubicin (5 mg kg-1) was administered intravenously to C57 mice bearing subcutaneous B16F10 melanomas, distributing into the tumour with an area under the concentration-time curve (0-48 h; AUC) of 8.7 micrograms h g-1.",Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917909/),[h·μg] / [g],8.7,104593,DB00997,Doxorubicin
,7917909,AUC,"Injection of doxorubicin-N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate, containing 5 mg of doxorubicin equivalent per kg, mediated an AUC for free doxorubicin (i.e. doxorubicin released from the conjugate) of 15.2 micrograms h g-1 and for total doxorubicin (i.e. free plus conjugated) of 149.1 micrograms h g-1.",Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917909/),[h·μg] / [g],15.2,104594,DB00997,Doxorubicin
,7917909,AUC,"Injection of doxorubicin-N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugate, containing 5 mg of doxorubicin equivalent per kg, mediated an AUC for free doxorubicin (i.e. doxorubicin released from the conjugate) of 15.2 micrograms h g-1 and for total doxorubicin (i.e. free plus conjugated) of 149.1 micrograms h g-1.",Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917909/),[h·μg] / [g],149.1,104595,DB00997,Doxorubicin
,7917909,AUC,An increased dose of doxorubicin-HPMA copolymer conjugate (18 mg of doxorubicin equivalent per kg) produced AUC values of 40.1 micrograms h g-1 and 671.7 micrograms h g-1 for free and total doxorubicin respectively.,Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917909/),[h·μg] / [g],40.1,104596,DB00997,Doxorubicin
,7917909,AUC,An increased dose of doxorubicin-HPMA copolymer conjugate (18 mg of doxorubicin equivalent per kg) produced AUC values of 40.1 micrograms h g-1 and 671.7 micrograms h g-1 for free and total doxorubicin respectively.,Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7917909/),[h·μg] / [g],671.7,104597,DB00997,Doxorubicin
,30521919,zeta potential,"Dox-loaded CMC-stabilized AuNPs (Dox/CMC-AuNPs) with a mean diameter of 104.0 nm, zeta potential of -48.32 mV, and drug loading efficiency of 60.14% were prepared.",Polyethylene glycol-decorated doxorubicin/carboxymethyl chitosan/gold nanocomplex for reducing drug efflux in cancer cells and extending circulation in blood stream. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30521919/),mv,48.32,104802,DB00997,Doxorubicin
,24637466,bioavailability,This was followed by a slower clearance phase that reflected both absorption from the lungs (bioavailability 10-13%) and biodegradation of the dendrimer scaffold.,Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24637466/),%,10-13,105040,DB00997,Doxorubicin
,16136309,C (max),"The mean values of C (max) and AUC(infinity) were 360+/-69.3 microM and 6.8+/-2.1 micromol min/ml, respectively.",A phase I study of monohydroxyethylrutoside in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16136309/),μM,360,105330,DB00997,Doxorubicin
,16136309,AUC(infinity),"The mean values of C (max) and AUC(infinity) were 360+/-69.3 microM and 6.8+/-2.1 micromol min/ml, respectively.",A phase I study of monohydroxyethylrutoside in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16136309/),[min·μM] / [ml],6.8,105331,DB00997,Doxorubicin
,21920350,growth inhibition rates,"The antitumor analysis using H22 and A549 mice xenograft models revealed that the growth inhibition rates of MDS-11P at 50 mg/kg (twice a day for three weeks) reached 59.4%, 60.5% respectively without obvious weight loss.",Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920350/),%,59.4,105348,DB00997,Doxorubicin
,21920350,growth inhibition rates,"The antitumor analysis using H22 and A549 mice xenograft models revealed that the growth inhibition rates of MDS-11P at 50 mg/kg (twice a day for three weeks) reached 59.4%, 60.5% respectively without obvious weight loss.",Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920350/),%,60.5,105349,DB00997,Doxorubicin
,9699664,area under the time concentration curve,"Thus, the area under the time concentration curve for the prefilter drug level in the HAI group (6.90+/-0.96 microg min/ml) was significantly lower than that in the PVI group (18.10+/-2.90 microg min/ml, P < 0.01).",Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699664/),[min·μg] / [ml],6.90,105554,DB00997,Doxorubicin
,9699664,area under the time concentration curve,"Thus, the area under the time concentration curve for the prefilter drug level in the HAI group (6.90+/-0.96 microg min/ml) was significantly lower than that in the PVI group (18.10+/-2.90 microg min/ml, P < 0.01).",Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699664/),[min·μg] / [ml],18.10,105555,DB00997,Doxorubicin
,9699664,hepatic extraction ratio,"Conversely, the hepatic extraction ratio in the HAI group (84.6+/-2.9%) was significantly higher than that in the PVI group (58.1+/-3.4%, P < 0.01).",Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699664/),%,84.6,105556,DB00997,Doxorubicin
,9699664,hepatic extraction ratio,"Conversely, the hepatic extraction ratio in the HAI group (84.6+/-2.9%) was significantly higher than that in the PVI group (58.1+/-3.4%, P < 0.01).",Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9699664/),%,58.1,105557,DB00997,Doxorubicin
,26696583,elimination half-life,The median MTX elimination half-life was 21.7 h (range 9.4-204.4).,The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696583/),h,21.7,105605,DB00997,Doxorubicin
,8622023,overall response rate,"The overall response rate was 72% (28 of 39 patients; 95% confidence interval [CI], 55% to 85%), with 8% complete responses (CRs) (three of 39; 95% CI, 2% to 21%) and a median response duration of 9 months.",Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622023/),%,72,105947,DB00997,Doxorubicin
,8622023,overall survival time,"The median overall survival time for all patients is 23 months, with a median follow-up duration of 28 months.",Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622023/),month,23,105948,DB00997,Doxorubicin
,12910529,area under the curve (AUC),The mean area under the curve (AUC) in 4 patients experiencing Grade 4 toxicity (76.4 +/- 29.3 ng x hr/mL) was significantly greater (P = 0.034) than that in those for whom the most severe toxicity was Grade 3 (39.5 +/- 17.2 ng x hr/mL [n = 12]) or Grade 1-2 (52.6 +/- 15.6 ng x hr/mL [n = 5]).,Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12910529/),[h·ng] / [ml],76.4,107296,DB00997,Doxorubicin
,12910529,area under the curve (AUC),The mean area under the curve (AUC) in 4 patients experiencing Grade 4 toxicity (76.4 +/- 29.3 ng x hr/mL) was significantly greater (P = 0.034) than that in those for whom the most severe toxicity was Grade 3 (39.5 +/- 17.2 ng x hr/mL [n = 12]) or Grade 1-2 (52.6 +/- 15.6 ng x hr/mL [n = 5]).,Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12910529/),[h·ng] / [ml],39.5,107297,DB00997,Doxorubicin
,12910529,area under the curve (AUC),The mean area under the curve (AUC) in 4 patients experiencing Grade 4 toxicity (76.4 +/- 29.3 ng x hr/mL) was significantly greater (P = 0.034) than that in those for whom the most severe toxicity was Grade 3 (39.5 +/- 17.2 ng x hr/mL [n = 12]) or Grade 1-2 (52.6 +/- 15.6 ng x hr/mL [n = 5]).,Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12910529/),[h·ng] / [ml],52.6,107298,DB00997,Doxorubicin
,17652269,Tissue half-life,Tissue half-life was 16.7 days for nLs-CPT-11 and 10.9 days for Doxil.,Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17652269/),d,16.7,107365,DB00997,Doxorubicin
,17652269,Tissue half-life,Tissue half-life was 16.7 days for nLs-CPT-11 and 10.9 days for Doxil.,Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17652269/),d,10.9,107366,DB00997,Doxorubicin
,10388001,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 µmol/l and 1.58 µmol/l, respectively.",Clinical Reversal of Multidrug Resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388001/),[μM] / [l],1.66,108553,DB00997,Doxorubicin
,10388001,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 µmol/l and 1.58 µmol/l, respectively.",Clinical Reversal of Multidrug Resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388001/),[μM] / [l],1.58,108554,DB00997,Doxorubicin
,10388001,peak total reversing concentration,"Since both are comparable antagonists, a median peak total reversing concentration of 3.24 µmol/l was achieved.",Clinical Reversal of Multidrug Resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388001/),[μM] / [l],3.24,108555,DB00997,Doxorubicin
,3690533,elimination half-life,"A triexponential equation gave the best fit for plasma levels and the values (mean +/- SE) were: elimination half-life, 37.6 +/- 4.9 hours; volume of distribution, 605 +/- 61 L/m2; and clearance 200 +/- 27 ml/min/m2.",Doxorubicin distribution in human breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690533/),h,37.6,108835,DB00997,Doxorubicin
,3690533,volume of distribution,"A triexponential equation gave the best fit for plasma levels and the values (mean +/- SE) were: elimination half-life, 37.6 +/- 4.9 hours; volume of distribution, 605 +/- 61 L/m2; and clearance 200 +/- 27 ml/min/m2.",Doxorubicin distribution in human breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690533/),[l] / [m2],605,108836,DB00997,Doxorubicin
,3690533,clearance,"A triexponential equation gave the best fit for plasma levels and the values (mean +/- SE) were: elimination half-life, 37.6 +/- 4.9 hours; volume of distribution, 605 +/- 61 L/m2; and clearance 200 +/- 27 ml/min/m2.",Doxorubicin distribution in human breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690533/),[ml] / [m2·min],200,108837,DB00997,Doxorubicin
,8392545,flow rate,"Optimum chromatographic conditions, obtained with a mobile phase gradient from 85 to 50% (v/v) 16 mM ammonium formate buffer in tetrahydrofuran at a flow rate of 2 mL/min, gave a detection limit of 0.3 pmol/injection.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),[ml] / [min],2,109283,DB00997,Doxorubicin
,8392545,detection limit,"Optimum chromatographic conditions, obtained with a mobile phase gradient from 85 to 50% (v/v) 16 mM ammonium formate buffer in tetrahydrofuran at a flow rate of 2 mL/min, gave a detection limit of 0.3 pmol/injection.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),[pM] / [injection],0.3,109284,DB00997,Doxorubicin
,8392545,alpha,"The data are best described by a three-compartment model with alpha, beta, and gamma elimination half-lives of 0.0721, 2.84, and 25.2 h for the 60-mg/m2 group and 0.103, 2.56, and 14.9 h for the 75-mg/m2 patients.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),h,0.0721,109285,DB00997,Doxorubicin
,8392545,alpha,"The data are best described by a three-compartment model with alpha, beta, and gamma elimination half-lives of 0.0721, 2.84, and 25.2 h for the 60-mg/m2 group and 0.103, 2.56, and 14.9 h for the 75-mg/m2 patients.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),h,0.103,109286,DB00997,Doxorubicin
,8392545,beta,"The data are best described by a three-compartment model with alpha, beta, and gamma elimination half-lives of 0.0721, 2.84, and 25.2 h for the 60-mg/m2 group and 0.103, 2.56, and 14.9 h for the 75-mg/m2 patients.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),h,2.84,109287,DB00997,Doxorubicin
,8392545,beta,"The data are best described by a three-compartment model with alpha, beta, and gamma elimination half-lives of 0.0721, 2.84, and 25.2 h for the 60-mg/m2 group and 0.103, 2.56, and 14.9 h for the 75-mg/m2 patients.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),h,25.2,109288,DB00997,Doxorubicin
,8392545,beta,"The data are best described by a three-compartment model with alpha, beta, and gamma elimination half-lives of 0.0721, 2.84, and 25.2 h for the 60-mg/m2 group and 0.103, 2.56, and 14.9 h for the 75-mg/m2 patients.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),h,0.103,109289,DB00997,Doxorubicin
,8392545,beta,"The data are best described by a three-compartment model with alpha, beta, and gamma elimination half-lives of 0.0721, 2.84, and 25.2 h for the 60-mg/m2 group and 0.103, 2.56, and 14.9 h for the 75-mg/m2 patients.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),h,2.56,109290,DB00997,Doxorubicin
,8392545,gamma elimination half-lives,"The data are best described by a three-compartment model with alpha, beta, and gamma elimination half-lives of 0.0721, 2.84, and 25.2 h for the 60-mg/m2 group and 0.103, 2.56, and 14.9 h for the 75-mg/m2 patients.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),h,25.2,109291,DB00997,Doxorubicin
,8392545,gamma elimination half-lives,"The data are best described by a three-compartment model with alpha, beta, and gamma elimination half-lives of 0.0721, 2.84, and 25.2 h for the 60-mg/m2 group and 0.103, 2.56, and 14.9 h for the 75-mg/m2 patients.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),h,14.9,109292,DB00997,Doxorubicin
,8392545,plasma clearance,"A mean plasma clearance of 9.89 L/h (range: 1.95 to 23.4 L/h) was found for the 60-mg/m2 patients, with that from the 75-mg/m2 group being within these values.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),[l] / [h],9.89,109293,DB00997,Doxorubicin
,8392545,area under the plasma concentration versus time curve,"Mean area under the plasma concentration versus time curve estimates of 37.1 and 47.9 microM/h were observed for the patients receiving 60 and 75 mg/m2, respectively.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),[μM] / [h],37.1,109294,DB00997,Doxorubicin
,8392545,area under the plasma concentration versus time curve,"Mean area under the plasma concentration versus time curve estimates of 37.1 and 47.9 microM/h were observed for the patients receiving 60 and 75 mg/m2, respectively.",Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8392545/),[μM] / [h],47.9,109295,DB00997,Doxorubicin
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,2.7,109481,DB00997,Doxorubicin
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,2,109482,DB00997,Doxorubicin
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,1.3,109483,DB00997,Doxorubicin
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,1.6,109484,DB00997,Doxorubicin
,17239468,AUC,"The tumor AUC after administration of PLD-100 and PLD-75 were 1285.3 ugh/g and 762.0 ugh/g, respectively (p<0.001).",Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239468/),[ugh] / [g],1285.3,109654,DB00997,Doxorubicin
,17239468,AUC,"The tumor AUC after administration of PLD-100 and PLD-75 were 1285.3 ugh/g and 762.0 ugh/g, respectively (p<0.001).",Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239468/),[ugh] / [g],762.0,109655,DB00997,Doxorubicin
,17239468,Maximum drug levels,"Maximum drug levels achieved in the tumors were 33.80 microg/g (for PLD-100) and 20.85 microg/g (for PLD-75), and peak tumor concentration was achieved faster in PLD-75 group.",Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239468/),[μg] / [g],33.80,109656,DB00997,Doxorubicin
,17239468,Maximum drug levels,"Maximum drug levels achieved in the tumors were 33.80 microg/g (for PLD-100) and 20.85 microg/g (for PLD-75), and peak tumor concentration was achieved faster in PLD-75 group.",Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239468/),[μg] / [g],20.85,109657,DB00997,Doxorubicin
,31685080,EE%,"The EE% and DL% for EPI in EPI-FIDCR are 74.02±0.55 % and 3.78±0.28 %, respectively.",Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31685080/),%,74.02,109874,DB00997,Doxorubicin
,31685080,DL%,"The EE% and DL% for EPI in EPI-FIDCR are 74.02±0.55 % and 3.78±0.28 %, respectively.",Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31685080/),%,3.78,109875,DB00997,Doxorubicin
,31685080,IC50,"The IC50 values of EPI-FIDCR and EPI solution (EPI-Free) for tumor cells were 7.03 μg/mL and 5.54 μg/mL, showing that EPI-FIDCR still maintained strong cytotoxicity.",Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31685080/),[μg] / [ml],7.03,109876,DB00997,Doxorubicin
,31685080,IC50,"The IC50 values of EPI-FIDCR and EPI solution (EPI-Free) for tumor cells were 7.03 μg/mL and 5.54 μg/mL, showing that EPI-FIDCR still maintained strong cytotoxicity.",Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31685080/),[μg] / [ml],5.54,109877,DB00997,Doxorubicin
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],299,110190,DB00997,Doxorubicin
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],384,110191,DB00997,Doxorubicin
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],245,110192,DB00997,Doxorubicin
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],321,110193,DB00997,Doxorubicin
,23802659,troughs,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110194,DB00997,Doxorubicin
,23802659,t½,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110195,DB00997,Doxorubicin
,10873078,MTD,"In conclusion, the MTD of this schedule is 10 mg/day and the DLTs are neutropenia and diarrhea.",Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873078/),,10,110284,DB00997,Doxorubicin
,11432625,volume of distribution,"Pharmacokinetic analysis showed a large volume of distribution (13.5-17.5 l/kg), a high plasma clearance (0.65-1.74 l/h/kg) and a long elimination half-life (14.7-31.9 h).","Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432625/),[l] / [kg],13.5-17.5,110575,DB00997,Doxorubicin
,11432625,plasma clearance,"Pharmacokinetic analysis showed a large volume of distribution (13.5-17.5 l/kg), a high plasma clearance (0.65-1.74 l/h/kg) and a long elimination half-life (14.7-31.9 h).","Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432625/),[l] / [h·kg],0.65-1.74,110576,DB00997,Doxorubicin
,11432625,elimination half-life,"Pharmacokinetic analysis showed a large volume of distribution (13.5-17.5 l/kg), a high plasma clearance (0.65-1.74 l/h/kg) and a long elimination half-life (14.7-31.9 h).","Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432625/),h,14.7-31.9,110577,DB00997,Doxorubicin
,6544898,maximum plasma concentration,"The maximum plasma concentration found after intrapleural instillation of 50 mg was 100 ng ml-1, the adriamycin half-life being about 2.5 h.",Plasma pharmacokinetics of adriamycin after intrapleural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6544898/),[ng] / [ml],100,111012,DB00997,Doxorubicin
,6544898,half-life,"The maximum plasma concentration found after intrapleural instillation of 50 mg was 100 ng ml-1, the adriamycin half-life being about 2.5 h.",Plasma pharmacokinetics of adriamycin after intrapleural administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6544898/),h,2.5,111013,DB00997,Doxorubicin
,1337040,relative bioavailability,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.76,111813,DB00997,Doxorubicin
,1337040,relative bioavailability,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.45,111814,DB00997,Doxorubicin
,1337040,relative bioavailability,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.80,111815,DB00997,Doxorubicin
,1337040,relative bioavailability,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.73,111816,DB00997,Doxorubicin
,1337040,relative bioavailability,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),%,100,111817,DB00997,Doxorubicin
,1337040,F,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.76,111818,DB00997,Doxorubicin
,1337040,F,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.45,111819,DB00997,Doxorubicin
,1337040,F,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),%,100,111820,DB00997,Doxorubicin
,7939757,complete response rates,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is a very active agent for the treatment of breast cancer, with associated complete response rates of 12% in patients with minimally pretreated metastatic disease.",Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7939757/),%,12,112473,DB00997,Doxorubicin
,7939757,overall response rate,Simultaneous paclitaxel and doxorubicin administration by 72-hour continuous infusion in patients with previously untreated metastatic breast cancer has yielded an overall response rate of 72% with 8% complete responses.,Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7939757/),%,72,112474,DB00997,Doxorubicin
,17442993,steady-state G3139 concentration,"At this dose, the average (+/- standard deviation) steady-state G3139 concentration was 2.04 +/- 1 microg/mL, a concentration associated with biologic activity.","Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442993/),[μg] / [ml],2.04,113860,DB00997,Doxorubicin
,8987115,AUC0-8 h,The AUC0-8 h of M1 (189 versus 78.5 mg min/ml) was significantly greater in the AIDM rats than that in the control rats.,"Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987115/),[mg·min] / [ml],189,113898,DB00997,Doxorubicin
,8987115,AUC0-8 h,The AUC0-8 h of M1 (189 versus 78.5 mg min/ml) was significantly greater in the AIDM rats than that in the control rats.,"Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987115/),[mg·min] / [ml],78.5,113899,DB00997,Doxorubicin
,8987115,AUCts,"However, the AUCts of M2 (32.7 versus 44.3 micrograms min/ml) and M4 (not measurable versus 19.7 micrograms min/ml) were significantly smaller in the AIDM rats.","Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987115/),[min·μg] / [ml],32.7,113900,DB00997,Doxorubicin
,8987115,AUCts,"However, the AUCts of M2 (32.7 versus 44.3 micrograms min/ml) and M4 (not measurable versus 19.7 micrograms min/ml) were significantly smaller in the AIDM rats.","Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987115/),[min·μg] / [ml],44.3,113901,DB00997,Doxorubicin
,8987115,AUCts,"However, the AUCts of M2 (32.7 versus 44.3 micrograms min/ml) and M4 (not measurable versus 19.7 micrograms min/ml) were significantly smaller in the AIDM rats.","Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987115/),[min·μg] / [ml],not,113902,DB00997,Doxorubicin
,8987115,AUCts,"However, the AUCts of M2 (32.7 versus 44.3 micrograms min/ml) and M4 (not measurable versus 19.7 micrograms min/ml) were significantly smaller in the AIDM rats.","Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987115/),[min·μg] / [ml],19.7,113903,DB00997,Doxorubicin
,8987115,renal clearances,"The renal clearances of both M1 (0.157 versus 0.334 ml/min/kg) and M2 (0.726 versus 14.6 ml/min/kg) decreased significantly in the AIDM rats, presumably due to their impaired kidney function.","Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987115/),[ml] / [kg·min],0.157,113904,DB00997,Doxorubicin
,8987115,renal clearances,"The renal clearances of both M1 (0.157 versus 0.334 ml/min/kg) and M2 (0.726 versus 14.6 ml/min/kg) decreased significantly in the AIDM rats, presumably due to their impaired kidney function.","Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987115/),[ml] / [kg·min],0.334,113905,DB00997,Doxorubicin
,8987115,renal clearances,"The renal clearances of both M1 (0.157 versus 0.334 ml/min/kg) and M2 (0.726 versus 14.6 ml/min/kg) decreased significantly in the AIDM rats, presumably due to their impaired kidney function.","Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987115/),[ml] / [kg·min],0.726,113906,DB00997,Doxorubicin
,8987115,renal clearances,"The renal clearances of both M1 (0.157 versus 0.334 ml/min/kg) and M2 (0.726 versus 14.6 ml/min/kg) decreased significantly in the AIDM rats, presumably due to their impaired kidney function.","Pharmacokinetic changes of M1, M2, M3, and M4 after intravenous administration of a new anthracycline, DA-125, to alloxan-induced diabetes mellitus rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8987115/),[ml] / [kg·min],14.6,113907,DB00997,Doxorubicin
,3842695,t1/2 el,"In the mean, t1/2 el and Cl tot of antipyrine were found to be 16.1 h and 32.9 ml/min, t1/2 beta and Cl tot of adriamycin were 23.1 h and 877 ml/min.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),h,16.1,114078,DB00997,Doxorubicin
,3842695,Cl tot,"In the mean, t1/2 el and Cl tot of antipyrine were found to be 16.1 h and 32.9 ml/min, t1/2 beta and Cl tot of adriamycin were 23.1 h and 877 ml/min.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),[ml] / [min],32.9,114079,DB00997,Doxorubicin
,3842695,t1/2 beta,"In the mean, t1/2 el and Cl tot of antipyrine were found to be 16.1 h and 32.9 ml/min, t1/2 beta and Cl tot of adriamycin were 23.1 h and 877 ml/min.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),h,23.1,114080,DB00997,Doxorubicin
,3842695,Cl tot,"In the mean, t1/2 el and Cl tot of antipyrine were found to be 16.1 h and 32.9 ml/min, t1/2 beta and Cl tot of adriamycin were 23.1 h and 877 ml/min.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),[ml] / [min],877,114081,DB00997,Doxorubicin
,3842695,AUC adriamycinol/AUC adriamycin ratio,A relationship between the AUC adriamycinol/AUC adriamycin ratio (which was 0.52 in the mean) and the antipyrine elimination rate did not exist.,Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),,0.52,114082,DB00997,Doxorubicin
less,3842695,elimination half-life,"As compared to the patients with elimination half-life values of less than 20 h, five patients with antipyrine elimination half-life values of more than 20 h had a significantly longer adriamycin elimination beta-phase and a stronger depressive effect on the white blood cells.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),h,20,114083,DB00997,Doxorubicin
more,3842695,elimination half-life,"As compared to the patients with elimination half-life values of less than 20 h, five patients with antipyrine elimination half-life values of more than 20 h had a significantly longer adriamycin elimination beta-phase and a stronger depressive effect on the white blood cells.",Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3842695/),h,20,114084,DB00997,Doxorubicin
less,9660038,Biliary excretion,"Biliary excretion of M1 and M2 was negligible; less than 0.320 and 4.76% of M1 and M2, respectively, were excreted in 96 h bile when expressed in terms of DA-125 i.v. dose.","Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660038/),%,0.320,115045,DB00997,Doxorubicin
,9660038,Biliary excretion,"Biliary excretion of M1 and M2 was negligible; less than 0.320 and 4.76% of M1 and M2, respectively, were excreted in 96 h bile when expressed in terms of DA-125 i.v. dose.","Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660038/),%,4.76,115046,DB00997,Doxorubicin
,30668404,flow rate,"The chromatographic separation was performed on a Acquity HSS C18 column (100 mm × 2.1 mm, 1.8 µm) by a gradient elution using a mobile phase consisting of water and acetonitrile at a flow rate of 0.35 ml/min.",Determination of a astragaloside IV derivative LS-102 in plasma by ultra-performance liquid chromatography-tandem mass spectrometry in dog plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668404/),[ml] / [min],0.35,116153,DB00997,Doxorubicin
,30668404,half-life,Peak plasma concentrations are attained within approximately 2 h after oral administration with a half-life ranging from 1.55 h to 4.49 h.,Determination of a astragaloside IV derivative LS-102 in plasma by ultra-performance liquid chromatography-tandem mass spectrometry in dog plasma and its application in a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668404/),h,1.55,116154,DB00997,Doxorubicin
,30668404,half-life,Peak plasma concentrations are attained within approximately 2 h after oral administration with a half-life ranging from 1.55 h to 4.49 h.,Determination of a astragaloside IV derivative LS-102 in plasma by ultra-performance liquid chromatography-tandem mass spectrometry in dog plasma and its application in a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30668404/),h,4.49,116155,DB00997,Doxorubicin
,26513413,circulation half-life,Dox in stealth PoP liposomes had a long circulation half-life in mice of 21.9 h and was stable in storage for months.,Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26513413/),h,21.9,116386,DB00997,Doxorubicin
,12196374,overall survival,"Of 29 patients with evaluable disease, there was one complete response and six partial responses [24% response rate [95% confidence interval (CI) 10% to 44%]], a median PFS of 22 weeks (95% CI 17-27 weeks) and median overall survival of 34 weeks (95% CI 19-49 weeks).",A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12196374/),weeks,34,117162,DB00997,Doxorubicin
,12196374,t(max),"Capecitabine was rapidly absorbed after oral administration, with a t(max) of 1-2 h for capecitabine, DFCR (5'-deoxy-5-fluorocytidine) and DFUR (5'-deoxy-5-fluorouridine).",A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12196374/),h,1-2,117163,DB00997,Doxorubicin
<,23666532,AUC,"Area under the plasma concentration-time curve (AUC) of docetaxel was the only independent predictive factor of the total absence of response in breast (Sataloff T-D): OR: 14.3, (95 % CI: 1.7-118), p = 0.015, for AUC of docetaxel <3,500 μg h/L versus ≥3,500 μg h/L.",Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666532/),[h·μg] / [l],"3,500",117290,DB00997,Doxorubicin
≥,23666532,AUC,"Area under the plasma concentration-time curve (AUC) of docetaxel was the only independent predictive factor of the total absence of response in breast (Sataloff T-D): OR: 14.3, (95 % CI: 1.7-118), p = 0.015, for AUC of docetaxel <3,500 μg h/L versus ≥3,500 μg h/L.",Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666532/),[h·μg] / [l],"3,500",117291,DB00997,Doxorubicin
,21812324,encapsulation efficiency,The obtained DOX-OA-LNs could achieve high encapsulation efficiency of 93.7 +/- 1.2% under optimal conditions.,"Lipid nanoemulsions loaded with doxorubicin-oleic acid ionic complex: characterization, in vitro and in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21812324/),%,93.7,117305,DB00997,Doxorubicin
,28355069,EC50,"12k possessed high potency (EC50 = 57.9 ± 3.5 nM), low cytotoxicity, and long duration of activity in reversing doxorubicin (DOX) resistance in K562/A02 cells.","Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28355069/),nM,57.9,117971,DB00997,Doxorubicin
,22407250,low inhibitory concentration (IC(50),"Further, we showed that GL-GN-DOX had greater growth inhibitory effect on HepG2 in terms of low inhibitory concentration (IC(50); 0.35 µg/ml) compared with GN-DOX (0.75 µg/ml) and induced caspase-3-mediated apoptosis in HepG2 cells.",Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407250/),[μg] / [ml],0.35,118985,DB00997,Doxorubicin
,22407250,low inhibitory concentration (IC(50),"Further, we showed that GL-GN-DOX had greater growth inhibitory effect on HepG2 in terms of low inhibitory concentration (IC(50); 0.35 µg/ml) compared with GN-DOX (0.75 µg/ml) and induced caspase-3-mediated apoptosis in HepG2 cells.",Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22407250/),[μg] / [ml],0.75,118986,DB00997,Doxorubicin
,28177682,EC50,"The results suggest that WYX-5 is a potent P-gp inhibitor with EC50 in nanomole range (EC50 = 204.3 ± 20.2 nmol·L-1), relative safety (therapeutic index = 446.4), which performs as a substrate of P-gp and retrains its function.",Reversal of P-glycoprotein-mediated multidrug resistance and pharmacokinetics study in rats by WYX-5. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28177682/),[nM] / [l],204.3,119234,DB00997,Doxorubicin
,28177682,T1/2,"Further, WYX-5 (5 mg·kg-1) had relatively ideal pharmacokinetic properties (T1/2 = 6.448 h, F = 96.05%) without interactions with ADM metabolism in vivo.",Reversal of P-glycoprotein-mediated multidrug resistance and pharmacokinetics study in rats by WYX-5. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28177682/),h,6.448,119235,DB00997,Doxorubicin
,28177682,F,"Further, WYX-5 (5 mg·kg-1) had relatively ideal pharmacokinetic properties (T1/2 = 6.448 h, F = 96.05%) without interactions with ADM metabolism in vivo.",Reversal of P-glycoprotein-mediated multidrug resistance and pharmacokinetics study in rats by WYX-5. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28177682/),%,96.05,119236,DB00997,Doxorubicin
,31542274,area under the curve,"The area under the curve and maximum concentrations of epirubicin in plasma were 0.45 ± 0.18 μg min/mL and 0.13 ± 0.06 μg/mL, respectively, in the device group and 0.71 ± 0.45 μg min/mL and 0.22 ± 0.17 μg/mL, respectively, in the 3-way-stopcock group (P = .013 and P = .021, respectively).",Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),[min·μg] / [ml],0.45,119271,DB00997,Doxorubicin
,31542274,area under the curve,"The area under the curve and maximum concentrations of epirubicin in plasma were 0.45 ± 0.18 μg min/mL and 0.13 ± 0.06 μg/mL, respectively, in the device group and 0.71 ± 0.45 μg min/mL and 0.22 ± 0.17 μg/mL, respectively, in the 3-way-stopcock group (P = .013 and P = .021, respectively).",Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),[min·μg] / [ml],0.71,119272,DB00997,Doxorubicin
,31542274,maximum concentrations,"The area under the curve and maximum concentrations of epirubicin in plasma were 0.45 ± 0.18 μg min/mL and 0.13 ± 0.06 μg/mL, respectively, in the device group and 0.71 ± 0.45 μg min/mL and 0.22 ± 0.17 μg/mL, respectively, in the 3-way-stopcock group (P = .013 and P = .021, respectively).",Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),[μg] / [ml],0.13,119273,DB00997,Doxorubicin
,31542274,maximum concentrations,"The area under the curve and maximum concentrations of epirubicin in plasma were 0.45 ± 0.18 μg min/mL and 0.13 ± 0.06 μg/mL, respectively, in the device group and 0.71 ± 0.45 μg min/mL and 0.22 ± 0.17 μg/mL, respectively, in the 3-way-stopcock group (P = .013 and P = .021, respectively).",Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),[μg] / [ml],0.22,119274,DB00997,Doxorubicin
,31542274,tumor necrosis ratios,The tumor necrosis ratios at 48 hours were 62 ± 11% in the device group and 51 ± 13% in the 3-way-stopcock group (P = .039).,Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),%,62,119275,DB00997,Doxorubicin
,31542274,tumor necrosis ratios,The tumor necrosis ratios at 48 hours were 62 ± 11% in the device group and 51 ± 13% in the 3-way-stopcock group (P = .039).,Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),%,51,119276,DB00997,Doxorubicin
,20377363,tissue drug concentration,Modelling LTSL-DOX treatment resulted in tumour tissue drug concentration of approximately 9.3 microg/g with highest values within 1 cm outside the ablation zone boundary.,Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20377363/),[μg] / [g],9.3,119780,DB00997,Doxorubicin
,20377363,peak level of drug concentration in,Administration of free-DOX resulted in a considerably higher peak level of drug concentration in the systemic plasma compartment (16.1 microg/g) compared to LTSL-DOX (4.4 microg/g).,Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20377363/),[μg] / [g],16.1,119781,DB00997,Doxorubicin
,20377363,peak level of drug concentration in,Administration of free-DOX resulted in a considerably higher peak level of drug concentration in the systemic plasma compartment (16.1 microg/g) compared to LTSL-DOX (4.4 microg/g).,Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20377363/),[μg] / [g],4.4,119782,DB00997,Doxorubicin
,3828961,half-life time (t0.5),"The mean phenazone half-life time (t0.5) was significantly shorter in patients with breast cancer (8.880 +/- 2.5585 h) than in healthy persons (12.024 +/- 3.8486 h, P less than 0.001).",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),h,8.880,120567,DB00997,Doxorubicin
,3828961,half-life time (t0.5),"The mean phenazone half-life time (t0.5) was significantly shorter in patients with breast cancer (8.880 +/- 2.5585 h) than in healthy persons (12.024 +/- 3.8486 h, P less than 0.001).",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),h,12.024,120568,DB00997,Doxorubicin
,3828961,elimination rate constant (K,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),1/[h],0.063,120569,DB00997,Doxorubicin
,3828961,metabolic clearance rate (MCR,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),[ml] / [min],54.968,120570,DB00997,Doxorubicin
,3828961,K,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),1/[h],0.063,120571,DB00997,Doxorubicin
,3828961,MCR,"Mean elimination rate constant (K, 0.063 +/- 0.0197 h-1) and mean metabolic clearance rate (MCR, 54.968 +/- 20.3476 ml/min) differed statistically (P less than 0.01) from the same parameters in control group, where K was 0.063 +/- 0.0197 h-1, MCR was 41.832 +/- 14.7153 ml/min.",Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828961/),[ml] / [min],41.832,120572,DB00997,Doxorubicin
,22491400,50% inhibitory concentrations (IC₅₀),"The 50% inhibitory concentrations (IC₅₀) of doxorubicin (Doxo) and Lipo-dox in RPE cells were 0.01-0.1 and 0.1-1.0 μg/mL, respectively.",Attenuated glial reaction in experimental proliferative vitreoretinopathy treated with liposomal doxorubicin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22491400/),[μg] / [ml],0.01-0.1,121029,DB00997,Doxorubicin
,22491400,50% inhibitory concentrations (IC₅₀),"The 50% inhibitory concentrations (IC₅₀) of doxorubicin (Doxo) and Lipo-dox in RPE cells were 0.01-0.1 and 0.1-1.0 μg/mL, respectively.",Attenuated glial reaction in experimental proliferative vitreoretinopathy treated with liposomal doxorubicin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22491400/),[μg] / [ml],0.1-1.0,121030,DB00997,Doxorubicin
,27447545,CL),"Population estimates for parent drug (CL) and metabolite (CLm ) clearance were 62 l h-1 and 27 l h-1 , respectively.",Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),[l] / [h],62,121257,DB00997,Doxorubicin
,27447545,clearance,"Population estimates for parent drug (CL) and metabolite (CLm ) clearance were 62 l h-1 and 27 l h-1 , respectively.",Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),[l] / [h],27,121258,DB00997,Doxorubicin
,27447545,fraction metabolized to DOXol (Fm ),The fraction metabolized to DOXol (Fm ) was estimated at 0.22.,Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),,0.22,121259,DB00997,Doxorubicin
,22027537,Oral bioavailability,"Oral bioavailability in rats was 48-73% of parenteral administration, and antitumor activity in mice was equivalent by both routes.","Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22027537/),%,48-73,121436,DB00997,Doxorubicin
more,22888235,encapsulation efficiency,The encapsulation efficiency of doxorubicin in liposomes was more than 98%.,Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888235/),%,98,121863,DB00997,Doxorubicin
,22888235,t(1/2),Both the targeted (t(1/2) = 24.10 hours) and non-targeted (t(1/2) = 25.32 hours) liposomes showed long circulating properties in rat plasma.,Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888235/),h,24.10,121864,DB00997,Doxorubicin
,22888235,t(1/2),Both the targeted (t(1/2) = 24.10 hours) and non-targeted (t(1/2) = 25.32 hours) liposomes showed long circulating properties in rat plasma.,Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22888235/),h,25.32,121865,DB00997,Doxorubicin
,15070087,time required,"To reach 30 microg/g doxorubicin concentration at the ablation boundary (targeted site of action), the time required was 6 days and 1.5 days for sustained- and dual-release millirods, respectively.",Comparison of doxorubicin concentration profiles in radiofrequency-ablated rat livers from sustained- and dual-release PLGA millirods. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070087/),d,6,122459,DB00997,Doxorubicin
,15070087,time required,"To reach 30 microg/g doxorubicin concentration at the ablation boundary (targeted site of action), the time required was 6 days and 1.5 days for sustained- and dual-release millirods, respectively.",Comparison of doxorubicin concentration profiles in radiofrequency-ablated rat livers from sustained- and dual-release PLGA millirods. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070087/),d,1.5,122460,DB00997,Doxorubicin
,30782249,drug loading capacity,"The prepared nanodrugs (ADM-CHSP-SAN) were characterized as uniform size (112.8±1.02 nm), high drug loading capacity (7.65±0.58 %), and sustained release.",Intranasal administration of pullulan-based nanoparticles for enhanced delivery of adriamycin into the brain: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30782249/),%,7.65,122524,DB00997,Doxorubicin
,23314734,clearance,"For a patient with the body surface area of 1.8 m², the clearance of doxorubicin was 53.3 L/h (inter-individual variability 31%, inter-occasion variability 13%) and the volume of distribution of the central compartment was 17.7 L (inter-individual variability 19%, inter-occasion variability 21%), respectively.",Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23314734/),[l] / [h],53.3,122798,DB00997,Doxorubicin
,23314734,volume of distribution of the central compartment,"For a patient with the body surface area of 1.8 m², the clearance of doxorubicin was 53.3 L/h (inter-individual variability 31%, inter-occasion variability 13%) and the volume of distribution of the central compartment was 17.7 L (inter-individual variability 19%, inter-occasion variability 21%), respectively.",Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23314734/),l,17.7,122799,DB00997,Doxorubicin
,23314734,clearance,"The clearance of doxorubicinol was estimated at 44 L/h (inter-individual variability 50%) and the volume of distribution of the metabolite compartment at 1,150 L (inter-individual variability 57%).",Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23314734/),[l] / [h],44,122800,DB00997,Doxorubicin
,23314734,volume of distribution of the metabolite compartment,"The clearance of doxorubicinol was estimated at 44 L/h (inter-individual variability 50%) and the volume of distribution of the metabolite compartment at 1,150 L (inter-individual variability 57%).",Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23314734/),l,"1,150",122801,DB00997,Doxorubicin
,1394799,half-lives,"The mean half-lives calculated for the fast and slow distributive and terminal elimination phases in the saline/doxorubicin group were 3.0 +/- 0.5 and 32.2 +/- 12.8 min and 30.0 +/- 4.0 h, respectively.",Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394799/),min,3.0,122833,DB00997,Doxorubicin
,1394799,half-lives,"The mean half-lives calculated for the fast and slow distributive and terminal elimination phases in the saline/doxorubicin group were 3.0 +/- 0.5 and 32.2 +/- 12.8 min and 30.0 +/- 4.0 h, respectively.",Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394799/),min,32.2,122834,DB00997,Doxorubicin
,1394799,half-lives,"The mean half-lives calculated for the fast and slow distributive and terminal elimination phases in the saline/doxorubicin group were 3.0 +/- 0.5 and 32.2 +/- 12.8 min and 30.0 +/- 4.0 h, respectively.",Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394799/),h,30.0,122835,DB00997,Doxorubicin
,29484528,death rate,"For example, the death rate in the parental line under low-dose doxorubicin treatment is increased from 0.64 (± 0.22) × 10-2 to 1.46 (± 0.58) × 10-2 h-1 with increasing fractions of MDR1-overexpressing cells.",Variable Cell Line Pharmacokinetics Contribute to Non-Linear Treatment Response in Heterogeneous Cell Populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29484528/),10-,0.64,122876,DB00997,Doxorubicin
,29484528,death rate,"For example, the death rate in the parental line under low-dose doxorubicin treatment is increased from 0.64 (± 0.22) × 10-2 to 1.46 (± 0.58) × 10-2 h-1 with increasing fractions of MDR1-overexpressing cells.",Variable Cell Line Pharmacokinetics Contribute to Non-Linear Treatment Response in Heterogeneous Cell Populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29484528/),1/[(10)^2·h],1.46,122877,DB00997,Doxorubicin
,8453681,maximal tolerated dose (MTD),The maximal tolerated dose (MTD) of PCZ in this schedule was 75 mg/m2.,Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453681/),[mg] / [m],75,123132,DB00997,Doxorubicin
,8453681,peak plasma PCZ levels,Pharmacokinetic analysis indicated a large interpatient variation in peak plasma PCZ levels that ranged from 95 to 1100 ng/ml.,Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453681/),[ng] / [ml],95 to 1100,123133,DB00997,Doxorubicin
,8453681,t1/2 alpha,"The three plasma half-lives of PCZ were: t1/2 alpha (+/- SE), 20.9 +/- 5.3 min; t1/2 beta, 1.8 +/- 0.3 h; and t1/2 gamma, 21.9 +/- 5.3 h.",Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453681/),min,20.9,123134,DB00997,Doxorubicin
,8453681,t1/2 beta,"The three plasma half-lives of PCZ were: t1/2 alpha (+/- SE), 20.9 +/- 5.3 min; t1/2 beta, 1.8 +/- 0.3 h; and t1/2 gamma, 21.9 +/- 5.3 h.",Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453681/),h,1.8,123135,DB00997,Doxorubicin
,8453681,t1/2 gamma,"The three plasma half-lives of PCZ were: t1/2 alpha (+/- SE), 20.9 +/- 5.3 min; t1/2 beta, 1.8 +/- 0.3 h; and t1/2 gamma, 21.9 +/- 5.3 h.",Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453681/),h,21.9,123136,DB00997,Doxorubicin
,8453681,volume of distribution (Vd),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) for PCZ were 2254 +/- 886 l/m2, 60.2 +/- 13.5 l m-2 h-1, and 1624 +/- 686 ng ml-1 h, respectively.",Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453681/),[l] / [m2],2254,123137,DB00997,Doxorubicin
,8453681,total clearance (ClT),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) for PCZ were 2254 +/- 886 l/m2, 60.2 +/- 13.5 l m-2 h-1, and 1624 +/- 686 ng ml-1 h, respectively.",Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453681/),[l] / [(m)^2·h],60.2,123138,DB00997,Doxorubicin
,8453681,area under the curve (AUC),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) for PCZ were 2254 +/- 886 l/m2, 60.2 +/- 13.5 l m-2 h-1, and 1624 +/- 686 ng ml-1 h, respectively.",Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453681/),[h·ng] / [ml],1624,123139,DB00997,Doxorubicin
,23618629,half-life,"Further, enhanced persistence of the drug was observed with the coated systems, significantly increasing the drug half-life from 2 to 3 min for free drug and 1.87 h for the uncoated core to 4.17 h and 4.54 h for the coated systems.",The architecture and biological performance of drug-loaded LbL nanoparticles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618629/),min,2 to 3,124053,DB00997,Doxorubicin
,23618629,half-life,"Further, enhanced persistence of the drug was observed with the coated systems, significantly increasing the drug half-life from 2 to 3 min for free drug and 1.87 h for the uncoated core to 4.17 h and 4.54 h for the coated systems.",The architecture and biological performance of drug-loaded LbL nanoparticles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618629/),h,1.87,124054,DB00997,Doxorubicin
,23618629,half-life,"Further, enhanced persistence of the drug was observed with the coated systems, significantly increasing the drug half-life from 2 to 3 min for free drug and 1.87 h for the uncoated core to 4.17 h and 4.54 h for the coated systems.",The architecture and biological performance of drug-loaded LbL nanoparticles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618629/),h,4.17,124055,DB00997,Doxorubicin
,23618629,half-life,"Further, enhanced persistence of the drug was observed with the coated systems, significantly increasing the drug half-life from 2 to 3 min for free drug and 1.87 h for the uncoated core to 4.17 h and 4.54 h for the coated systems.",The architecture and biological performance of drug-loaded LbL nanoparticles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23618629/),h,4.54,124056,DB00997,Doxorubicin
,25925711,CL,"Estimates of CL were lower (26.6 L/h/m(2) in children aged >3 years and 21.1 L/h/m(2) in children aged ≤3 years, p = 0.0004) in children aged <3 years, compared with older children.",Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25925711/),[h·l] / [m(2],26.6,125195,DB00997,Doxorubicin
,25925711,CL,"Estimates of CL were lower (26.6 L/h/m(2) in children aged >3 years and 21.1 L/h/m(2) in children aged ≤3 years, p = 0.0004) in children aged <3 years, compared with older children.",Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25925711/),[h·l] / [m(2],21.1,125196,DB00997,Doxorubicin
,15726371,area under the plasma concentration-time curve (AUC),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[h·μg] / [l],566,125229,DB00997,Doxorubicin
,15726371,maximum plasma concentration (c(max)),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[μg] / [l],599,125230,DB00997,Doxorubicin
,15726371,elimination half-life (t(1/2)),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),h,30.8,125231,DB00997,Doxorubicin
,15726371,clearance,"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[l] / [h],61.8,125232,DB00997,Doxorubicin
,15726371,intercompartmental clearance (Q),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[l] / [h],112,125233,DB00997,Doxorubicin
,15726371,volume of the central compartment (V(1)),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),l,23.3,125234,DB00997,Doxorubicin
,15726371,volume of the peripheral compartment (V(2)),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),l,"1,130",125235,DB00997,Doxorubicin
,32163849,unbound fractions,"The geometrics means were 0.26 for DOXOL/DOX AUC ratio, 15 % and 17 % for unbound fractions of DOX and DOXOL, respectively, 30.70 L⋅h-1 for total clearance, 0.66 L⋅h-1 for renal clearance, 29.97 L⋅h-1 for hepatic clearance and 0.39 L⋅h-1 for the formation clearance of the metabolite DOXOL.","Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32163849/),%,15,125795,DB00997,Doxorubicin
,32163849,unbound fractions,"The geometrics means were 0.26 for DOXOL/DOX AUC ratio, 15 % and 17 % for unbound fractions of DOX and DOXOL, respectively, 30.70 L⋅h-1 for total clearance, 0.66 L⋅h-1 for renal clearance, 29.97 L⋅h-1 for hepatic clearance and 0.39 L⋅h-1 for the formation clearance of the metabolite DOXOL.","Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32163849/),%,17,125796,DB00997,Doxorubicin
,32163849,total clearance,"The geometrics means were 0.26 for DOXOL/DOX AUC ratio, 15 % and 17 % for unbound fractions of DOX and DOXOL, respectively, 30.70 L⋅h-1 for total clearance, 0.66 L⋅h-1 for renal clearance, 29.97 L⋅h-1 for hepatic clearance and 0.39 L⋅h-1 for the formation clearance of the metabolite DOXOL.","Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32163849/),%,17,125797,DB00997,Doxorubicin
,32163849,total clearance,"The geometrics means were 0.26 for DOXOL/DOX AUC ratio, 15 % and 17 % for unbound fractions of DOX and DOXOL, respectively, 30.70 L⋅h-1 for total clearance, 0.66 L⋅h-1 for renal clearance, 29.97 L⋅h-1 for hepatic clearance and 0.39 L⋅h-1 for the formation clearance of the metabolite DOXOL.","Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32163849/),[l] / [h],30.70,125798,DB00997,Doxorubicin
,32163849,renal clearance,"The geometrics means were 0.26 for DOXOL/DOX AUC ratio, 15 % and 17 % for unbound fractions of DOX and DOXOL, respectively, 30.70 L⋅h-1 for total clearance, 0.66 L⋅h-1 for renal clearance, 29.97 L⋅h-1 for hepatic clearance and 0.39 L⋅h-1 for the formation clearance of the metabolite DOXOL.","Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32163849/),[l] / [h],0.66,125799,DB00997,Doxorubicin
,32163849,hepatic clearance,"The geometrics means were 0.26 for DOXOL/DOX AUC ratio, 15 % and 17 % for unbound fractions of DOX and DOXOL, respectively, 30.70 L⋅h-1 for total clearance, 0.66 L⋅h-1 for renal clearance, 29.97 L⋅h-1 for hepatic clearance and 0.39 L⋅h-1 for the formation clearance of the metabolite DOXOL.","Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32163849/),[l] / [h],29.97,125800,DB00997,Doxorubicin
,32163849,formation clearance,"The geometrics means were 0.26 for DOXOL/DOX AUC ratio, 15 % and 17 % for unbound fractions of DOX and DOXOL, respectively, 30.70 L⋅h-1 for total clearance, 0.66 L⋅h-1 for renal clearance, 29.97 L⋅h-1 for hepatic clearance and 0.39 L⋅h-1 for the formation clearance of the metabolite DOXOL.","Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32163849/),[l] / [h],0.39,125801,DB00997,Doxorubicin
,32163849,hepatic extraction ratio,"The 95 % confidence interval of the estimated hepatic extraction ratio of DOX ranged from 0.14 to 0.79, which characterizes DOX as a drug of low, intermediate or high hepatic extraction ratio.","Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32163849/),,0.14 to 0.79,125802,DB00997,Doxorubicin
,32800518,overall un,"The overall unconfirmed response rate was 84%, and the confirmed complete response rate was 44%.",Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),%,84,126296,DB00997,Doxorubicin
,32800518,confirmed complete response rate,"The overall unconfirmed response rate was 84%, and the confirmed complete response rate was 44%.",Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),%,44,126297,DB00997,Doxorubicin
,32800518,progression free-survival,The median progression free-survival was 27.6 months.,Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),month,27.6,126298,DB00997,Doxorubicin
,32800518,total body residence time,The median total body residence time was 94.5 hours.,Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),h,94.5,126299,DB00997,Doxorubicin
≤,28587612,%T/C,"High antitumour activity (%T/C ≤ 10) was seen from Day 21 and Day 14 onwards in SPIL and reference DXR HCl liposome injection-treated syngeneic fibrosarcoma-bearing mice, respectively, at 9 mg/kg.",Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28587612/),,10,126448,DB00997,Doxorubicin
≤,28587612,%T/C,"Moderate antitumour activity (%T/C ≤ 20) was seen from Day 17 and Day 24 onwards in SPIL and reference DXR HCl liposome injection-treated MX-1-bearing mice, respectively, at 6 mg/kg.",Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28587612/),,20,126449,DB00997,Doxorubicin
,27388491,releasing duration,"However, the LipDOX+C/GP group with lower initial burst release had a much longer releasing duration than DOX+C/GP group (21days vs. 24h).",Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27388491/),d,21,126560,DB00997,Doxorubicin
,27388491,releasing duration,"However, the LipDOX+C/GP group with lower initial burst release had a much longer releasing duration than DOX+C/GP group (21days vs. 24h).",Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27388491/),h,24,126561,DB00997,Doxorubicin
,11127949,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) for liposomal annamycin defined in this study is 210 mg/m2.,Phase I study of liposomal annamycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127949/),[mg] / [m2],210,126564,DB00997,Doxorubicin
excess,16886603,initial half-life,"Liposomal 223Ra circulated in the blood with an initial half-life in excess of 24 hours, which agreed well with that reported for PLD in rodents, while the blood half-life of cationic 223Ra was considerably less than an hour.",First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16886603/),h,24,127585,DB00997,Doxorubicin
less,16886603,blood half-life,"Liposomal 223Ra circulated in the blood with an initial half-life in excess of 24 hours, which agreed well with that reported for PLD in rodents, while the blood half-life of cationic 223Ra was considerably less than an hour.",First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16886603/),h,an,127586,DB00997,Doxorubicin
,30756483,plasma half-life,"The albumin-binding ABD-Dox conjugate exhibits nanomolar affinity for human and mouse albumin, and upon administration in mice, shows a plasma half-life of 29.4 h, which is close to that of mouse albumin.",Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30756483/),h,29.4,128864,DB00997,Doxorubicin
,3004725,Peak plasma levels,"Peak plasma levels were 7.96, 10.84, 18.24, 21.0, and 24.0 micrograms/ml for dosages of etoposide of 75, 100, 150, 200, and 250 mg, respectively.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[μg] / [ml],7.96,129400,DB00997,Doxorubicin
,3004725,Peak plasma levels,"Peak plasma levels were 7.96, 10.84, 18.24, 21.0, and 24.0 micrograms/ml for dosages of etoposide of 75, 100, 150, 200, and 250 mg, respectively.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[μg] / [ml],10.84,129401,DB00997,Doxorubicin
,3004725,Peak plasma levels,"Peak plasma levels were 7.96, 10.84, 18.24, 21.0, and 24.0 micrograms/ml for dosages of etoposide of 75, 100, 150, 200, and 250 mg, respectively.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[μg] / [ml],18.24,129402,DB00997,Doxorubicin
,3004725,Peak plasma levels,"Peak plasma levels were 7.96, 10.84, 18.24, 21.0, and 24.0 micrograms/ml for dosages of etoposide of 75, 100, 150, 200, and 250 mg, respectively.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[μg] / [ml],21.0,129403,DB00997,Doxorubicin
,3004725,Peak plasma levels,"Peak plasma levels were 7.96, 10.84, 18.24, 21.0, and 24.0 micrograms/ml for dosages of etoposide of 75, 100, 150, 200, and 250 mg, respectively.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[μg] / [ml],24.0,129404,DB00997,Doxorubicin
,3004725,half-life times of the elimination phase,"No accumulation occurred, half-life times of the elimination phase were between 8.7 and 23.0 hours, apparent distribution volumes of the central compartment were between 9.2 and 14.5 L, and the total-body clearances were between 2.1 and 2.8 L/hour.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),h,8.7 and 23.0,129405,DB00997,Doxorubicin
,3004725,apparent distribution volumes of the central compartment,"No accumulation occurred, half-life times of the elimination phase were between 8.7 and 23.0 hours, apparent distribution volumes of the central compartment were between 9.2 and 14.5 L, and the total-body clearances were between 2.1 and 2.8 L/hour.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),l,9.2 and 14.5,129406,DB00997,Doxorubicin
,3004725,total-body clearances,"No accumulation occurred, half-life times of the elimination phase were between 8.7 and 23.0 hours, apparent distribution volumes of the central compartment were between 9.2 and 14.5 L, and the total-body clearances were between 2.1 and 2.8 L/hour.",Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3004725/),[l] / [h],2.1 and 2.8,129407,DB00997,Doxorubicin
,10905565,Hepatic extraction ratio,Hepatic extraction ratio of doxorubicin remained constant at 60.3+/-12.1%. independent of the dose escalation.,A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10905565/),%,60.3,129904,DB00997,Doxorubicin
,10905565,intrahepatic concentration,The calculated intrahepatic concentration of doxorubicin ranged from 30 to 88 microg/ml when the dosage of doxorubicin was escalated from 50 to 120 mg/m2.,A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10905565/),μ,30 to 88,129905,DB00997,Doxorubicin
,10905565,overall survival,"The median overall survival of responders was 23 months, and for nonresponders it was 8 months.",A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10905565/),month,23,129906,DB00997,Doxorubicin
,10905565,overall survival,"The median overall survival of responders was 23 months, and for nonresponders it was 8 months.",A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10905565/),month,8,129907,DB00997,Doxorubicin
,9596890,maximum ADM level (Cmax),"The maximum ADM level (Cmax) in the lymph nodes of lipo-ADM was 91.23 micrograms/g, which was 2 times higher than that of the free-ADM group.",[Targeting delivery of liposomal adriamycin by intra-lymphatic infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596890/),[μg] / [g],91.23,130162,DB00997,Doxorubicin
,9596890,area under the ADM concentrations-time curve (AUC),"The area under the ADM concentrations-time curve (AUC) of the regional lymph nodes of lipo-ADM and free-ADM was 138.34 micrograms/day x g-1, 31.86 micrograms/day x g-1 respectively (P < 0.01).",[Targeting delivery of liposomal adriamycin by intra-lymphatic infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596890/),[μg] / [d·g],138.34,130163,DB00997,Doxorubicin
,9596890,area under the ADM concentrations-time curve (AUC),"The area under the ADM concentrations-time curve (AUC) of the regional lymph nodes of lipo-ADM and free-ADM was 138.34 micrograms/day x g-1, 31.86 micrograms/day x g-1 respectively (P < 0.01).",[Targeting delivery of liposomal adriamycin by intra-lymphatic infusion]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9596890/),[μg] / [d·g],31.86,130164,DB00997,Doxorubicin
,9084887,mean dissolution times,"The in vitro mean dissolution times of DOX with solution, fibrin glue, and fibrin glue containing sodium alginate were 3.7 h, 8.7 h, and 81 h, respectively, indicating a sustained release of DOX from fibrin glue, especially in the presence of sodium alginate.",Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084887/),h,3.7,130905,DB00997,Doxorubicin
,9084887,mean dissolution times,"The in vitro mean dissolution times of DOX with solution, fibrin glue, and fibrin glue containing sodium alginate were 3.7 h, 8.7 h, and 81 h, respectively, indicating a sustained release of DOX from fibrin glue, especially in the presence of sodium alginate.",Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084887/),h,8.7,130906,DB00997,Doxorubicin
,9084887,mean dissolution times,"The in vitro mean dissolution times of DOX with solution, fibrin glue, and fibrin glue containing sodium alginate were 3.7 h, 8.7 h, and 81 h, respectively, indicating a sustained release of DOX from fibrin glue, especially in the presence of sodium alginate.",Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084887/),h,81,130907,DB00997,Doxorubicin
>,9084887,AUC ratio,"Local application of DOX using fibrin glue containing sodium alginate to the tumor resulted in extremely higher concentrations in the tumor extracellular fluid than those in plasma (AUC ratio > 800), indicating an advantage of the site-specific delivery of DOX using fibrin glue with sodium alginate.",Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084887/),,800,130908,DB00997,Doxorubicin
,27739306,p,"Because of the pKa (5.6) of VitB6, DOX-B6-SA-NP showed positive charge and enhanced release of DOX at pH 5.",Vitamin B6 Tethered Endosomal pH Responsive Lipid Nanoparticles for Triggered Intracellular Release of Doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27739306/),,5.6,131100,DB00997,Doxorubicin
,8983394,AUCt,"The AUCt values of M1 (115 against 82.5 micrograms min mL-1), M2 (33.0 against 23.6 micrograms min mL-1), and M4 (26.3 against 15.1 micrograms min mL-1) were significantly higher in the U-ARF rats than in the control rats.","Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983394/),[min·μg] / [ml],115,131178,DB00997,Doxorubicin
,8983394,AUCt,"The AUCt values of M1 (115 against 82.5 micrograms min mL-1), M2 (33.0 against 23.6 micrograms min mL-1), and M4 (26.3 against 15.1 micrograms min mL-1) were significantly higher in the U-ARF rats than in the control rats.","Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983394/),[min·μg] / [ml],82.5,131179,DB00997,Doxorubicin
,8983394,AUCt,"The AUCt values of M1 (115 against 82.5 micrograms min mL-1), M2 (33.0 against 23.6 micrograms min mL-1), and M4 (26.3 against 15.1 micrograms min mL-1) were significantly higher in the U-ARF rats than in the control rats.","Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983394/),[min·μg] / [ml],33.0,131180,DB00997,Doxorubicin
,8983394,AUCt,"The AUCt values of M1 (115 against 82.5 micrograms min mL-1), M2 (33.0 against 23.6 micrograms min mL-1), and M4 (26.3 against 15.1 micrograms min mL-1) were significantly higher in the U-ARF rats than in the control rats.","Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983394/),[min·μg] / [ml],23.6,131181,DB00997,Doxorubicin
,8983394,AUCt,"The AUCt values of M1 (115 against 82.5 micrograms min mL-1), M2 (33.0 against 23.6 micrograms min mL-1), and M4 (26.3 against 15.1 micrograms min mL-1) were significantly higher in the U-ARF rats than in the control rats.","Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983394/),[min·μg] / [ml],26.3,131182,DB00997,Doxorubicin
,8983394,AUCt,"The AUCt values of M1 (115 against 82.5 micrograms min mL-1), M2 (33.0 against 23.6 micrograms min mL-1), and M4 (26.3 against 15.1 micrograms min mL-1) were significantly higher in the U-ARF rats than in the control rats.","Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983394/),[min·μg] / [ml],15.1,131183,DB00997,Doxorubicin
,32550808,IC50,"Concentration of DOX within MCL of both cell lines exceeded the IC50 under monolayer conditions (2.3 ± 0.6 µM and 0.6 ± 0.1 µM, respectively).",Intra-tumoral drug concentration mapping within solid tumor micro-milieu using in-vitro model and doxorubicin as a model drug. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32550808/),μM,2.3,131383,DB00997,Doxorubicin
,32550808,IC50,"Concentration of DOX within MCL of both cell lines exceeded the IC50 under monolayer conditions (2.3 ± 0.6 µM and 0.6 ± 0.1 µM, respectively).",Intra-tumoral drug concentration mapping within solid tumor micro-milieu using in-vitro model and doxorubicin as a model drug. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32550808/),μM,0.6,131384,DB00997,Doxorubicin
,10632085,biological half-life,"The pretreatment resulted in an increase in biological half-life (5.8 +/- 1.5 vs 3.7 +/- 0.93 h control group, P < 0.05) and area under plasma concentration-time curve (19.6 +/- 1.7 vs 14.65 +/- 1.68 mg h L(-1) control group, P < 0.05).","Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632085/),h,5.8,132028,DB00997,Doxorubicin
,10632085,biological half-life,"The pretreatment resulted in an increase in biological half-life (5.8 +/- 1.5 vs 3.7 +/- 0.93 h control group, P < 0.05) and area under plasma concentration-time curve (19.6 +/- 1.7 vs 14.65 +/- 1.68 mg h L(-1) control group, P < 0.05).","Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632085/),h,3.7,132029,DB00997,Doxorubicin
,10632085,area under plasma concentration-time curve,"The pretreatment resulted in an increase in biological half-life (5.8 +/- 1.5 vs 3.7 +/- 0.93 h control group, P < 0.05) and area under plasma concentration-time curve (19.6 +/- 1.7 vs 14.65 +/- 1.68 mg h L(-1) control group, P < 0.05).","Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632085/),[h·mg] / [l],19.6,132030,DB00997,Doxorubicin
,10632085,area under plasma concentration-time curve,"The pretreatment resulted in an increase in biological half-life (5.8 +/- 1.5 vs 3.7 +/- 0.93 h control group, P < 0.05) and area under plasma concentration-time curve (19.6 +/- 1.7 vs 14.65 +/- 1.68 mg h L(-1) control group, P < 0.05).","Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632085/),[h·mg] / [l],14.65,132031,DB00997,Doxorubicin
,23252722,hepatic first-pass extraction ratio,"Nearly all (82.1-99.7%) of the orally administered doxorubicin remained unabsorbed, and the hepatic first-pass extraction ratio and oral bioavailability of doxorubicin were approximately 0.5% and 1%, respectively.",The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23252722/),%,0.5,132168,DB00997,Doxorubicin
,23252722,oral bioavailability,"Nearly all (82.1-99.7%) of the orally administered doxorubicin remained unabsorbed, and the hepatic first-pass extraction ratio and oral bioavailability of doxorubicin were approximately 0.5% and 1%, respectively.",The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23252722/),%,1,132169,DB00997,Doxorubicin
,25910045,flow rate,The chromatographic separation was performed on a C18 column with acetonitrile and 0.1% formic acid water as mobile phase and with gradient elution at a flow rate of 0.2 mL/min.,Simultaneous determination of doxorubicin and curcumin in rat plasma by LC-MS/MS and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25910045/),[ml] / [min],0.2,132387,DB00997,Doxorubicin
,8646796,50% inhibitory concentrations (IC50,"Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10(-10) and 2.1 x 10(-9) M, respectively; P < 0.05] and more potent than paclitaxel or vinblastine.",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),M,2.3 x 10(-10),133271,DB00997,Doxorubicin
,8646796,50% inhibitory concentrations (IC50,"Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10(-10) and 2.1 x 10(-9) M, respectively; P < 0.05] and more potent than paclitaxel or vinblastine.",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),M,2.1 x 10(-9),133272,DB00997,Doxorubicin
,8646796,limit of detection,A radioimmunoassay for dolastatin 10 (limit of detection in mouse plasma 5 ng/ml) was developed.,Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[ng] / [ml],5,133273,DB00997,Doxorubicin
,8646796,areas under the plasma concentration-time curve (AUC values),"In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h).",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[h·ng] / [ml],333,133274,DB00997,Doxorubicin
,8646796,areas under the plasma concentration-time curve (AUC values),"In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h).",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[h·ng] / [ml],208,133275,DB00997,Doxorubicin
exceeded,8646796,Plasma binding,Plasma binding of dolastatin 10 exceeded 90%.,Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),%,90,133276,DB00997,Doxorubicin
,12123337,terminal half-life,"Pharmacokinetics were assessed in 15 patients, and confirmed the long terminal half-life of the agent (median 77 h) demonstrated in earlier studies.","EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123337/),h,77,133550,DB00997,Doxorubicin
,15041715,clearance,Mean +/- SD docetaxel clearance values were similar with weekly and 3-weekly schedules (25.2 +/- 7.7 versus 23.7 +/- 7.9 liter/h/m(2)); half-lives were also similar with both schedules of administration (16.5 +/- 11.2 versus 17.6 +/- 7.4 h).,Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041715/),[h·l] / [m(2],25.2,133703,DB00997,Doxorubicin
,15041715,clearance,Mean +/- SD docetaxel clearance values were similar with weekly and 3-weekly schedules (25.2 +/- 7.7 versus 23.7 +/- 7.9 liter/h/m(2)); half-lives were also similar with both schedules of administration (16.5 +/- 11.2 versus 17.6 +/- 7.4 h).,Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041715/),[h·l] / [m(2],23.7,133704,DB00997,Doxorubicin
,15041715,half-lives,Mean +/- SD docetaxel clearance values were similar with weekly and 3-weekly schedules (25.2 +/- 7.7 versus 23.7 +/- 7.9 liter/h/m(2)); half-lives were also similar with both schedules of administration (16.5 +/- 11.2 versus 17.6 +/- 7.4 h).,Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041715/),h,16.5,133705,DB00997,Doxorubicin
,15041715,half-lives,Mean +/- SD docetaxel clearance values were similar with weekly and 3-weekly schedules (25.2 +/- 7.7 versus 23.7 +/- 7.9 liter/h/m(2)); half-lives were also similar with both schedules of administration (16.5 +/- 11.2 versus 17.6 +/- 7.4 h).,Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041715/),h,17.6,133706,DB00997,Doxorubicin
less,32787769,polydispersity index (PDI),DOX liposomes were near-spherical morphology with the average size of 90 nm and polydispersity index (PDI) of less than 0.30.,A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32787769/),,0.30,134044,DB00997,Doxorubicin
up to,32787769,drug loading,"The drug loading was up to 7.5%, and the entrapment efficiency was over 80%.",A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32787769/),%,7.5,134045,DB00997,Doxorubicin
higher,31011340,encapsulation,Drug encapsulation was higher than 97% in all liposomes.,"Preparation, In-Vitro Characterization and Pharmacokinetic Evaluation of Brij Decorated Doxorubicin Liposomes as a Potential Nanocarrier for Cancer Therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31011340/),%,97,135205,DB00997,Doxorubicin
,1450047,half-lives,"Bolus injection was followed by a three exponential decay in plasma, with half-lives of 2.43 min, 1.95 h and 21.7 h; 48-h infusions were characterized by the very rapid establishment of a plasma plateau concentration followed by a biexponential decay after stopping the infusion.",Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1450047/),min,2.43,135219,DB00997,Doxorubicin
,1450047,half-lives,"Bolus injection was followed by a three exponential decay in plasma, with half-lives of 2.43 min, 1.95 h and 21.7 h; 48-h infusions were characterized by the very rapid establishment of a plasma plateau concentration followed by a biexponential decay after stopping the infusion.",Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1450047/),h,1.95,135220,DB00997,Doxorubicin
,1450047,half-lives,"Bolus injection was followed by a three exponential decay in plasma, with half-lives of 2.43 min, 1.95 h and 21.7 h; 48-h infusions were characterized by the very rapid establishment of a plasma plateau concentration followed by a biexponential decay after stopping the infusion.",Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1450047/),h,21.7,135221,DB00997,Doxorubicin
,32381487,objective response rate,The objective response rate in the evaluable population was 11%.,"A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32381487/),%,11,135663,DB00997,Doxorubicin
,3470504,detection limit,"The detection limit in plasma was 4 X 10(-8) M for the glucuronides, 7 X 10(-9) M for the glycosides, and 1 X 10(-9) M for the aglycones.","Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470504/),M,4 X 10(-8),136224,DB00997,Doxorubicin
,3470504,detection limit,"The detection limit in plasma was 4 X 10(-8) M for the glucuronides, 7 X 10(-9) M for the glycosides, and 1 X 10(-9) M for the aglycones.","Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470504/),M,7 X 10(-9),136225,DB00997,Doxorubicin
,3470504,detection limit,"The detection limit in plasma was 4 X 10(-8) M for the glucuronides, 7 X 10(-9) M for the glycosides, and 1 X 10(-9) M for the aglycones.","Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470504/),M,1 X 10(-9),136226,DB00997,Doxorubicin
,3470504,detection limit,The detection limit in urine was approximately 5 X 10(-8) M. Plasma and urine of two patients who had received 4'-epidoxorubicin by iv bolus injection were analyzed.,"Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470504/),M,5 X,136227,DB00997,Doxorubicin
,24422857,Maximum tauro,Maximum taurolidine serum concentrations ranged between 229 to 646 μM.,Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24422857/),μM,229 to 646,137053,DB00997,Doxorubicin
,24422857,serum concentrations,Maximum taurolidine serum concentrations ranged between 229 to 646 μM.,Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24422857/),μM,229 to 646,137054,DB00997,Doxorubicin
,33095287,maximum tolerated dose (MTD),"In Part D, the maximum tolerated dose (MTD) was exceeded at 165 mg/m2/dose of crizotinib cMS.","Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33095287/),mg,165,138074,DB00997,Doxorubicin
,30361524,overall response rate (ORR),"With MM-302 ≥ 30 mg/m2, overall response rate (ORR) was 13% and median progression-free survival (mPFS) 7.4 months (95% CI: 3·5-10·9) in all arms.","Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30361524/),%,13,138929,DB00997,Doxorubicin
,30361524,progression-free survival,"With MM-302 ≥ 30 mg/m2, overall response rate (ORR) was 13% and median progression-free survival (mPFS) 7.4 months (95% CI: 3·5-10·9) in all arms.","Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30361524/),month,7,138930,DB00997,Doxorubicin
,1503923,clearance,"Median methotrexate clearance tended to be lower in four infants (0.26-0.99 years) vs 108 children (1-19 years): 80 vs 103 ml min-1 m-2, respectively (P = 0.01).",Disposition of antineoplastic agents in the very young child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503923/),[ml] / [(m)^2·min],80,139441,DB00997,Doxorubicin
,1503923,clearance,"Median methotrexate clearance tended to be lower in four infants (0.26-0.99 years) vs 108 children (1-19 years): 80 vs 103 ml min-1 m-2, respectively (P = 0.01).",Disposition of antineoplastic agents in the very young child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1503923/),[ml] / [(m)^2·min],103,139442,DB00997,Doxorubicin
,31824933,zeta potential,The spherically shaped WED-M (particle size: 160.5 ± 3.4 nm; zeta potential: -30.1 ± 0.9 mV; entrapment efficiency: 94.41 ± 1.64%; drug loading: 8.58 ± 0.25%; solubility: 1.89 ± 0.06 mg/ml) has continuous stability over 14 days and a sustained release profile.,Wedelolactone-Loaded Micelles Ameliorate Doxorubicin-Induced Oxidative Injury in Podocytes by Improving Permeability and Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31824933/),mv,-,139806,DB00997,Doxorubicin
,31824933,zeta potential,The spherically shaped WED-M (particle size: 160.5 ± 3.4 nm; zeta potential: -30.1 ± 0.9 mV; entrapment efficiency: 94.41 ± 1.64%; drug loading: 8.58 ± 0.25%; solubility: 1.89 ± 0.06 mg/ml) has continuous stability over 14 days and a sustained release profile.,Wedelolactone-Loaded Micelles Ameliorate Doxorubicin-Induced Oxidative Injury in Podocytes by Improving Permeability and Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31824933/),mv,30.1,139807,DB00997,Doxorubicin
,31824933,entrapment efficiency,The spherically shaped WED-M (particle size: 160.5 ± 3.4 nm; zeta potential: -30.1 ± 0.9 mV; entrapment efficiency: 94.41 ± 1.64%; drug loading: 8.58 ± 0.25%; solubility: 1.89 ± 0.06 mg/ml) has continuous stability over 14 days and a sustained release profile.,Wedelolactone-Loaded Micelles Ameliorate Doxorubicin-Induced Oxidative Injury in Podocytes by Improving Permeability and Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31824933/),%,94.41,139808,DB00997,Doxorubicin
,31824933,drug loading,The spherically shaped WED-M (particle size: 160.5 ± 3.4 nm; zeta potential: -30.1 ± 0.9 mV; entrapment efficiency: 94.41 ± 1.64%; drug loading: 8.58 ± 0.25%; solubility: 1.89 ± 0.06 mg/ml) has continuous stability over 14 days and a sustained release profile.,Wedelolactone-Loaded Micelles Ameliorate Doxorubicin-Induced Oxidative Injury in Podocytes by Improving Permeability and Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31824933/),%,8.58,139809,DB00997,Doxorubicin
,31824933,solubility,The spherically shaped WED-M (particle size: 160.5 ± 3.4 nm; zeta potential: -30.1 ± 0.9 mV; entrapment efficiency: 94.41 ± 1.64%; drug loading: 8.58 ± 0.25%; solubility: 1.89 ± 0.06 mg/ml) has continuous stability over 14 days and a sustained release profile.,Wedelolactone-Loaded Micelles Ameliorate Doxorubicin-Induced Oxidative Injury in Podocytes by Improving Permeability and Bioavailability. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31824933/),[mg] / [ml],1.89,139810,DB00997,Doxorubicin
,13678734,overall objective response rate,"There were 4 patients with a complete response and 7 with partial responses, for an overall objective response rate of 29%, among the 38 evaluable patients.",Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13678734/),%,29,140014,DB00997,Doxorubicin
,13678734,Response rates,Response rates for the subset of 13 women with tumor recurrence occurring at least 6 months after prior platinum-based therapy was 54%.,Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13678734/),%,54,140015,DB00997,Doxorubicin
,15150584,maximum tolerated dose,The maximum tolerated dose was 70 mg m(-2) and is recommended for future trials.,Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15150584/),[mg] / [(m)^2],70,140060,DB00997,Doxorubicin
,10589782,tumor-accumulation efficiency (AUC(Tumor)/AUC(Plasma)),"The tumor-accumulation efficiency (AUC(Tumor)/AUC(Plasma)) of liposomal doxorubicin without PEG was 0.87, and this was more than twice that of the liposomal doxorubicin with 6% PEG-DSPE (0.31).",Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589782/),,0.87,140231,DB00997,Doxorubicin
,10589782,tumor-accumulation efficiency (AUC(Tumor)/AUC(Plasma)),"The tumor-accumulation efficiency (AUC(Tumor)/AUC(Plasma)) of liposomal doxorubicin without PEG was 0.87, and this was more than twice that of the liposomal doxorubicin with 6% PEG-DSPE (0.31).",Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589782/),,0.31,140232,DB00997,Doxorubicin
,29796830,flow rate,"For chromatography, Waters ACQUITY UPLC™ along with a BEH C-18 column (2.1 mm × 100 mm; 1.7 μm), mobile phase conditions (acetonitrile: 0.1% formic acid::1:1 v/v) and flow rate (0.20 ml/min) was used.",Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29796830/),[ml] / [min],0.20,140795,DB00997,Doxorubicin
,29796830,zeta potential,"Nanoformulation with a particle size (183.10 ± 7.41 nm), zeta potential (- 13.10 ± 1.04 mV), drug content (42.69 ± 1.97 µg/mg) and a spherical shape and smooth surface was developed.",Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29796830/),m,-,140796,DB00997,Doxorubicin
,29796830,zeta potential,"Nanoformulation with a particle size (183.10 ± 7.41 nm), zeta potential (- 13.10 ± 1.04 mV), drug content (42.69 ± 1.97 µg/mg) and a spherical shape and smooth surface was developed.",Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29796830/),m,13.10,140797,DB00997,Doxorubicin
,29796830,elution time,"An elution time of 1.61 and 1.75 min along with a transition at m/z 544.42/397.27 and 528.46/321.41 were observed for DOX and internal standard (IS) Daunorubicin, respectively.",Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29796830/),min,1.61,140798,DB00997,Doxorubicin
,29796830,elution time,"An elution time of 1.61 and 1.75 min along with a transition at m/z 544.42/397.27 and 528.46/321.41 were observed for DOX and internal standard (IS) Daunorubicin, respectively.",Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29796830/),min,1.75,140799,DB00997,Doxorubicin
,29796830,m/,"An elution time of 1.61 and 1.75 min along with a transition at m/z 544.42/397.27 and 528.46/321.41 were observed for DOX and internal standard (IS) Daunorubicin, respectively.",Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29796830/),,544.42,140800,DB00997,Doxorubicin
,29796830,m/,"An elution time of 1.61 and 1.75 min along with a transition at m/z 544.42/397.27 and 528.46/321.41 were observed for DOX and internal standard (IS) Daunorubicin, respectively.",Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29796830/),,397.27,140801,DB00997,Doxorubicin
,29796830,m/,"An elution time of 1.61 and 1.75 min along with a transition at m/z 544.42/397.27 and 528.46/321.41 were observed for DOX and internal standard (IS) Daunorubicin, respectively.",Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29796830/),,528.46,140802,DB00997,Doxorubicin
,29796830,m/,"An elution time of 1.61 and 1.75 min along with a transition at m/z 544.42/397.27 and 528.46/321.41 were observed for DOX and internal standard (IS) Daunorubicin, respectively.",Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29796830/),,321.41,140803,DB00997,Doxorubicin
,2224762,Maximum tolerated dose,"Maximum tolerated dose in good-risk patients was 70 mg/m2, and in poor-risk patients, 60 mg/m2.",A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2224762/),[mg] / [m2],70,141011,DB00997,Doxorubicin
,2224762,Maximum tolerated dose,"Maximum tolerated dose in good-risk patients was 70 mg/m2, and in poor-risk patients, 60 mg/m2.",A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2224762/),[mg] / [m],60,141012,DB00997,Doxorubicin
,2224762,plasma T 1/2 alpha,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2224762/),min,2.5,141013,DB00997,Doxorubicin
,2224762,T beta 1/2,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2224762/),min,25.6,141014,DB00997,Doxorubicin
,2224762,T 1/2 gamma,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2224762/),h,23.6,141015,DB00997,Doxorubicin
,2224762,area under the curve,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2224762/),[ng] / [h·ml],537,141016,DB00997,Doxorubicin
,2224762,volume of distribution (Vd),"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2224762/),[l] / [m2],3504,141017,DB00997,Doxorubicin
,2224762,total clearance (ClT),"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2224762/),[l] / [h·m2],204,141018,DB00997,Doxorubicin
less,2224762,Urinary excretion,Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%.,A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2224762/),%,10,141019,DB00997,Doxorubicin
,3556376,elimination half-life,Mean elimination half-life was 34.7 +/- 16.6 h and the total plasma clearance was 29.5 +/- 9.31 X h-1 X m-2.,Pharmacokinetics of doxorubicin in sarcoma patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3556376/),h,34.7,141140,DB00997,Doxorubicin
,3556376,total plasma clearance,Mean elimination half-life was 34.7 +/- 16.6 h and the total plasma clearance was 29.5 +/- 9.31 X h-1 X m-2.,Pharmacokinetics of doxorubicin in sarcoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3556376/),1/[(m)^2·h],29.5,141141,DB00997,Doxorubicin
,23311544,α circulation half-life,Pharmacokinetic studies showed that DOX-PCB had an α circulation half-life of 10 min which was comparable to that of DOX at 20 min.,Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23311544/),min,10,142612,DB00997,Doxorubicin
,26965003,survival time,"The median survival time of xenograft rats after administering FA-BO-PAMAM/DOX (28days) was significantly prolonged compared to free DOX (18days, P<0.05) or other controls.","A novel doxorubicin loaded folic acid conjugated PAMAM modified with borneol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26965003/),d,28,142853,DB00997,Doxorubicin
,26965003,survival time,"The median survival time of xenograft rats after administering FA-BO-PAMAM/DOX (28days) was significantly prolonged compared to free DOX (18days, P<0.05) or other controls.","A novel doxorubicin loaded folic acid conjugated PAMAM modified with borneol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26965003/),d,18,142854,DB00997,Doxorubicin
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],357,143077,DB00997,Doxorubicin
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],603,143078,DB00997,Doxorubicin
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],640,143079,DB00997,Doxorubicin
,12123338,tC0.1,"The only pharmacokinetic/pharmacodynamic relationship observed was between neutropenia and the time spent above the threshold plasma level of 0.1 micromol/l (tC0.1) of paclitaxel, with the time required to obtain a 50% decrease in neutrophil count (Et50) of GEP being 7.8 h, similar to that of EP.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[μM] / [l],0.1,143080,DB00997,Doxorubicin
,9225946,o,"The octanol:water partitioning coefficients of taxol, doxorubicin, and mitomycin were > 99, 0.52, and 0.41, which parallels the rank order of the partitioning across urothelium, i.e. taxol (approximately 50%) > > doxorubicin approximately mitomycin C (-3%).",Bladder tissue pharmacokinetics of intravesical taxol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225946/),,99,143203,DB00997,Doxorubicin
,9225946,o,"The octanol:water partitioning coefficients of taxol, doxorubicin, and mitomycin were > 99, 0.52, and 0.41, which parallels the rank order of the partitioning across urothelium, i.e. taxol (approximately 50%) > > doxorubicin approximately mitomycin C (-3%).",Bladder tissue pharmacokinetics of intravesical taxol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225946/),,0.52,143204,DB00997,Doxorubicin
,9225946,o,"The octanol:water partitioning coefficients of taxol, doxorubicin, and mitomycin were > 99, 0.52, and 0.41, which parallels the rank order of the partitioning across urothelium, i.e. taxol (approximately 50%) > > doxorubicin approximately mitomycin C (-3%).",Bladder tissue pharmacokinetics of intravesical taxol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9225946/),,0.41,143205,DB00997,Doxorubicin
,29328653,plasma half life,"Pharmacokinetics study in Sprague-Dawley rats showed that ABD-HFn/DOX nanoparticle possessed significantly prolonged plasma half life of ∼17.2 h, exhibiting nearly 19 times longer than that of free doxorubicin and 12 times for HFn/DOX.",Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29328653/),h,∼17.2,144099,DB00997,Doxorubicin
,15626743,MTD,"The MTD based on cycle 1 was 1.50 and 30 mg/m2 of bortezomib and PegLD, respectively.",Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626743/),[mg] / [m2],1.50,144532,DB00997,Doxorubicin
,15626743,MTD,"The MTD based on cycle 1 was 1.50 and 30 mg/m2 of bortezomib and PegLD, respectively.",Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626743/),[mg] / [m2],30,144533,DB00997,Doxorubicin
,22871060,PDI,"Optimization of various process variables were carried out, and optimized formulation was found to have particle size of 520.4 ± 15.0 nm, PDI of 0.312 ± 0.062, ζ potential of +30.4 ± 5.32 mV, and encapsulation efficiency of 63.4 ± 4.26%.",Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22871060/),,0.312,145194,DB00997,Doxorubicin
,22871060,ζ potential,"Optimization of various process variables were carried out, and optimized formulation was found to have particle size of 520.4 ± 15.0 nm, PDI of 0.312 ± 0.062, ζ potential of +30.4 ± 5.32 mV, and encapsulation efficiency of 63.4 ± 4.26%.",Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22871060/),m,30.4,145195,DB00997,Doxorubicin
,22871060,encapsulation efficiency,"Optimization of various process variables were carried out, and optimized formulation was found to have particle size of 520.4 ± 15.0 nm, PDI of 0.312 ± 0.062, ζ potential of +30.4 ± 5.32 mV, and encapsulation efficiency of 63.4 ± 4.26%.",Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22871060/),%,63.4,145196,DB00997,Doxorubicin
,6866757,half-lives,"Our results corroborate the existence of three successive phases of doxorubicin plasma decay, with mean half-lives of 3.81 min, 1.19 h and 29 h.",[Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6866757/),min,3.81,146500,DB00997,Doxorubicin
,6866757,half-lives,"Our results corroborate the existence of three successive phases of doxorubicin plasma decay, with mean half-lives of 3.81 min, 1.19 h and 29 h.",[Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6866757/),h,1.19,146501,DB00997,Doxorubicin
,6866757,half-lives,"Our results corroborate the existence of three successive phases of doxorubicin plasma decay, with mean half-lives of 3.81 min, 1.19 h and 29 h.",[Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6866757/),h,29,146502,DB00997,Doxorubicin
,6866757,total plasmatic clearance,The total plasmatic clearance ranged between 32 and 67 l/h.,[Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6866757/),[l] / [h],32 and 67,146503,DB00997,Doxorubicin
,6866757,total plasmatic clearance,The total plasmatic clearance ranged between 32 and 67 l/h.,[Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6866757/),[l] / [h],32 and 67,146504,DB00997,Doxorubicin
,3802377,AUC,Doxorubicin plasma pharmacokinetics were prolonged after cimetidine pretreatment [AUC 0.76 +/- 0.22 vs.,The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802377/),,0.76,146570,DB00997,Doxorubicin
,3802377,half-life,"2.85 +/- 1.22 microM X h, no pretreatment vs pretreatment (p = 0.005), half-life = 11.7 +/- 6.55 vs 28.0 +/- 8.16 h (P = 0.0002), and clearance = 0.129 +/- 0.036 vs 0.036 +/- 0.011 l/min-1 kg-1 (P = 0.0007)].",The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802377/),h,11.7,146571,DB00997,Doxorubicin
,3802377,half-life,"2.85 +/- 1.22 microM X h, no pretreatment vs pretreatment (p = 0.005), half-life = 11.7 +/- 6.55 vs 28.0 +/- 8.16 h (P = 0.0002), and clearance = 0.129 +/- 0.036 vs 0.036 +/- 0.011 l/min-1 kg-1 (P = 0.0007)].",The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802377/),h,28.0,146572,DB00997,Doxorubicin
,3802377,clearance,"2.85 +/- 1.22 microM X h, no pretreatment vs pretreatment (p = 0.005), half-life = 11.7 +/- 6.55 vs 28.0 +/- 8.16 h (P = 0.0002), and clearance = 0.129 +/- 0.036 vs 0.036 +/- 0.011 l/min-1 kg-1 (P = 0.0007)].",The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802377/),[l] / [min],0.129,146573,DB00997,Doxorubicin
,3802377,clearance,"2.85 +/- 1.22 microM X h, no pretreatment vs pretreatment (p = 0.005), half-life = 11.7 +/- 6.55 vs 28.0 +/- 8.16 h (P = 0.0002), and clearance = 0.129 +/- 0.036 vs 0.036 +/- 0.011 l/min-1 kg-1 (P = 0.0007)].",The effects of cimetidine upon the plasma pharmacokinetics of doxorubicin in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802377/),[l] / [min],0.036,146574,DB00997,Doxorubicin
,26115930,central volume of distribution at steady state,"Mean estimates of central volume of distribution at steady state, clearance, and elimination half-life of doxorubicin were 24.8 L, 15 L/h/m(2), and 34.8 h, respectively, with a large interpatient variability.",Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26115930/),l,24.8,147056,DB00997,Doxorubicin
,26115930,clearance,"Mean estimates of central volume of distribution at steady state, clearance, and elimination half-life of doxorubicin were 24.8 L, 15 L/h/m(2), and 34.8 h, respectively, with a large interpatient variability.",Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26115930/),[h·l] / [m(2],15,147057,DB00997,Doxorubicin
,26115930,elimination half-life,"Mean estimates of central volume of distribution at steady state, clearance, and elimination half-life of doxorubicin were 24.8 L, 15 L/h/m(2), and 34.8 h, respectively, with a large interpatient variability.",Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26115930/),h,34.8,147058,DB00997,Doxorubicin
,26115930,RD,The RD of Myocet® administered every 3 weeks to paediatric patients was 60 mg/m(2).,Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26115930/),,60,147059,DB00997,Doxorubicin
,32893368,IC50,Compound 15 showed the highest activity with an IC50 value of 3.48 µM.,"Novel 1,2,4-triazole derivatives: Design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32893368/),μM,3.48,147096,DB00997,Doxorubicin
,32893368,IC50,"Also, compound 20 revealed an equipotent activity with the reference cytotoxic drug, with an IC50 value of 5.95 µM.","Novel 1,2,4-triazole derivatives: Design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32893368/),μM,5.95,147097,DB00997,Doxorubicin
,6850648,initial half-life,The disappearance kinetics of Adriamycin could adequately be described by a biexponential equation with an initial half-life of 8-min and a terminal half-life of 30 hr.,Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850648/),min,8,147369,DB00997,Doxorubicin
,6850648,terminal half-life,The disappearance kinetics of Adriamycin could adequately be described by a biexponential equation with an initial half-life of 8-min and a terminal half-life of 30 hr.,Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6850648/),h,30,147370,DB00997,Doxorubicin
,11900234,Maximum tolerated dose,"Maximum tolerated dose was 15.25 and 43.00 mg L(-1) for doxorubicin and cisplatin, respectively.",Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11900234/),[mg] / [l],15.25,147490,DB00997,Doxorubicin
,11900234,Maximum tolerated dose,"Maximum tolerated dose was 15.25 and 43.00 mg L(-1) for doxorubicin and cisplatin, respectively.",Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11900234/),[mg] / [l],43.00,147491,DB00997,Doxorubicin
,11900234,perfusate/plasma area under the curve ratios,"The perfusate/plasma area under the curve ratios were favorable for both drugs, at 162+/-113 and 20.6+/-6.0, respectively, for doxorubicin and cisplatin.",Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11900234/),,162,147492,DB00997,Doxorubicin
,11900234,perfusate/plasma area under the curve ratios,"The perfusate/plasma area under the curve ratios were favorable for both drugs, at 162+/-113 and 20.6+/-6.0, respectively, for doxorubicin and cisplatin.",Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11900234/),,20.6,147493,DB00997,Doxorubicin
,21372831,overall response rate (ORR),"The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),%,45.5,147623,DB00997,Doxorubicin
,21372831,CR rate,"The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),%,27,147624,DB00997,Doxorubicin
,21372831,progression-free survival (PFS) rate,"The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36).",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),,6.5,147625,DB00997,Doxorubicin
,21372831,survival rate,"The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36).",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),,11,147626,DB00997,Doxorubicin
,21372831,plasma concentration,The PLD plasma concentration from nine patients ranged from 1.7036 to 9.2207 mg·L(-1) after administration of the CCOP regimen (0-168 h).,Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[mg] / [l],1.7036 to 9.2207,147627,DB00997,Doxorubicin
,21372831,AUC(0-∞),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[mg] / [h·l],910.76,147628,DB00997,Doxorubicin
,21372831,CL,"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [(m)^2·h],0.043,147629,DB00997,Doxorubicin
,21372831,CL,"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),h,68.40,147630,DB00997,Doxorubicin
,21372831,t(1/2),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [(m)^2·h],0.043,147631,DB00997,Doxorubicin
,21372831,t(1/2),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),h,68.40,147632,DB00997,Doxorubicin
,21372831,V(d),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [m(2],3.56,147633,DB00997,Doxorubicin
,12736762,response rate,"Four had a partial response (response rate 10%, confidence interval 0-20%).",A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12736762/),%,10,147897,DB00997,Doxorubicin
,12736762,duration of response,The median duration of response was 5.6 months.,A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12736762/),month,5.6,147898,DB00997,Doxorubicin
,12736762,time to tumor progression,"The median time to tumor progression and the median survival of all patients was only 2 and 3 months, respectively.",A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12736762/),month,2,147899,DB00997,Doxorubicin
,12736762,survival,"The median time to tumor progression and the median survival of all patients was only 2 and 3 months, respectively.",A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12736762/),month,3,147900,DB00997,Doxorubicin
,22983312,half-life (t1/2),"The mean half-life (t1/2) of perfusate cisplatin was 18.4 min, with area under the time-concentration curve (AUC) 0-90 min of 2.87 mM·min and estimated 0-60 min of 2.45 mM·min.",Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22983312/),min,18.4,148407,DB00997,Doxorubicin
,22983312,area under the time-concentration curve (AUC) 0-90 min,"The mean half-life (t1/2) of perfusate cisplatin was 18.4 min, with area under the time-concentration curve (AUC) 0-90 min of 2.87 mM·min and estimated 0-60 min of 2.45 mM·min.",Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22983312/),mM·min,2.87,148408,DB00997,Doxorubicin
,22983312,0-60 min,"The mean half-life (t1/2) of perfusate cisplatin was 18.4 min, with area under the time-concentration curve (AUC) 0-90 min of 2.87 mM·min and estimated 0-60 min of 2.45 mM·min.",Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22983312/),mM·min,2.45,148409,DB00997,Doxorubicin
,22983312,absorption t1/2,The absorption t1/2 was 9.0 min for cisplatin and 18.2 min for oxaliplatin.,Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22983312/),min,9.0,148410,DB00997,Doxorubicin
,22983312,absorption t1/2,The absorption t1/2 was 9.0 min for cisplatin and 18.2 min for oxaliplatin.,Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22983312/),min,18.2,148411,DB00997,Doxorubicin
,22983312,perfusion time,"Lowering the perfusion time to 60 min does not significantly change the pharmacokinetics of cisplatin, and is therefore to be considered.",Pharmacokinetics of cisplatin during hyperthermic intraperitoneal treatment of peritoneal carcinomatosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22983312/),min,60,148412,DB00997,Doxorubicin
,1686240,Terminal elimination half-lives,"Terminal elimination half-lives of I-DOX were similar, 6-7 hr, in all three species.","Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686240/),h,6-7,148433,DB00997,Doxorubicin
,1686240,AUC ratios,"Mean I-DOXOL/I-DOX AUC ratios were 0.02, 0.47, and 0.58, respectively, in rat, dog, and monkey, values considerably lower than reported in human studies.","Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686240/),,0.02,148434,DB00997,Doxorubicin
,1686240,AUC ratios,"Mean I-DOXOL/I-DOX AUC ratios were 0.02, 0.47, and 0.58, respectively, in rat, dog, and monkey, values considerably lower than reported in human studies.","Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686240/),,0.47,148435,DB00997,Doxorubicin
,1686240,AUC ratios,"Mean I-DOXOL/I-DOX AUC ratios were 0.02, 0.47, and 0.58, respectively, in rat, dog, and monkey, values considerably lower than reported in human studies.","Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686240/),,0.58,148436,DB00997,Doxorubicin
,1686240,terminal half-lives,"I-DOXOL remained slightly longer in the body than I-DOX, as seen both from terminal half-lives (9-11 hr) and mean residence times.","Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686240/),h,9-11,148437,DB00997,Doxorubicin
,1686240,bioavailabilities,"Mean bioavailabilities of I-DOX were 0.23 and 0.46 in rat and dog, respectively, and, in the latter, about half of I-DOXOL formation occurred during or before the first pass.","Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686240/),,0.23,148438,DB00997,Doxorubicin
,1686240,bioavailabilities,"Mean bioavailabilities of I-DOX were 0.23 and 0.46 in rat and dog, respectively, and, in the latter, about half of I-DOXOL formation occurred during or before the first pass.","Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686240/),,0.46,148439,DB00997,Doxorubicin
more,34219092,serum half-life,"The pharmacokinetics of rituximab differs substantially among individuals and its serum half-life is approximately more than 500 hours; therefore, the peak concentration increases cumulatively by weekly infusion.",[Optimization of rituximab dosing schedule in R-CHOP therapy for diffuse large B-cell lymphoma]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34219092/),h,500,148482,DB00997,Doxorubicin
,27002506,maximal tolerated dose,The maximal tolerated dose was 100 mg given every 2 weeks.,Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002506/),,100,149477,DB00997,Doxorubicin
,27002506,response rate,"The response rate was 45 %; median progression-free survival was 10.4 months, whereas 54.6 months of median overall survival was achieved.",Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002506/),%,45,149478,DB00997,Doxorubicin
,27002506,progression-free survival,"The response rate was 45 %; median progression-free survival was 10.4 months, whereas 54.6 months of median overall survival was achieved.",Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002506/),month,10.4,149479,DB00997,Doxorubicin
,27002506,overall survival,"The response rate was 45 %; median progression-free survival was 10.4 months, whereas 54.6 months of median overall survival was achieved.",Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002506/),month,54.,149480,DB00997,Doxorubicin
,7888700,CED,The CED of NVB was provisionally decided to be 4.8 mg/kg based on the comparison of AUC values at 24-infinity h between human patients and nude mice.,Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888700/),[mg] / [kg],4.8,149596,DB00997,Doxorubicin
≥,26031219,signal-to-noise ratio,"The lower limits of quantification for catalpol and acteoside in rat plasma were 2.62 and 0.61 ng/mL, with a signal-to-noise ratio of ≥10.",Comparative pharmacokinetics of catalpol and acteoside in normal and chronic kidney disease rats after oral administration of Rehmannia glutinosa extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26031219/),,10,150028,DB00997,Doxorubicin
>,26031219,extraction recoveries,The extraction recoveries of catalpol and acteoside were both >68.24% and the matrix effects ranged from 96.59 to 101.62%.,Comparative pharmacokinetics of catalpol and acteoside in normal and chronic kidney disease rats after oral administration of Rehmannia glutinosa extract. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26031219/),%,68.24,150029,DB00997,Doxorubicin
,22155412,loading,High entrapment (>90 %) and high loading (38.11 ± 0.37 %w/w) of hydrophilic Dox in lipid nanocarrier of polyglyceryl-6-distearate was achieved using poly(methyl vinyl ether-co-maleic anhydride) (Gantrez AN 119) and a modified nanoprecipitation method.,Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22155412/),[%w] / [w],38.11,150463,DB00997,Doxorubicin
,16133795,maximum tolerated dose,Thus the maximum tolerated dose of 60 mg/m(2) was declared.,An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16133795/),[mg] / [m],60,150776,DB00997,Doxorubicin
,2313718,ratio,The ratio of I-DOXOL to I-DOX plasma AUC was 12.8 +/- 7.3 SD.,Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2313718/),,12,150855,DB00997,Doxorubicin
,2313718,IC50,"The LD10 in mice was 6.8 mg/kg for I-DOXOL and 6 mg/kg for I-DOX, and the concentration of drug that inhibited by 50% (IC50) the growth of human granulocyte-macrophage colony-forming units (CFU-GM) was 80 nM for I-DOXOL and 50 nM for I-DOX.",Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2313718/),nM,80,150856,DB00997,Doxorubicin
,2313718,IC50,"The LD10 in mice was 6.8 mg/kg for I-DOXOL and 6 mg/kg for I-DOX, and the concentration of drug that inhibited by 50% (IC50) the growth of human granulocyte-macrophage colony-forming units (CFU-GM) was 80 nM for I-DOXOL and 50 nM for I-DOX.",Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2313718/),nM,50,150857,DB00997,Doxorubicin
,30610857,encapsulation efficiency,"The average encapsulation efficiency of AMD and QUE was 97.49% and 95.50%, respectively.",Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30610857/),%,97.49,150911,DB00997,Doxorubicin
,30610857,encapsulation efficiency,"The average encapsulation efficiency of AMD and QUE was 97.49% and 95.50%, respectively.",Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30610857/),%,95.50,150912,DB00997,Doxorubicin
,30610857,zeta potential,"The average particle size is 85 nm (n = 3), and the average zeta potential is -14.9 mV.",Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30610857/),m,14.9,150913,DB00997,Doxorubicin
,30610857,Cmax,"First, the pharmacokinetic study proved that codelivery liposomes enveloping QUE and AMD (AMD_QUE_SL) can obviously increase the blood concentration of AMD (Cmax: 140.50 ± 32.37 μg/mL) and extend the half-life period of AMD in plasma (t1/2:14.02 ± 1.54 h).",Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30610857/),[μg] / [ml],140.50,150914,DB00997,Doxorubicin
,30610857,t1/2,"First, the pharmacokinetic study proved that codelivery liposomes enveloping QUE and AMD (AMD_QUE_SL) can obviously increase the blood concentration of AMD (Cmax: 140.50 ± 32.37 μg/mL) and extend the half-life period of AMD in plasma (t1/2:14.02 ± 1.54 h).",Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30610857/),h,14.02,150915,DB00997,Doxorubicin
,2549204,overall response rate,"In the 24-hour arm, two patients achieved a partial remission, resulting in an overall response rate of 10%.",A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,10,151311,DB00997,Doxorubicin
,2549204,overall response rate,"In the 5-day schedule, 16 patients had a partial response and one had a complete remission, producing an overall response rate of 89%, which was significantly superior to that in the 24-hour arm (P less than .001).",A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,89,151312,DB00997,Doxorubicin
,2549204,duration of remission,The median duration of remission to etoposide in the 5-day arm was 4.5 months.,A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),month,4.5,151313,DB00997,Doxorubicin
excess,2549204,response rate,The response rate to single-agent etoposide using an efficacious schedule in extensive small-cell lung cancer has been determined to be in excess of 80%.,A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,80,151314,DB00997,Doxorubicin
,7632762,maximum cross section,"The excitation function for the 59Co(p,3n)57Ni reaction shows a maximum cross section of 13.8 +/- 1.5 mb at 38 MeV.","Nickel-57-doxorubicin, a potential radiotracer for pharmacokinetic studies using PET: production and radiolabelling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7632762/),mb,13.8,152918,DB00997,Doxorubicin
,15258103,recovery,"The recovery of doxorubicin was less than that of liposomal doxorubicin (70 +/- 24% versus 94 +/- 17%, P < 0.05).",The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15258103/),%,70,153000,DB00997,Doxorubicin
,15258103,recovery,"The recovery of doxorubicin was less than that of liposomal doxorubicin (70 +/- 24% versus 94 +/- 17%, P < 0.05).",The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15258103/),%,94,153001,DB00997,Doxorubicin
,15258103,permeability - surface area product,The transfer of doxorubicin across the hepatocyte membrane was symmetrical (permeability - surface area product for influx 0.02 +/- 0.01 ml s/g versus 0.03 +/- 0.02 ml s/g for efflux) and consistent with diffusion.,The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15258103/),[ml·s] / [g],0.02,153002,DB00997,Doxorubicin
,15258103,efflux,The transfer of doxorubicin across the hepatocyte membrane was symmetrical (permeability - surface area product for influx 0.02 +/- 0.01 ml s/g versus 0.03 +/- 0.02 ml s/g for efflux) and consistent with diffusion.,The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15258103/),[ml·s] / [g],0.03,153003,DB00997,Doxorubicin
,29897223,particle size,"Results showed that the average particle size and zeta potential of DOX-NPs/CS/γ-PGA were 180.6 ± 5.4 nm and-38.53 ± 0.29 m V, respectively.",[Polyelectrolyte layer-by-layer assembled lipid nanoparticles for improving oral absorption of doxorubicin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897223/),nm,180.6,153472,DB00997,Doxorubicin
,29897223,zeta potential,"Results showed that the average particle size and zeta potential of DOX-NPs/CS/γ-PGA were 180.6 ± 5.4 nm and-38.53 ± 0.29 m V, respectively.",[Polyelectrolyte layer-by-layer assembled lipid nanoparticles for improving oral absorption of doxorubicin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897223/),m·v,-,153473,DB00997,Doxorubicin
,29897223,zeta potential,"Results showed that the average particle size and zeta potential of DOX-NPs/CS/γ-PGA were 180.6 ± 5.4 nm and-38.53 ± 0.29 m V, respectively.",[Polyelectrolyte layer-by-layer assembled lipid nanoparticles for improving oral absorption of doxorubicin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897223/),m·v,38.53,153474,DB00997,Doxorubicin
,29897223,C(max),"The C(max), t(max) were 0.76 ± 0.25 μg·m L(-1) and 0.5 h, respectively; AUC(0-24 h) was 3.02 folds and the relative bioavailability was 302.46% with DOX solution as reference.",[Polyelectrolyte layer-by-layer assembled lipid nanoparticles for improving oral absorption of doxorubicin]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897223/),[m·μg] / [l],0.76,153475,DB00997,Doxorubicin
,29897223,t(max),"The C(max), t(max) were 0.76 ± 0.25 μg·m L(-1) and 0.5 h, respectively; AUC(0-24 h) was 3.02 folds and the relative bioavailability was 302.46% with DOX solution as reference.",[Polyelectrolyte layer-by-layer assembled lipid nanoparticles for improving oral absorption of doxorubicin]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897223/),h,0.5,153476,DB00997,Doxorubicin
,29897223,relative bioavailability,"The C(max), t(max) were 0.76 ± 0.25 μg·m L(-1) and 0.5 h, respectively; AUC(0-24 h) was 3.02 folds and the relative bioavailability was 302.46% with DOX solution as reference.",[Polyelectrolyte layer-by-layer assembled lipid nanoparticles for improving oral absorption of doxorubicin]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897223/),%,302.46,153477,DB00997,Doxorubicin
,24531558,clearance (CL),"During pregnancy, mean (±SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 ± 80 mL/min/m(2); steady-state volume of distribution (Vss), 1,132 ± 476 L/m(2); and terminal half-life (T1/2), 40.3 ± 8.9 h.",Pharmacokinetics of doxorubicin in pregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24531558/),[min·ml] / [m(2],412,153633,DB00997,Doxorubicin
,24531558,steady-state volume of distribution (Vss),"During pregnancy, mean (±SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 ± 80 mL/min/m(2); steady-state volume of distribution (Vss), 1,132 ± 476 L/m(2); and terminal half-life (T1/2), 40.3 ± 8.9 h.",Pharmacokinetics of doxorubicin in pregnant women. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24531558/),[l] / [m(2],"1,132",153634,DB00997,Doxorubicin
,24531558,terminal half-life (T1/2),"During pregnancy, mean (±SD) doxorubicin PK parameters utilizing 72 h sampling were: clearance (CL), 412 ± 80 mL/min/m(2); steady-state volume of distribution (Vss), 1,132 ± 476 L/m(2); and terminal half-life (T1/2), 40.3 ± 8.9 h.",Pharmacokinetics of doxorubicin in pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24531558/),h,40.3,153635,DB00997,Doxorubicin
,24531558,CL,"Truncating our data to 48 h, PK parameters were: CL, 499 ± 116 ml/min/m(2); Vss, 843 ± 391 L/m(2); and T1/2, 24.8 ± 5.9 h.",Pharmacokinetics of doxorubicin in pregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24531558/),[min·ml] / [m(2],499,153636,DB00997,Doxorubicin
,24531558,Vss,"Truncating our data to 48 h, PK parameters were: CL, 499 ± 116 ml/min/m(2); Vss, 843 ± 391 L/m(2); and T1/2, 24.8 ± 5.9 h.",Pharmacokinetics of doxorubicin in pregnant women. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24531558/),[l] / [m(2],843,153637,DB00997,Doxorubicin
,24531558,T1/2,"Truncating our data to 48 h, PK parameters were: CL, 499 ± 116 ml/min/m(2); Vss, 843 ± 391 L/m(2); and T1/2, 24.8 ± 5.9 h.",Pharmacokinetics of doxorubicin in pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24531558/),h,24.8,153638,DB00997,Doxorubicin
,21290248,AUC,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[h·μg] / [ml],195.0,154011,DB00997,Doxorubicin
,21290248,AUC,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[h·μg] / [ml],174.8,154012,DB00997,Doxorubicin
,21290248,clearance,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[l] / [h],5.1,154013,DB00997,Doxorubicin
,21290248,clearance,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[l] / [h],5.7,154014,DB00997,Doxorubicin
,27393274,maximum plasma concentration of do,Mean maximum plasma concentration of doxorubicin C max ± SD was 284.9 ± 276.2 ng/mL for the high and 108.5 ± 77.6 ng/mL for the low loading (p < 0.001).,"Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393274/),[ng] / [ml],284.9,154549,DB00997,Doxorubicin
,27393274,maximum plasma concentration of do,Mean maximum plasma concentration of doxorubicin C max ± SD was 284.9 ± 276.2 ng/mL for the high and 108.5 ± 77.6 ng/mL for the low loading (p < 0.001).,"Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393274/),[ng] / [ml],108.5,154550,DB00997,Doxorubicin
,27393274,overall objective response,According to m-RECIST overall objective response after two sessions reached 61.22 and 63.82 % at 6 months.,"Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393274/),%,61.22,154551,DB00997,Doxorubicin
,27393274,overall objective response,According to m-RECIST overall objective response after two sessions reached 61.22 and 63.82 % at 6 months.,"Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393274/),%,63.82,154552,DB00997,Doxorubicin
,27393274,Overall survival (OS),"Overall survival (OS) at 6 months, 1 , 2, and 3 years was 98.08, 92.3, 88.46, and 82.6 %, respectively.","Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393274/),%,98.08,154553,DB00997,Doxorubicin
,27393274,Overall survival (OS),"Overall survival (OS) at 6 months, 1 , 2, and 3 years was 98.08, 92.3, 88.46, and 82.6 %, respectively.","Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393274/),%,92.3,154554,DB00997,Doxorubicin
,27393274,Overall survival (OS),"Overall survival (OS) at 6 months, 1 , 2, and 3 years was 98.08, 92.3, 88.46, and 82.6 %, respectively.","Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393274/),%,88.46,154555,DB00997,Doxorubicin
,27393274,Overall survival (OS),"Overall survival (OS) at 6 months, 1 , 2, and 3 years was 98.08, 92.3, 88.46, and 82.6 %, respectively.","Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27393274/),%,82.6,154556,DB00997,Doxorubicin
,15367419,MTD,The MTD was 30/90 and 35/80 mg/m(2) for PLD/wPTX.,Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15367419/),[mg] / [m(2],30,154765,DB00997,Doxorubicin
,15367419,MTD,The MTD was 30/90 and 35/80 mg/m(2) for PLD/wPTX.,Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15367419/),[mg] / [m(2],35/80,154766,DB00997,Doxorubicin
,10430255,progression free,Median progression free and overall survival were both 8 months.,Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430255/),month,8,155777,DB00997,Doxorubicin
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,2.7,155899,DB00997,Doxorubicin
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,6.5,155900,DB00997,Doxorubicin
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,4.2,155901,DB00997,Doxorubicin
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,9.9,155902,DB00997,Doxorubicin
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,43,155903,DB00997,Doxorubicin
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,58,155904,DB00997,Doxorubicin
,26291333,EC50,"FD18 is a potent (EC50 = 148 nM for paclitaxel), safe (selective index = 574), and selective P-glycoprotein (P-gp) modulator.","A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26291333/),nM,148,155958,DB00997,Doxorubicin
,26291333,EC50,Pharmacokinetics studies indicated that intraperitoneal administration of 45 mg/kg FD18 was enough to maintain a plasma level above EC50 (148 nM) for more than 600 min.,"A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26291333/),nM,148,155959,DB00997,Doxorubicin
,27770238,clearance,"Age dependence of doxorubicin clearance was demonstrated, with children less than 3 years having a statistically significant lower clearance (21.1 ± 5.8 l/h/m2) than older children (26.6 ± 6.7 l/h/m2) (p = 0.0004) after correcting for body surface area.","Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a ""European Pediatric Oncology Off-patents Medicines Consortium"" trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27770238/),[l] / [h·m2],21.1,156129,DB00997,Doxorubicin
,27770238,clearance,"Age dependence of doxorubicin clearance was demonstrated, with children less than 3 years having a statistically significant lower clearance (21.1 ± 5.8 l/h/m2) than older children (26.6 ± 6.7 l/h/m2) (p = 0.0004) after correcting for body surface area.","Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a ""European Pediatric Oncology Off-patents Medicines Consortium"" trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27770238/),[l] / [h·m2],26.6,156130,DB00997,Doxorubicin
more,26185503,extraction recovery,"Sample preparation includes a simple one-step liquid-liquid extraction using a minimum amount of organic solvent, with extraction recovery more than 95%.",A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26185503/),%,95,156933,DB00997,Doxorubicin
,26185503,flow-rate,"The flow-rate was kept at 1 mL/min and the column effluent was monitored with a fluorescence detector at an excitation and emission wavelength of 470 and 555 nm, respectively.",A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26185503/),[ml] / [min],1,156934,DB00997,Doxorubicin
,26185503,detection limit,The detection limit was 5 ng/mL.,A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26185503/),[ng] / [ml],5,156935,DB00997,Doxorubicin
,7574759,Areas under the time-concentration curves,Areas under the time-concentration curves of prefilter levels in groups I and II were 6.1 +/- 1.6 and 16.9 +/- 5.0 micrograms.,[Pharmacokinetic comparison of intraarterial and intraportal infusion of adriamycin in regional chemotherapy of the liver]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574759/),μg,6.1,157300,DB00997,Doxorubicin
,7574759,Areas under the time-concentration curves,Areas under the time-concentration curves of prefilter levels in groups I and II were 6.1 +/- 1.6 and 16.9 +/- 5.0 micrograms.,[Pharmacokinetic comparison of intraarterial and intraportal infusion of adriamycin in regional chemotherapy of the liver]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574759/),μg,16.9,157301,DB00997,Doxorubicin
,7574759,HER,"On the contrary, HER of group I (81.2%) was significantly higher than that of group II (47.2%, p < 0.01).",[Pharmacokinetic comparison of intraarterial and intraportal infusion of adriamycin in regional chemotherapy of the liver]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574759/),,81,157302,DB00997,Doxorubicin
,7574759,HER,"On the contrary, HER of group I (81.2%) was significantly higher than that of group II (47.2%, p < 0.01).",[Pharmacokinetic comparison of intraarterial and intraportal infusion of adriamycin in regional chemotherapy of the liver]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574759/),,47,157303,DB00997,Doxorubicin
,16133530,half lethal dose,"The results revealed that liposomal daunorubicin significantly reduced the toxicity of the drug, with a half lethal dose of 29.35 mg/kg, compared with 5.45 mg/kg for free drug.",Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16133530/),[mg] / [kg],29.35,157573,DB00997,Doxorubicin
,16133530,half lethal dose,"The results revealed that liposomal daunorubicin significantly reduced the toxicity of the drug, with a half lethal dose of 29.35 mg/kg, compared with 5.45 mg/kg for free drug.",Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16133530/),[mg] / [kg],5.45,157574,DB00997,Doxorubicin
,25177016,polydispersity index,"The optimized formulation comprising of 5% w/v PGPR and 3% w/v Tween 20 in the oil phase and external water phase, respectively, with 0.5% w/v of DOX had a particle size of 0.440±0.007 µm and polydispersity index of 0.220±0.087, which was supported by the transmission electron microscopy image.","Fabrication, characterization and pharmacokinetic evaluation of doxorubicin-loaded water-in-oil-in-water microemulsions using a membrane emulsification technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25177016/),,0.220,158082,DB00997,Doxorubicin
,19558359,minimum diameter,"Nanoparticles were visible as approximate spherical particles with good disparity, with an average diameter of 184.6 nm, a minimum diameter of 59.07 nm, and a maximum diameter of 291.66 nm as demonstrated by transmission electron microscopy.",Polybutylcyanoacrylate magnetic nanoparticles as carriers of adriamycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19558359/),nm,59.07,158249,DB00997,Doxorubicin
,19558359,maximum diameter,"Nanoparticles were visible as approximate spherical particles with good disparity, with an average diameter of 184.6 nm, a minimum diameter of 59.07 nm, and a maximum diameter of 291.66 nm as demonstrated by transmission electron microscopy.",Polybutylcyanoacrylate magnetic nanoparticles as carriers of adriamycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19558359/),nm,291.66,158250,DB00997,Doxorubicin
,19558359,total release rate,"In vitro study demonstrated that the release reached a balance after 72 h, with a total release rate of approximately 80%.",Polybutylcyanoacrylate magnetic nanoparticles as carriers of adriamycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19558359/),%,80,158251,DB00997,Doxorubicin
,10811677,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) of epirubicin was higher in the TE group (2,346 ng/mL. h v 1,717 ng/mL. h; P =.002).",Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10811677/),[ng] / [h·ml],"2,346",158274,DB00997,Doxorubicin
,10811677,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) of epirubicin was higher in the TE group (2,346 ng/mL. h v 1,717 ng/mL. h; P =.002).",Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10811677/),[ng] / [h·ml],"1,717",158275,DB00997,Doxorubicin
,10511918,area under the concentration-time curve (AUC),"Likewise, patients given epirubicin 90 mg/m2 had a sudden rebound of epirubicinol plasma concentrations shortly after the start of infusion of paclitaxel 200 mg/m2, with a significant increase in the area under the concentration-time curve (AUC) of epirubicinol as compared with epirubicin alone (1.27 +/- 0.2 vs 0.61 +/- 0.1 mumol/L.h).",Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511918/),[μM] / [h·l],1.27,161516,DB00997,Doxorubicin
,10511918,area under the concentration-time curve (AUC),"Likewise, patients given epirubicin 90 mg/m2 had a sudden rebound of epirubicinol plasma concentrations shortly after the start of infusion of paclitaxel 200 mg/m2, with a significant increase in the area under the concentration-time curve (AUC) of epirubicinol as compared with epirubicin alone (1.27 +/- 0.2 vs 0.61 +/- 0.1 mumol/L.h).",Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511918/),[μM] / [h·l],0.61,161517,DB00997,Doxorubicin
,18927308,progression-free survival,Median progression-free survival was 9.2 months.,Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18927308/),month,9.2,161686,DB00997,Doxorubicin
,30689002,CL,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],3.58,161752,DB00997,Doxorubicin
,30689002,Vmale,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,32.2,161753,DB00997,Doxorubicin
,30689002,Vfemale,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,28.7,161754,DB00997,Doxorubicin
,30689002,CL,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],51.1,161755,DB00997,Doxorubicin
,30689002,Q,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],49.6,161756,DB00997,Doxorubicin
,30689002,V1,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,29.4,161757,DB00997,Doxorubicin
,30689002,V2,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,"1,130",161758,DB00997,Doxorubicin
,30689002,V1,VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02).,Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,29.4,161759,DB00997,Doxorubicin
,30689002,V1,VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02).,Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,57.5,161760,DB00997,Doxorubicin
,10071279,MTD,"The MTD of paclitaxel was 150 mg/m2, and adjunctive therapy with G-CSF was required to prevent febrile neutropenia.",Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071279/),[mg] / [m2],150,161889,DB00997,Doxorubicin
,29043471,T1/2 α,"Blood clearance showed a relatively long half-life, with blood levels decaying in a biphasic manner (T1/2 α = 38.7 min; T1/2 β = 516.5 min).",Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043471/),min,38.7,162076,DB00997,Doxorubicin
,29043471,T1/2 β,"Blood clearance showed a relatively long half-life, with blood levels decaying in a biphasic manner (T1/2 α = 38.7 min; T1/2 β = 516.5 min).",Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043471/),min,516.5,162077,DB00997,Doxorubicin
,3459594,terminal half-life,"In nine patients who received DMDR IV the unchanged drug disappeared from the plasma biphasically with a mean terminal half-life of 27.0 +/- 5.5 h, an apparent volume of distribution of 63.9 +/- 12.61 kg-1, and a total clearance of 1.9 +/- 0.41 kg-1 h-1.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),h,27.0,162106,DB00997,Doxorubicin
,3459594,apparent volume of distribution,"In nine patients who received DMDR IV the unchanged drug disappeared from the plasma biphasically with a mean terminal half-life of 27.0 +/- 5.5 h, an apparent volume of distribution of 63.9 +/- 12.61 kg-1, and a total clearance of 1.9 +/- 0.41 kg-1 h-1.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),1/[kg],63.9,162107,DB00997,Doxorubicin
,3459594,total clearance,"In nine patients who received DMDR IV the unchanged drug disappeared from the plasma biphasically with a mean terminal half-life of 27.0 +/- 5.5 h, an apparent volume of distribution of 63.9 +/- 12.61 kg-1, and a total clearance of 1.9 +/- 0.41 kg-1 h-1.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),1/[h·kg],1.9,162108,DB00997,Doxorubicin
,3459594,plasma half-life,"In comparison, in 19 studies the plasma half-life of DMDR given PO was 34.8 +/- 6.7 h, 2.3% +/- 1.3% was excreted in the urine in 24 h, and the maximum plasma drug concentration was reached in about 1 h.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),h,34.8,162109,DB00997,Doxorubicin
,3459594,plasma half-life,"In comparison, in 19 studies the plasma half-life of DMDR given PO was 34.8 +/- 6.7 h, 2.3% +/- 1.3% was excreted in the urine in 24 h, and the maximum plasma drug concentration was reached in about 1 h.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),%,2.3,162110,DB00997,Doxorubicin
,3459594,bioavailability,"The bioavailability of DMDR given PO was about 39% according to comparison of the areas under the plasma DMDR concentration versus time curves for the two routes, but 45% according to comparison of the 24-h cumulative urinary excretion rates.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),%,39,162111,DB00997,Doxorubicin
,3459594,bioavailability,"The bioavailability of DMDR given PO was about 39% according to comparison of the areas under the plasma DMDR concentration versus time curves for the two routes, but 45% according to comparison of the 24-h cumulative urinary excretion rates.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),%,45,162112,DB00997,Doxorubicin
,3459594,half-life,"In one patient with severe liver dysfunction following oral administration, the plasma DMDR half-life was 56.8 h, more than twice the average length.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),h,56.8,162113,DB00997,Doxorubicin
,3459594,plasma half-life,"The plasma half-life of DMDR-ol was 72.5 +/- 24.7 h, or 35.7 +/- 7.4 when DMDR was administered IV or PO.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),h,72.5,162114,DB00997,Doxorubicin
,3459594,plasma half-life,"The plasma half-life of DMDR-ol was 72.5 +/- 24.7 h, or 35.7 +/- 7.4 when DMDR was administered IV or PO.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),,35.7,162115,DB00997,Doxorubicin
,3459594,cumulative urinary excretion,"Moreover, the 24 h cumulative urinary excretion of DMDR-ol as a percentage of the dose of DMDR administered was 7.8 following IV and 7.4 following PO administration.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),,7.8,162116,DB00997,Doxorubicin
,3459594,cumulative urinary excretion,"Moreover, the 24 h cumulative urinary excretion of DMDR-ol as a percentage of the dose of DMDR administered was 7.8 following IV and 7.4 following PO administration.",Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459594/),,7.4,162117,DB00997,Doxorubicin
,10210721,encapsulation efficiencies,"The encapsulation efficiencies of monensin in MLVs and small unilamellar vesicles (SUVs) was 6x10++(-6) and 10(-7) M, respectively.",Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210721/),M,6x10,162492,DB00997,Doxorubicin
,10210721,encapsulation efficiencies,"The encapsulation efficiencies of monensin in MLVs and small unilamellar vesicles (SUVs) was 6x10++(-6) and 10(-7) M, respectively.",Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210721/),M,10(-7),162493,DB00997,Doxorubicin
,10210721,t1/2,"The in vitro release of monensin from SMLs in human serum was determined, and t1/2 was found to be 10 h.",Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210721/),h,10,162494,DB00997,Doxorubicin
,27178807,elimination half-life time,"The in vivo pharmacokinetics studies displayed that DOX-loaded cRGD20/PEG-SS-PCL micelles had a prolonged elimination half-life time of 3.51h, which was comparable to that of cRGD20/PEG-PCL counterparts, indicating that disulfide bonds in the PEG-SS-PCL micelles are stable in the circulation.",cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27178807/),h,3.51,162980,DB00997,Doxorubicin
,25586675,z,"Optimized formulation had molar ratio of 60:30:8:2 (HSPC:Chol:DSPG:mPEG-DSPE) with entrapment efficiency ∼83%, particle size below 200 nm and zeta potential about -20 mV.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),,20,163179,DB00997,Doxorubicin
,25586675,IC50,"The IC50 value obtained for epirubicin solution, non-targeted and targeted liposomes was 0.675, 0.532 and 0.192 µg/ml, respectively.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),[μg] / [ml],0.675,163180,DB00997,Doxorubicin
,25586675,IC50,"The IC50 value obtained for epirubicin solution, non-targeted and targeted liposomes was 0.675, 0.532 and 0.192 µg/ml, respectively.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),[μg] / [ml],0.532,163181,DB00997,Doxorubicin
,25586675,IC50,"The IC50 value obtained for epirubicin solution, non-targeted and targeted liposomes was 0.675, 0.532 and 0.192 µg/ml, respectively.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),[μg] / [ml],0.192,163182,DB00997,Doxorubicin
,8830976,AUC,"The mean plasma concentrations of M1 were detected up to 8 h after i.v. administration of both DA-125 and ME2303 to mice, and were significantly higher for DA-125 than ME2303; this resulted in a considerably greater AUC (303 against 148 micrograms min mL(-1)) and a considerably slower CL of M1 (69.3 against 136 mL min-1 kg(-1)) after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),[min·μg] / [ml],303,163202,DB00997,Doxorubicin
,8830976,AUC,"The mean plasma concentrations of M1 were detected up to 8 h after i.v. administration of both DA-125 and ME2303 to mice, and were significantly higher for DA-125 than ME2303; this resulted in a considerably greater AUC (303 against 148 micrograms min mL(-1)) and a considerably slower CL of M1 (69.3 against 136 mL min-1 kg(-1)) after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),[min·μg] / [ml],148,163203,DB00997,Doxorubicin
,8830976,CL,"The mean plasma concentrations of M1 were detected up to 8 h after i.v. administration of both DA-125 and ME2303 to mice, and were significantly higher for DA-125 than ME2303; this resulted in a considerably greater AUC (303 against 148 micrograms min mL(-1)) and a considerably slower CL of M1 (69.3 against 136 mL min-1 kg(-1)) after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),[ml] / [kg·min],69.3,163204,DB00997,Doxorubicin
,8830976,CL,"The mean plasma concentrations of M1 were detected up to 8 h after i.v. administration of both DA-125 and ME2303 to mice, and were significantly higher for DA-125 than ME2303; this resulted in a considerably greater AUC (303 against 148 micrograms min mL(-1)) and a considerably slower CL of M1 (69.3 against 136 mL min-1 kg(-1)) after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),[ml] / [kg·min],136,163205,DB00997,Doxorubicin
,8830976,MRT,"The MRT (371 against 189 min) and CLNR of M1 (68.7 against 136 mL min-1 kg(-1)) were considerably greater and slower, respectively, after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),min,371,163206,DB00997,Doxorubicin
,8830976,MRT,"The MRT (371 against 189 min) and CLNR of M1 (68.7 against 136 mL min-1 kg(-1)) were considerably greater and slower, respectively, after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),min,189,163207,DB00997,Doxorubicin
,8830976,CLNR,"The MRT (371 against 189 min) and CLNR of M1 (68.7 against 136 mL min-1 kg(-1)) were considerably greater and slower, respectively, after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),[ml] / [kg·min],68.7,163208,DB00997,Doxorubicin
,8830976,CLNR,"The MRT (371 against 189 min) and CLNR of M1 (68.7 against 136 mL min-1 kg(-1)) were considerably greater and slower, respectively, after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),[ml] / [kg·min],136,163209,DB00997,Doxorubicin
,8830976,AUC,"The mean plasma concentrations of M2 were detected up to 8 and 4 h after i.v. administration of DA-125 and ME2303, respectively, to mice and were significantly higher for DA-125 than ME2303, resulting in a considerably greater AUC of M2 (148 against 27.1 micrograms min mL(-1)) after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),[min·μg] / [ml],148,163210,DB00997,Doxorubicin
,8830976,AUC,"The mean plasma concentrations of M2 were detected up to 8 and 4 h after i.v. administration of DA-125 and ME2303, respectively, to mice and were significantly higher for DA-125 than ME2303, resulting in a considerably greater AUC of M2 (148 against 27.1 micrograms min mL(-1)) after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),[min·μg] / [ml],27.1,163211,DB00997,Doxorubicin
,8830976,AUC,"The mean plasma concentrations of M4 were detected up to 8 h after i.v. administration of both DA-125 and ME2303 to mice, and were higher after i.v. administration of DA-125 than ME2303, resulting in a considerably greater AUC of M4 (197 against 61.9 micrograms min mL(-1)) after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),[min·μg] / [ml],197,163212,DB00997,Doxorubicin
,8830976,AUC,"The mean plasma concentrations of M4 were detected up to 8 h after i.v. administration of both DA-125 and ME2303 to mice, and were higher after i.v. administration of DA-125 than ME2303, resulting in a considerably greater AUC of M4 (197 against 61.9 micrograms min mL(-1)) after i.v. administration of DA-125.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),[min·μg] / [ml],61.9,163213,DB00997,Doxorubicin
,8830976,terminal half-life,"However, after i.v. administration of M2, 5 mg kg(-1), to rats, the mean plasma concentrations of M2 were detected up to 60 min with a mean terminal half-life of only 38.8 min, and the concentrations of M3 were negligible.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),min,38.8,163214,DB00997,Doxorubicin
,8830976,terminal half-life,"After i.v. administration of M4, 5 mg kg(-1), to rats, the mean plasma concentrations of M4 decayed fast with a mean terminal half-life of 43.9 min and neither M2 nor M3 were detected in plasma.","Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830976/),min,43.9,163215,DB00997,Doxorubicin
,32222808,volume of distribution,"Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively.",Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),[ml] / [kg],57.3 to 95.6,163246,DB00997,Doxorubicin
,32222808,clearance,"Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively.",Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),[ml] / [d·kg],12.7 to 18.2,163247,DB00997,Doxorubicin
,32222808,elimination half-life,acMMAE exhibited multi-exponential decay (elimination half-life ~ 1 week).,Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),week,1,163248,DB00997,Doxorubicin
,8933293,area under the plasma concentration-time curve (AUC,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[μg] / [ml],56.4,164010,DB00997,Doxorubicin
,8933293,area under the plasma concentration-time curve (AUC,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[min·μg] / [ml],69.0,164011,DB00997,Doxorubicin
,8933293,terminal half-life (t1/2,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),h,3.51,164012,DB00997,Doxorubicin
,8933293,terminal half-life (t1/2,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),h,3.01,164013,DB00997,Doxorubicin
,8933293,total body clearance (Cl,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[ml] / [kg·min],70.9,164014,DB00997,Doxorubicin
,8933293,total body clearance (Cl,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[ml] / [kg·min],58.0,164015,DB00997,Doxorubicin
,8933293,renal clearance (ClR,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[ml] / [kg·min],0.193,164016,DB00997,Doxorubicin
,8933293,renal clearance (ClR,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[ml] / [kg·min],0.336,164017,DB00997,Doxorubicin
,8933293,nonrenal clearance (ClNR,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[ml] / [kg·min],70.7,164018,DB00997,Doxorubicin
,8933293,nonrenal clearance (ClNR,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[ml] / [kg·min],57.7,164019,DB00997,Doxorubicin
,8933293,plasma AUC,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[min·μg] / [ml],39.4,164020,DB00997,Doxorubicin
,8933293,plasma AUC,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[min·μg] / [ml],41.9,164021,DB00997,Doxorubicin
,8933293,t1/2,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),h,6.15,164022,DB00997,Doxorubicin
,8933293,t1/2,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),h,7.34,164023,DB00997,Doxorubicin
,8933293,ClR,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[ml] / [·kg·min],10.5,164024,DB00997,Doxorubicin
,8933293,ClR,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),[ml] / [kg·min],13.8,164025,DB00997,Doxorubicin
,8933293,plasma AUC,"The mean pharmacokinetic parameters of M1, such as area under the plasma concentration-time curve (AUC: 56.4 micrograms/ml vs. 69.0 micrograms min/ml), terminal half-life (t1/2: 3.51 h vs. 3.01 h), total body clearance (Cl: 70.9 ml/min/kg vs. 58.0 ml/min/kg), renal clearance (ClR: 0.193 ml/min/kg vs. 0.336 ml/min/kg) and nonrenal clearance (ClNR: 70.7 ml/min/kg vs. 57.7 ml/min/kg); of M2, such as plasma AUC (39.4 micrograms min/ml vs. 41.9 micrograms min/ ml), t1/2 (6.15 h vs. 7.34 h) and ClR (10.5 ml/min/ kg vs. 13.8 ml/min/kg); and of M4, such as plasma AUC (4.82 micrograms min/ml vs. 6.54 micrograms min/ml) and t1/2 (3.33 h vs 4.02 h), were comparable between single and multiple administrations of DA-125.","Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),μ,4.82,164026,DB00997,Doxorubicin
,8933293,M2,The corresponding values for M2 were 27.8% and 22.5%.,"Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),,27,164027,DB00997,Doxorubicin
,8933293,M2,The corresponding values for M2 were 27.8% and 22.5%.,"Pharmacokinetics of four metabolites of DA-125, a new anthracycline antineoplastic agent after single and multiple intravenous administration to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8933293/),,22,164028,DB00997,Doxorubicin
,20929434,tumor inhibitory rate,"The mean tumor inhibitory rate for EPI-LTSL, EPI-NTSL, and EPI-solution were 61.1, 39.6, and 43.1%, respectively.",Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929434/),%,61.1,164357,DB00997,Doxorubicin
,20929434,tumor inhibitory rate,"The mean tumor inhibitory rate for EPI-LTSL, EPI-NTSL, and EPI-solution were 61.1, 39.6, and 43.1%, respectively.",Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929434/),%,39.6,164358,DB00997,Doxorubicin
,20929434,tumor inhibitory rate,"The mean tumor inhibitory rate for EPI-LTSL, EPI-NTSL, and EPI-solution were 61.1, 39.6, and 43.1%, respectively.",Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929434/),%,43.1,164359,DB00997,Doxorubicin
,18608462,peak plasma concentration,Administration of DOX in normal mice resulted in a peak plasma concentration of 19.45 microM (t = 30 minutes).,"Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608462/),μM,19.45,164889,DB00997,Doxorubicin
,18608462,t,Administration of DOX in normal mice resulted in a peak plasma concentration of 19.45 microM (t = 30 minutes).,"Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608462/),min,30,164890,DB00997,Doxorubicin
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.66,165049,DB00997,Doxorubicin
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.58,165050,DB00997,Doxorubicin
,8820952,peak total reversing concentration,"Since both are comparable antagonists, a median peak total reversing concentration of 3.24 mumol/l was achieved.",Clinical reversal of multidrug resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],3.24,165051,DB00997,Doxorubicin
greater,25817532,release rates,"Drug release rate from TSL has a saturable effect on peak intracellular drug concentration, and no further gain could be achieved for release rates greater than 0.1018 s(-1).",A systematic study of temperature sensitive liposomal delivery of doxorubicin using a mathematical model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25817532/),1/[s],0.1018,165356,DB00997,Doxorubicin
,18525298,MTD,The MTD of epirubicin was 50 mg/m2.,"Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18525298/),[mg] / [m2],50,165644,DB00997,Doxorubicin
,3566297,Renal excretion,Renal excretion over 48 hours was 9% and biliary excretion over the same period was 20%.,[Pharmacokinetic studies on THP-ADM (tetrahydropyranyl adriamycin)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566297/),%,9,166178,DB00997,Doxorubicin
,3566297,biliary excretion,Renal excretion over 48 hours was 9% and biliary excretion over the same period was 20%.,[Pharmacokinetic studies on THP-ADM (tetrahydropyranyl adriamycin)]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566297/),%,20,166179,DB00997,Doxorubicin
,8347482,tumour foci,"The mean number (+/- s.d.) of tumour foci was (a) 8.62 (+/- 5.4), (b) 4.62 (+/- 3.2), (c) 2.25 (+/- 1.4) (P < 0.05 a vs c).",Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347482/),,8.62,166773,DB00997,Doxorubicin
,8347482,tumour foci,"The mean number (+/- s.d.) of tumour foci was (a) 8.62 (+/- 5.4), (b) 4.62 (+/- 3.2), (c) 2.25 (+/- 1.4) (P < 0.05 a vs c).",Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347482/),,4.62,166774,DB00997,Doxorubicin
,8347482,tumour foci,"The mean number (+/- s.d.) of tumour foci was (a) 8.62 (+/- 5.4), (b) 4.62 (+/- 3.2), (c) 2.25 (+/- 1.4) (P < 0.05 a vs c).",Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347482/),,2.25,166775,DB00997,Doxorubicin
,8347482,tumour area,"The mean tumour area was (a) 6.31 (+/- 6.1), (b) 1.31 (+/- 2.2), (c) 0.43 (+/- 0.4 cm2) (P < 0.05 a vs c) and the percentage (95% C.I.) of rabbits with lung metastasis was: (a) 87.5% (47-99%), (b) 75% (35-97%), (c) 12.5% (3-52%) (P < 0.02 b vs c).",Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347482/),cm2,6.31,166776,DB00997,Doxorubicin
,8347482,tumour area,"The mean tumour area was (a) 6.31 (+/- 6.1), (b) 1.31 (+/- 2.2), (c) 0.43 (+/- 0.4 cm2) (P < 0.05 a vs c) and the percentage (95% C.I.) of rabbits with lung metastasis was: (a) 87.5% (47-99%), (b) 75% (35-97%), (c) 12.5% (3-52%) (P < 0.02 b vs c).",Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347482/),cm2,1.31,166777,DB00997,Doxorubicin
,8347482,tumour area,"The mean tumour area was (a) 6.31 (+/- 6.1), (b) 1.31 (+/- 2.2), (c) 0.43 (+/- 0.4 cm2) (P < 0.05 a vs c) and the percentage (95% C.I.) of rabbits with lung metastasis was: (a) 87.5% (47-99%), (b) 75% (35-97%), (c) 12.5% (3-52%) (P < 0.02 b vs c).",Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347482/),cm2,0.43,166778,DB00997,Doxorubicin
,24899600,AUC(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [h·l],15.371,167278,DB00997,Doxorubicin
,24899600,AUC(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [h·l],6.901,167279,DB00997,Doxorubicin
,24899600,MRT(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,8.751,167280,DB00997,Doxorubicin
,24899600,MRT(0-t),"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,6.032,167281,DB00997,Doxorubicin
,24899600,t1/2,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,3.88,167282,DB00997,Doxorubicin
,24899600,t1/2,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,3.602,167283,DB00997,Doxorubicin
,24899600,Tmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,6.2,167284,DB00997,Doxorubicin
,24899600,Tmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),h,1.95,167285,DB00997,Doxorubicin
,24899600,CL/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [h·kg],0.038,167286,DB00997,Doxorubicin
,24899600,CL/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [h·kg],0.107,167287,DB00997,Doxorubicin
,24899600,V/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [kg],0.212,167288,DB00997,Doxorubicin
,24899600,V/F,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[l] / [kg],0.567,167289,DB00997,Doxorubicin
,24899600,Cmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [l],1.853,167290,DB00997,Doxorubicin
,24899600,Cmax,"The pharmacokinetics parameter of tolbutamide in ADR-group and Control-group were AUC(0-t) 15.371 ± 4.107, 6.901 ± 5.738 (mg/L*h), MRT(0-t) 8.751 ± 0.754, 6.032 ± 0.63 (h), t1/2 3.88 ± 0.423, 3.602 ± 0.693 (h), Tmax 6.2 ± 3.768, 1.95 ± 0.798 (h), CL/F 0.038 ± 0.005, 0.107 ± 0.037 (L/h/kg), V/F 0.212 ± 0.043, 0.567 ± 0.258 (L/kg), Cmax 1.853 ± 0.384, 1.422 ± 1.312 (mg/L).",Pharmacokinetic of four probe drugs in adriamycin-induced nephropathy rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24899600/),[mg] / [l],1.422,167291,DB00997,Doxorubicin
,28957779,Recovery,"Recovery (59.28-69.53% for DOX-S-S-DOX and 99.13-100.10% for DOX) and matrix effect (99.69-111.19%) was consistent, precise, and reproducible at different quality control levels in accordance with FDA guidance.",A sensitive liquid chromatography/electrospray tandem mass spectroscopy method for simultaneous quantification of a disulfide bond doxorubicin conjugation prodrug and activated doxorubicin: Application to cellular pharmacokinetic and catabolism studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28957779/),%,59.28-69.53,167372,DB00997,Doxorubicin
,28957779,Recovery,"Recovery (59.28-69.53% for DOX-S-S-DOX and 99.13-100.10% for DOX) and matrix effect (99.69-111.19%) was consistent, precise, and reproducible at different quality control levels in accordance with FDA guidance.",A sensitive liquid chromatography/electrospray tandem mass spectroscopy method for simultaneous quantification of a disulfide bond doxorubicin conjugation prodrug and activated doxorubicin: Application to cellular pharmacokinetic and catabolism studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28957779/),%,99.13-100.10,167373,DB00997,Doxorubicin
,9863159,Ver,"Dox cytotoxicity was enhanced 2.0-fold in Swiss-3T3 cells by Ver (3 mumol.L-1) and 3.6-fold in MCF-7Adr cells by Ver (6 mumol.L-1), but not in MCF-7WT cells (Ver 6 mumol.L-1).",Doxorubicin cellular pharmacokinetics plays no role in chemosensitizing effect of verapamil on Swiss-3T3 cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863159/),[μM] / [l],6,167494,DB00997,Doxorubicin
,6590528,Urine excretion,"Urine excretion amounts to a total of about 11% of the administered dose during 48 h after drug administration, and less than 1% during the following 48 h.",Pharmacokinetics of 4'-epi-doxorubicin in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6590528/),%,11,168039,DB00997,Doxorubicin
less,6590528,Urine excretion,"Urine excretion amounts to a total of about 11% of the administered dose during 48 h after drug administration, and less than 1% during the following 48 h.",Pharmacokinetics of 4'-epi-doxorubicin in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6590528/),%,1,168040,DB00997,Doxorubicin
,10829049,maximum dose,"At higher doses, BR96-Dox was associated with nausea, vomiting, and endoscopically documented exudative gastritis of the upper GI tract, which was dose-limiting at a maximum dose of 875 mg/m(2) (doxorubicin equivalent, 25 mg/m(2)) administered every 3 weeks.",Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829049/),[mg] / [m(2],875,168140,DB00997,Doxorubicin
,10829049,half-life,"At the 550-mg/m(2) dose, the half-life (mean +/- SD) of BR96 and doxorubicin was 300 +/- 95 hours and 43 +/- 4 hours, respectively.",Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829049/),h,300,168141,DB00997,Doxorubicin
,10829049,half-life,"At the 550-mg/m(2) dose, the half-life (mean +/- SD) of BR96 and doxorubicin was 300 +/- 95 hours and 43 +/- 4 hours, respectively.",Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10829049/),h,43,168142,DB00997,Doxorubicin
up to,32263336,drug loading,"High drug loading - up to 18 w/w% - was observed for tamoxifen, a hydrophobic drug which bears an amino group able to form ion pairs with MCH acidic functionalities.",Novel pH-responsive nanovectors for controlled release of ionisable drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32263336/),[w] / [w%],18,168792,DB00997,Doxorubicin
,11761453,Peak plasma MEN-10755 levels,"Peak plasma MEN-10755 levels ranged between 474 and 21,587 microg/l.","Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11761453/),[μg] / [l],"474 and 21,587",168967,DB00997,Doxorubicin
,11761453,elimination half-life (T(1/2gamma)),The mean elimination half-life (T(1/2gamma)) was 20.7+/-9.0 h.,"Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11761453/),h,20.7,168968,DB00997,Doxorubicin
,11761453,plasma clearance,The mean plasma clearance of MEN-10755 was 6.0+/-2.2 l/h per m2 with a mean volume of distribution (Vss) of 95.6+/-43.4 l/m2.,"Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11761453/),[l] / [h·m2],6.0,168969,DB00997,Doxorubicin
,11761453,volume of distribution (Vss),The mean plasma clearance of MEN-10755 was 6.0+/-2.2 l/h per m2 with a mean volume of distribution (Vss) of 95.6+/-43.4 l/m2.,"Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11761453/),[l] / [m2],95.6,168970,DB00997,Doxorubicin
,11761453,renal excretion of unchanged drug,The mean renal excretion of unchanged drug within 24 h was 4.3+/-1.8%.,"Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11761453/),%,4.3,168971,DB00997,Doxorubicin
,3723990,T 1/2 of the first distribution phase,T 1/2 of the first distribution phase was 5.4 min.,[The pharmacokinetics of doxorubicin]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723990/),min,5.4,169226,DB00997,Doxorubicin
,3723990,T 1/2 of the terminal steady-state elimination phase,T 1/2 of the terminal steady-state elimination phase was 1273 min.,[The pharmacokinetics of doxorubicin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723990/),min,1273,169227,DB00997,Doxorubicin
,25400424,peak time (Tmax,Pharmacokinetic analysis showed that carboplatin rapidly entered systemic circulation with an early peak time (Tmax ~30 min) with a corresponding plasma ultrafiltrate area under the curve (AUC) consistent with the Calvert Formula using estimated glomerular filtration rate (GFR).,The safety parameters of the study on intraductal cytotoxic agent delivery to the breast before mastectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25400424/),min,30,169247,DB00997,Doxorubicin
,17387591,volume doubling time (VDT),Antitumor efficacy of P(DA-DDDA) copolymers containing 5% adriamycin hydrochloride (ADM) implanted subcutaneously in mice bearing Sarcoma-180 tumor exhibited increased volume doubling time (VDT) (31 +/- 1.5 days) compared to plain subcutaneous injection of ADM (7 +/- 0.9 days).,Antitumor efficacy of poly(dimer acid-dodecanedioic acid) copolymer in mice bearing Sarcoma-180 tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17387591/),d,31,170129,DB00997,Doxorubicin
,17387591,volume doubling time (VDT),Antitumor efficacy of P(DA-DDDA) copolymers containing 5% adriamycin hydrochloride (ADM) implanted subcutaneously in mice bearing Sarcoma-180 tumor exhibited increased volume doubling time (VDT) (31 +/- 1.5 days) compared to plain subcutaneous injection of ADM (7 +/- 0.9 days).,Antitumor efficacy of poly(dimer acid-dodecanedioic acid) copolymer in mice bearing Sarcoma-180 tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17387591/),d,7,170130,DB00997,Doxorubicin
,16536473,T(1/2),TAB2.5 also showed prolonged retention (T(1/2) = 36.9 h) in tumor-bearing mice with tumor/plasma ratios of up to 1000.,Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16536473/),h,36.9,170969,DB00997,Doxorubicin
up to,16536473,tumor/plasma ratios,TAB2.5 also showed prolonged retention (T(1/2) = 36.9 h) in tumor-bearing mice with tumor/plasma ratios of up to 1000.,Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16536473/),,1000,170970,DB00997,Doxorubicin
,22881479,Half-life,Half-life values of DOX release ranged from 2 to 40 h at pH 5.0.,PolyMPC-doxorubicin prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22881479/),h,2 to 40,171520,DB00997,Doxorubicin
,22881479,maximum tolerated dose,"Cell culture experiments showed that highly loaded polyMPC-DOX conjugates exhibited higher intracellular drug accumulation and lower half-maximal inhibitory concentration (IC(50)) values, while a polymer with 30 wt % drug loading showed a maximum tolerated dose in the range of 30-50 mg/kg DOX equivalent weight in healthy mice.",PolyMPC-doxorubicin prodrugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22881479/),[mg] / [kg],30-50,171521,DB00997,Doxorubicin
,19246257,In,"Intra-assay recoveries ranged from 94.7 to 99.9%, and inter-assay recoveries were in the range of 95.2-101%.",Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246257/),%,94.7 to 99.9,171571,DB00997,Doxorubicin
,19246257,recoveries,"Intra-assay recoveries ranged from 94.7 to 99.9%, and inter-assay recoveries were in the range of 95.2-101%.",Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246257/),%,94.7 to 99.9,171572,DB00997,Doxorubicin
,19246257,inter-assay recoveries,"Intra-assay recoveries ranged from 94.7 to 99.9%, and inter-assay recoveries were in the range of 95.2-101%.",Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246257/),%,95.2-101,171573,DB00997,Doxorubicin
,8832911,apparent 'constant' plasma levels,"After 1 min i.v. infusion of ADM, apparent 'constant' plasma levels of ADM were maintained from 2 to 12 hr in the U-ARF rats, whereas the levels were detected for only up to 3 hr in the control rats.",Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to uranyl nitrate-induced acute renal failure rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832911/),h,2 to 12,172553,DB00997,Doxorubicin
,7723219,area under the ADR concentration-time curve (AUC),The area under the ADR concentration-time curve (AUC) of the tumors was 181.6 micrograms.,Antitumor effects and distribution of adriamycin incorporated into hydroxyapatite implants in a cancer rat model bearing swarm rat chondrosarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7723219/),μg,181.6,173240,DB00997,Doxorubicin
,7723219,ratio of the AUC,"The targeting index of the tumors, defined as the ratio of the AUC after the implantation of the ADR-HAP bead to that after administration of free ADR, was 34.8.(ABSTRACT TRUNCATED AT 250 WORDS)",Antitumor effects and distribution of adriamycin incorporated into hydroxyapatite implants in a cancer rat model bearing swarm rat chondrosarcoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7723219/),,34,173241,DB00997,Doxorubicin
,26410808,four,"Compared to 1st generation conjugate (P-EPI, Mw <50 kDa), 2P-EPI demonstrated remarkably improved PK such as fourfold terminal half-life (33.22 ± 3.18 h for 2P-EPI vs. 7.55 ± 3.18 h for P-EPI), which is primarily attributed to the increased molecular weight of the polymer carrier.",FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26410808/),h,33.22,173242,DB00997,Doxorubicin
,26410808,terminal half-life,"Compared to 1st generation conjugate (P-EPI, Mw <50 kDa), 2P-EPI demonstrated remarkably improved PK such as fourfold terminal half-life (33.22 ± 3.18 h for 2P-EPI vs. 7.55 ± 3.18 h for P-EPI), which is primarily attributed to the increased molecular weight of the polymer carrier.",FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26410808/),h,33.22,173243,DB00997,Doxorubicin
,26410808,terminal half-life,"Compared to 1st generation conjugate (P-EPI, Mw <50 kDa), 2P-EPI demonstrated remarkably improved PK such as fourfold terminal half-life (33.22 ± 3.18 h for 2P-EPI vs. 7.55 ± 3.18 h for P-EPI), which is primarily attributed to the increased molecular weight of the polymer carrier.",FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26410808/),h,7.55,173244,DB00997,Doxorubicin
,17273824,plasma peak concentration,The plasma peak concentration of Tet was about 2 micromol/L and not less than 1 micromol/L until 18 h following Tet administration (i.p.) at 30 mg/kg.,Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17273824/),[μM] / [l],2,173364,DB00997,Doxorubicin
less,17273824,plasma peak concentration,The plasma peak concentration of Tet was about 2 micromol/L and not less than 1 micromol/L until 18 h following Tet administration (i.p.) at 30 mg/kg.,Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17273824/),[μM] / [l],1,173365,DB00997,Doxorubicin
,2714916,CL,Its CL varied between 75 and 119 percent intra-individually.,Investigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714916/),%,75 and 119,174345,DB00997,Doxorubicin
,18442869,CL,"Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemic exposure (median AUC(VP16): 260mgh/L vs. 339mgh/L).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[l] / [h],2.42,174976,DB00997,Doxorubicin
,18442869,CL,"Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemic exposure (median AUC(VP16): 260mgh/L vs. 339mgh/L).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[l] / [h],1.89,174977,DB00997,Doxorubicin
,18442869,AUC,"Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemic exposure (median AUC(VP16): 260mgh/L vs. 339mgh/L).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[mgh] / [l],260,174978,DB00997,Doxorubicin
,18442869,AUC,"Ifosfamide (IFO) coadministration increased etoposide clearance by 28% (median CL(VP16): 2.42L/h vs. 1.89L/h, p<0.0005) leading to a reduced systemic exposure (median AUC(VP16): 260mgh/L vs. 339mgh/L).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[mgh] / [l],339,174979,DB00997,Doxorubicin
,18442869,OS,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),month,11.0,174980,DB00997,Doxorubicin
,18442869,OS,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),month,7.0,174981,DB00997,Doxorubicin
,18442869,OS,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),month,7,174982,DB00997,Doxorubicin
<,18442869,CL,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[l] / [h],2.22,174983,DB00997,Doxorubicin
>,18442869,AUC(,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),[mgh] / [l],254.8,174984,DB00997,Doxorubicin
,18442869,AUC(,"Median OS was significantly longer in patients treated without ifosfamide (11.0 months vs. 7.0 months, p=0.049) and in patients with CL(VP16)<2.22L/h (14 months vs. 7 months, p=0.013) and AUC(VP16)>254.8mgh/L (11 months vs. 7 months, p=0.048).",Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18442869/),month,7,174985,DB00997,Doxorubicin
,8547077,maximum rhIL-3 serum concentration,Following s.c. injection on cycle day 2. the maximum rhIL-3 serum concentration ranged from 289 pg/ml (0.5 micrograms/kg) to 4690 pg/ml (10 micrograms/kg).,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[pg] / [ml],289,175451,DB00997,Doxorubicin
,8547077,maximum rhIL-3 serum concentration,Following s.c. injection on cycle day 2. the maximum rhIL-3 serum concentration ranged from 289 pg/ml (0.5 micrograms/kg) to 4690 pg/ml (10 micrograms/kg).,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[pg] / [ml],4690,175452,DB00997,Doxorubicin
,8547077,elimination half-life T1/2 beta,"The elimination half-life T1/2 beta was 160 min for 0.5 micrograms/kg and 134 min for 10 micrograms/kg, with no apparent dose relationship.",Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),min,160,175453,DB00997,Doxorubicin
,8547077,elimination half-life T1/2 beta,"The elimination half-life T1/2 beta was 160 min for 0.5 micrograms/kg and 134 min for 10 micrograms/kg, with no apparent dose relationship.",Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),min,134,175454,DB00997,Doxorubicin
,8547077,systemic clearance,The systemic clearance of 3.0-6.0 ml/min/kg was comparable at all dose levels.,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[ml] / [kg·min],3.0-6.0,175455,DB00997,Doxorubicin
,2611038,half-life time of the alpha-phase,"Typically, the half-life time of the alpha-phase is 3-5 min and the terminal half-life time in the order 20-30 h.",Pharmacokinetics of anthracyclines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611038/),min,3-5,175736,DB00997,Doxorubicin
,2611038,terminal half-life time,"Typically, the half-life time of the alpha-phase is 3-5 min and the terminal half-life time in the order 20-30 h.",Pharmacokinetics of anthracyclines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611038/),h,20-30,175737,DB00997,Doxorubicin
,2702975,COext,The mean concentration-time profile for 25 patients with normal liver function tests fitted well with a two-compartment model: COext (nM) = 2905 +/- 1834; t 1/2 alpha = 0.08 +/- 0.03 h; t 1/2 beta = 10.4 +/- 3.6 h; clearance (1/h) = 55.4 +/- 24.8; Vd (1) = 809 +/- 434.,Pharmacokinetics of weekly low dose doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702975/),n,2905,176161,DB00997,Doxorubicin
,2702975,t 1/2 alpha,The mean concentration-time profile for 25 patients with normal liver function tests fitted well with a two-compartment model: COext (nM) = 2905 +/- 1834; t 1/2 alpha = 0.08 +/- 0.03 h; t 1/2 beta = 10.4 +/- 3.6 h; clearance (1/h) = 55.4 +/- 24.8; Vd (1) = 809 +/- 434.,Pharmacokinetics of weekly low dose doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702975/),h,0.08,176162,DB00997,Doxorubicin
,2702975,t 1/2 beta,The mean concentration-time profile for 25 patients with normal liver function tests fitted well with a two-compartment model: COext (nM) = 2905 +/- 1834; t 1/2 alpha = 0.08 +/- 0.03 h; t 1/2 beta = 10.4 +/- 3.6 h; clearance (1/h) = 55.4 +/- 24.8; Vd (1) = 809 +/- 434.,Pharmacokinetics of weekly low dose doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702975/),h,10.4,176163,DB00997,Doxorubicin
,2702975,clearance (1/h),The mean concentration-time profile for 25 patients with normal liver function tests fitted well with a two-compartment model: COext (nM) = 2905 +/- 1834; t 1/2 alpha = 0.08 +/- 0.03 h; t 1/2 beta = 10.4 +/- 3.6 h; clearance (1/h) = 55.4 +/- 24.8; Vd (1) = 809 +/- 434.,Pharmacokinetics of weekly low dose doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702975/),,55.4,176164,DB00997,Doxorubicin
,2702975,Vd (1),The mean concentration-time profile for 25 patients with normal liver function tests fitted well with a two-compartment model: COext (nM) = 2905 +/- 1834; t 1/2 alpha = 0.08 +/- 0.03 h; t 1/2 beta = 10.4 +/- 3.6 h; clearance (1/h) = 55.4 +/- 24.8; Vd (1) = 809 +/- 434.,Pharmacokinetics of weekly low dose doxorubicin. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702975/),,809,176165,DB00997,Doxorubicin
,21656756,area under the concentration-time curve,"Treatment was comprised of 12 cycles of chemotherapy administered over 35 weeks: 3 cycles of carboplatin (dose targeted to area under the concentration-time curve of 8 mg/mL × min on Day 1) and ifosfamide (at a dose of 2.65 g/m(2) daily ×3 days) and 1 cycle of doxorubicin (at a dose of 25 mg/m(2) daily ×3 days) before surgical resection, followed by 2 additional cycles of the combination of carboplatin and ifosfamide and 3 cycles each of doxorubicin (25 mg/m(2) daily ×2 days) combined with ifosfamide or carboplatin.",Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656756/),[mg] / [min·ml],8,176531,DB00997,Doxorubicin
,21656756,event-free survival rate,The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98).,Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656756/),%,66.7,176532,DB00997,Doxorubicin
,21656756,event-free survival rate,The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98).,Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656756/),%,66.0,176533,DB00997,Doxorubicin
,34189636,MTD,The MTD of trabectedin was determined as 1.1 mg/m2.,A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34189636/),[mg] / [m2],1.1,176967,DB00997,Doxorubicin
,34189636,overall response rate,The overall response rate was 27.8%.,A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34189636/),%,27.8,176968,DB00997,Doxorubicin
,3470178,Plasma clearance,"Plasma clearance (nine patients, mean: 93.4 l/hr; range: 69.3-129.5 l/hr) is higher than the corresponding parameter determined in patients with hepatic metastases after intravenous therapy.",Intrahepatic arterial administration of 4'epidoxorubicin (epirubicin) in advanced cancer patients. A pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470178/),[l] / [h],93.4,177085,DB00997,Doxorubicin
,3470178,plasma clearance,"The remaining patient is characterised by an abnormally low plasma clearance (13.6 l/hr), due to a hepato-pulmonary shunt.",Intrahepatic arterial administration of 4'epidoxorubicin (epirubicin) in advanced cancer patients. A pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470178/),[l] / [h],13.6,177086,DB00997,Doxorubicin
,28950700,IC50,The A549 cell cytotoxicity of peptide-DOXO conjugates was presented with IC50 values and shown in the range of about 9-11 μM.,Albumin Binding Domain Fusing R/K-X-X-R/K Sequence for Enhancing Tumor Delivery of Doxorubicin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28950700/),μM,9-11,177138,DB00997,Doxorubicin
,19020877,clearance,The population mean clearance of doxorubicin was 420 ml/min/m(2).,Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19020877/),[min·ml] / [m(2],420,177820,DB00997,Doxorubicin
,22129650,clearance,"Doxorubicin clearance was 58.8 L/h, with interpatient variability of 29.2% and intrapatient variability of 18.9%.",[Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22129650/),[l] / [h],58.8,178359,DB00997,Doxorubicin
,22129650,volume of distribution at steady state,"The estimated volume of distribution at steady state was 2294 L, with inter-and intrapatient variability of 7.3% and 26.1%, respectively.",[Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22129650/),l,2294,178360,DB00997,Doxorubicin
,3480081,Peak plasma ADM concentrations,Peak plasma ADM concentrations after bolus injections were 1640 +/- 470 ng/ml (n = 7).,Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480081/),[ng] / [ml],1640,179138,DB00997,Doxorubicin
,3480081,Maximum levels,Maximum levels were 176 +/- 34 ng/ml during 4-h infusion (n = 5); 85 +/- 50 ng/ml during 8-h infusion (n = 4); and 47 +/- 5 ng/ml (n = 2) after 72-h infusion.,Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480081/),[ng] / [ml],176,179139,DB00997,Doxorubicin
,3480081,Maximum levels,Maximum levels were 176 +/- 34 ng/ml during 4-h infusion (n = 5); 85 +/- 50 ng/ml during 8-h infusion (n = 4); and 47 +/- 5 ng/ml (n = 2) after 72-h infusion.,Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480081/),[ng] / [ml],85,179140,DB00997,Doxorubicin
,3480081,Maximum levels,Maximum levels were 176 +/- 34 ng/ml during 4-h infusion (n = 5); 85 +/- 50 ng/ml during 8-h infusion (n = 4); and 47 +/- 5 ng/ml (n = 2) after 72-h infusion.,Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480081/),[ng] / [ml],47,179141,DB00997,Doxorubicin
,3480081,half-life,The final cellular ADM half-life was approximately 85-110 h.,Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480081/),h,85-110,179142,DB00997,Doxorubicin
greater,1648946,drug delivery rates,Repeated low dose bolus injections did not cause down-regulation of the galactose receptor and targeted drug delivery rates of greater than or equal to 2 micrograms DOX g-1 liver h-1 were achieved.,N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: pharmacokinetics in DBA2 mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1648946/),μg,2,179587,DB00997,Doxorubicin
,2379173,peak concentration,Administration of the 150 mg/m2 dose over the 6 h compared to the bolus administration was associated with a 92% decrease in peak concentration from 3088 +/- 1503 to 234 +/- 126 ng/ml.,Pharmacokinetics and toxicity of two schedules of high dose epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379173/),[ng] / [ml],3088,179847,DB00997,Doxorubicin
,2379173,peak concentration,Administration of the 150 mg/m2 dose over the 6 h compared to the bolus administration was associated with a 92% decrease in peak concentration from 3088 +/- 1503 to 234 +/- 126 ng/ml.,Pharmacokinetics and toxicity of two schedules of high dose epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379173/),[ng] / [ml],234,179848,DB00997,Doxorubicin
,2379173,distribution half-life,The median distribution half-life was 10 min and the median elimination half-life was 42.0 h.,Pharmacokinetics and toxicity of two schedules of high dose epirubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379173/),min,10,179849,DB00997,Doxorubicin
,2379173,elimination half-life,The median distribution half-life was 10 min and the median elimination half-life was 42.0 h.,Pharmacokinetics and toxicity of two schedules of high dose epirubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379173/),h,42.0,179850,DB00997,Doxorubicin
,14735687,time to disease progression,Median time to disease progression was 163 days.,"A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14735687/),d,163,179920,DB00997,Doxorubicin
,11410492,plasma CL(ss),"Dexrazoxane plasma CL(ss) and elimination t(1/2) were 7.2 +/- 1.6 l/h/m(2) and 2.0 +/- 0.8 h, respectively.",Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11410492/),[h·l] / [m(2],7.2,179963,DB00997,Doxorubicin
,11410492,elimination t(1/2),"Dexrazoxane plasma CL(ss) and elimination t(1/2) were 7.2 +/- 1.6 l/h/m(2) and 2.0 +/- 0.8 h, respectively.",Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11410492/),h,2.0,179964,DB00997,Doxorubicin
,10029808,terminal half-life,"Daunorubicin elimination from plasma was triphasic with a terminal half-life of 5.9 +/- 1.8 hours, area under the concentration-time curve (AUC) 22.5 +/- 9.2 mumol/L.min, and clearance 2790 +/- 960 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),h,5.9,179988,DB00997,Doxorubicin
,10029808,area under the concentration-time curve (AUC),"Daunorubicin elimination from plasma was triphasic with a terminal half-life of 5.9 +/- 1.8 hours, area under the concentration-time curve (AUC) 22.5 +/- 9.2 mumol/L.min, and clearance 2790 +/- 960 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[μM] / [l·min],22.5,179989,DB00997,Doxorubicin
,10029808,clearance,"Daunorubicin elimination from plasma was triphasic with a terminal half-life of 5.9 +/- 1.8 hours, area under the concentration-time curve (AUC) 22.5 +/- 9.2 mumol/L.min, and clearance 2790 +/- 960 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[ml] / [m2·min],2790,179990,DB00997,Doxorubicin
,10029808,terminal half-life,Daunorubicinol elimination was biphasic with a terminal half-life 10.2 +/- 2.3 hours and an AUC 74.5 +/- 5.3 mumol/L.min.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),h,10.2,179991,DB00997,Doxorubicin
,10029808,AUC,Daunorubicinol elimination was biphasic with a terminal half-life 10.2 +/- 2.3 hours and an AUC 74.5 +/- 5.3 mumol/L.min.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[μM] / [l·min],74.5,179992,DB00997,Doxorubicin
,10029808,terminal half-life,"Idarubicin elimination was triphasic with terminal half-life of 12.3 +/- 11.4 hours, a AUC 10.8 +/- 3.7 mumol/L.min, and clearance 1650 +/- 610 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),h,12.3,179993,DB00997,Doxorubicin
,10029808,AUC,"Idarubicin elimination was triphasic with terminal half-life of 12.3 +/- 11.4 hours, a AUC 10.8 +/- 3.7 mumol/L.min, and clearance 1650 +/- 610 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[μM] / [l·min],10.8,179994,DB00997,Doxorubicin
,10029808,clearance,"Idarubicin elimination was triphasic with terminal half-life of 12.3 +/- 11.4 hours, a AUC 10.8 +/- 3.7 mumol/L.min, and clearance 1650 +/- 610 mL/min/m2.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[ml] / [m2·min],1650,179995,DB00997,Doxorubicin
,10029808,terminal half-life,Idarubicinol elimination was biphasic with a terminal half-life 28.7 +/- 4.2 hours and AUC 67 +/- 9.8 mumol/L.min.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),h,28.7,179996,DB00997,Doxorubicin
,10029808,AUC,Idarubicinol elimination was biphasic with a terminal half-life 28.7 +/- 4.2 hours and AUC 67 +/- 9.8 mumol/L.min.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[μM] / [l·min],67,179997,DB00997,Doxorubicin
,10029808,CSF to plasma concentration ratio,The CSF to plasma concentration ratio at that time point was 8% in 1 animal and 15% in the other.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),%,8,179998,DB00997,Doxorubicin
,10029808,CSF to plasma concentration ratio,The CSF to plasma concentration ratio at that time point was 8% in 1 animal and 15% in the other.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),%,15,179999,DB00997,Doxorubicin
,10029808,CSF to plasma concentration ratio,The CSF to plasma concentration ratio at corresponding time points was 1.9 +/- 0.6%.,"Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),%,1.9,180000,DB00997,Doxorubicin
,10029808,terminal half-life,"The terminal half-life of daunorubicinol in CSF was 8.8 +/- 1.3 hours, the AUC was 1.8 +/- 1.5 mumol/L.min, and the AUCCSF to AUCplasma ratio was 2.4 +/- 1.9%.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),h,8.8,180001,DB00997,Doxorubicin
,10029808,AUC,"The terminal half-life of daunorubicinol in CSF was 8.8 +/- 1.3 hours, the AUC was 1.8 +/- 1.5 mumol/L.min, and the AUCCSF to AUCplasma ratio was 2.4 +/- 1.9%.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),[μM] / [l·min],1.8,180002,DB00997,Doxorubicin
,10029808,AUCCSF to AUCplasma ratio,"The terminal half-life of daunorubicinol in CSF was 8.8 +/- 1.3 hours, the AUC was 1.8 +/- 1.5 mumol/L.min, and the AUCCSF to AUCplasma ratio was 2.4 +/- 1.9%.","Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10029808/),%,2.4,180003,DB00997,Doxorubicin
,7184432,clinical response rate (CR + PR),"A high clinical response rate (CR + PR) of 70.0% was obtained by the treatment, and also remarkable degenerative changes of tumor cells were histologically noted in 5 out of 9 surgical specimens (55.6%).",[Intra-arterial infusion chemotherapy with adriamycin for the treatment of locally advanced breast cancer--studies of serum and tissue concentrations of adriamycin]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7184432/),%,70.0,180683,DB00997,Doxorubicin
,20978165,t(1/2),"Pegylation improved serum half-life (t(1/2) = 10.3 hours), making it feasible to probe the effects of sustained HA depletion on tumor physiology.",Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20978165/),h,10.3,181491,DB00997,Doxorubicin
,11069404,recovery rate,The mean recovery rate of pirarubicin in the drained fluid was 73%.,The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069404/),%,73,181947,DB00997,Doxorubicin
,18693438,mean residence time,"The results showed that the mean residence time of HEPC-SSL in blood is 23.3 h, while that of EPC-SSL is 12.0 h.",[Preparation of the EPC and HEPC sterically stabilized doxorubicin liposomes and further studies on pharmacokinetics in rats]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693438/),h,23.3,182153,DB00997,Doxorubicin
,18693438,mean residence time,"The results showed that the mean residence time of HEPC-SSL in blood is 23.3 h, while that of EPC-SSL is 12.0 h.",[Preparation of the EPC and HEPC sterically stabilized doxorubicin liposomes and further studies on pharmacokinetics in rats]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18693438/),h,12.0,182154,DB00997,Doxorubicin
,7083240,area under the plasma concentration-time curve,The area under the plasma concentration-time curve was unchanged for parent drug but increased from 2010 micrograms/ml . min at 37 degrees C to 4477 micrograms/ml . min at 41 degrees C for total drug equivalents.,Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083240/),[μg] / [min·ml],2010,182361,DB00997,Doxorubicin
,7083240,area under the plasma concentration-time curve,The area under the plasma concentration-time curve was unchanged for parent drug but increased from 2010 micrograms/ml . min at 37 degrees C to 4477 micrograms/ml . min at 41 degrees C for total drug equivalents.,Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083240/),[μg] / [min·ml],4477,182362,DB00997,Doxorubicin
,7083240,Biliary excretion,Biliary excretion of total Ad equivalents was 7.39% +/- 1.35% of the total dose at 37 degrees C and 2.56% +/- 2.08% of the total dose at 41 degrees C (P less than 0.05).,Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083240/),%,7.39,182363,DB00997,Doxorubicin
,7083240,Biliary excretion,Biliary excretion of total Ad equivalents was 7.39% +/- 1.35% of the total dose at 37 degrees C and 2.56% +/- 2.08% of the total dose at 41 degrees C (P less than 0.05).,Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083240/),%,2.56,182364,DB00997,Doxorubicin
,7083240,Biliary excretion,Biliary excretion of Ad was 2.07% +/- 0.37% of the total dose at 37 degrees C and 1.31% +/- 0.84% of the total dose at 41 degrees C (P less than 0.05).,Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083240/),%,2.07,182365,DB00997,Doxorubicin
,7083240,Biliary excretion,Biliary excretion of Ad was 2.07% +/- 0.37% of the total dose at 37 degrees C and 1.31% +/- 0.84% of the total dose at 41 degrees C (P less than 0.05).,Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083240/),%,1.31,182366,DB00997,Doxorubicin
,7083240,total Ad equivalents,Hepatic tissue levels of total Ad equivalents were 288.7 +/- 21.2 micrograms/g at 37 degrees C and 322.7 +/- 10.6 micrograms/g at 41 degrees C (P less than 0.05).,Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083240/),[μg] / [g],288.7,182367,DB00997,Doxorubicin
,7083240,total Ad equivalents,Hepatic tissue levels of total Ad equivalents were 288.7 +/- 21.2 micrograms/g at 37 degrees C and 322.7 +/- 10.6 micrograms/g at 41 degrees C (P less than 0.05).,Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083240/),[μg] / [g],322.7,182368,DB00997,Doxorubicin
,7083240,Ad,Tissue levels of Ad were 57.5 +/- 14 micrograms/g at 37 degrees C and 23.0 +/- 10.7 micrograms/g at 41 degrees C (P less than 0.05).,Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083240/),[μg] / [g],57.5,182369,DB00997,Doxorubicin
,7083240,Ad,Tissue levels of Ad were 57.5 +/- 14 micrograms/g at 37 degrees C and 23.0 +/- 10.7 micrograms/g at 41 degrees C (P less than 0.05).,Altered hepatic disposition of doxorubicin in the perfused rat liver at hyperthermic temperatures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7083240/),[μg] / [g],23.0,182370,DB00997,Doxorubicin
,16880787,Maximum tolerated dose,Maximum tolerated dose was defined as 155 mg m(-2) for Group A and 100 mg m(-2) for Group B.,A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16880787/),[mg] / [(m)^2],155,183031,DB00997,Doxorubicin
,16880787,Maximum tolerated dose,Maximum tolerated dose was defined as 155 mg m(-2) for Group A and 100 mg m(-2) for Group B.,A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16880787/),[mg] / [(m)^2],100,183032,DB00997,Doxorubicin
,10600267,area under the serum DOX time-concentration curve (AUC(0-24 h)),In STZ diabetic rats the area under the serum DOX time-concentration curve (AUC(0-24 h)) increased (13.35+/-1.33 compared with 7.13+/-0.71 microg h(-1) ml(-1); P<0.0001) and plasma and renal DOX clearance decreased.,Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10600267/),[μg] / [h·ml],13.35,183088,DB00997,Doxorubicin
,10600267,area under the serum DOX time-concentration curve (AUC(0-24 h)),In STZ diabetic rats the area under the serum DOX time-concentration curve (AUC(0-24 h)) increased (13.35+/-1.33 compared with 7.13+/-0.71 microg h(-1) ml(-1); P<0.0001) and plasma and renal DOX clearance decreased.,Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10600267/),[μg] / [h·ml],7.13,183089,DB00997,Doxorubicin
,10600267,accumulation,"The DOX accumulation in STZ-induced diabetic rat heart (12.7+/-1.2 microg g(-1)) was increased (P<0.05) compared with non-diabetic hearts (11.0+/-0.9 microg/g), 24 h after DOX administration.",Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10600267/),[μg] / [g],12.7,183090,DB00997,Doxorubicin
,10600267,accumulation,"The DOX accumulation in STZ-induced diabetic rat heart (12.7+/-1.2 microg g(-1)) was increased (P<0.05) compared with non-diabetic hearts (11.0+/-0.9 microg/g), 24 h after DOX administration.",Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10600267/),[μg] / [g],11.0,183091,DB00997,Doxorubicin
,3865777,total plasma clearance,The pharmacokinetic parameters of epirubicin were characterized by a high total plasma clearance (mean value: 70-85 1/hr) and a mean elimination half-life of 25-35 hr.,Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865777/),[1] / [h],70-85,183310,DB00997,Doxorubicin
,3865777,elimination half-life,The pharmacokinetic parameters of epirubicin were characterized by a high total plasma clearance (mean value: 70-85 1/hr) and a mean elimination half-life of 25-35 hr.,Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865777/),h,25-35,183311,DB00997,Doxorubicin
,3865777,cumulative urinary excretion,The cumulative urinary excretion was 11-12% of the dose administered and did not vary significantly as a function of time or dose.,Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865777/),%,11-12,183312,DB00997,Doxorubicin
greater,12408897,recoveries,The average recoveries were greater than 89% for all analytes.,Determination of doxorubicin and its metabolites in rat serum and bile by LC: application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12408897/),%,89,183373,DB00997,Doxorubicin
,3550609,half-lives,"The plasma decay of doxorubicin levels is triphasic, with successive half-lives of 5 min, 1 h and 30 h.",[Pharmacokinetics and metabolism of anthracyclines in man]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3550609/),min,5,183501,DB00997,Doxorubicin
,3550609,half-lives,"The plasma decay of doxorubicin levels is triphasic, with successive half-lives of 5 min, 1 h and 30 h.",[Pharmacokinetics and metabolism of anthracyclines in man]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3550609/),h,1,183502,DB00997,Doxorubicin
,3550609,half-lives,"The plasma decay of doxorubicin levels is triphasic, with successive half-lives of 5 min, 1 h and 30 h.",[Pharmacokinetics and metabolism of anthracyclines in man]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3550609/),h,30,183503,DB00997,Doxorubicin
,21436695,response rate,"The response rate was 42.8% (95% confidence interval [CI], 34.5%-51.1%), with 17.1% (6/35) complete responses and 25.7% (9/35) partial responses.",Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21436695/),%,42.8,185846,DB00997,Doxorubicin
,21436695,progression-free survival,"The median progression-free survival was 7.7 months (95% CI, 2.2-13.1).",Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21436695/),month,7.7,185847,DB00997,Doxorubicin
,21436695,overall survival,"The median overall survival was 13.9 months (95% CI, 9.4-18.4).",Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21436695/),month,13.9,185848,DB00997,Doxorubicin
,24101870,half-life,"The liposomes are characterized as stable, with very good pharmacokinetics (half-life 18.6 hours).",Vitamin C-driven epirubicin loading into liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24101870/),h,18.6,186056,DB00997,Doxorubicin
,33255658,overall response rate,"Among all evaluable patients, the overall response rate was 40.0% (95%CI, 16.3-67.7) with a median duration of response of 6.9 months (95%CI, 4.8-9.1).","Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255658/),%,40.0,186214,DB00997,Doxorubicin
,33255658,duration of response,"Among all evaluable patients, the overall response rate was 40.0% (95%CI, 16.3-67.7) with a median duration of response of 6.9 months (95%CI, 4.8-9.1).","Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255658/),month,6.9,186215,DB00997,Doxorubicin
,33255658,Clinical benefit rate,"Clinical benefit rate was 66.7% (95%CI, 38.4-88.2) and median progression-free survival was 7.2 months (95%CI, 4.5-9.6).","Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255658/),%,66.7,186216,DB00997,Doxorubicin
,33255658,progression-free survival,"Clinical benefit rate was 66.7% (95%CI, 38.4-88.2) and median progression-free survival was 7.2 months (95%CI, 4.5-9.6).","Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33255658/),month,7.2,186217,DB00997,Doxorubicin
,20515395,zeta potential,"When L-THP was reconstituted in a proper amount of normal saline for injection, it had a mean diameter of around 220.0 nm, a zeta potential of about -33.0 mV, and a high THP entrapment efficiency of more than 93.1%.",Characterization and pharmacokinetics of a novel pirarubicin liposome powder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515395/),mv,33.0,186350,DB00997,Doxorubicin
more,20515395,entrapment efficiency,"When L-THP was reconstituted in a proper amount of normal saline for injection, it had a mean diameter of around 220.0 nm, a zeta potential of about -33.0 mV, and a high THP entrapment efficiency of more than 93.1%.",Characterization and pharmacokinetics of a novel pirarubicin liposome powder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515395/),%,93.1,186351,DB00997,Doxorubicin
,11419744,retention time,The retention time of monoHER was about 5.2 min and no endogenous peaks were interfering.,Determination of monohydroxyethylrutoside in heart tissue by high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11419744/),min,5.2,186459,DB00997,Doxorubicin
,11419744,recovery,The recovery of monoHER from heart tissue ranged from 104.1 to 114.3% and was concentration independent.,Determination of monohydroxyethylrutoside in heart tissue by high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11419744/),%,104.1 to 114.3,186460,DB00997,Doxorubicin
,3460699,half-life,"In serum, a rapid initial distribution phase, with a half-life of about 5 minutes for DOX and 4 minutes for epi-DOX, was followed by a slower decrease in the drug levels.",Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3460699/),min,5,186538,DB00997,Doxorubicin
,3460699,half-life,"In serum, a rapid initial distribution phase, with a half-life of about 5 minutes for DOX and 4 minutes for epi-DOX, was followed by a slower decrease in the drug levels.",Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3460699/),min,4,186539,DB00997,Doxorubicin
,2040035,t1/2 gamma,"Large interindividual differences were demonstrated (mean t1/2 gamma, 21.6 +/- 7.9 h; range, 10.6-69 h; n = 110).",Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040035/),h,21.6,187706,DB00997,Doxorubicin
,2040035,t1/2 gamma,"The metabolite epirubicinol appeared quickly after epirubicin administration and its half-lives were shorter than that of the parent compound (mean t1/2 gamma, 18.1 +/- 4.8 h; range, 8.2-38.4 h; n = 105).",Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040035/),h,18.1,187707,DB00997,Doxorubicin
,2040035,t1/2 gamma,"Formation of the aglycone metabolite was delayed and the half-life of this metabolite was shorter than that of epirubicin (mean t1/2 gamma, 13 +/- 4.6 h; range, 2.7-29 h; n = 104).",Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040035/),h,13,187708,DB00997,Doxorubicin
,7987996,oral bioavailability,"Pharmacokinetic studies in BALB/c mice showed the oral bioavailability to be 20%, with 35% of the drug being excreted unchanged in the faeces over the first 24 h.","Preclinical pharmacology of 1069C85, a novel tubulin binder. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987996/),%,20,188284,DB00997,Doxorubicin
,7913721,progression-free,"With a median potential follow-up duration of 60 weeks, the median progression-free and overall survival durations were 27 and 43 weeks, respectively.",Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913721/),weeks,27,188629,DB00997,Doxorubicin
more,7913721,serum steady-state concentrations (Css),"Paclitaxel pharmacokinetics showed a correlation between both granulocyte and mucosal toxicity, and serum steady-state concentrations (Css) more than 0.07 mumol/L.",Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7913721/),[μM] / [l],0.07,188630,DB00997,Doxorubicin
,9523732,biological half-life,"The biological half-life of Adriamycin in the intact rats (control A, 10 h) was significantly higher than in the bile-duct-cannulated rats (control B, 4 h).",Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523732/),h,10,188948,DB00997,Doxorubicin
,9523732,biological half-life,"The biological half-life of Adriamycin in the intact rats (control A, 10 h) was significantly higher than in the bile-duct-cannulated rats (control B, 4 h).",Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523732/),h,4,188949,DB00997,Doxorubicin
,18497430,MTD,The MTD of trabectedin was 1.1 mg/m(2).,A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18497430/),[mg] / [m(2],1.1,189108,DB00997,Doxorubicin
,24640601,bioavailability,"By comparing the area under the serum concentration-time curve (AUC) after ip and intravenous (iv) dosing of 5 mg/kg DOX, the bioavailability of intraperitoneally administered DOX was estimated as 43.8%.",Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24640601/),%,43.8,189807,DB00997,Doxorubicin
,24468044,total release,"A total release of 80% in saline was measured, with similar fast-release profiles for both sphere sizes.",Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24468044/),%,80,190105,DB00997,Doxorubicin
,8765436,50% growth-inhibitory concentration (IC50),"DSB-120 was shown to be a potent cytotoxic agent in vitro against a panel of human colon carcinomas [50% growth-inhibitory concentration (IC50) 42 +/- 7.9 nM, mean +/- SE, n = 7] and two rodent tumours (L1210 and ADJ/PC6).",Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765436/),nM,42,190345,DB00997,Doxorubicin
,8765436,t1/2 beta,"After a single i.v. dose at the maximum tolerated dose (MTD, 5 mgkg-1) the plasma elimination was biphasic, with a short distribution phase (t1/2 alpha 4 min) being followed by a longer elimination phase (t1/2 beta 38 min).",Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765436/),min,38,190346,DB00997,Doxorubicin
,8765436,Peak plasma concentrations,"Peak plasma concentrations were 25 micrograms ml-1, the clearance was 1.3 ml g-1 h-1 and the AUC0-infinity was 230 micrograms ml-1 min.",Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765436/),[μg] / [ml],25,190347,DB00997,Doxorubicin
,8765436,clearance,"Peak plasma concentrations were 25 micrograms ml-1, the clearance was 1.3 ml g-1 h-1 and the AUC0-infinity was 230 micrograms ml-1 min.",Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765436/),[ml] / [g·h],1.3,190348,DB00997,Doxorubicin
,8765436,AUC0-infinity,"Peak plasma concentrations were 25 micrograms ml-1, the clearance was 1.3 ml g-1 h-1 and the AUC0-infinity was 230 micrograms ml-1 min.",Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765436/),[min·μg] / [ml],230,190349,DB00997,Doxorubicin
,8765436,peak,"Concentrations of DSB-120 in ADJ/PC6 tumours were very low, showing a peak of 0.4 micrograms g-1 at 5 min.",Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765436/),[μg] / [g],0.4,190350,DB00997,Doxorubicin
,8765436,steady-state tumour/plasma ratio,The steady-state tumour/plasma ratio was about 5% and the AUC was only 2.5% of that occurring in the plasma.,Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8765436/),%,5,190351,DB00997,Doxorubicin
,11804182,Response rates,Response rates in patients with visceral and liver metastases were 78% and 55% respectively.,Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11804182/),%,78,190849,DB00997,Doxorubicin
,11804182,Response rates,Response rates in patients with visceral and liver metastases were 78% and 55% respectively.,Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11804182/),%,55,190850,DB00997,Doxorubicin
,11804182,disease-free survival,"After a median follow-up of 19 months (12-36), median disease-free survival is 11 months and median overall survival has not been reached.",Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11804182/),month,11,190851,DB00997,Doxorubicin
,26780638,tumour doxorubicin,"Mean tumour doxorubicin concentrations were 922.83 nM (SD = 722.05) and 361.48 nM (SD = 473.23) for the SDB and LDB, respectively (p = 0.005).",Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26780638/),nM,922.83,190893,DB00997,Doxorubicin
,26780638,tumour doxorubicin,"Mean tumour doxorubicin concentrations were 922.83 nM (SD = 722.05) and 361.48 nM (SD = 473.23) for the SDB and LDB, respectively (p = 0.005).",Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26780638/),nM,361.48,190894,DB00997,Doxorubicin
,26780638,concentrations,"Mean tumour doxorubicin concentrations were 922.83 nM (SD = 722.05) and 361.48 nM (SD = 473.23) for the SDB and LDB, respectively (p = 0.005).",Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26780638/),nM,922.83,190895,DB00997,Doxorubicin
,26780638,concentrations,"Mean tumour doxorubicin concentrations were 922.83 nM (SD = 722.05) and 361.48 nM (SD = 473.23) for the SDB and LDB, respectively (p = 0.005).",Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26780638/),nM,361.48,190896,DB00997,Doxorubicin
,23770213,half life,"An in vivo study demonstrated that STL-DOX is highly stable, with a long circulating property (half life=2.03±0.77 h) in HIFU-untreated mice, and resulted in significant tumor regression for 2 days after intravenous injection of STL-DOX at 5 mg DOX/kg in combination with HIFU.","Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23770213/),h,2.03,193081,DB00997,Doxorubicin
,23770213,blood circulation time,"These results are better than conventional LTSL, for which the blood circulation time is short (0.92±0.17 h) and inhibition of tumor growth is weak.","Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation, and in vivo study combined with high-intensity focused ultrasound (HIFU). ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23770213/),h,0.92,193082,DB00997,Doxorubicin
,8894117,encapsulation efficiency,"Liposomal preparations by the FDEL method had an encapsulation efficiency of 2.9 and 6.7% for [3H]-inulin and [3H]-mannitol, respectively, when rehydrated and incubated at 70 degrees C.",Biopharmaceutical evaluation of the liposomes prepared by rehydration of freeze-dried empty liposomes (FDELs) with an aqueous solution of a drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894117/),%,2.9,193437,DB00997,Doxorubicin
,8894117,encapsulation efficiency,"Liposomal preparations by the FDEL method had an encapsulation efficiency of 2.9 and 6.7% for [3H]-inulin and [3H]-mannitol, respectively, when rehydrated and incubated at 70 degrees C.",Biopharmaceutical evaluation of the liposomes prepared by rehydration of freeze-dried empty liposomes (FDELs) with an aqueous solution of a drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894117/),%,6.7,193438,DB00997,Doxorubicin
,12764671,clearance (CL),Individual clearance (CL) estimates ranged from 4 to 86 l/h and the final model included CL as a function of aspartate aminotransferase (AST): CL (l/h)=72.9-(72.9x0.135xlnAST).,A population model of epirubicin pharmacokinetics and application to dosage guidelines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12764671/),[l] / [h],4 to 86,193805,DB00997,Doxorubicin
,12764671,AUC,"Using a target AUC of 4000 ng.h/ml, the following doses were predicted to achieve this exposure with the greatest precision: AST <150 IU/l 125 mg; AST 150-250 IU/l 90 mg; AST 250-500 IU/l 60 mg; AST >500 IU/l 30 mg.",A population model of epirubicin pharmacokinetics and application to dosage guidelines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12764671/),[h·ng] / [ml],4000,193806,DB00997,Doxorubicin
,1600594,clearance,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[ml] / [kg·min],48,194338,DB00997,Doxorubicin
,1600594,clearance,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[ml] / [kg·min],59,194339,DB00997,Doxorubicin
,1600594,terminal elimination half-life,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,28,194340,DB00997,Doxorubicin
,1600594,terminal elimination half-life,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,22,194341,DB00997,Doxorubicin
,1600594,area under the plasma concentration/time curve extrapolated to infinity,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[h·ng] / [ml],1722,194342,DB00997,Doxorubicin
,1600594,area under the plasma concentration/time curve extrapolated to infinity,"The low-protein diet significantly decreased doxorubicin clearance (48 +/- 3 vs 59 +/- 4 ml min-1 kg-1; P less than 0.05), prolonged the terminal elimination half-life (28 +/- 2 vs 22 +/- 2 h; P less than 0.05), and increased the area under the plasma concentration/time curve extrapolated to infinity (1722 +/- 122 vs 1405 +/- 71 ng h ml-1; P less than 0.05) as compared with the values determined for rabbits fed the standard rabbit chow (15% protein).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),[h·ng] / [ml],1405,194343,DB00997,Doxorubicin
,1600594,terminal elimination half-life,"In addition, in rabbits fed the the low-protein diet, the terminal elimination half-life of the alcohol metabolite, doxorubicinol was prolonged (52 +/- 5 vs 40 +/- 2 h; P less than 0.05).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,52,194344,DB00997,Doxorubicin
,1600594,terminal elimination half-life,"In addition, in rabbits fed the the low-protein diet, the terminal elimination half-life of the alcohol metabolite, doxorubicinol was prolonged (52 +/- 5 vs 40 +/- 2 h; P less than 0.05).",Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1600594/),h,40,194345,DB00997,Doxorubicin
,2348224,maximum plasma concentrations,"Depending upon the dose and the infusion time, maximum plasma concentrations ranged from 2.6 mumol/L to 36.89 mumol/L and the area under the plasma concentration x time curve (AUC) values ranged from 1.86 mumol/L x h/L to 49.57 mumol x h/L.",A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348224/),[μM] / [l],2.6,194630,DB00997,Doxorubicin
,2348224,maximum plasma concentrations,"Depending upon the dose and the infusion time, maximum plasma concentrations ranged from 2.6 mumol/L to 36.89 mumol/L and the area under the plasma concentration x time curve (AUC) values ranged from 1.86 mumol/L x h/L to 49.57 mumol x h/L.",A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348224/),[μM] / [l],36.89,194631,DB00997,Doxorubicin
,2348224,area under the plasma concentration x time curve (AUC),"Depending upon the dose and the infusion time, maximum plasma concentrations ranged from 2.6 mumol/L to 36.89 mumol/L and the area under the plasma concentration x time curve (AUC) values ranged from 1.86 mumol/L x h/L to 49.57 mumol x h/L.",A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348224/),[μM] / [h·l·l],1.86,194632,DB00997,Doxorubicin
,2348224,area under the plasma concentration x time curve (AUC),"Depending upon the dose and the infusion time, maximum plasma concentrations ranged from 2.6 mumol/L to 36.89 mumol/L and the area under the plasma concentration x time curve (AUC) values ranged from 1.86 mumol/L x h/L to 49.57 mumol x h/L.",A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348224/),[h·μM] / [l],49.57,194633,DB00997,Doxorubicin
,2348224,Urinary excretion,Urinary excretion of LED was approximately 10% after 24 hours.,A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348224/),%,10,194634,DB00997,Doxorubicin
,17708397,overall survival time,Both the median overall survival time and the median disease-free interval in dogs treated with LDC were 178 days.,Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17708397/),d,178,195038,DB00997,Doxorubicin
,17708397,overall survival time,"By comparison, the overall survival time and disease-free interval in dogs treated with DOX were 133 and 126 days, respectively.",Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17708397/),d,133,195039,DB00997,Doxorubicin
,17708397,disease-free interval,"By comparison, the overall survival time and disease-free interval in dogs treated with DOX were 133 and 126 days, respectively.",Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17708397/),d,126,195040,DB00997,Doxorubicin
,33037507,PS,"Spiral-shaped ANDNCs demonstrated ZP, PS, and EE of - 121.46 ± 15.12 mV, 360 ± 47 nm, and 68.12 ± 3.81% respectively.","Investigation of 1,2-Dimyristoyl-sn-Glycero-3-Phosphoglycerol-Sodium (DMPG-Na) Lipid with Various Metal Cations in Nanocochleate Preformulation: Application for Andrographolide Oral Delivery in Cancer Therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33037507/),nm,360,195133,DB00997,Doxorubicin
,33037507,EE,"Spiral-shaped ANDNCs demonstrated ZP, PS, and EE of - 121.46 ± 15.12 mV, 360 ± 47 nm, and 68.12 ± 3.81% respectively.","Investigation of 1,2-Dimyristoyl-sn-Glycero-3-Phosphoglycerol-Sodium (DMPG-Na) Lipid with Various Metal Cations in Nanocochleate Preformulation: Application for Andrographolide Oral Delivery in Cancer Therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33037507/),%,68.12,195134,DB00997,Doxorubicin
,11839657,central volume of distribution,"Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m(2), 0.03 liter/h/m(2), and 36.4 h, respectively.",Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839657/),[l] / [m(2],1.45,195160,DB00997,Doxorubicin
,11839657,clearance,"Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m(2), 0.03 liter/h/m(2), and 36.4 h, respectively.",Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839657/),[h·l] / [m(2],0.03,195161,DB00997,Doxorubicin
,11839657,elimination half-life,"Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m(2), 0.03 liter/h/m(2), and 36.4 h, respectively.",Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839657/),h,36.4,195162,DB00997,Doxorubicin
,1341719,maximum plasma concentrations,"The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in patients with CR, PR, SD and PD, respectively.",Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341719/),[ng] / [ml],322,195227,DB00997,Doxorubicin
,1341719,maximum plasma concentrations,"The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in patients with CR, PR, SD and PD, respectively.",Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341719/),[ng] / [ml],316,195228,DB00997,Doxorubicin
,1341719,maximum plasma concentrations,"The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in patients with CR, PR, SD and PD, respectively.",Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341719/),[ng] / [ml],336,195229,DB00997,Doxorubicin
,1341719,maximum plasma concentrations,"The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in patients with CR, PR, SD and PD, respectively.",Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341719/),[ng] / [ml],288,195230,DB00997,Doxorubicin
,12739982,elimination half-life,Most of the drug is cleared with an elimination half-life of 20-30 hours.,Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739982/),h,20-30,195321,DB00997,Doxorubicin
,12739982,half-life,"The pharmacokinetic profile in humans at doses between 10 and 80 mg/m(2) is similar to that in animals, with one or two distribution phases: an initial phase with a half-life of 1-3 hours and a second phase with a half-life of 30-90 hours.",Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739982/),h,1-3,195322,DB00997,Doxorubicin
,12739982,half-life,"The pharmacokinetic profile in humans at doses between 10 and 80 mg/m(2) is similar to that in animals, with one or two distribution phases: an initial phase with a half-life of 1-3 hours and a second phase with a half-life of 30-90 hours.",Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12739982/),h,30-90,195323,DB00997,Doxorubicin
,33735711,IC50,"In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively.","Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,85,195812,DB00997,Doxorubicin
,33735711,IC50,"In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively.","Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,71.5,195813,DB00997,Doxorubicin
,33735711,IC50,"In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively.","Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,37.85-41.19,195814,DB00997,Doxorubicin
,33735711,IC50,"In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively.","Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,31.8,195815,DB00997,Doxorubicin
,33735711,IC50,"In addition, the inhibitory activity against both wild EGFRWT and mutant EGFRL858R-TK for these derivatives revealed that compounds 5, 14c, and 17 have IC50 value ranging from 85 nM to 71.5 nM against wild EGFRWT and 37.85-41.19 nM against the mutant type, Lapatinib was used as a reference standard with IC50 values of 31.8 nM and 39.53 nM, respectively.","Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,39.53,195816,DB00997,Doxorubicin
,33735711,IC50,The most potent derivatives were subjected to further evaluation against double mutant EGFR L858R/T790M and showed good IC50 values between (0.27-0.78 nM) compared to Lapatinib (0.18 nM) and Erlotinib (0.21 nM).,"Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,0.27-0.78,195817,DB00997,Doxorubicin
,33735711,IC50,The most potent derivatives were subjected to further evaluation against double mutant EGFR L858R/T790M and showed good IC50 values between (0.27-0.78 nM) compared to Lapatinib (0.18 nM) and Erlotinib (0.21 nM).,"Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,0.18,195818,DB00997,Doxorubicin
,33735711,IC50,The most potent derivatives were subjected to further evaluation against double mutant EGFR L858R/T790M and showed good IC50 values between (0.27-0.78 nM) compared to Lapatinib (0.18 nM) and Erlotinib (0.21 nM).,"Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33735711/),nM,0.21,195819,DB00997,Doxorubicin
,9296319,infusion rate (ko),"After a loading dose (0.15 mg kg-1 followed by 12 h continuous i.v. infusion at 0.20 mg kg-1 h-1), the infusion rate (ko) of verapamil was increased every 24 h (0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[mg] / [h·kg],0.,195826,DB00997,Doxorubicin
,9296319,infusion rate (ko),"After a loading dose (0.15 mg kg-1 followed by 12 h continuous i.v. infusion at 0.20 mg kg-1 h-1), the infusion rate (ko) of verapamil was increased every 24 h (0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[mg] / [h·kg],0,195827,DB00997,Doxorubicin
,9296319,CL,"CL was dose-dependent and in all nine patients a significant reduction in CL was observed over the dose range (mean CL +/- s.d. were 0.51 +/- 0.31, 0.38 +/- 0.16, 0.32 +/- 0.18, and 0.27 +/- 0.11 l h-1 kg-1, respectively, at 0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1; P = 0.0001).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[l] / [h],0.51,195828,DB00997,Doxorubicin
,9296319,CL,"CL was dose-dependent and in all nine patients a significant reduction in CL was observed over the dose range (mean CL +/- s.d. were 0.51 +/- 0.31, 0.38 +/- 0.16, 0.32 +/- 0.18, and 0.27 +/- 0.11 l h-1 kg-1, respectively, at 0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1; P = 0.0001).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[l] / [h],0.38,195829,DB00997,Doxorubicin
,9296319,CL,"CL was dose-dependent and in all nine patients a significant reduction in CL was observed over the dose range (mean CL +/- s.d. were 0.51 +/- 0.31, 0.38 +/- 0.16, 0.32 +/- 0.18, and 0.27 +/- 0.11 l h-1 kg-1, respectively, at 0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1; P = 0.0001).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[l] / [h],0.32,195830,DB00997,Doxorubicin
,9296319,CL,"CL was dose-dependent and in all nine patients a significant reduction in CL was observed over the dose range (mean CL +/- s.d. were 0.51 +/- 0.31, 0.38 +/- 0.16, 0.32 +/- 0.18, and 0.27 +/- 0.11 l h-1 kg-1, respectively, at 0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1; P = 0.0001).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[l] / [h],0.27,195831,DB00997,Doxorubicin
,9296319,K(m),"Css increased more than proportionally to the dose rate and the Css vs rate relationship was best defined by a Michaelis-Menten equation (K(m) = 730 micrograms l-1; V.Vm = 0.55 mg kg-1 h-1), (r = 0.994; P = 0.006).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[μg] / [l],730,195832,DB00997,Doxorubicin
,9296319,V.Vm,"Css increased more than proportionally to the dose rate and the Css vs rate relationship was best defined by a Michaelis-Menten equation (K(m) = 730 micrograms l-1; V.Vm = 0.55 mg kg-1 h-1), (r = 0.994; P = 0.006).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[mg] / [h·kg],0.55,195833,DB00997,Doxorubicin
,12634619,AUC(0-infinity),"The mean AUC(0-infinity) of doxorubicinol for patients receiving TLC D-99 (1.5+/-0.4 M x h) was not statistically different than that in patients receiving conventional doxorubicin (1.8+/-0.4 M x h), although the appearance of the peak doxorubicinol concentration occurred later and was lower in patients receiving TLC D-99.",Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12634619/),M·h,1.5,196176,DB00997,Doxorubicin
,12634619,AUC(0-infinity),"The mean AUC(0-infinity) of doxorubicinol for patients receiving TLC D-99 (1.5+/-0.4 M x h) was not statistically different than that in patients receiving conventional doxorubicin (1.8+/-0.4 M x h), although the appearance of the peak doxorubicinol concentration occurred later and was lower in patients receiving TLC D-99.",Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12634619/),M·h,1.8,196177,DB00997,Doxorubicin
,29122661,first order rate constant,We show that crystalline doxorubicin dissolution can be described by a first order rate constant of 1.0×10-9cms-1 at 37°C.,"Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29122661/),1/[cms],1.0×10-9,196197,DB00997,Doxorubicin
,8347000,Heart concentration,Heart concentration of doxorubicin was significantly lower after isolated lung perfusion with 255.2 +/- 12.8 micrograms/mL of doxorubicin as compared with 5 or 7 mg/kg of intravenous doxorubicin (p < 0.001).,Isolated single-lung perfusion with doxorubicin is pharmacokinetically superior to intravenous injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347000/),[μg] / [ml],255.2,196242,DB00997,Doxorubicin
,11994057,AUC,"A significant increase in epirubicin AUC (+0.74 micromol l-1 h [95% CI for the difference: 0.14, 1.34] and +1.09 micromol l-1 h [95% CI for the difference: 0.44, 1.74]) and decrease in drug clearance (CLTB) (-25.35 l h-1 m-2[95% CI for the difference: -50.18, -0.52] and -35.9 l h-1 m-2[95% CI for the difference -63,4,-8,36]) occurred in combination with paclitaxel 200 and 225 mg m-2 with respect to the AUC (3.16+/-0.6 micromol l-1 h) and CLTB (74.4+/-28.4 l h-1 m-2) of epirubicin followed by paclitaxel 30 h later.",Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994057/),[h·μM] / [l],3.16,196498,DB00997,Doxorubicin
,11994057,CLTB,"A significant increase in epirubicin AUC (+0.74 micromol l-1 h [95% CI for the difference: 0.14, 1.34] and +1.09 micromol l-1 h [95% CI for the difference: 0.44, 1.74]) and decrease in drug clearance (CLTB) (-25.35 l h-1 m-2[95% CI for the difference: -50.18, -0.52] and -35.9 l h-1 m-2[95% CI for the difference -63,4,-8,36]) occurred in combination with paclitaxel 200 and 225 mg m-2 with respect to the AUC (3.16+/-0.6 micromol l-1 h) and CLTB (74.4+/-28.4 l h-1 m-2) of epirubicin followed by paclitaxel 30 h later.",Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994057/),[l] / [(m)^2·h],74.4,196499,DB00997,Doxorubicin
,11994057,tC0.1,The tC0.1 value predicted to yield a 50% decrease in neutrophil count was 7.7 h.,Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994057/),h,7.7,196500,DB00997,Doxorubicin
,19827298,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of DOX in the presence of baicalein was 3.5-4.4%, which was significantly enhanced compared with that of the control group (2.2%).","Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19827298/),%,3.5-4.4,196606,DB00997,Doxorubicin
,19827298,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of DOX in the presence of baicalein was 3.5-4.4%, which was significantly enhanced compared with that of the control group (2.2%).","Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19827298/),%,2.2,196607,DB00997,Doxorubicin
,20150618,tumor-to-muscle ratio,"Additionally, (188)Re-liposome and (188)Re-DXR-liposome had a higher tumor-to-muscle ratio at 24 h (14.4+/-2 .7 and 17.14+/-4.1, respectively) than (188)Re-BMEDA (1.6+/-0.1).",MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150618/),,14.4,197026,DB00997,Doxorubicin
,20150618,tumor-to-muscle ratio,"Additionally, (188)Re-liposome and (188)Re-DXR-liposome had a higher tumor-to-muscle ratio at 24 h (14.4+/-2 .7 and 17.14+/-4.1, respectively) than (188)Re-BMEDA (1.6+/-0.1).",MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150618/),,17.14,197027,DB00997,Doxorubicin
,20150618,tumor-to-muscle ratio,"Additionally, (188)Re-liposome and (188)Re-DXR-liposome had a higher tumor-to-muscle ratio at 24 h (14.4+/-2 .7 and 17.14+/-4.1, respectively) than (188)Re-BMEDA (1.6+/-0.1).",MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150618/),,1.6,197028,DB00997,Doxorubicin
,19520292,labeling efficiency,(186)Re labeling efficiency was 76.1+/-8.3% with Doxil.,"[(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19520292/),%,76.1,197471,DB00997,Doxorubicin
,19520292,serum stability,The in vitro serum stability of [(186)Re]Doxil at 37 degrees C was 38.06+/-12.13% at 24 h.,"[(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19520292/),%,38.06,197472,DB00997,Doxorubicin
,19520292,half clearance times,Pharmacokinetic studies revealed that [(186)Re]Doxil had a two-phase blood clearance with half clearance times of 0.8 and 28.2 h.,"[(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19520292/),h,0.8,197473,DB00997,Doxorubicin
,19520292,half clearance times,Pharmacokinetic studies revealed that [(186)Re]Doxil had a two-phase blood clearance with half clearance times of 0.8 and 28.2 h.,"[(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19520292/),h,28.2,197474,DB00997,Doxorubicin
,17239480,Response rate,Response rate was 75% (66.6% on intention-to-treat).,Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239480/),%,75,197501,DB00997,Doxorubicin
,17239480,Cmax,"Doxorubicin Cmax and AUC were significantly lower in DEB-TACE patients (78.97+/-38.3 ng/mL and 662.6+/-417.6 ng/mLmin) than in conventional TACE (2341.5+/-3951.9 ng/mL and 1812.2+/-1093.7 ng/mLmin, p=0.00002 and p=0.001, respectively).",Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239480/),[ng] / [ml],78.97,197502,DB00997,Doxorubicin
,17239480,Cmax,"Doxorubicin Cmax and AUC were significantly lower in DEB-TACE patients (78.97+/-38.3 ng/mL and 662.6+/-417.6 ng/mLmin) than in conventional TACE (2341.5+/-3951.9 ng/mL and 1812.2+/-1093.7 ng/mLmin, p=0.00002 and p=0.001, respectively).",Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239480/),[ng] / [ml],2341.5,197503,DB00997,Doxorubicin
,17239480,AUC,"Doxorubicin Cmax and AUC were significantly lower in DEB-TACE patients (78.97+/-38.3 ng/mL and 662.6+/-417.6 ng/mLmin) than in conventional TACE (2341.5+/-3951.9 ng/mL and 1812.2+/-1093.7 ng/mLmin, p=0.00002 and p=0.001, respectively).",Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239480/),[ng] / [mlmin],662.6,197504,DB00997,Doxorubicin
,17239480,AUC,"Doxorubicin Cmax and AUC were significantly lower in DEB-TACE patients (78.97+/-38.3 ng/mL and 662.6+/-417.6 ng/mLmin) than in conventional TACE (2341.5+/-3951.9 ng/mL and 1812.2+/-1093.7 ng/mLmin, p=0.00002 and p=0.001, respectively).",Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17239480/),[ng] / [mlmin],1812.2,197505,DB00997,Doxorubicin
,9261889,total body clearance,The total body clearance was significantly slower (80.3 compared with 110 mL min-1 kg-1) in water deprived rats than that in control rats.,Pharmacokinetics of adriamycin and adriamycinol after intravenous administration of adriamycin to rats with water-deprivation for 48 hours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9261889/),[ml] / [kg·min],80.3,197629,DB00997,Doxorubicin
,9261889,total body clearance,The total body clearance was significantly slower (80.3 compared with 110 mL min-1 kg-1) in water deprived rats than that in control rats.,Pharmacokinetics of adriamycin and adriamycinol after intravenous administration of adriamycin to rats with water-deprivation for 48 hours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9261889/),[ml] / [kg·min],110,197630,DB00997,Doxorubicin
,1350628,t1/2,Plasma levels then declined rapidly (t1/2 for 1-6 h period was 0.58 and 0.86 h respectively for conjugated and unconjugated daunorubicin).,"Method for analysis, and distribution profile, of covalently-linked ferritin-daunorubicin conjugate in the blood of trypanosome-infected mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350628/),h,0.58,198040,DB00997,Doxorubicin
,1350628,t1/2,Plasma levels then declined rapidly (t1/2 for 1-6 h period was 0.58 and 0.86 h respectively for conjugated and unconjugated daunorubicin).,"Method for analysis, and distribution profile, of covalently-linked ferritin-daunorubicin conjugate in the blood of trypanosome-infected mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350628/),h,0.86,198041,DB00997,Doxorubicin
,26363490,Oral bioavailability,"Oral bioavailability of SB-505124 was calculated as 76.4%, indicating the potential of SB-505124 as an orally administered drug.",Development and validation of an LC-MS/MS method for the determination of SB-505124 in rat plasma: Application to pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363490/),%,76.4,198538,DB00997,Doxorubicin
,21479746,peak plasma concentration,"The peak plasma concentration of doxorubicin was lower in the QuadraSphere group (309.9 ng/ml) than in the HAI (673.4 ng/ml) or TACE (360.5 ng/ml) groups, suggesting higher tumor retention in the QuadraSphere group.",Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21479746/),[ng] / [ml],309.9,198850,DB00997,Doxorubicin
,21479746,peak plasma concentration,"The peak plasma concentration of doxorubicin was lower in the QuadraSphere group (309.9 ng/ml) than in the HAI (673.4 ng/ml) or TACE (360.5 ng/ml) groups, suggesting higher tumor retention in the QuadraSphere group.",Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21479746/),[ng] / [ml],673.4,198851,DB00997,Doxorubicin
,21479746,peak plasma concentration,"The peak plasma concentration of doxorubicin was lower in the QuadraSphere group (309.9 ng/ml) than in the HAI (673.4 ng/ml) or TACE (360.5 ng/ml) groups, suggesting higher tumor retention in the QuadraSphere group.",Hepatic arterial embolization with doxorubicin-loaded superabsorbent polymer microspheres in a rabbit liver tumor model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21479746/),[ng] / [ml],360.5,198852,DB00997,Doxorubicin
,11249051,progression-free,"At five years progression-free and overall survival rates are 37.5% and 65%, respectively.",High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249051/),%,37.,199261,DB00997,Doxorubicin
,11249051,overall survival,"At five years progression-free and overall survival rates are 37.5% and 65%, respectively.",High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249051/),%,65,199262,DB00997,Doxorubicin
,8321835,distribution half-lives,"In beagle dogs, clearance was significantly slower for DOX encapsulated in PEG/DSPE-containing liposomes than in HPI-containing liposomes, with distribution half-lives of 29 and 13 hr, respectively.",Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321835/),h,29,200355,DB00997,Doxorubicin
,8321835,distribution half-lives,"In beagle dogs, clearance was significantly slower for DOX encapsulated in PEG/DSPE-containing liposomes than in HPI-containing liposomes, with distribution half-lives of 29 and 13 hr, respectively.",Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321835/),h,13,200356,DB00997,Doxorubicin
,27329361,volume of distribution of central compartment,"The volume of distribution of central compartment and clearance of Reditux™ were estimated at 0.95 L and 5.98 mL/h, respectively.","Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329361/),l,0.95,200467,DB00997,Doxorubicin
,27329361,clearance of Reditux™,"The volume of distribution of central compartment and clearance of Reditux™ were estimated at 0.95 L and 5.98 mL/h, respectively.","Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329361/),[ml] / [h],5.98,200468,DB00997,Doxorubicin
,19111045,Tissue-absorbed dose,"Tissue-absorbed dose in the liver was 0.24-0.40 and 0.17-0.26 (mGy/MBq) and in red marrow was 0.033-0.050 and 0.038-0.046 (mGy/MBq), respectively, for (188)Re-liposome and (188)Re-DXR-liposome.",Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19111045/),[mgy] / [Mbq],0.24-0.40,201830,DB00997,Doxorubicin
,19111045,Tissue-absorbed dose,"Tissue-absorbed dose in the liver was 0.24-0.40 and 0.17-0.26 (mGy/MBq) and in red marrow was 0.033-0.050 and 0.038-0.046 (mGy/MBq), respectively, for (188)Re-liposome and (188)Re-DXR-liposome.",Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19111045/),[mgy] / [Mbq],0.17-0.26,201831,DB00997,Doxorubicin
,19111045,Tissue-absorbed dose,"Tissue-absorbed dose in the liver was 0.24-0.40 and 0.17-0.26 (mGy/MBq) and in red marrow was 0.033-0.050 and 0.038-0.046 (mGy/MBq), respectively, for (188)Re-liposome and (188)Re-DXR-liposome.",Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19111045/),[mgy] / [Mbq],0.033-0.050,201832,DB00997,Doxorubicin
,19111045,Tissue-absorbed dose,"Tissue-absorbed dose in the liver was 0.24-0.40 and 0.17-0.26 (mGy/MBq) and in red marrow was 0.033-0.050 and 0.038-0.046 (mGy/MBq), respectively, for (188)Re-liposome and (188)Re-DXR-liposome.",Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19111045/),[mgy] / [Mbq],0.038-0.046,201833,DB00997,Doxorubicin
,31622204,encapsulation percentage,"The encapsulation percentage of PTX and DXR was 74.1 ± 1.8 % and 89.6 ± 12.3%, respectively, and the mean diameter of the liposomes was 244.4 ± 28.1 nm.",Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622204/),%,74.1,202282,DB00997,Doxorubicin
,31622204,encapsulation percentage,"The encapsulation percentage of PTX and DXR was 74.1 ± 1.8 % and 89.6 ± 12.3%, respectively, and the mean diameter of the liposomes was 244.4 ± 28.1 nm.",Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622204/),%,89.6,202283,DB00997,Doxorubicin
,31622204,inhibitory concentration 50% (IC50),Cytotoxicity studies using 4T1 breast cancer cells showed lower inhibitory concentration 50% (IC50) value for LCFL-PTX/DXR treatment (0.27 ± 0.11 µm) compared to the values of free drugs treatment.,Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622204/),µm,0.27,202284,DB00997,Doxorubicin
,9215819,peak plasma concentration,The mean peak plasma concentration of paclitaxel ranged between 5.1 and 6.2 micromol/L at doses of 175 to 225 mg/m2.,Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215819/),[μM] / [l],5.1 and 6.2,202728,DB00997,Doxorubicin
,1320447,peak plasma concentration,Pharmacokinetics results showed the following: the peak plasma concentration was significantly higher in Group 1 as compared with Groups 2 or 3 (Group 1: 2.1 +/- 0.9 mg/ml; Group 2: 0.9 +/- 0.3 mg/ml; Group 3: 0.5 +/- 0.2 mg/ml); the area under curve calculated from time zero to 1 hour was lower in Groups 2 and 3 compared with Group 1.,Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),[mg] / [ml],2.1,202965,DB00997,Doxorubicin
,1320447,peak plasma concentration,Pharmacokinetics results showed the following: the peak plasma concentration was significantly higher in Group 1 as compared with Groups 2 or 3 (Group 1: 2.1 +/- 0.9 mg/ml; Group 2: 0.9 +/- 0.3 mg/ml; Group 3: 0.5 +/- 0.2 mg/ml); the area under curve calculated from time zero to 1 hour was lower in Groups 2 and 3 compared with Group 1.,Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),[mg] / [ml],0.9,202966,DB00997,Doxorubicin
,1320447,peak plasma concentration,Pharmacokinetics results showed the following: the peak plasma concentration was significantly higher in Group 1 as compared with Groups 2 or 3 (Group 1: 2.1 +/- 0.9 mg/ml; Group 2: 0.9 +/- 0.3 mg/ml; Group 3: 0.5 +/- 0.2 mg/ml); the area under curve calculated from time zero to 1 hour was lower in Groups 2 and 3 compared with Group 1.,Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),[mg] / [ml],0.5,202967,DB00997,Doxorubicin
,1320447,binding ratio,"The liver/liver+lungs+abdomen binding ratio was 28% +/- 1% in Group 1, 36% +/- 5% in Group 2, and 63% +/- 7% in Group 3.",Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),%,28,202968,DB00997,Doxorubicin
,1320447,binding ratio,"The liver/liver+lungs+abdomen binding ratio was 28% +/- 1% in Group 1, 36% +/- 5% in Group 2, and 63% +/- 7% in Group 3.",Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),%,36,202969,DB00997,Doxorubicin
,1320447,binding ratio,"The liver/liver+lungs+abdomen binding ratio was 28% +/- 1% in Group 1, 36% +/- 5% in Group 2, and 63% +/- 7% in Group 3.",Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),%,63,202970,DB00997,Doxorubicin
,1320447,T/NT ratios,"The T/NT ratios were 1.0 +/- 0 (Group 1), 1.5 +/- 0.1 (Group 2), and 4.7 +/- 0.5 (Group 3).",Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),,1.0,202971,DB00997,Doxorubicin
,1320447,T/NT ratios,"The T/NT ratios were 1.0 +/- 0 (Group 1), 1.5 +/- 0.1 (Group 2), and 4.7 +/- 0.5 (Group 3).",Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),,1.5,202972,DB00997,Doxorubicin
,1320447,T/NT ratios,"The T/NT ratios were 1.0 +/- 0 (Group 1), 1.5 +/- 0.1 (Group 2), and 4.7 +/- 0.5 (Group 3).",Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),,4.7,202973,DB00997,Doxorubicin
,1320447,half-lives,"The doxorubicin half-lives in tumourous tissue were 0.7 +/- 0.1 days (Group 1), 1.8 +/- 0.2 days (Group 2), and 2.6 days (n = 1; Group 3).",Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),d,0.7,202974,DB00997,Doxorubicin
,1320447,half-lives,"The doxorubicin half-lives in tumourous tissue were 0.7 +/- 0.1 days (Group 1), 1.8 +/- 0.2 days (Group 2), and 2.6 days (n = 1; Group 3).",Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),d,1.8,202975,DB00997,Doxorubicin
,1320447,half-lives,"The doxorubicin half-lives in tumourous tissue were 0.7 +/- 0.1 days (Group 1), 1.8 +/- 0.2 days (Group 2), and 2.6 days (n = 1; Group 3).",Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320447/),d,2.6,202976,DB00997,Doxorubicin
,10964334,T(1/2),"Doxil pharmacokinetics was well described by a monoexponential elimination curve with a long T(1/2) (median, 79 hours), a slow clearance (median, 40 mL/hour), and a small volume of distribution (median, 3.9 L).",Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10964334/),h,79,203174,DB00997,Doxorubicin
,10964334,clearance,"Doxil pharmacokinetics was well described by a monoexponential elimination curve with a long T(1/2) (median, 79 hours), a slow clearance (median, 40 mL/hour), and a small volume of distribution (median, 3.9 L).",Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10964334/),[ml] / [h],40,203175,DB00997,Doxorubicin
,10964334,volume of distribution,"Doxil pharmacokinetics was well described by a monoexponential elimination curve with a long T(1/2) (median, 79 hours), a slow clearance (median, 40 mL/hour), and a small volume of distribution (median, 3.9 L).",Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10964334/),l,3.9,203176,DB00997,Doxorubicin
,26060065,Cmax,"After TACE, mean idarubicin Cmax and AUC0-24h were 12.5 ± 9.4 ng/mL and 52 ± 16 ng/mL*h.",Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26060065/),[ng] / [ml],12.5,203352,DB00997,Doxorubicin
,26060065,AUC0-24h,"After TACE, mean idarubicin Cmax and AUC0-24h were 12.5 ± 9.4 ng/mL and 52 ± 16 ng/mL*h.",Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26060065/),[ng] / [h·ml],52,203353,DB00997,Doxorubicin
,11187897,MTD,The MTD of cinchonine administered by continuous i.v. infusion was 30 mg/kg/d.,"Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11187897/),[mg] / [d·kg],30,204899,DB00997,Doxorubicin
,20555126,Trough levels,"Trough levels of 4 patients on three-monthly schedule maintenance therapy remained constant, with a median concentration of 6 mu g/mL (range 0.5-11.7 microg/mL).",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),[g·mu] / [ml],6,204913,DB00997,Doxorubicin
,20555126,elimination half-life at steady state,"The elimination half-life at steady state of rituximab in all patients was estimated to be 19.2 (+/- 15.2%) days with a between-subject variability of 54%, indicating wide variability.",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),d,19.2,204914,DB00997,Doxorubicin
,11207053,V(max),This novel prodrug was completely activated to the parent drug by human beta-glucuronidase with V(max)= 25.0 micromol x min(-1) x mg(-1) and K(m) = 1100 microM.,A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207053/),[μM] / [mg·min],25.0,205178,DB00997,Doxorubicin
,11207053,K(m),This novel prodrug was completely activated to the parent drug by human beta-glucuronidase with V(max)= 25.0 micromol x min(-1) x mg(-1) and K(m) = 1100 microM.,A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207053/),μM,1100,205179,DB00997,Doxorubicin
,11207053,peak plasma concentration,"Administration of DOX at 8 mg x kg(-1) i.v. (maximum tolerated dose, MTD) to OVCAR-3-bearing mice resulted in a peak plasma concentration of the drug of 16.4 microM (t = 1 min).",A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207053/),μM,16.4,205180,DB00997,Doxorubicin
,11207053,t,"Administration of DOX at 8 mg x kg(-1) i.v. (maximum tolerated dose, MTD) to OVCAR-3-bearing mice resulted in a peak plasma concentration of the drug of 16.4 microM (t = 1 min).",A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207053/),min,1,205181,DB00997,Doxorubicin
,11207053,peak concentration,DOX-GA3 activation by beta-glucuronidase in the tumour yielded an almost 5-fold higher DOX peak concentration of 9.57 nmol x g(-1) (P< 0.05) than the peak concentration of only 2.14 nmol x g(-1) observed after DOX.,A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207053/),[nM] / [g],9.57,205182,DB00997,Doxorubicin
,11207053,peak concentration,DOX-GA3 activation by beta-glucuronidase in the tumour yielded an almost 5-fold higher DOX peak concentration of 9.57 nmol x g(-1) (P< 0.05) than the peak concentration of only 2.14 nmol x g(-1) observed after DOX.,A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207053/),[nM] / [g],2.14,205183,DB00997,Doxorubicin
,11207053,area under the curve,"As a consequence, the area under the curve of DOX calculated in tumour tissue after DOX-GA3 (13.1 micromol x min(-1) x g(-1)) was 10-fold higher than after DOX (1.31 micromol x min(-1) x g(-1)).",A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207053/),[μM] / [g·min],13.1,205184,DB00997,Doxorubicin
,11207053,area under the curve,"As a consequence, the area under the curve of DOX calculated in tumour tissue after DOX-GA3 (13.1 micromol x min(-1) x g(-1)) was 10-fold higher than after DOX (1.31 micromol x min(-1) x g(-1)).",A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11207053/),[μM] / [g·min],1.31,205185,DB00997,Doxorubicin
,18157576,length of stay,"The median postoperative length of stay was 7 days (range, 4-29 days), three patients required readmissions within 30 days, and there were no operative mortalities The median follow-up time for was 13.7 months (range, 3-38 months).",Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18157576/),d,7,205514,DB00997,Doxorubicin
,18157576,overall survival,The median overall survival was 30.6 months with a median disease-free survival of 25 months.,Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18157576/),month,30.6,205515,DB00997,Doxorubicin
,18157576,disease-free survival,The median overall survival was 30.6 months with a median disease-free survival of 25 months.,Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18157576/),month,25,205516,DB00997,Doxorubicin
,11304775,Response rate,Response rate was 76% (28% complete).,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),%,76,206733,DB00997,Doxorubicin
,11304775,overall survival,Median overall survival was 29 months.,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),month,29,206734,DB00997,Doxorubicin
,11304775,Urinary excretion,Urinary excretion of EPI dose went from 8.2% in E --> T to 11.8% in ET cycles.,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),%,8.2,206735,DB00997,Doxorubicin
,11304775,Urinary excretion,Urinary excretion of EPI dose went from 8.2% in E --> T to 11.8% in ET cycles.,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),%,11.8,206736,DB00997,Doxorubicin
,25265550,loading efficiency,"The DOX loading efficiency was as high as 91.7% and 93.5% for PEG5K-EB2 and FA-PEG5K-EB2, respectively.",Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25265550/),%,91.7,206831,DB00997,Doxorubicin
,25265550,loading efficiency,"The DOX loading efficiency was as high as 91.7% and 93.5% for PEG5K-EB2 and FA-PEG5K-EB2, respectively.",Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25265550/),%,93.5,206832,DB00997,Doxorubicin
,25265550,maximum tolerated dose,"The maximum tolerated dose of DOX-loaded PEG5K-EB2 micelles was 15 mg/kg in mice, which was 1.5-fold greater than that for free DOX.",Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25265550/),[mg] / [kg],15,206833,DB00997,Doxorubicin
,27473308,zeta potential,Particles size was below 100nm in diameter and zeta potential ranged - (25-30).,Modified-chitosan nanoparticles: Novel drug delivery systems improve oral bioavailability of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27473308/),,25-30,206887,DB00997,Doxorubicin
,7497603,half-life of the first disposition phase (t1/2 alpha),"The concentration-time curves of THP-ADM in plasma were best described by an open three-compartment model [half-life of the first disposition phase (t1/2 alpha), 3.15 min; terminal elimination half-life (t1/2 gamma), 13.9 h] with a mean area under the curve (AUC) of 12.2 ng h ml-1mg-1 m-2, resulting in a mean plasma clearance of 86.9 1h-1 m-2.",Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497603/),min,3.15,207117,DB00997,Doxorubicin
,7497603,terminal elimination half-life (t1/2 gamma),"The concentration-time curves of THP-ADM in plasma were best described by an open three-compartment model [half-life of the first disposition phase (t1/2 alpha), 3.15 min; terminal elimination half-life (t1/2 gamma), 13.9 h] with a mean area under the curve (AUC) of 12.2 ng h ml-1mg-1 m-2, resulting in a mean plasma clearance of 86.9 1h-1 m-2.",Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497603/),h,13.9,207118,DB00997,Doxorubicin
,7497603,area under the curve (AUC),"The concentration-time curves of THP-ADM in plasma were best described by an open three-compartment model [half-life of the first disposition phase (t1/2 alpha), 3.15 min; terminal elimination half-life (t1/2 gamma), 13.9 h] with a mean area under the curve (AUC) of 12.2 ng h ml-1mg-1 m-2, resulting in a mean plasma clearance of 86.9 1h-1 m-2.",Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497603/),[h·ng] / [(m)^2·ml],12.2,207119,DB00997,Doxorubicin
,7497603,plasma clearance,"The concentration-time curves of THP-ADM in plasma were best described by an open three-compartment model [half-life of the first disposition phase (t1/2 alpha), 3.15 min; terminal elimination half-life (t1/2 gamma), 13.9 h] with a mean area under the curve (AUC) of 12.2 ng h ml-1mg-1 m-2, resulting in a mean plasma clearance of 86.9 1h-1 m-2.",Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497603/),1/[(m)^2·1h],86.9,207120,DB00997,Doxorubicin
,7497603,maximal plasma concentrations,"Metabolism included the formation of Adriamycin (ADM), Adriamycinol (ADM-OH), 13-dihydro-4'-O-tetrahydropyranyladriamycin (THP-OH), 7-deoxyadriamycinone (7H-ADn), and 7-deoxy-13-dihydroadriamycinone (7H-ADn-OH), with maximal plasma concentrations ranging from 2.8 to 5.5 ng/ml.",Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7497603/),[ng] / [ml],2.8 to 5.5,207121,DB00997,Doxorubicin
,10718184,AUCintrahepatic/AUCintravenous ratios,In the liver AUCintrahepatic/AUCintravenous ratios were 3.45 and 3.6 with 4.8 mg and 96 mg of doxorubicin respectively.,Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718184/),,3.45,207594,DB00997,Doxorubicin
,10718184,AUCintrahepatic/AUCintravenous ratios,In the liver AUCintrahepatic/AUCintravenous ratios were 3.45 and 3.6 with 4.8 mg and 96 mg of doxorubicin respectively.,Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718184/),,3.6,207595,DB00997,Doxorubicin
,10718184,AUCintrahepatic/AUCintraarterial ratios,The AUCintrahepatic/AUCintraarterial ratios were 1.97 and 1.65 respectively.,Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718184/),,1.97,207596,DB00997,Doxorubicin
,10718184,AUCintrahepatic/AUCintraarterial ratios,The AUCintrahepatic/AUCintraarterial ratios were 1.97 and 1.65 respectively.,Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718184/),,1.65,207597,DB00997,Doxorubicin
,10718184,liver extraction ratio (AUCliver/AUCplasma),The liver extraction ratio (AUCliver/AUCplasma) after intravenous administration with 4.8 mg and 96 mg of doxorubicin was 31.9 with both doses of doxorubicin.,Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718184/),,31.9,207598,DB00997,Doxorubicin
,10718184,extraction ratios,The corresponding extraction ratios were 107.6 and 51 for intra-arterial administration and 425.2 and 237.7 for intrahepatic administration for the two doses of doxorubicin.,Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718184/),,107.6,207599,DB00997,Doxorubicin
,10718184,extraction ratios,The corresponding extraction ratios were 107.6 and 51 for intra-arterial administration and 425.2 and 237.7 for intrahepatic administration for the two doses of doxorubicin.,Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718184/),,51,207600,DB00997,Doxorubicin
,10718184,extraction ratios,The corresponding extraction ratios were 107.6 and 51 for intra-arterial administration and 425.2 and 237.7 for intrahepatic administration for the two doses of doxorubicin.,Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718184/),,425.2,207601,DB00997,Doxorubicin
,10718184,extraction ratios,The corresponding extraction ratios were 107.6 and 51 for intra-arterial administration and 425.2 and 237.7 for intrahepatic administration for the two doses of doxorubicin.,Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718184/),,237.7,207602,DB00997,Doxorubicin
,2153767,area under the plasma concentration curve (AUC),"The area under the plasma concentration curve (AUC) was 277 +/- 226 ng.h/mL and 359 +/- 282 ng.h/mL at 40 and 80 micrograms/kg, respectively.",Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2153767/),[h·ng] / [ml],277,207685,DB00997,Doxorubicin
,2153767,area under the plasma concentration curve (AUC),"The area under the plasma concentration curve (AUC) was 277 +/- 226 ng.h/mL and 359 +/- 282 ng.h/mL at 40 and 80 micrograms/kg, respectively.",Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2153767/),[h·ng] / [ml],359,207686,DB00997,Doxorubicin
,2153767,total body clearance,The total body clearance was 0.319 +/- 0.315 L/kg/hr and 0.483 +/- 0.504 L/kg/hr at the 40 and 80 micrograms/kg doses.,Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2153767/),[l] / [h·kg],0.319,207687,DB00997,Doxorubicin
,2153767,total body clearance,The total body clearance was 0.319 +/- 0.315 L/kg/hr and 0.483 +/- 0.504 L/kg/hr at the 40 and 80 micrograms/kg doses.,Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2153767/),[l] / [h·kg],0.483,207688,DB00997,Doxorubicin
,26668251,time to ANC recovery,"Between-group efficacy parameters were comparable except for time to ANC recovery in cycle 1 (40 mg of balugrastim, 2.0 days; 50 mg of balugrastim, 2.1; pegfilgrastim, 2.6).",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),d,2.0,208259,DB00997,Doxorubicin
,26668251,time to ANC recovery,"Between-group efficacy parameters were comparable except for time to ANC recovery in cycle 1 (40 mg of balugrastim, 2.0 days; 50 mg of balugrastim, 2.1; pegfilgrastim, 2.6).",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),,2,208260,DB00997,Doxorubicin
,26668251,terminal elimination half-life,"Median terminal elimination half-life was ≈37 hours for 40 mg of balugrastim, ≈36 for 50 mg of balugrastim, and ≈45 for pegfilgrastim.",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),h,37,208261,DB00997,Doxorubicin
,26668251,terminal elimination half-life,"Median terminal elimination half-life was ≈37 hours for 40 mg of balugrastim, ≈36 for 50 mg of balugrastim, and ≈45 for pegfilgrastim.",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),,36,208262,DB00997,Doxorubicin
,26668251,terminal elimination half-life,"Median terminal elimination half-life was ≈37 hours for 40 mg of balugrastim, ≈36 for 50 mg of balugrastim, and ≈45 for pegfilgrastim.",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),,45,208263,DB00997,Doxorubicin
,26633878,half-life (t1/2),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),h,1.455,208515,DB00997,Doxorubicin
,26633878,half-life (t1/2),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),h,2.344,208516,DB00997,Doxorubicin
,26633878,clearance (CL),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),[ml] / [h],10.997,208517,DB00997,Doxorubicin
,26633878,clearance (CL),"In this study, the co-administration of fentanyl and paclitaxel prolonged the half-life (t1/2) of paclitaxel from 1.455 hours to 2.344 hours and decreased the clearance (CL) from 10.997 ml/h to 7.014 ml/h in mice.",Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26633878/),[ml] / [h],7.014,208518,DB00997,Doxorubicin
,31152925,particle size,"The mean particle size and zeta potential of the RGD-DOX-SLNs was 96.3 nm and 35.6 mV, respectively.","Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152925/),nm,96.3,208915,DB00997,Doxorubicin
,31152925,zeta potential,"The mean particle size and zeta potential of the RGD-DOX-SLNs was 96.3 nm and 35.6 mV, respectively.","Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152925/),mv,35.6,208916,DB00997,Doxorubicin
,31152925,Terminal half life (T1/2),Terminal half life (T1/2) and peak concentration (Cmax) of RGD-DOX-SLNs was 10.85 h and 39.12 ± 2.71 L/kg/h. in vitro and in vivo antitumor results indicate that RGD-DOX-SLNs might be a promising novel lipid carrier which could improve breast cancer therapy.,"Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152925/),h,10.85,208917,DB00997,Doxorubicin
,31152925,peak concentration (Cmax),Terminal half life (T1/2) and peak concentration (Cmax) of RGD-DOX-SLNs was 10.85 h and 39.12 ± 2.71 L/kg/h. in vitro and in vivo antitumor results indicate that RGD-DOX-SLNs might be a promising novel lipid carrier which could improve breast cancer therapy.,"Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152925/),[l] / [h·kg],39.12,208918,DB00997,Doxorubicin
,29373094,bpCR rates,"The bpCR rates were 51.7% and 42.0% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,51.7,209179,DB00997,Doxorubicin
,29373094,bpCR rates,"The bpCR rates were 51.7% and 42.0% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,42.0,209180,DB00997,Doxorubicin
,29373094,total pathologic complete response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,45.8,209181,DB00997,Doxorubicin
,29373094,total pathologic complete response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,35.8,209182,DB00997,Doxorubicin
,29373094,overall response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,96.3,209183,DB00997,Doxorubicin
,29373094,overall response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,91.2,209184,DB00997,Doxorubicin
,3380821,plasma half-life,Its plasma half-life was found to be 8.4 hrs.,Renal handling of adriamycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3380821/),h,8.4,209239,DB00997,Doxorubicin
,3380821,biliary clearance ratio,The biliary clearance ratio between ADR and creatinine was ranged from 30-100.,Renal handling of adriamycin. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3380821/),,30-100,209240,DB00997,Doxorubicin
,3697976,peak plasma concentration,The peak plasma concentration with free doxorubicin at 5 min was 1.7 micrograms/ml which was reduced to 0.3 micrograms/ml by 1 h.,Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697976/),[μg] / [ml],1.7,209796,DB00997,Doxorubicin
,3697976,peak plasma concentration,The peak plasma concentration with free doxorubicin at 5 min was 1.7 micrograms/ml which was reduced to 0.3 micrograms/ml by 1 h.,Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697976/),[μg] / [ml],0.3,209797,DB00997,Doxorubicin
,3697976,peak plasma concentration,"With cardiolipin liposomes, the peak plasma concentration of doxorubicin achieved at 5 min was 20.9 micrograms/ml.",Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697976/),[μg] / [ml],20.9,209798,DB00997,Doxorubicin
,3697976,terminal half-life,The terminal half-life with free doxorubicin in plasma was 17.3 h whereas it was 69.3 h with drug entrapped in liposomes.,Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697976/),h,17.3,209799,DB00997,Doxorubicin
,3697976,terminal half-life,The terminal half-life with free doxorubicin in plasma was 17.3 h whereas it was 69.3 h with drug entrapped in liposomes.,Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697976/),h,69.3,209800,DB00997,Doxorubicin
,3697976,area under the plasma concentration curve,The area under the plasma concentration curve with liposomal doxorubicin was 81.4 micrograms X h X ml-1 compared to 1.95 micrograms X h X ml-1 observed with free doxorubicin.,Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697976/),[h·μg] / [ml],81.4,209801,DB00997,Doxorubicin
,3697976,area under the plasma concentration curve,The area under the plasma concentration curve with liposomal doxorubicin was 81.4 micrograms X h X ml-1 compared to 1.95 micrograms X h X ml-1 observed with free doxorubicin.,Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697976/),[h·μg] / [ml],1.95,209802,DB00997,Doxorubicin
,3697976,terminal half-life,The terminal half-life with free doxorubicin in cardiac tissue was 17.9 h compared to 12.6 h with drug encapsulated in liposomes.,Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697976/),h,17.9,209803,DB00997,Doxorubicin
,3697976,terminal half-life,The terminal half-life with free doxorubicin in cardiac tissue was 17.9 h compared to 12.6 h with drug encapsulated in liposomes.,Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3697976/),h,12.6,209804,DB00997,Doxorubicin
,9067319,AUC(P),"The AUC(P) after administration of free doxorubicin, doxorubicin encapsulated in distearoyl phosphatidylcholine/cholesterol liposomes and doxorubicin encapsulated in distearoyl phosphatidylcholine/cholesterol/PEG-PE-stabilized liposomes were 0.087 micromol x ml(-1) x h, 50 micromol x ml(-1) x h and 78 micromol x ml(-1) x h, respectively.",Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9067319/),[h·μM] / [ml],0.087,209858,DB00997,Doxorubicin
,9067319,AUC(P),"The AUC(P) after administration of free doxorubicin, doxorubicin encapsulated in distearoyl phosphatidylcholine/cholesterol liposomes and doxorubicin encapsulated in distearoyl phosphatidylcholine/cholesterol/PEG-PE-stabilized liposomes were 0.087 micromol x ml(-1) x h, 50 micromol x ml(-1) x h and 78 micromol x ml(-1) x h, respectively.",Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9067319/),[h·μM] / [ml],50,209859,DB00997,Doxorubicin
,9067319,AUC(P),"The AUC(P) after administration of free doxorubicin, doxorubicin encapsulated in distearoyl phosphatidylcholine/cholesterol liposomes and doxorubicin encapsulated in distearoyl phosphatidylcholine/cholesterol/PEG-PE-stabilized liposomes were 0.087 micromol x ml(-1) x h, 50 micromol x ml(-1) x h and 78 micromol x ml(-1) x h, respectively.",Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9067319/),[h·μM] / [ml],78,209860,DB00997,Doxorubicin
,9067319,Maximum drug levels,"Maximum drug levels achieved in the tumors were similar for both liposomal doxorubicin formulations, 140 microg (250 nmol)/g tumor; however, this level was achieved faster when the liposomes did not contain PEG-PE.",Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9067319/),μg,140,209861,DB00997,Doxorubicin
less,9067319,Maximum levels,"Maximum levels measured after administration of free drug were less than 5 microg/g tumor, and these were achieved within 15 min.",Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9067319/),[μg] / [g],5,209862,DB00997,Doxorubicin
,9219502,total systemic plasma clearance (CL),"The mean total systemic plasma clearance (CL) of MX2 was 2.98 +/- 1.68 l/min, the mean volume of distribution at steady state was 1460 +/- 749 l and mean elimination half-life was 10.8 +/- 5.1 h.",Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219502/),[l] / [min],2.98,209980,DB00997,Doxorubicin
,9219502,volume of distribution at steady state,"The mean total systemic plasma clearance (CL) of MX2 was 2.98 +/- 1.68 l/min, the mean volume of distribution at steady state was 1460 +/- 749 l and mean elimination half-life was 10.8 +/- 5.1 h.",Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219502/),l,1460,209981,DB00997,Doxorubicin
,9219502,elimination half-life,"The mean total systemic plasma clearance (CL) of MX2 was 2.98 +/- 1.68 l/min, the mean volume of distribution at steady state was 1460 +/- 749 l and mean elimination half-life was 10.8 +/- 5.1 h.",Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219502/),h,10.8,209982,DB00997,Doxorubicin
,9219502,elimination half-lives,"The mean elimination half-lives of the metabolites M1, M2, M3 and M4 were 11.8 +/- 5.0, 21.9 +/- 11.8, 19.0 +/- 11.3 and 12.3 +/- 6.3 h, respectively.",Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219502/),h,11.8,209983,DB00997,Doxorubicin
,9219502,elimination half-lives,"The mean elimination half-lives of the metabolites M1, M2, M3 and M4 were 11.8 +/- 5.0, 21.9 +/- 11.8, 19.0 +/- 11.3 and 12.3 +/- 6.3 h, respectively.",Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219502/),h,21.9,209984,DB00997,Doxorubicin
,9219502,elimination half-lives,"The mean elimination half-lives of the metabolites M1, M2, M3 and M4 were 11.8 +/- 5.0, 21.9 +/- 11.8, 19.0 +/- 11.3 and 12.3 +/- 6.3 h, respectively.",Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219502/),h,19.0,209985,DB00997,Doxorubicin
,9219502,elimination half-lives,"The mean elimination half-lives of the metabolites M1, M2, M3 and M4 were 11.8 +/- 5.0, 21.9 +/- 11.8, 19.0 +/- 11.3 and 12.3 +/- 6.3 h, respectively.",Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9219502/),h,12.3,209986,DB00997,Doxorubicin
,3713196,total urinary excretion,"The total urinary excretion was not different between the II and III groups and amounted to 11.6 and 12.8% of the injected dose of doxorubicin and daunorubicin, respectively.","Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3713196/),%,11.6,210541,DB00997,Doxorubicin
,3713196,total urinary excretion,"The total urinary excretion was not different between the II and III groups and amounted to 11.6 and 12.8% of the injected dose of doxorubicin and daunorubicin, respectively.","Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3713196/),%,12.8,210542,DB00997,Doxorubicin
,22245954,area under concentration-time curve (AUC(0-t),"The geometric mean area under concentration-time curve (AUC(0-t) μg/mL h) for cyclophosphamide was 282 following aprepitant and 230 following placebo (ratio 1.23; 90% CI 1.13, 1.33).",The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22245954/),[μg] / [h·ml],282,211078,DB00997,Doxorubicin
,22245954,area under concentration-time curve (AUC(0-t),"The geometric mean area under concentration-time curve (AUC(0-t) μg/mL h) for cyclophosphamide was 282 following aprepitant and 230 following placebo (ratio 1.23; 90% CI 1.13, 1.33).",The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22245954/),[μg] / [h·ml],230,211079,DB00997,Doxorubicin
,22245954,AUC(0-t),"DCE AUC(0-t) (μg/mL h) was 6.76 following aprepitant and 9.37 following placebo (ratio 0.72; 90% CI 0.64, 0.81).",The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22245954/),[μg] / [h·ml],6,211080,DB00997,Doxorubicin
,22245954,AUC(0-t),"DCE AUC(0-t) (μg/mL h) was 6.76 following aprepitant and 9.37 following placebo (ratio 0.72; 90% CI 0.64, 0.81).",The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22245954/),[μg] / [h·ml],9,211081,DB00997,Doxorubicin
,11095134,MTD,"The MTD was 120 mg/m2/day and the dose-limiting toxicities were leukopenia, thrombocytopenia, anemia and diarrhea.",Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095134/),mg,120,212125,DB00997,Doxorubicin
,23063411,GI(50),"A 59-fold difference in GI(50) was observed between MDCKII-WT and MDCKII-ABCB1 cells (12.7 nM vs. 745 nM, p<0.0001).","Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23063411/),nM,12.7,212152,DB00997,Doxorubicin
,23063411,GI(50),"A 59-fold difference in GI(50) was observed between MDCKII-WT and MDCKII-ABCB1 cells (12.7 nM vs. 745 nM, p<0.0001).","Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23063411/),nM,745,212153,DB00997,Doxorubicin
,23063411,GI(50),"Reduced sensitivity was also seen in MDCKII-ABCC1 and ABCC2 cells (GI(50) 25.7 and 40.4 nM respectively, p<0.0001).","Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23063411/),nM,25.7,212154,DB00997,Doxorubicin
,23063411,GI(50),"Reduced sensitivity was also seen in MDCKII-ABCC1 and ABCC2 cells (GI(50) 25.7 and 40.4 nM respectively, p<0.0001).","Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23063411/),nM,40.4,212155,DB00997,Doxorubicin
,23063411,intracellular accumulation,"Lower intracellular accumulation of actinomycin D was observed in MDCKII-ABCB1 cells as compared to MDCKII-WT (0.98 nM vs. 0.1 nM, p<0.0001), which was reversed upon ABCB1 inhibition.","Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23063411/),nM,0.98,212156,DB00997,Doxorubicin
,23063411,intracellular accumulation,"Lower intracellular accumulation of actinomycin D was observed in MDCKII-ABCB1 cells as compared to MDCKII-WT (0.98 nM vs. 0.1 nM, p<0.0001), which was reversed upon ABCB1 inhibition.","Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23063411/),nM,0.1,212157,DB00997,Doxorubicin
,23063411,AUC(0-6 h),In vivo studies showed that actinomycin D plasma concentrations were significantly higher in Abcb1a/1b(-/-) as compared to WT mice following administration of 0.5 mg/kg actinomycin D (AUC(0-6 h) 242 vs. 152 μg/Lh respectively).,"Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23063411/),[μg] / [lh],242,212158,DB00997,Doxorubicin
,23063411,AUC(0-6 h),In vivo studies showed that actinomycin D plasma concentrations were significantly higher in Abcb1a/1b(-/-) as compared to WT mice following administration of 0.5 mg/kg actinomycin D (AUC(0-6 h) 242 vs. 152 μg/Lh respectively).,"Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23063411/),[μg] / [lh],152,212159,DB00997,Doxorubicin
,12915867,overall response rate,"Of 34 patients with evaluable disease, one patient had a complete response and nine patients had partial response, yielding an overall response rate of 29.4%.","Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915867/),%,29.4,212168,DB00997,Doxorubicin
,22607766,MTD,"The MTD of ixabepilone in combination with epirubicin 75 mg/m(2) was 30 mg/m(2), and the DLT dose was 35 mg/m(2) with grade 4 neutropenia.",A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22607766/),,30,212954,DB00997,Doxorubicin
,9010632,area under the plasma concentration-time curve from time 0 to last measured time [AUCT,"Mean plasma concentrations of both M2 and M4, and the resultant area under the plasma concentration-time curve from time 0 to last measured time [AUCT; M2 (68.9 vs. 29.3 micrograms-min/ml) and M4 (53.4 vs. 33.4 micrograms-min/ml)], increased significantly in SHRs at 16 weeks of age, compared with their control rats.","Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010632/),[μgrams-min] / [ml],68.9,213208,DB00997,Doxorubicin
,9010632,area under the plasma concentration-time curve from time 0 to last measured time [AUCT,"Mean plasma concentrations of both M2 and M4, and the resultant area under the plasma concentration-time curve from time 0 to last measured time [AUCT; M2 (68.9 vs. 29.3 micrograms-min/ml) and M4 (53.4 vs. 33.4 micrograms-min/ml)], increased significantly in SHRs at 16 weeks of age, compared with their control rats.","Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010632/),[μgrams-min] / [ml],29.3,213209,DB00997,Doxorubicin
,9010632,area under the plasma concentration-time curve from time 0 to last measured time [AUCT,"Mean plasma concentrations of both M2 and M4, and the resultant area under the plasma concentration-time curve from time 0 to last measured time [AUCT; M2 (68.9 vs. 29.3 micrograms-min/ml) and M4 (53.4 vs. 33.4 micrograms-min/ml)], increased significantly in SHRs at 16 weeks of age, compared with their control rats.","Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010632/),[μgrams-min] / [ml],53.4,213210,DB00997,Doxorubicin
,9010632,area under the plasma concentration-time curve from time 0 to last measured time [AUCT,"Mean plasma concentrations of both M2 and M4, and the resultant area under the plasma concentration-time curve from time 0 to last measured time [AUCT; M2 (68.9 vs. 29.3 micrograms-min/ml) and M4 (53.4 vs. 33.4 micrograms-min/ml)], increased significantly in SHRs at 16 weeks of age, compared with their control rats.","Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010632/),[μgrams-min] / [ml],33.4,213211,DB00997,Doxorubicin
,21544726,50% inhibition concentration (IC(50)),Quercetin inhibited CYP3A4 enzyme activity in a concentration-dependent manner with a 50% inhibition concentration (IC(50)) of 1.97 μM.,Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21544726/),μM,1.97,213383,DB00997,Doxorubicin
,16736150,Response rate,"Response rate in 23 patients was 4% (95% CI: 0-24%), and in 8 of 11 patients stable disease lasted > 6 months.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,4,214233,DB00997,Doxorubicin
,16736150,Progression-free rate (PFR),"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,48,214234,DB00997,Doxorubicin
,16736150,Progression-free rate (PFR),"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),%,28,214235,DB00997,Doxorubicin
,16736150,overall survival,"Progression-free rate (PFR) at 3 and 6 months was, respectively, 48 and 28%, and median overall survival 37 weeks.",Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736150/),weeks,37,214236,DB00997,Doxorubicin
,2225316,terminal half-life,The terminal half-life from 24 to 72 h was not significantly changed by the partial hepatectomy.,The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225316/),h,24 to 72,214763,DB00997,Doxorubicin
,2225316,fraction of unbound Epi-A,The fraction of unbound Epi-A was 0.16 in partially hepatectomized animals and 0.20 in sham-operated rats.,The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225316/),,0.16,214764,DB00997,Doxorubicin
,2225316,fraction of unbound Epi-A,The fraction of unbound Epi-A was 0.16 in partially hepatectomized animals and 0.20 in sham-operated rats.,The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225316/),,0.20,214765,DB00997,Doxorubicin
,8246031,steady-state plasma concentration,"The steady-state plasma concentration of progesterone at a dose level of 4 g was 4.1 +/- 0.9 mumol/L, which was higher than the minimal concentration required to reverse multidrug resistance (MDR) in vitro.",Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8246031/),[μM] / [l],4.1,215185,DB00997,Doxorubicin
,31728628,progression-free survival (PFS),"Median progression-free survival (PFS) and overall survival (OS) was of 3.6 (1.5-8.1) and 7.5 (1.7-26.7) months, respectively.",Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31728628/),month,3.6,215610,DB00997,Doxorubicin
,31728628,overall survival (OS),"Median progression-free survival (PFS) and overall survival (OS) was of 3.6 (1.5-8.1) and 7.5 (1.7-26.7) months, respectively.",Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31728628/),month,7.5,215611,DB00997,Doxorubicin
,19267770,Vd,"For example, Vd was almost five times larger when using saam ii compared with p-pharm (9.6 L/kg vs. 2.0 L/kg, respectively), whereas t((1/2)beta) was about 30 times larger in the latter (7.7 h vs. 206.9 h, respectively).",Discrepancies in pharmacokinetic analysis results obtained by using two standard population pharmacokinetics software programs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19267770/),[l] / [kg],9.6,215852,DB00997,Doxorubicin
,19267770,Vd,"For example, Vd was almost five times larger when using saam ii compared with p-pharm (9.6 L/kg vs. 2.0 L/kg, respectively), whereas t((1/2)beta) was about 30 times larger in the latter (7.7 h vs. 206.9 h, respectively).",Discrepancies in pharmacokinetic analysis results obtained by using two standard population pharmacokinetics software programs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19267770/),[l] / [kg],2.0,215853,DB00997,Doxorubicin
,19267770,t((1/2)beta),"For example, Vd was almost five times larger when using saam ii compared with p-pharm (9.6 L/kg vs. 2.0 L/kg, respectively), whereas t((1/2)beta) was about 30 times larger in the latter (7.7 h vs. 206.9 h, respectively).",Discrepancies in pharmacokinetic analysis results obtained by using two standard population pharmacokinetics software programs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19267770/),h,7.7,215854,DB00997,Doxorubicin
,19267770,t((1/2)beta),"For example, Vd was almost five times larger when using saam ii compared with p-pharm (9.6 L/kg vs. 2.0 L/kg, respectively), whereas t((1/2)beta) was about 30 times larger in the latter (7.7 h vs. 206.9 h, respectively).",Discrepancies in pharmacokinetic analysis results obtained by using two standard population pharmacokinetics software programs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19267770/),h,206.9,215855,DB00997,Doxorubicin
,26045308,K1,"Delivery of (18)F-C-SNAT to the tumor tissue, quantified as K1, increased from 0.31 g⋅(mL⋅min)(-1) in untreated mice to 1.03 g⋅(mL⋅min)(-1) in treated mice, a measurement closely related to changes in blood flow.",Preclinical Kinetic Analysis of the Caspase-3/7 PET Tracer 18F-C-SNAT: Quantifying the Changes in Blood Flow and Tumor Retention After Chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26045308/),[g] / [min·ml],0.31,216696,DB00997,Doxorubicin
,26045308,K1,"Delivery of (18)F-C-SNAT to the tumor tissue, quantified as K1, increased from 0.31 g⋅(mL⋅min)(-1) in untreated mice to 1.03 g⋅(mL⋅min)(-1) in treated mice, a measurement closely related to changes in blood flow.",Preclinical Kinetic Analysis of the Caspase-3/7 PET Tracer 18F-C-SNAT: Quantifying the Changes in Blood Flow and Tumor Retention After Chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26045308/),[g] / [min·ml],1.03,216697,DB00997,Doxorubicin
,26045308,k3,"Accumulation of (18)F-C-SNAT, quantified as k3, increased from 0.03 to 0.12 min(-1), proving a higher retention of (18)F-C-SNAT in treated tumors independent from changes in blood flow.",Preclinical Kinetic Analysis of the Caspase-3/7 PET Tracer 18F-C-SNAT: Quantifying the Changes in Blood Flow and Tumor Retention After Chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26045308/),1/[min],0.03,216698,DB00997,Doxorubicin
,26045308,k3,"Accumulation of (18)F-C-SNAT, quantified as k3, increased from 0.03 to 0.12 min(-1), proving a higher retention of (18)F-C-SNAT in treated tumors independent from changes in blood flow.",Preclinical Kinetic Analysis of the Caspase-3/7 PET Tracer 18F-C-SNAT: Quantifying the Changes in Blood Flow and Tumor Retention After Chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26045308/),1/[min],0.12,216699,DB00997,Doxorubicin
,28552692,polydispersity index,"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),,0.183,216930,DB00997,Doxorubicin
,28552692,polydispersity index,"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),,0.225,216931,DB00997,Doxorubicin
,28552692,zeta potential,"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),mv,-,216932,DB00997,Doxorubicin
,28552692,zeta potential,"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),mv,26.8,216933,DB00997,Doxorubicin
,28552692,zeta potential,"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),mv,23.3,216934,DB00997,Doxorubicin
,28552692,percentage entrapment efficiency (% EE),"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),%,92.3,216935,DB00997,Doxorubicin
,28552692,percentage entrapment efficiency (% EE),"Formulations optimized using statistical hybrid-design approach exhibited particle size of 152.0 ± 1.78 and 248.8 ± 1.83 nm, polydispersity index of 0.183 ± 0.021 and 0.225 ± 0.018 with zeta potential of -26.8 ± 0.76 and -23.3 ± 0.22 mV and percentage entrapment efficiency (% EE) of 92.3 ± 4.99% and 94.7 ± 5.67%, for GCBMs and PCBMs, respectively.",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),%,94.7,216936,DB00997,Doxorubicin
,28552692,AUC0→∞,"The comparative bioavailability profiles of UDC from GCBMs and PCBMs (AUC0→∞ = 19,546.8 ± 512.88 ng·h/L for GCBMs and 27,961.99 ± 602.46 ng·h/L for PCBMs) were approximately 6.5- and 7.0-fold higher than that of UDC suspension (AUC0→∞ = 3132.806 ± 405.44 ng·h/L).",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),[h·ng] / [l],"19,546.8",216937,DB00997,Doxorubicin
,28552692,AUC0→∞,"The comparative bioavailability profiles of UDC from GCBMs and PCBMs (AUC0→∞ = 19,546.8 ± 512.88 ng·h/L for GCBMs and 27,961.99 ± 602.46 ng·h/L for PCBMs) were approximately 6.5- and 7.0-fold higher than that of UDC suspension (AUC0→∞ = 3132.806 ± 405.44 ng·h/L).",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),[h·ng] / [l],"27,961.99",216938,DB00997,Doxorubicin
,28552692,AUC0→∞,"The comparative bioavailability profiles of UDC from GCBMs and PCBMs (AUC0→∞ = 19,546.8 ± 512.88 ng·h/L for GCBMs and 27,961.99 ± 602.46 ng·h/L for PCBMs) were approximately 6.5- and 7.0-fold higher than that of UDC suspension (AUC0→∞ = 3132.806 ± 405.44 ng·h/L).",A Combinatorial Statistical Design Approach to Optimize the Nanostructured Cubosomal Carrier System for Oral Delivery of Ubidecarenone for Management of Doxorubicin-Induced Cardiotoxicity: In Vitro-In Vivo Investigations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552692/),[h·ng] / [l],3132.806,216939,DB00997,Doxorubicin
,9295863,plasma concentration peak,Mean doxorubicin plasma concentration peak was 42.6 ng/ml (standard deviation (SD): 13.3).,[Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9295863/),[ng] / [ml],42.6,217831,DB00997,Doxorubicin
,9295863,terminal half-lives,"The mean terminal half-lives were 32.6 h (SD: 22.0) and 39.2 h (SD: 21.6) for doxorubicin and doxorubicinol, respectively.",[Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9295863/),h,32.6,217832,DB00997,Doxorubicin
,9295863,terminal half-lives,"The mean terminal half-lives were 32.6 h (SD: 22.0) and 39.2 h (SD: 21.6) for doxorubicin and doxorubicinol, respectively.",[Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9295863/),h,39.2,217833,DB00997,Doxorubicin
,9295863,areas under the plasma concentration-time curve (AUC),"Mean areas under the plasma concentration-time curve (AUC) were 413 ng/h-1 ml (SD: 103) and 1,707 ng/h-1 ml (SD: 815) for doxorubicin and doxorubicinol respectively.",[Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9295863/),[ng] / [h],413,217834,DB00997,Doxorubicin
,9295863,areas under the plasma concentration-time curve (AUC),"Mean areas under the plasma concentration-time curve (AUC) were 413 ng/h-1 ml (SD: 103) and 1,707 ng/h-1 ml (SD: 815) for doxorubicin and doxorubicinol respectively.",[Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9295863/),[ng] / [h],"1,707",217835,DB00997,Doxorubicin
,9295863,ratio of the AUC,"Consequently, the ratio of the AUC of doxorubicinol to that of doxorubicin was high (mean: 4.1 (SD: 1.6)) contrasting with previous studies reporting ratios less than 1 in patients with normal liver function.",[Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9295863/),,4.1,217836,DB00997,Doxorubicin
less,9295863,ratios,"Consequently, the ratio of the AUC of doxorubicinol to that of doxorubicin was high (mean: 4.1 (SD: 1.6)) contrasting with previous studies reporting ratios less than 1 in patients with normal liver function.",[Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9295863/),,1,217837,DB00997,Doxorubicin
,9295863,systemic clearance,The systemic clearance of doxorubicin was 5.23 l/min/m2 (SD: 1.91).,[Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9295863/),[l] / [m2·min],5.23,217838,DB00997,Doxorubicin
,32110010,polydispersity index (PDI),"Each Lq-SE droplet had a mean particle size of 221.7 ± 5.80 nm, a polydispersity index (PDI) of 0.106 ± 0.068 and a zeta potential of -28.23 ± 0.42 mV.","Liquiritigenin-Loaded Submicron Emulsion Protects Against Doxorubicin-Induced Cardiotoxicity via Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110010/),,0.106,217915,DB00997,Doxorubicin
,32110010,zeta potential,"Each Lq-SE droplet had a mean particle size of 221.7 ± 5.80 nm, a polydispersity index (PDI) of 0.106 ± 0.068 and a zeta potential of -28.23 ± 0.42 mV.","Liquiritigenin-Loaded Submicron Emulsion Protects Against Doxorubicin-Induced Cardiotoxicity via Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32110010/),mv,-28.23,217916,DB00997,Doxorubicin
,8408728,apparent volume of distribution of the central compartment (Vc,"A significant decrease in the apparent volume of distribution of the central compartment (Vc = 16.6 versus 10.4 L/m2; P < .05), and a nonsignificant decrease in clearance (CL = 748 versus 658 mL/min/m2) was observed on the second course of therapy.",The disposition of doxorubicin on repeated dosing. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408728/),[l] / [m2],16.6,218264,DB00997,Doxorubicin
,8408728,apparent volume of distribution of the central compartment (Vc,"A significant decrease in the apparent volume of distribution of the central compartment (Vc = 16.6 versus 10.4 L/m2; P < .05), and a nonsignificant decrease in clearance (CL = 748 versus 658 mL/min/m2) was observed on the second course of therapy.",The disposition of doxorubicin on repeated dosing. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408728/),[l] / [m2],10.4,218265,DB00997,Doxorubicin
,8408728,clearance (CL,"A significant decrease in the apparent volume of distribution of the central compartment (Vc = 16.6 versus 10.4 L/m2; P < .05), and a nonsignificant decrease in clearance (CL = 748 versus 658 mL/min/m2) was observed on the second course of therapy.",The disposition of doxorubicin on repeated dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408728/),[ml] / [m2·min],748,218266,DB00997,Doxorubicin
,8408728,clearance (CL,"A significant decrease in the apparent volume of distribution of the central compartment (Vc = 16.6 versus 10.4 L/m2; P < .05), and a nonsignificant decrease in clearance (CL = 748 versus 658 mL/min/m2) was observed on the second course of therapy.",The disposition of doxorubicin on repeated dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408728/),[ml] / [m2·min],658,218267,DB00997,Doxorubicin
,6329539,total renal excretion,The total renal excretion of anthracyclines during the experiment was calculated to approximately 6% of the administered dose.,Pharmacokinetics of doxorubicin and its metabolite doxorubicinol in rabbits with induced acid and alkaline urine. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6329539/),%,6,218830,DB00997,Doxorubicin
,8874332,plasma,The mean end-of-infusion plasma doxorubicin concentrations (Cmax) were 70% higher in the paclitaxel-doxorubicin sequence compared with the reverse sequence (45 +/- 8 ng/mL v 26 +/- 5 ng/ mL).,Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),[ng] / [ml],45,218976,DB00997,Doxorubicin
,8874332,concentrations (Cmax),The mean end-of-infusion plasma doxorubicin concentrations (Cmax) were 70% higher in the paclitaxel-doxorubicin sequence compared with the reverse sequence (45 +/- 8 ng/mL v 26 +/- 5 ng/ mL).,Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),[ng] / [ml],45,218977,DB00997,Doxorubicin
,8874332,concentrations (Cmax),The mean end-of-infusion plasma doxorubicin concentrations (Cmax) were 70% higher in the paclitaxel-doxorubicin sequence compared with the reverse sequence (45 +/- 8 ng/mL v 26 +/- 5 ng/ mL).,Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),[ng] / [ml],26,218978,DB00997,Doxorubicin
,8874332,clearance,"The mean doxorubicin clearance was 32% lower in the paclitaxel-doxorubicin sequence (34.3 +/- 10.3 L/h v 51.6 +/- 16.1 L/h, P < .01).",Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),[l] / [h],34.3,218979,DB00997,Doxorubicin
,8874332,clearance,"The mean doxorubicin clearance was 32% lower in the paclitaxel-doxorubicin sequence (34.3 +/- 10.3 L/h v 51.6 +/- 16.1 L/h, P < .01).",Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),[l] / [h],51.6,218980,DB00997,Doxorubicin
,8874332,absolute granulocyte count,The median absolute granulocyte count was 0.2/microL in the paclitaxel-doxorubicin sequence and 1.3/microL in the doxorubicin-paclitaxel sequence.,Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),1/[μl],0.2,218981,DB00997,Doxorubicin
,8874332,absolute granulocyte count,The median absolute granulocyte count was 0.2/microL in the paclitaxel-doxorubicin sequence and 1.3/microL in the doxorubicin-paclitaxel sequence.,Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8874332/),1/[μl],1.3,218982,DB00997,Doxorubicin
,6342772,plasma clearance,"A high plasma clearance (0.9-1.41/min), a terminal half-life of about 30-40 hr and a large volume of distribution were the main pharmacokinetic characteristics of 4'-epi-DX.","4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342772/),1/[min],0.9-1.41,219247,DB00997,Doxorubicin
,6342772,terminal half-life,"A high plasma clearance (0.9-1.41/min), a terminal half-life of about 30-40 hr and a large volume of distribution were the main pharmacokinetic characteristics of 4'-epi-DX.","4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342772/),h,30-40,219248,DB00997,Doxorubicin
,8070004,maximal tolerated dose (MTD),"In an earlier phase I study, we reported that the maximal tolerated dose (MTD) of prochlorperazine (PCZ) given as a 15-min i.v. infusion was 75 mg/m2.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),mg,75,219578,DB00997,Doxorubicin
,8070004,peak plasma PCZ concentration,The highest peak plasma PCZ concentration achieved was 1100 ng/ml.,Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[ng] / [ml],1100,219579,DB00997,Doxorubicin
,8070004,MTD,The MTD of PCZ was 180 mg/m2.,Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[mg] / [m2],180,219580,DB00997,Doxorubicin
,8070004,peak PCZ plasma levels,"Large interpatient variation in peak PCZ plasma levels (91-3215 ng/ml) was seen, with the plasma half-life (t1/2 alpha) being approximately 57 min in patients given 135-180 mg/m2 PCZ.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[ng] / [ml],91-3215,219581,DB00997,Doxorubicin
,8070004,plasma half-life (t1/2 alpha),"Large interpatient variation in peak PCZ plasma levels (91-3215 ng/ml) was seen, with the plasma half-life (t1/2 alpha) being approximately 57 min in patients given 135-180 mg/m2 PCZ.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),min,57,219582,DB00997,Doxorubicin
,8070004,volume of distribution (Vd),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) were 350.1 +/- 183.8 1/m2, 260.7 +/- 142.7 l m2 h-1 and 1539 +/- 922 ng ml h-1, respectively, in patients given 180 mg/m2 PCZ and the respective values for patients receiving 135 mg/m2 were 48.9 +/- 23.76 l/m2, 33.2 +/- 2.62 l m2 h-1, and 4117 +/- 302 ng ml h-1.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[1] / [m2],350.1,219583,DB00997,Doxorubicin
,8070004,total clearance (ClT),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) were 350.1 +/- 183.8 1/m2, 260.7 +/- 142.7 l m2 h-1 and 1539 +/- 922 ng ml h-1, respectively, in patients given 180 mg/m2 PCZ and the respective values for patients receiving 135 mg/m2 were 48.9 +/- 23.76 l/m2, 33.2 +/- 2.62 l m2 h-1, and 4117 +/- 302 ng ml h-1.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[l·m2] / [h],260.7,219584,DB00997,Doxorubicin
,8070004,total clearance (ClT),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) were 350.1 +/- 183.8 1/m2, 260.7 +/- 142.7 l m2 h-1 and 1539 +/- 922 ng ml h-1, respectively, in patients given 180 mg/m2 PCZ and the respective values for patients receiving 135 mg/m2 were 48.9 +/- 23.76 l/m2, 33.2 +/- 2.62 l m2 h-1, and 4117 +/- 302 ng ml h-1.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[l] / [m2],48.9,219585,DB00997,Doxorubicin
,8070004,total clearance (ClT),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) were 350.1 +/- 183.8 1/m2, 260.7 +/- 142.7 l m2 h-1 and 1539 +/- 922 ng ml h-1, respectively, in patients given 180 mg/m2 PCZ and the respective values for patients receiving 135 mg/m2 were 48.9 +/- 23.76 l/m2, 33.2 +/- 2.62 l m2 h-1, and 4117 +/- 302 ng ml h-1.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[l·m2] / [h],33.2,219586,DB00997,Doxorubicin
,8070004,area under the curve (AUC),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) were 350.1 +/- 183.8 1/m2, 260.7 +/- 142.7 l m2 h-1 and 1539 +/- 922 ng ml h-1, respectively, in patients given 180 mg/m2 PCZ and the respective values for patients receiving 135 mg/m2 were 48.9 +/- 23.76 l/m2, 33.2 +/- 2.62 l m2 h-1, and 4117 +/- 302 ng ml h-1.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[ml·ng] / [h],1539,219587,DB00997,Doxorubicin
,8070004,area under the curve (AUC),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) were 350.1 +/- 183.8 1/m2, 260.7 +/- 142.7 l m2 h-1 and 1539 +/- 922 ng ml h-1, respectively, in patients given 180 mg/m2 PCZ and the respective values for patients receiving 135 mg/m2 were 48.9 +/- 23.76 l/m2, 33.2 +/- 2.62 l m2 h-1, and 4117 +/- 302 ng ml h-1.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[l] / [m2],48.9,219588,DB00997,Doxorubicin
,8070004,area under the curve (AUC),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) were 350.1 +/- 183.8 1/m2, 260.7 +/- 142.7 l m2 h-1 and 1539 +/- 922 ng ml h-1, respectively, in patients given 180 mg/m2 PCZ and the respective values for patients receiving 135 mg/m2 were 48.9 +/- 23.76 l/m2, 33.2 +/- 2.62 l m2 h-1, and 4117 +/- 302 ng ml h-1.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[l·m2] / [h],33.2,219589,DB00997,Doxorubicin
,8070004,area under the curve (AUC),"The volume of distribution (Vd), total clearance (ClT), and area under the curve (AUC) were 350.1 +/- 183.8 1/m2, 260.7 +/- 142.7 l m2 h-1 and 1539 +/- 922 ng ml h-1, respectively, in patients given 180 mg/m2 PCZ and the respective values for patients receiving 135 mg/m2 were 48.9 +/- 23.76 l/m2, 33.2 +/- 2.62 l m2 h-1, and 4117 +/- 302 ng ml h-1.",Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070004/),[ml·ng] / [h],4117,219590,DB00997,Doxorubicin
,20831683,elimination T(1/2),"The pharmacokinetics of PLD was best described by a one-compartment linear structural model with a long elimination T(1/2) (64 h), a slow clearance (0·025 L/h/m2) and a small volume of distribution (2·310 L/m2).",Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831683/),h,64,219653,DB00997,Doxorubicin
,20831683,clearance,"The pharmacokinetics of PLD was best described by a one-compartment linear structural model with a long elimination T(1/2) (64 h), a slow clearance (0·025 L/h/m2) and a small volume of distribution (2·310 L/m2).",Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831683/),[l] / [h·m2],0·025,219654,DB00997,Doxorubicin
,20831683,volume of distribution,"The pharmacokinetics of PLD was best described by a one-compartment linear structural model with a long elimination T(1/2) (64 h), a slow clearance (0·025 L/h/m2) and a small volume of distribution (2·310 L/m2).",Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831683/),[l] / [m2],2·310,219655,DB00997,Doxorubicin
,1375115,peak concentrations,"After SC injection, absorption was prolonged, with peak concentrations of G-CSF (3 to 117 ng/mL) being reached after 4 to 12 hours.",Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1375115/),[ng] / [ml],3 to 117,219768,DB00997,Doxorubicin
,1375115,elimination half-life,"The relatively slow absorption, with a mean elimination half-life of 5.8 hours on day 1 and 4.5 hours on day 10, provided measurable G-CSF concentrations for the entire 24-hour dosing interval in all patients at each dosage level.",Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1375115/),h,5.8,219769,DB00997,Doxorubicin
,1375115,elimination half-life,"The relatively slow absorption, with a mean elimination half-life of 5.8 hours on day 1 and 4.5 hours on day 10, provided measurable G-CSF concentrations for the entire 24-hour dosing interval in all patients at each dosage level.",Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1375115/),h,4.5,219770,DB00997,Doxorubicin
,1375115,apparent clearance,"The median apparent clearance of G-CSF on day 10 was significantly higher than on day 1 (0.57 v 0.31 mL/min/kg, P = .02), and was positively correlated with the absolute neutrophil count (ANC) (r2 = .33, P = .003).",Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1375115/),[ml] / [kg·min],0.57,219771,DB00997,Doxorubicin
,1375115,apparent clearance,"The median apparent clearance of G-CSF on day 10 was significantly higher than on day 1 (0.57 v 0.31 mL/min/kg, P = .02), and was positively correlated with the absolute neutrophil count (ANC) (r2 = .33, P = .003).",Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1375115/),[ml] / [kg·min],0.31,219772,DB00997,Doxorubicin
,2724094,plateau levels,The AmB plateau levels assayed by HPLC ranged from 0.7 to 1.9 micrograms/mL and were directly related to the infusion rate.,Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724094/),[μg] / [ml],0.7 to 1.9,220416,DB00997,Doxorubicin
,2724094,half-lives,"The AmB plasma disposition was biphasic, with mean half-lives of 17 h for the first phase and 11 d for the terminal phase, and a mean residence time of 12 d.",Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724094/),h,17,220417,DB00997,Doxorubicin
,2724094,half-lives,"The AmB plasma disposition was biphasic, with mean half-lives of 17 h for the first phase and 11 d for the terminal phase, and a mean residence time of 12 d.",Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724094/),d,11,220418,DB00997,Doxorubicin
,2724094,mean residence time,"The AmB plasma disposition was biphasic, with mean half-lives of 17 h for the first phase and 11 d for the terminal phase, and a mean residence time of 12 d.",Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2724094/),d,12,220419,DB00997,Doxorubicin
,15322827,Total body clearance,Total body clearance for total doxorubicin was 5.6 l/h/m2 while the volume (Vss) was 82 l/m2.,"Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15322827/),[l] / [h·m2],5.6,220977,DB00997,Doxorubicin
,15322827,volume (Vss),Total body clearance for total doxorubicin was 5.6 l/h/m2 while the volume (Vss) was 82 l/m2.,"Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15322827/),[l] / [m2],82,220978,DB00997,Doxorubicin
,15322827,terminal half-life,The terminal half-life was 52.6 h.,"Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15322827/),h,52.6,220979,DB00997,Doxorubicin
,15322827,AUC,Doxorubicinol was detected in all patients; the mean AUC was 2.03+/-1.10 micromol/l/h.,"Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15322827/),[μM] / [h·l],2.03,220980,DB00997,Doxorubicin
,28902176,area under the curve (AUC),DoxQ intact IV showed a 5-fold increase in the area under the curve (AUC)-18.6 ± 1.98 compared to 3.97 ± 0.71 μg * h/mL after Dox-and a significant reduction in the volume of distribution (Vss): 0.138 ± 0.015 versus 6.35 ± 1.06 L/kg.,Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902176/),[h·μg] / [ml],18.6,221063,DB00997,Doxorubicin
,28902176,area under the curve (AUC),DoxQ intact IV showed a 5-fold increase in the area under the curve (AUC)-18.6 ± 1.98 compared to 3.97 ± 0.71 μg * h/mL after Dox-and a significant reduction in the volume of distribution (Vss): 0.138 ± 0.015 versus 6.35 ± 1.06 L/kg.,Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902176/),[h·μg] / [ml],3.97,221064,DB00997,Doxorubicin
,28902176,volume of distribution (Vss),DoxQ intact IV showed a 5-fold increase in the area under the curve (AUC)-18.6 ± 1.98 compared to 3.97 ± 0.71 μg * h/mL after Dox-and a significant reduction in the volume of distribution (Vss): 0.138 ± 0.015 versus 6.35 ± 1.06 L/kg.,Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902176/),[l] / [kg],0.138,221065,DB00997,Doxorubicin
,28902176,volume of distribution (Vss),DoxQ intact IV showed a 5-fold increase in the area under the curve (AUC)-18.6 ± 1.98 compared to 3.97 ± 0.71 μg * h/mL after Dox-and a significant reduction in the volume of distribution (Vss): 0.138 ± 0.015 versus 6.35 ± 1.06 L/kg.,Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902176/),[l] / [kg],6.35,221066,DB00997,Doxorubicin
,28902176,fraction excreted unchanged in urine (fe),"The fraction excreted unchanged in urine (fe) of IV DoxQ and Dox was ~5% and ~11%, respectively.",Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902176/),%,5,221067,DB00997,Doxorubicin
,28902176,fraction excreted unchanged in urine (fe),"The fraction excreted unchanged in urine (fe) of IV DoxQ and Dox was ~5% and ~11%, respectively.",Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902176/),%,11,221068,DB00997,Doxorubicin
,6819097,clearance,"There was a significant decrease in plasma adriamycin clearance, from 125 to 48 ml/min/kg, and a significant decrease in the apparent volume of the peripheral compartment of adriamycin distribution, from 51.7 to 25.6 l/kg, in cyclophosphamide-pretreated as against control rats.",Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6819097/),[ml] / [kg·min],125 to 48,221415,DB00997,Doxorubicin
,6819097,apparent volume of the peripheral compartment of ad,"There was a significant decrease in plasma adriamycin clearance, from 125 to 48 ml/min/kg, and a significant decrease in the apparent volume of the peripheral compartment of adriamycin distribution, from 51.7 to 25.6 l/kg, in cyclophosphamide-pretreated as against control rats.",Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6819097/),[l] / [kg],51.,221416,DB00997,Doxorubicin
,6819097,apparent volume of the peripheral compartment of ad,"There was a significant decrease in plasma adriamycin clearance, from 125 to 48 ml/min/kg, and a significant decrease in the apparent volume of the peripheral compartment of adriamycin distribution, from 51.7 to 25.6 l/kg, in cyclophosphamide-pretreated as against control rats.",Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6819097/),[l] / [kg],25.6,221417,DB00997,Doxorubicin
,7516606,peak concentrations,The peak concentrations were (0.558 micrograms/ml for AD-CM-DMS and 1.013 micrograms/ml for ADM solution.,[Studies on pharmacologic disposition of adriamycin in dog after hepatic arterial embolization with adriamycin carboxymethyl-dextran-microspheres]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7516606/),[μg] / [ml],0.558,221542,DB00997,Doxorubicin
,7516606,peak concentrations,The peak concentrations were (0.558 micrograms/ml for AD-CM-DMS and 1.013 micrograms/ml for ADM solution.,[Studies on pharmacologic disposition of adriamycin in dog after hepatic arterial embolization with adriamycin carboxymethyl-dextran-microspheres]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7516606/),[μg] / [ml],1.013,221543,DB00997,Doxorubicin
,2742972,blood flow,"For typical values of tumor blood flow (4-20 ml/min/100 gr) and size (1,000 gm), it is estimated that with intravenous injection of Adriamycin the tumor is exposed to only 4-19% of the injected drug.",An analytical model for intra-arterial versus intravenous infusion of Adriamycin. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2742972/),[ml] / [100·gr·min],4-20,222498,DB00997,Doxorubicin
,3971478,Areas under the curve,Areas under the curve for doxorubicin by HPLC (3.36 +/- 2.30 microM X h) and TLC (4.16 +/- 2.50 microM X h) were not significantly different (P = 0.5).,Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971478/),h·μM,3.36,222660,DB00997,Doxorubicin
,3971478,Areas under the curve,Areas under the curve for doxorubicin by HPLC (3.36 +/- 2.30 microM X h) and TLC (4.16 +/- 2.50 microM X h) were not significantly different (P = 0.5).,Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971478/),h·μM,4.16,222661,DB00997,Doxorubicin
,3971478,Terminal half-life,Terminal half-life of doxorubicin by HPLC (28.0 +/- 6.98 h) and TLC (23.2 +/- 7.8) (P = 0.29) and the calculated total-body clearances by HPLC (0.55 +/- 0.29 l/min) and TLC (0.45 +/- 0.23) (P = 0.55) were not significantly different.,Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971478/),h,28.0,222662,DB00997,Doxorubicin
,3971478,Terminal half-life,Terminal half-life of doxorubicin by HPLC (28.0 +/- 6.98 h) and TLC (23.2 +/- 7.8) (P = 0.29) and the calculated total-body clearances by HPLC (0.55 +/- 0.29 l/min) and TLC (0.45 +/- 0.23) (P = 0.55) were not significantly different.,Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971478/),,23.2,222663,DB00997,Doxorubicin
,3971478,total-body clearances,Terminal half-life of doxorubicin by HPLC (28.0 +/- 6.98 h) and TLC (23.2 +/- 7.8) (P = 0.29) and the calculated total-body clearances by HPLC (0.55 +/- 0.29 l/min) and TLC (0.45 +/- 0.23) (P = 0.55) were not significantly different.,Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971478/),[l] / [min],0.55,222664,DB00997,Doxorubicin
,3971478,total-body clearances,Terminal half-life of doxorubicin by HPLC (28.0 +/- 6.98 h) and TLC (23.2 +/- 7.8) (P = 0.29) and the calculated total-body clearances by HPLC (0.55 +/- 0.29 l/min) and TLC (0.45 +/- 0.23) (P = 0.55) were not significantly different.,Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971478/),,0.45,222665,DB00997,Doxorubicin
,3971478,Areas under the curve,Areas under the curve for doxorubicinol by HPLC (2.75 +/- 1.4 microM X h) and TLC (2.53 +/- 7.1 microM X h) (P = 0.73) showed no significant differences.,Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971478/),h·μM,2.75,222666,DB00997,Doxorubicin
,3971478,Areas under the curve,Areas under the curve for doxorubicinol by HPLC (2.75 +/- 1.4 microM X h) and TLC (2.53 +/- 7.1 microM X h) (P = 0.73) showed no significant differences.,Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971478/),h·μM,2.53,222667,DB00997,Doxorubicin
,11021735,specific activity,"pretreated orally for 10 days with corn oil or tamoxifen in corn oil (1 mg/kg per day), received 14C-doxorubicin (specific activity 0.4 microCi/mg, 10 mg/kg) intravenously.","Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11021735/),[μci] / [mg],0.4,223583,DB00997,Doxorubicin
,25456831,DLC,"Doxorubicin (DOX) could be effectively loaded into PEG5K-Fmoc-VE2 micelles at a DLC of 39.9%, which compares favorably to most reported DOX nanoformulations.",An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25456831/),%,39.9,223643,DB00997,Doxorubicin
,3178926,terminal half-life,The mean disposition of cyclophosphamide conformed to a 2-compartment model with a mean terminal half-life of 7.14 h on the first course and 8.77 h on the second course.,Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3178926/),h,7.14,224186,DB00997,Doxorubicin
,3178926,terminal half-life,The mean disposition of cyclophosphamide conformed to a 2-compartment model with a mean terminal half-life of 7.14 h on the first course and 8.77 h on the second course.,Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3178926/),h,8.77,224187,DB00997,Doxorubicin
,3178926,area under the plasma concentration versus time curve,Mean area under the plasma concentration versus time curve appeared to increase from 248.8 mg.h/l for the initial course to 282.2 mg.h/l on the second.,Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3178926/),[h·mg] / [l],248.8,224188,DB00997,Doxorubicin
,3178926,area under the plasma concentration versus time curve,Mean area under the plasma concentration versus time curve appeared to increase from 248.8 mg.h/l for the initial course to 282.2 mg.h/l on the second.,Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3178926/),[h·mg] / [l],282.2,224189,DB00997,Doxorubicin
,3178926,total body clearance,Mean total body clearance was 2.01 l/h/m2 on the first course and 1.77 l/h/m2 on the second.,Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3178926/),[l] / [h·m2],2.01,224190,DB00997,Doxorubicin
,3178926,total body clearance,Mean total body clearance was 2.01 l/h/m2 on the first course and 1.77 l/h/m2 on the second.,Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3178926/),[l] / [h·m2],1.77,224191,DB00997,Doxorubicin
,3178926,Volume of distribution,"Volume of distribution on the first and second courses were 15.3 l/m2 and 18.1 l/m2, respectively.",Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3178926/),[l] / [m2],15.3,224192,DB00997,Doxorubicin
,3178926,Volume of distribution,"Volume of distribution on the first and second courses were 15.3 l/m2 and 18.1 l/m2, respectively.",Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3178926/),[l] / [m2],18.1,224193,DB00997,Doxorubicin
,33418486,progression-free survival (PFS),The estimated median progression-free survival (PFS) and overall survival (OS) were 5.5 (95% CI:4.1-5.7) and 10.5 (95% CI:7.5-14) months.,"A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418486/),month,5.5,224302,DB00997,Doxorubicin
,33418486,overall survival (OS),The estimated median progression-free survival (PFS) and overall survival (OS) were 5.5 (95% CI:4.1-5.7) and 10.5 (95% CI:7.5-14) months.,"A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS). ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33418486/),month,10.5,224303,DB00997,Doxorubicin
,2298407,total body clearance (TBC),The average total body clearance (TBC) was 16.3 ml/kg/min (range 10.6-20.4 ml/kg/min) and the mean volume of distribution (VD) was 42.4 liter/kg (range 27.6-46.9 liter/kg).,Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298407/),[ml] / [kg·min],16.3,225322,DB00997,Doxorubicin
,2298407,volume of distribution (VD),The average total body clearance (TBC) was 16.3 ml/kg/min (range 10.6-20.4 ml/kg/min) and the mean volume of distribution (VD) was 42.4 liter/kg (range 27.6-46.9 liter/kg).,Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298407/),[l] / [kg],42.4,225323,DB00997,Doxorubicin
,2298407,Half-life of elimination (t 1/2 beta),Half-life of elimination (t 1/2 beta) was 2.6 hr.,Pharmacokinetics of intraperitoneal doxorubicin in combination with systemic cyclophosphamide and cis-platinum in the treatment of stage III ovarian cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298407/),h,2.6,225324,DB00997,Doxorubicin
,27730471,tumor-to-muscle ratio (T/M),"The tumor-to-muscle ratio (T/M) derived from 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT) micro positron emission tomography (PET) images of D1V1- and D1fV1-treated mice and the controls on day 7 was 6.88 ± 0.54, 7.50 ± 0.84, and 9.87 ± 0.73, respectively, suggesting that D1V1 is a more efficacious regimen against CT-26 xenografts.",Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27730471/),,6.88,226135,DB00997,Doxorubicin
,27730471,tumor-to-muscle ratio (T/M),"The tumor-to-muscle ratio (T/M) derived from 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT) micro positron emission tomography (PET) images of D1V1- and D1fV1-treated mice and the controls on day 7 was 6.88 ± 0.54, 7.50 ± 0.84, and 9.87 ± 0.73, respectively, suggesting that D1V1 is a more efficacious regimen against CT-26 xenografts.",Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27730471/),,7.50,226136,DB00997,Doxorubicin
,27730471,tumor-to-muscle ratio (T/M),"The tumor-to-muscle ratio (T/M) derived from 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT) micro positron emission tomography (PET) images of D1V1- and D1fV1-treated mice and the controls on day 7 was 6.88 ± 0.54, 7.50 ± 0.84, and 9.87 ± 0.73, respectively, suggesting that D1V1 is a more efficacious regimen against CT-26 xenografts.",Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27730471/),,9.87,226137,DB00997,Doxorubicin
,23802738,overall response rate,The overall response rate was 96% (69/72) including complete response (CR) in 65 (90%) and unconfirmed CR in 2 (3%).,"Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802738/),%,96,226475,DB00997,Doxorubicin
,25880143,Tmax,The Tmax values of the two NPs were prolonged from 0.25 to 1 h.,Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880143/),h,0.25,226499,DB00997,Doxorubicin
,25880143,Tmax,The Tmax values of the two NPs were prolonged from 0.25 to 1 h.,Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880143/),h,1,226500,DB00997,Doxorubicin
,25880143,MRT,"The AUC0-t values were 1.55- and 3.05-folds higher than that of free DOX, and MRT increased to 15.99 h for DOX/P(HB-HO) NPs and 25.14 h for DOX/FA-PEG-P(HB-HO) NPs.",Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880143/),h,15.99,226501,DB00997,Doxorubicin
,25880143,MRT,"The AUC0-t values were 1.55- and 3.05-folds higher than that of free DOX, and MRT increased to 15.99 h for DOX/P(HB-HO) NPs and 25.14 h for DOX/FA-PEG-P(HB-HO) NPs.",Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880143/),h,25.14,226502,DB00997,Doxorubicin
,15728147,AUC(0-8),"When indinavir was given concomitantly with CHOP, the AUC(0-8) increased by 38% (20.5 +/- 9.0 versus 14.9 +/- 9.5 mg.h/L; P=0.03), and was comparable to historical controls.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[h·mg] / [l],20.5,227142,DB00997,Doxorubicin
,15728147,AUC(0-8),"When indinavir was given concomitantly with CHOP, the AUC(0-8) increased by 38% (20.5 +/- 9.0 versus 14.9 +/- 9.5 mg.h/L; P=0.03), and was comparable to historical controls.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[h·mg] / [l],14.9,227143,DB00997,Doxorubicin
,15728147,IC(50),"Likewise, we observed a significant number of patients with C(0) and C(8) below the IC(50) for the wild-type virus (0.1 mg/L) when the drug was administered without CHOP.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[mg] / [l],0.1,227144,DB00997,Doxorubicin
,18521419,Progression-free rate,"Progression-free rate at 3 and 6 months was, respectively, 48 and 22%, median progression-free survival 5.8 months and median overall survival 8.7 months.",Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521419/),%,48,227235,DB00997,Doxorubicin
,18521419,Progression-free rate,"Progression-free rate at 3 and 6 months was, respectively, 48 and 22%, median progression-free survival 5.8 months and median overall survival 8.7 months.",Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521419/),%,22,227236,DB00997,Doxorubicin
,18521419,progression-free survival,"Progression-free rate at 3 and 6 months was, respectively, 48 and 22%, median progression-free survival 5.8 months and median overall survival 8.7 months.",Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521419/),month,5.8,227237,DB00997,Doxorubicin
,18521419,overall survival,"Progression-free rate at 3 and 6 months was, respectively, 48 and 22%, median progression-free survival 5.8 months and median overall survival 8.7 months.",Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18521419/),month,8.7,227238,DB00997,Doxorubicin
,18751444,Overall response rate,"Overall response rate was 30%, with 3% complete responses and 27% partial responses.",Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751444/),%,30,227283,DB00997,Doxorubicin
,18751444,response duration,Median response duration and overall median survival were 5.5 and 10 months respectively.,Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751444/),month,5.5,227284,DB00997,Doxorubicin
,18751444,overall median survival,Median response duration and overall median survival were 5.5 and 10 months respectively.,Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751444/),month,10,227285,DB00997,Doxorubicin
,23954628,l,"The recovery of doxorubicin in the sentinel lymph nodes draining the subcutaneous injection site was also quantified directly, and consistent with the lymph pharmacokinetic data, lymph node recovery was greatest for the dendrimer formulation (12% of dosed doxorubicin/g node) when compared to the liposome (1.4%/g node) and solution (<1%/g node) formulations.",PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23954628/),%,12,227768,DB00997,Doxorubicin
,23954628,l,"The recovery of doxorubicin in the sentinel lymph nodes draining the subcutaneous injection site was also quantified directly, and consistent with the lymph pharmacokinetic data, lymph node recovery was greatest for the dendrimer formulation (12% of dosed doxorubicin/g node) when compared to the liposome (1.4%/g node) and solution (<1%/g node) formulations.",PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23954628/),%,1.4,227769,DB00997,Doxorubicin
,8304970,ID50 concentration,Since the ID50 concentration for Ro11-2933 is 17.7 microM (5-12-fold less than the other modifiers) we have used isobologram analysis to demonstrate that the interaction with doxorubicin is supra-additive and cannot be explained by additive toxicity.,"Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304970/),μM,17.7,228549,DB00997,Doxorubicin
,16549995,total body clearance,"Four children with Down's syndrome (DS), 1.2-2.3 years old, had a median total body clearance of 523 ml/min/m2.",Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16549995/),[ml] / [m2·min],523,228755,DB00997,Doxorubicin
,16549995,clearance,"The median clearance in non-DS children, 0.6-1.8 years old (n = 4) and 2.5-17.7 years old (n = 33), was 446 and 538 ml/min/m2, respectively.",Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16549995/),[ml] / [m2·min],446,228756,DB00997,Doxorubicin
,16549995,clearance,"The median clearance in non-DS children, 0.6-1.8 years old (n = 4) and 2.5-17.7 years old (n = 33), was 446 and 538 ml/min/m2, respectively.",Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16549995/),[ml] / [m2·min],538,228757,DB00997,Doxorubicin
,16549995,plasma concentration,"Patients who went into complete remission (CR) after induction therapy had a significantly higher median plasma concentration of doxorubicin than those who did not, 249 compared with 180 ng/ml, respectively (P = 0.036; analysis restricted to non-DS patients).",Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16549995/),[ng] / [ml],249,228758,DB00997,Doxorubicin
,16549995,plasma concentration,"Patients who went into complete remission (CR) after induction therapy had a significantly higher median plasma concentration of doxorubicin than those who did not, 249 compared with 180 ng/ml, respectively (P = 0.036; analysis restricted to non-DS patients).",Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16549995/),[ng] / [ml],180,228759,DB00997,Doxorubicin
,16549995,clearance,"Patients who reached CR had a significantly lower doxorubicin clearance than those who did not, 513 and 657 ml/min/m2, respectively (P = 0.017).",Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16549995/),[ml] / [m2·min],513,228760,DB00997,Doxorubicin
,16549995,clearance,"Patients who reached CR had a significantly lower doxorubicin clearance than those who did not, 513 and 657 ml/min/m2, respectively (P = 0.017).",Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16549995/),[ml] / [m2·min],657,228761,DB00997,Doxorubicin
,25388939,half-life,"The long mean half-life (20.1-21.1 h), narrow mean volume of distribution (3.96-4.08 L/m(2)), and slow mean clearance rate (0.136-0.152 L/h/m(2)) suggest that aldoxorubicin is stable in circulation and does not accumulate readily in body compartments outside of the bloodstream.",Pharmacokinetic study of aldoxorubicin in patients with solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25388939/),h,20.1-21.1,229358,DB00997,Doxorubicin
,25388939,volume of distribution,"The long mean half-life (20.1-21.1 h), narrow mean volume of distribution (3.96-4.08 L/m(2)), and slow mean clearance rate (0.136-0.152 L/h/m(2)) suggest that aldoxorubicin is stable in circulation and does not accumulate readily in body compartments outside of the bloodstream.",Pharmacokinetic study of aldoxorubicin in patients with solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25388939/),[l] / [m(2],3.96-4.08,229359,DB00997,Doxorubicin
,25388939,clearance rate,"The long mean half-life (20.1-21.1 h), narrow mean volume of distribution (3.96-4.08 L/m(2)), and slow mean clearance rate (0.136-0.152 L/h/m(2)) suggest that aldoxorubicin is stable in circulation and does not accumulate readily in body compartments outside of the bloodstream.",Pharmacokinetic study of aldoxorubicin in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25388939/),[h·l] / [m(2],0.136-0.152,229360,DB00997,Doxorubicin
,3181250,half-lives,"Unchanged pirarubicin followed three similar plasma concentration curves, which could be fitted by a two-compartment model with successive half-lives of 22.0 min and 12.7 h.",Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181250/),min,22.0,229582,DB00997,Doxorubicin
,3181250,half-lives,"Unchanged pirarubicin followed three similar plasma concentration curves, which could be fitted by a two-compartment model with successive half-lives of 22.0 min and 12.7 h.",Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181250/),h,12.7,229583,DB00997,Doxorubicin
,3181250,Total plasma clearance,Total plasma clearance of the drug was 90 l/h/m2 and total volume of distribution 1380 l/m2.,Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181250/),[l] / [h·m2],90,229584,DB00997,Doxorubicin
,3181250,total volume of distribution,Total plasma clearance of the drug was 90 l/h/m2 and total volume of distribution 1380 l/m2.,Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181250/),[l] / [m2],1380,229585,DB00997,Doxorubicin
,2605093,IC50,"In the L1210 leukaemia model following 3 h drug exposure in vitro, the IC50 for AD198 was approximately 0.35 microgram ml-1 for the sensitive and 10-fold DOX resistant cells and 1.0 microgram ml-1 for the 40-fold DOX resistant cells.",N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605093/),[μg] / [ml],0.35,229857,DB00997,Doxorubicin
,2605093,IC50,"In the L1210 leukaemia model following 3 h drug exposure in vitro, the IC50 for AD198 was approximately 0.35 microgram ml-1 for the sensitive and 10-fold DOX resistant cells and 1.0 microgram ml-1 for the 40-fold DOX resistant cells.",N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605093/),[μg] / [ml],1.0,229858,DB00997,Doxorubicin
,8046321,elimination capacity,"Galactose elimination capacity decreased from 2.45 (+/- 0.48) mM min-1 to 2.04 (+/- 0.60) mM min-1 after the five planned courses of chemotherapy (P = 0.013, Wilcoxon signed-rank test), without any change in routine liver function tests.",High-dose methotrexate treatment and liver function in patients with osteosarcoma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8046321/),[mM] / [min],2.45,229939,DB00997,Doxorubicin
,8046321,elimination capacity,"Galactose elimination capacity decreased from 2.45 (+/- 0.48) mM min-1 to 2.04 (+/- 0.60) mM min-1 after the five planned courses of chemotherapy (P = 0.013, Wilcoxon signed-rank test), without any change in routine liver function tests.",High-dose methotrexate treatment and liver function in patients with osteosarcoma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8046321/),[mM] / [min],2.04,229940,DB00997,Doxorubicin
,6859829,LD50,"The LD50 of doxorubicin, prepared at the Institute of New Antibiotics of the Academy of Medical Sciences of the USSR was 4.6, 12.5, 13.5 and 570 mg/kg for single intraperitoneal, intravenous, subcutaneous and oral administrations to albino mice, respectively.","[Toxicity, pharmacokinetics and pharmacodynamics of Soviet-made doxorubicin]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859829/),[mg] / [kg],4.6,230626,DB00997,Doxorubicin
,6859829,LD50,"The LD50 of doxorubicin, prepared at the Institute of New Antibiotics of the Academy of Medical Sciences of the USSR was 4.6, 12.5, 13.5 and 570 mg/kg for single intraperitoneal, intravenous, subcutaneous and oral administrations to albino mice, respectively.","[Toxicity, pharmacokinetics and pharmacodynamics of Soviet-made doxorubicin]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859829/),[mg] / [kg],12.5,230627,DB00997,Doxorubicin
,6859829,LD50,"The LD50 of doxorubicin, prepared at the Institute of New Antibiotics of the Academy of Medical Sciences of the USSR was 4.6, 12.5, 13.5 and 570 mg/kg for single intraperitoneal, intravenous, subcutaneous and oral administrations to albino mice, respectively.","[Toxicity, pharmacokinetics and pharmacodynamics of Soviet-made doxorubicin]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859829/),[mg] / [kg],13.5,230628,DB00997,Doxorubicin
,6859829,LD50,"The LD50 of doxorubicin, prepared at the Institute of New Antibiotics of the Academy of Medical Sciences of the USSR was 4.6, 12.5, 13.5 and 570 mg/kg for single intraperitoneal, intravenous, subcutaneous and oral administrations to albino mice, respectively.","[Toxicity, pharmacokinetics and pharmacodynamics of Soviet-made doxorubicin]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859829/),[mg] / [kg],570,230629,DB00997,Doxorubicin
,25427107,EC50,"Our results suggest that LBM-A5 effectively reverses MDR (EC50 = 483.6 ± 81.7 nmol·L(-1)) by inhibiting the function of P-gp, with relatively ideal pharmacokinetics and in a safe manner, and so may be a promising candidate for cancer chemotherapy research.",Reversal of P-glycoprotein-medicated multidrug resistance by LBM-A5 in vitro and a study of its pharmacokinetics in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427107/),[nM] / [l],483.6,232962,DB00997,Doxorubicin
,8142261,response rate,The response rate was 14% (95% confidence intervals 4-40%); median time to progression was 3.5 months (range 0.7 to > 9.3) and median survival was 10.2 months (range 2.3 to > 20.4).,"Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8142261/),%,14,233567,DB00997,Doxorubicin
,8142261,time to progression,The response rate was 14% (95% confidence intervals 4-40%); median time to progression was 3.5 months (range 0.7 to > 9.3) and median survival was 10.2 months (range 2.3 to > 20.4).,"Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8142261/),month,3.5,233568,DB00997,Doxorubicin
,8142261,survival,The response rate was 14% (95% confidence intervals 4-40%); median time to progression was 3.5 months (range 0.7 to > 9.3) and median survival was 10.2 months (range 2.3 to > 20.4).,"Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8142261/),month,10.2,233569,DB00997,Doxorubicin
,26975227,CL/BSA (Lh-1m-2,"The homozygous variant allele at the ABCC5 g.+7161G>A (rs1533682) locus was significantly associated with higher doxorubicin clearance (g.+7161AA vs g.+7161GG, CL/BSA (Lh-1m-2): 30.34 (25.41-33.60) vs 22.46 (15.04-49.4), P=0.04).","Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26975227/),,30.34,233917,DB00997,Doxorubicin
,26975227,CL/BSA (Lh-1m-2,"The homozygous variant allele at the ABCC5 g.+7161G>A (rs1533682) locus was significantly associated with higher doxorubicin clearance (g.+7161AA vs g.+7161GG, CL/BSA (Lh-1m-2): 30.34 (25.41-33.60) vs 22.46 (15.04-49.4), P=0.04).","Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26975227/),,22.46,233918,DB00997,Doxorubicin
,26975227,AUC0-∞/dose,"Homozygosity for the reference allele at the ABCC5 g.-1679T>A locus was associated with significantly higher doxorubicinol exposure (g.-1679TT vs g.-1679TA, AUC0-∞/dose/BSA (hm-5): 15.48 (6.18-67.17) vs 8.88 (3.68-21.71), P=0.0001).","Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26975227/),1/[(hm)^5],15.48,233919,DB00997,Doxorubicin
,26975227,AUC0-∞/dose,"Homozygosity for the reference allele at the ABCC5 g.-1679T>A locus was associated with significantly higher doxorubicinol exposure (g.-1679TT vs g.-1679TA, AUC0-∞/dose/BSA (hm-5): 15.48 (6.18-67.17) vs 8.88 (3.68-21.71), P=0.0001).","Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26975227/),1/[(hm)^5],8.88,233920,DB00997,Doxorubicin
,2363946,maximum plasma concentrations,Measured maximum plasma concentrations of epirubicin during 2 hours' constant rate infusions of 70 mg m-2 to patients with lymphoma (median age: 46.5 years) were within the range 171-404 ng ml-1 (median value: 265 ng ml-1).,Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363946/),[ng] / [ml],171-404,234537,DB00997,Doxorubicin
,2363946,maximum plasma concentrations,Measured maximum plasma concentrations of epirubicin during 2 hours' constant rate infusions of 70 mg m-2 to patients with lymphoma (median age: 46.5 years) were within the range 171-404 ng ml-1 (median value: 265 ng ml-1).,Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363946/),[ng] / [ml],265,234538,DB00997,Doxorubicin
> or =,14692520,time to absolute neutrophil count (ANC) recovery,"The pharmacokinetics of pegfilgrastim were characterized and the duration of grade 4 neutropenia, time to absolute neutrophil count (ANC) recovery to > or = 2.0 x 10(9)/l, neutrophil nadir, and incidence of febrile neutropenia were determined in the first 21-day chemotherapy cycle.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),,2.0 x 10(9),234938,DB00997,Doxorubicin
,14692520,duration of grade 4 neutropenia,The incidence of grade 4 neutropenia in cycle 1 was 43% with a mean (SD) duration of grade 4 neutropenia value of 1.0 (1.4) day.,Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,1.0,234939,DB00997,Doxorubicin
,14692520,time to ANC recovery,"The median [quartiles] time to ANC recovery was 10 [9, 11] days.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,10,234940,DB00997,Doxorubicin
,14692520,terminal half-life,"After the second peak, concentration of pegfilgrastim declined linearly with a median terminal half-life of approximately 42 h.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),h,42,234941,DB00997,Doxorubicin
,16549998,peak serum MTX,The mean value of peak serum MTX was 801 micromol/l (range 298-1831) with significant intra- and inter-patient variability.,No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16549998/),[μM] / [l],801,235321,DB00997,Doxorubicin
,20801893,plasma half-life,"The plasma half-life of 10074-G5 in mice treated with 20 mg/kg i.v. was 37 min, and peak plasma concentration was 58 μM, which was 10-fold higher than peak tumor concentration.","In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20801893/),min,37,236068,DB00997,Doxorubicin
,20801893,peak plasma concentration,"The plasma half-life of 10074-G5 in mice treated with 20 mg/kg i.v. was 37 min, and peak plasma concentration was 58 μM, which was 10-fold higher than peak tumor concentration.","In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20801893/),μM,58,236069,DB00997,Doxorubicin
,9443628,AUC ratios (AUC peritoneal fluid/AUC blood),AUC ratios (AUC peritoneal fluid/AUC blood) were 87.9 for group NT and 82.9 for group HT.,"Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443628/),,87.9,236346,DB00997,Doxorubicin
,9443628,AUC ratios (AUC peritoneal fluid/AUC blood),AUC ratios (AUC peritoneal fluid/AUC blood) were 87.9 for group NT and 82.9 for group HT.,"Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443628/),,82.9,236347,DB00997,Doxorubicin
,1941503,AUC0-24 ratio,The AUC0-24 ratio of doxorubicin to pirarubicin in plasma was calculated to be 0.441.,Pharmacokinetics of pirarubicin in pediatric patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941503/),,0.441,237709,DB00997,Doxorubicin
,21625179,MTD,The MTD was 300 mg/m².,A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21625179/),[mg] / [m²],300,237867,DB00997,Doxorubicin
,10589787,Peak tumor levels,Peak tumor levels of released dox were 7-fold greater in the responsive MAC15A tumor (53 microg x ml(-1)) compared with the less responsive MAC26 tumor (7.7 microg x ml(-1)) and more than 18-fold greater in MAC15A than when free dox was given.,Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589787/),[μg] / [ml],53,237960,DB00997,Doxorubicin
,10589787,Peak tumor levels,Peak tumor levels of released dox were 7-fold greater in the responsive MAC15A tumor (53 microg x ml(-1)) compared with the less responsive MAC26 tumor (7.7 microg x ml(-1)) and more than 18-fold greater in MAC15A than when free dox was given.,Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589787/),[μg] / [ml],7.7,237961,DB00997,Doxorubicin
,10589787,AUCs,"Calculated AUCs for intratumoral dox released were 431 microg x h x g(-1) and 775 microg x h x g(-1) for MAC15A and MAC26, respectively.",Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589787/),[h·μg] / [g],431,237962,DB00997,Doxorubicin
,10589787,AUCs,"Calculated AUCs for intratumoral dox released were 431 microg x h x g(-1) and 775 microg x h x g(-1) for MAC15A and MAC26, respectively.",Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589787/),[h·μg] / [g],775,237963,DB00997,Doxorubicin
,23284832,drug accumulation,They showed highest drug accumulation in liver (22.4 and 19.5 µg/g).,"Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23284832/),[μg] / [g],22.4,238261,DB00997,Doxorubicin
,23284832,drug accumulation,They showed highest drug accumulation in liver (22.4 and 19.5 µg/g).,"Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23284832/),[μg] / [g],19.5,238262,DB00997,Doxorubicin
,7757312,Steady-state volume of distribution,"Steady-state volume of distribution, elimination clearance, and elimination half-life averaged 1,114 +/- 340 l/m2, 38 +/- 16 l/h/m2 and 40.3 +/- 30.3 hours, respectively.",Pharmacokinetics and acute cardiovascular effects of menogaril in patients with metastatic tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757312/),[l] / [m2],"1,114",238490,DB00997,Doxorubicin
,7757312,elimination clearance,"Steady-state volume of distribution, elimination clearance, and elimination half-life averaged 1,114 +/- 340 l/m2, 38 +/- 16 l/h/m2 and 40.3 +/- 30.3 hours, respectively.",Pharmacokinetics and acute cardiovascular effects of menogaril in patients with metastatic tumors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757312/),[l] / [h·m2],38,238491,DB00997,Doxorubicin
,7757312,elimination half-life,"Steady-state volume of distribution, elimination clearance, and elimination half-life averaged 1,114 +/- 340 l/m2, 38 +/- 16 l/h/m2 and 40.3 +/- 30.3 hours, respectively.",Pharmacokinetics and acute cardiovascular effects of menogaril in patients with metastatic tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757312/),h,40.3,238492,DB00997,Doxorubicin
,7757312,Heart rate,Heart rate (78 +/- 5 min-1) remained constant.,Pharmacokinetics and acute cardiovascular effects of menogaril in patients with metastatic tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757312/),1/[min],78,238493,DB00997,Doxorubicin
,7757312,half-life,The half-life for menogaril equilibration between plasma and this biophase was 41 +/- 22 minutes.,Pharmacokinetics and acute cardiovascular effects of menogaril in patients with metastatic tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757312/),min,41,238494,DB00997,Doxorubicin
,2706737,maximum tolerated dose,"The maximum tolerated dose was 25 mg/m2; for phase II studies using this schedule, a dose of 20 mg/m2 weekly for 3 weeks is recommended.",Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706737/),,25,238824,DB00997,Doxorubicin
,2706737,alpha,"Pharmacokinetic studies revealed a triphasic elimination of the parent compound with alpha, beta, and gamma half-lives of 5.6 min, 1.4 h, and 9.3 h, respectively.",Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706737/),min,5.6,238825,DB00997,Doxorubicin
,2706737,beta,"Pharmacokinetic studies revealed a triphasic elimination of the parent compound with alpha, beta, and gamma half-lives of 5.6 min, 1.4 h, and 9.3 h, respectively.",Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706737/),h,1.4,238826,DB00997,Doxorubicin
,2706737,gamma half-lives,"Pharmacokinetic studies revealed a triphasic elimination of the parent compound with alpha, beta, and gamma half-lives of 5.6 min, 1.4 h, and 9.3 h, respectively.",Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706737/),h,9.3,238827,DB00997,Doxorubicin
,7695982,Clearance,"Clearance, volume of distribution and half-life of the drug were 3.48 +/- 0.88 1/h/m2, 0.56 +/- 0.22 l/kg and 4.68 +/- 2.01 h, respectively.","Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695982/),[1] / [h·m2],3.48,239318,DB00997,Doxorubicin
,7695982,volume of distribution,"Clearance, volume of distribution and half-life of the drug were 3.48 +/- 0.88 1/h/m2, 0.56 +/- 0.22 l/kg and 4.68 +/- 2.01 h, respectively.","Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695982/),[l] / [kg],0.56,239319,DB00997,Doxorubicin
,7695982,half-life,"Clearance, volume of distribution and half-life of the drug were 3.48 +/- 0.88 1/h/m2, 0.56 +/- 0.22 l/kg and 4.68 +/- 2.01 h, respectively.","Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695982/),h,4.68,239320,DB00997,Doxorubicin
,7695982,total recovery,"Variation in recovery of the metabolites in urine varied over an even wider range, total recovery varying from 17.5 to 81.8% of the dose administered.","Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695982/),%,17.5 to 81.8,239321,DB00997,Doxorubicin
,9815717,Cmax,"The mean Cmax and area under the curve for safingol at the 120 mg/m2 dose level were 1040 +/- 196 ng/ml and 1251 +/- 317 mg x h/ml, respectively.",A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815717/),[ng] / [ml],1040,239501,DB00997,Doxorubicin
,9815717,area under the curve,"The mean Cmax and area under the curve for safingol at the 120 mg/m2 dose level were 1040 +/- 196 ng/ml and 1251 +/- 317 mg x h/ml, respectively.",A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815717/),[h·mg] / [ml],1251,239502,DB00997,Doxorubicin
,9815717,plasma half-life,"The mean plasma half-life for safingol was 3.97 +/- 2.51 h, the mean estimated clearance was 3140 +/- 765 ml/min, and the mean volume of distribution was of 995 +/- 421 liters.",A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815717/),h,3.97,239503,DB00997,Doxorubicin
,9815717,clearance,"The mean plasma half-life for safingol was 3.97 +/- 2.51 h, the mean estimated clearance was 3140 +/- 765 ml/min, and the mean volume of distribution was of 995 +/- 421 liters.",A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815717/),[ml] / [min],3140,239504,DB00997,Doxorubicin
,9815717,volume of distribution,"The mean plasma half-life for safingol was 3.97 +/- 2.51 h, the mean estimated clearance was 3140 +/- 765 ml/min, and the mean volume of distribution was of 995 +/- 421 liters.",A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815717/),l,995,239505,DB00997,Doxorubicin
,18651589,flow rate,"The mobile phase consisting of a mixture of methanol-water [containing 0.1% formic acid anhydrous and 0.1% ammonia solution (25%), pH 3.0], 60:40, was delivered at a flow rate of 1.0 mL/min.",Improved HPLC method for doxorubicin quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651589/),[ml] / [min],1.0,239655,DB00997,Doxorubicin
,18651589,extraction recoveries,The extraction recoveries of doxorubicin in the range of 10 ng/mL to 100 microg/mL in rat plasma were between 94.1 and 105.6%.,Improved HPLC method for doxorubicin quantification in rat plasma to study the pharmacokinetics of micelle-encapsulated and liposome-encapsulated doxorubicin formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651589/),%,94.1 and 105.6,239656,DB00997,Doxorubicin
,15166622,MTD,"The MTD for PLD was 45 mg/m (dose level 3) and the dose-limiting toxicity was febrile neutropenia, occurring in three of five patients.",Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166622/),[mg] / [m],45,239958,DB00997,Doxorubicin
,15166622,overall response rate,The overall response rate was 28% for patients with non-nasopharyngeal tumors [95% confidence interval (CI) 15-45%] and 28.6% for the study population (95% CI 17-43%).,Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166622/),%,28,239959,DB00997,Doxorubicin
,15166622,overall response rate,The overall response rate was 28% for patients with non-nasopharyngeal tumors [95% confidence interval (CI) 15-45%] and 28.6% for the study population (95% CI 17-43%).,Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166622/),%,28.6,239960,DB00997,Doxorubicin
,22884505,C(trough),The geometric mean presurgery C(trough) was 51·8 μg/mL (coefficient of variation 52·5%) in the intravenous group and 69·0 μg/mL (55·8%) in the subcutaneous group.,"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884505/),[μg] / [ml],51·8,240404,DB00997,Doxorubicin
,22884505,C(trough),The geometric mean presurgery C(trough) was 51·8 μg/mL (coefficient of variation 52·5%) in the intravenous group and 69·0 μg/mL (55·8%) in the subcutaneous group.,"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884505/),[μg] / [ml],69·0,240405,DB00997,Doxorubicin
,8595168,AUC,"With Cremophor present, doxorubicin AUC increased from 1420+/-440 to 2770+/-660 ng h ml(-1) (P<0.05) and doxorubicinol AUC increased from 130+/-76 to 320+/-88 ng h ml(-1) (p<0.05).","Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595168/),[h·ng] / [ml],1420,240817,DB00997,Doxorubicin
,8595168,AUC,"With Cremophor present, doxorubicin AUC increased from 1420+/-440 to 2770+/-660 ng h ml(-1) (P<0.05) and doxorubicinol AUC increased from 130+/-76 to 320+/-88 ng h ml(-1) (p<0.05).","Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595168/),[h·ng] / [ml],2770,240818,DB00997,Doxorubicin
,8595168,AUC,"With Cremophor present, doxorubicin AUC increased from 1420+/-440 to 2770+/-660 ng h ml(-1) (P<0.05) and doxorubicinol AUC increased from 130+/-76 to 320+/-88 ng h ml(-1) (p<0.05).","Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595168/),[h·ng] / [ml],130,240819,DB00997,Doxorubicin
,8595168,AUC,"With Cremophor present, doxorubicin AUC increased from 1420+/-440 to 2770+/-660 ng h ml(-1) (P<0.05) and doxorubicinol AUC increased from 130+/-76 to 320+/-88 ng h ml(-1) (p<0.05).","Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595168/),[h·ng] / [ml],320,240820,DB00997,Doxorubicin
,3653229,terminal half-time,The terminal half-time was 4.0 +/- 0.4 h and the total body clearance was 3.5 +/- 0.4 ml X min-1 X kg-1.,The pharmacokinetics of single high doses of dexamethasone in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653229/),h,4.0,241187,DB00997,Doxorubicin
,3653229,total body clearance,The terminal half-time was 4.0 +/- 0.4 h and the total body clearance was 3.5 +/- 0.4 ml X min-1 X kg-1.,The pharmacokinetics of single high doses of dexamethasone in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653229/),[ml] / [kg·min],3.5,241188,DB00997,Doxorubicin
,3653229,volume of the central compartment,The volume of the central compartment and the total apparent volume of distribution were 0.23 +/- 0.03 and 1.0 +/- 0.1 l X kg-1 respectively.,The pharmacokinetics of single high doses of dexamethasone in cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653229/),[l] / [kg],0.23,241189,DB00997,Doxorubicin
,3653229,total apparent volume of distribution,The volume of the central compartment and the total apparent volume of distribution were 0.23 +/- 0.03 and 1.0 +/- 0.1 l X kg-1 respectively.,The pharmacokinetics of single high doses of dexamethasone in cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653229/),[l] / [kg],1.0,241190,DB00997,Doxorubicin
,3855696,time to CR,"All remissions were induced with one course of treatment with a median time to CR of 28 days (range, 22 to 40 days).",Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855696/),d,28,241222,DB00997,Doxorubicin
,22545944,circulation half-life,In vivo pharmacokinetics studies using positron emission tomography showed a circulation half-life of 29.5 h and minimal accumulation in the liver and spleen.,Long-circulating 15 nm micelles based on amphiphilic 3-helix peptide-PEG conjugates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22545944/),h,29.5,242239,DB00997,Doxorubicin
,3815348,initial half-life,THP-adriamycin had a short initial half-life of 1.4 +/- 0.3 min (mean +/- SD) due to rapid cellular uptake.,Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815348/),min,1.4,242343,DB00997,Doxorubicin
,3815348,half-lives,The half-lives of THP-adriamycin in plasma were 19 +/- 2.8 min in an intermediate and 13 +/- 1.6 h in the terminal phase.,Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815348/),min,19,242344,DB00997,Doxorubicin
,3815348,half-lives,The half-lives of THP-adriamycin in plasma were 19 +/- 2.8 min in an intermediate and 13 +/- 1.6 h in the terminal phase.,Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815348/),h,13,242345,DB00997,Doxorubicin
,3815348,volume of distribution,The volume of distribution was 2124 +/- 221 liters/m2 and the total clearance rate 115 +/- 11 liters/m2h.,Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815348/),[l] / [m2],2124,242346,DB00997,Doxorubicin
,3815348,total clearance rate,The volume of distribution was 2124 +/- 221 liters/m2 and the total clearance rate 115 +/- 11 liters/m2h.,Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815348/),[l] / [m2h],115,242347,DB00997,Doxorubicin
,3815348,terminal half-life,The major metabolite was Adriamycin with a terminal half-life in plasma of 33 +/- 10 h.,Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815348/),h,33,242348,DB00997,Doxorubicin
,3815348,maximum tolerated dose,"The maximum tolerated dose was 70 mg/m2, and the dose-limiting toxicities were leukopenia and thrombocytopenia.",Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3815348/),,70,242349,DB00997,Doxorubicin
,15046711,nadir,The first patient had a baseline PSA of 34.7 ng/mL and a nadir of 17.0 ng/mL.,Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15046711/),ng,17.0,242721,DB00997,Doxorubicin
,15046711,nadir,The second patient had a baseline PSA of 5580.0 ng/mL and a nadir of 200.7 ng/mL.,Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15046711/),ng,200.7,242722,DB00997,Doxorubicin
,1714790,volume of distribution at steady-state,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [kg],0.398,242987,DB00997,Doxorubicin
,1714790,systemic clearance,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [h·kg],0.0956,242988,DB00997,Doxorubicin
,1714790,terminal elimination half-life,"The terminal elimination half-life (9.29 hours) of methotrexate was similar to other reported values in adult patients, thus indicating that increases in methotrexate volume of distribution and clearance may offset each other in obesity.",Disposition of high-dose methotrexate in an obese cancer patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),h,9.29,242989,DB00997,Doxorubicin
,17728083,terminal t(1/2),"The pharmacokinetic profiles of LTSL- and TSL-cisplatin indicated that these formulations were rapidly eliminated from circulation (terminal t(1/2) of 1.09 and 2.83 h, respectively).",Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17728083/),h,1.09,243053,DB00997,Doxorubicin
,17728083,terminal t(1/2),"The pharmacokinetic profiles of LTSL- and TSL-cisplatin indicated that these formulations were rapidly eliminated from circulation (terminal t(1/2) of 1.09 and 2.83 h, respectively).",Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17728083/),h,2.83,243054,DB00997,Doxorubicin
,9488597,MTD,The MTD of S9788 was 96 mg/m2.,"Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9488597/),[mg] / [m2],96,243275,DB00997,Doxorubicin
,9488597,apparent elimination half-life,"Since the mean apparent elimination half-life of S9788 was 46 +/- 23 h and the last plasma sampling time was 48 h, only model-independent parameters were considered.","Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9488597/),h,46,243276,DB00997,Doxorubicin
,9488597,MTD,The MTD of S9788 was 96 mg/m2.,"Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9488597/),[mg] / [m2],96,243277,DB00997,Doxorubicin
,8387903,clearance,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),[ml] / [m2·min],239,243504,DB00997,Doxorubicin
,8387903,clearance,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),[ml] / [m2·min],666,243505,DB00997,Doxorubicin
,8387903,AUC,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),[h·ng] / [ml],4610,243506,DB00997,Doxorubicin
,8387903,AUC,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),[h·ng] / [ml],1834,243507,DB00997,Doxorubicin
,8387903,elimination half-life,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),h,49.3,243508,DB00997,Doxorubicin
,8387903,elimination half-life,Four patients with impaired liver function showed a significant (p < 0.05) decrease in clearance (239 versus 666 ml/min/m2) and increases in AUC (4610 versus 1834 ng.hr/ml) and elimination half-life (49.3 versus 25.6 hours) compared with patients with normal hepatic function.,Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8387903/),h,25.6,243509,DB00997,Doxorubicin
,8230753,maximum tolerated dose,Granulocytopenia was found to be the dose limiting toxicity with a maximum tolerated dose of 150 mg/m2/course.,Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230753/),[mg] / [course·m2],150,243706,DB00997,Doxorubicin
,7195773,half-lives,"The mean corresponding half-lives are 30 minutes, 6 hours, and 5 days.",Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7195773/),min,30,244304,DB00997,Doxorubicin
,7195773,half-lives,"The mean corresponding half-lives are 30 minutes, 6 hours, and 5 days.",Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7195773/),h,6,244305,DB00997,Doxorubicin
,7195773,half-lives,"The mean corresponding half-lives are 30 minutes, 6 hours, and 5 days.",Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7195773/),d,5,244306,DB00997,Doxorubicin
,7195773,plasma peaks,"Depending on the rate of infusion, plasma peaks ranged between 1.1 micrograms/ml (5.7 X 10(-6) M) and 2.27 micrograms/ml (1.16 X 10(-5) M).",Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7195773/),[μg] / [ml],1.1,244307,DB00997,Doxorubicin
,7195773,plasma peaks,"Depending on the rate of infusion, plasma peaks ranged between 1.1 micrograms/ml (5.7 X 10(-6) M) and 2.27 micrograms/ml (1.16 X 10(-5) M).",Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7195773/),M,5.7 X 10(-6),244308,DB00997,Doxorubicin
,7195773,plasma peaks,"Depending on the rate of infusion, plasma peaks ranged between 1.1 micrograms/ml (5.7 X 10(-6) M) and 2.27 micrograms/ml (1.16 X 10(-5) M).",Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7195773/),[μg] / [ml],2.27,244309,DB00997,Doxorubicin
,7195773,plasma peaks,"Depending on the rate of infusion, plasma peaks ranged between 1.1 micrograms/ml (5.7 X 10(-6) M) and 2.27 micrograms/ml (1.16 X 10(-5) M).",Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7195773/),M,1.16 X 10(-5),244310,DB00997,Doxorubicin
,7195773,half-life,"During the hemofiltration process immediately following the infusion, the elimination rate was first-order, with a mean half-life of 60 minutes.",Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7195773/),min,60,244311,DB00997,Doxorubicin
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],7.71,244792,DB00997,Doxorubicin
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],4.32,244793,DB00997,Doxorubicin
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],7.95,244794,DB00997,Doxorubicin
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],6.51,244795,DB00997,Doxorubicin
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],118.30,244796,DB00997,Doxorubicin
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],82.11,244797,DB00997,Doxorubicin
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],245.54,244798,DB00997,Doxorubicin
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],86.62,244799,DB00997,Doxorubicin
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],346.69,244800,DB00997,Doxorubicin
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],2499.44,244801,DB00997,Doxorubicin
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],45.90,244802,DB00997,Doxorubicin
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],5800.05,244803,DB00997,Doxorubicin
,18712930,plasma terminal half-life ( t 1/2),"In athymic mice, QD-ILs significantly prolonged circulation of QDs, exhibiting a plasma terminal half-life ( t 1/2) of approximately 2.9 h as compared to free QDs with t 1/2 < 10 min.",Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18712930/),h,2.9,244929,DB00997,Doxorubicin
<,18712930,t 1/2,"In athymic mice, QD-ILs significantly prolonged circulation of QDs, exhibiting a plasma terminal half-life ( t 1/2) of approximately 2.9 h as compared to free QDs with t 1/2 < 10 min.",Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18712930/),min,10,244930,DB00997,Doxorubicin
,16019859,MTD,"Ten patients participated in the phase I portion of the study which demonstrated that the MTD of hyperthermia was 60 min after either average vaginal and rectal temperatures of 40 degrees C had been achieved or after 30 min of power application, whichever was shorter.",Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019859/),min,60,246468,DB00997,Doxorubicin
,16019859,response rate,"There were three partial responses for a response rate of 10% (95% CI: [2%, 27%]) and eight patients (27%; 95% CI: [12%, 46%]) had disease stabilization.",Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019859/),%,10,246469,DB00997,Doxorubicin
,16019859,time to progression or death,"The median time to progression or death was 3.4 months (95% CI: [2.6, 5.2]) and the median survival was 10.8 months (95% CI: [8.8, 17.4]).",Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019859/),month,3.4,246470,DB00997,Doxorubicin
,16019859,survival,"The median time to progression or death was 3.4 months (95% CI: [2.6, 5.2]) and the median survival was 10.8 months (95% CI: [8.8, 17.4]).",Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019859/),month,10.8,246471,DB00997,Doxorubicin
,24263774,AUC,"Doxorubicin AUC was significantly lower in patients with HepaSphere 30-60 μm (35,195 ± 27,873 ng × min/ml) than in patients with conventional TACE (103,960 ± 16,652 ng × min/ml; p = 0.009).",Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24263774/),[min·ng] / [ml],"35,195",246723,DB00997,Doxorubicin
,24263774,AUC,"Doxorubicin AUC was significantly lower in patients with HepaSphere 30-60 μm (35,195 ± 27,873 ng × min/ml) than in patients with conventional TACE (103,960 ± 16,652 ng × min/ml; p = 0.009).",Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24263774/),[min·ng] / [ml],"103,960",246724,DB00997,Doxorubicin
,24263774,Cmax,Cmax was also significantly lower with HepaSphere 30-60 μm (83.9 ± 32.1 ng/ml) compared with c-TACE (761.3 ± 58.8 ng/ml; p = 0.002).,Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24263774/),[ng] / [ml],83.9,246725,DB00997,Doxorubicin
,24263774,Cmax,Cmax was also significantly lower with HepaSphere 30-60 μm (83.9 ± 32.1 ng/ml) compared with c-TACE (761.3 ± 58.8 ng/ml; p = 0.002).,Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24263774/),[ng] / [ml],761.3,246726,DB00997,Doxorubicin
,16126736,MTD,The MTD of DP was 40/150.,"A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16126736/),-1,40,246850,DB00997,Doxorubicin
,11750714,time to progression,"Median time to progression was 9.5 weeks, median survival 18.6 weeks.",Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11750714/),weeks,9.5,247548,DB00997,Doxorubicin
,11750714,survival,"Median time to progression was 9.5 weeks, median survival 18.6 weeks.",Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11750714/),weeks,18.6,247549,DB00997,Doxorubicin
,3954376,Renal excretion,Renal excretion over 48 hours was 9% and biliary excretion over the same period was 20%.,[Pharmacokinetic studies of THP-ADM (tetrahydropyranyl adriamycin)]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954376/),%,9,247685,DB00997,Doxorubicin
,3954376,biliary excretion,Renal excretion over 48 hours was 9% and biliary excretion over the same period was 20%.,[Pharmacokinetic studies of THP-ADM (tetrahydropyranyl adriamycin)]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954376/),%,20,247686,DB00997,Doxorubicin
,12544259,AUC(perfusate):AUC(plasma) ratios,"The mean AUC(perfusate):AUC(plasma) ratios for doxorubicin and cisplatin (ultrafiltration for plasma) were 99 and 59, respectively.",Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544259/),,99,248308,DB00997,Doxorubicin
,12544259,AUC(perfusate):AUC(plasma) ratios,"The mean AUC(perfusate):AUC(plasma) ratios for doxorubicin and cisplatin (ultrafiltration for plasma) were 99 and 59, respectively.",Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544259/),,59,248309,DB00997,Doxorubicin
,12544259,half-lives,"During perfusion the concentration in the perfusate declined essentially according to first-order elimination kinetics for both doxorubicin and cisplatin with half-lives of 74 and 138 min, respectively.",Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544259/),min,74,248310,DB00997,Doxorubicin
,12544259,half-lives,"During perfusion the concentration in the perfusate declined essentially according to first-order elimination kinetics for both doxorubicin and cisplatin with half-lives of 74 and 138 min, respectively.",Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544259/),min,138,248311,DB00997,Doxorubicin
,30551427,tumor inhibition ratios,"The higher tumor inhibition ratios were observed for the treatments with free and co-encapsulated PTX:DXR in liposomes (66.87 and 66.52%, respectively, P>0.05) as compared to the control.",Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30551427/),%,66.87,248861,DB00997,Doxorubicin
,30551427,tumor inhibition ratios,"The higher tumor inhibition ratios were observed for the treatments with free and co-encapsulated PTX:DXR in liposomes (66.87 and 66.52%, respectively, P>0.05) as compared to the control.",Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30551427/),%,66.52,248862,DB00997,Doxorubicin
,25085588,C max,"C max in there groups after administration was 28.77 ± 7.15 μg/ml in c-TACE group, 83.84 ± 32.28 μg/ml in GSMs-TACE group, and 238.46 ± 23.44 μg/ml in HAI group at 5 min, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[μg] / [ml],28.77,249199,DB00997,Doxorubicin
,25085588,C max,"C max in there groups after administration was 28.77 ± 7.15 μg/ml in c-TACE group, 83.84 ± 32.28 μg/ml in GSMs-TACE group, and 238.46 ± 23.44 μg/ml in HAI group at 5 min, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[μg] / [ml],83.84,249200,DB00997,Doxorubicin
,25085588,C max,"C max in there groups after administration was 28.77 ± 7.15 μg/ml in c-TACE group, 83.84 ± 32.28 μg/ml in GSMs-TACE group, and 238.46 ± 23.44 μg/ml in HAI group at 5 min, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[μg] / [ml],238.46,249201,DB00997,Doxorubicin
,25085588,concentration,"The epirubicin concentration in tumor tissue was 53.06 ± 16.9 μg/g in c-TACE group, 44.49 ± 16.80 μg/g in the GSMs-TACE group, and 18.32 ± 8.30 μg/g in HAI group, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),μ,44,249202,DB00997,Doxorubicin
,25085588,concentration,"The epirubicin concentration in tumor tissue was 53.06 ± 16.9 μg/g in c-TACE group, 44.49 ± 16.80 μg/g in the GSMs-TACE group, and 18.32 ± 8.30 μg/g in HAI group, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),,18,249203,DB00997,Doxorubicin
,25085588,area under the curve (AUC) at 0-120 min,"The area under the curve (AUC) at 0-120 min in c-TACE, GSMs-TACE, and HAI groups were 1,815 ± 889.88, 3,416 ± 799.90, and 11,899 ± 2,717.17 μg min/ml, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[min·μg] / [ml],"1,815",249204,DB00997,Doxorubicin
,25085588,area under the curve (AUC) at 0-120 min,"The area under the curve (AUC) at 0-120 min in c-TACE, GSMs-TACE, and HAI groups were 1,815 ± 889.88, 3,416 ± 799.90, and 11,899 ± 2,717.17 μg min/ml, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[min·μg] / [ml],"3,416",249205,DB00997,Doxorubicin
,25085588,area under the curve (AUC) at 0-120 min,"The area under the curve (AUC) at 0-120 min in c-TACE, GSMs-TACE, and HAI groups were 1,815 ± 889.88, 3,416 ± 799.90, and 11,899 ± 2,717.17 μg min/ml, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[min·μg] / [ml],"11,899",249206,DB00997,Doxorubicin
,30954354,retention,The retention of PLD within the peritoneal tissues over a 90-min HIPEC was only approximately 20% and 180 min of HIPEC 40%.,Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30954354/),%,20,249261,DB00997,Doxorubicin
,30954354,retention,The retention of PLD within the peritoneal tissues over a 90-min HIPEC was only approximately 20% and 180 min of HIPEC 40%.,Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30954354/),%,40,249262,DB00997,Doxorubicin
over,30954354,area under the curve ratio,The median area under the curve ratio of peritoneal fluid concentration times time as compared to plasma concentration times was over 1000 and increased with dose escalation from 50 to 100 mg/m2.,Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30954354/),,1000,249263,DB00997,Doxorubicin
,26720701,flow rate,"Chromatographic separation was achieved using an Acquity UPLC BEH C18 column (100mm×2.1mm, 1.7μm) at a flow rate of 0.4mL/min, using gradient mode containing 0.1% formic acid in water and acetonitrile were used as the mobile phase A and B.","Simultaneous determination of loganin, morroniside, catalpol and acteoside in normal and chronic kidney disease rat plasma by UPLC-MS for investigating the pharmacokinetics of Rehmannia glutinosa and Cornus officinalis Sieb drug pair extract. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720701/),[ml] / [min],0.4,249922,DB00997,Doxorubicin
,26720701,m,"Loganin, morroniside, catalpol, acteoside and the internal standard (chloramphenicol) were detected by selected reaction monitoring in the negative ion mode with the mass transition of m/z 451.0→179.0 (morroniside), m/z 435.0→227.0 (loganin), m/z 407.1→199.1 (catalpol), m/z 623.2→161.0 (acteoside) and m/z 320.8→151.9 (chloramphenicol), respectively.","Simultaneous determination of loganin, morroniside, catalpol and acteoside in normal and chronic kidney disease rat plasma by UPLC-MS for investigating the pharmacokinetics of Rehmannia glutinosa and Cornus officinalis Sieb drug pair extract. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720701/),,435.0,249923,DB00997,Doxorubicin
,26720701,m,"Loganin, morroniside, catalpol, acteoside and the internal standard (chloramphenicol) were detected by selected reaction monitoring in the negative ion mode with the mass transition of m/z 451.0→179.0 (morroniside), m/z 435.0→227.0 (loganin), m/z 407.1→199.1 (catalpol), m/z 623.2→161.0 (acteoside) and m/z 320.8→151.9 (chloramphenicol), respectively.","Simultaneous determination of loganin, morroniside, catalpol and acteoside in normal and chronic kidney disease rat plasma by UPLC-MS for investigating the pharmacokinetics of Rehmannia glutinosa and Cornus officinalis Sieb drug pair extract. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720701/),,407.1,249924,DB00997,Doxorubicin
,26720701,m,"Loganin, morroniside, catalpol, acteoside and the internal standard (chloramphenicol) were detected by selected reaction monitoring in the negative ion mode with the mass transition of m/z 451.0→179.0 (morroniside), m/z 435.0→227.0 (loganin), m/z 407.1→199.1 (catalpol), m/z 623.2→161.0 (acteoside) and m/z 320.8→151.9 (chloramphenicol), respectively.","Simultaneous determination of loganin, morroniside, catalpol and acteoside in normal and chronic kidney disease rat plasma by UPLC-MS for investigating the pharmacokinetics of Rehmannia glutinosa and Cornus officinalis Sieb drug pair extract. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720701/),,623.2,249925,DB00997,Doxorubicin
,26720701,recovery,The recovery ranged from 67.62 to 80.14%.,"Simultaneous determination of loganin, morroniside, catalpol and acteoside in normal and chronic kidney disease rat plasma by UPLC-MS for investigating the pharmacokinetics of Rehmannia glutinosa and Cornus officinalis Sieb drug pair extract. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26720701/),%,67.62 to 80.14,249926,DB00997,Doxorubicin
,12898182,AUC(0-120 min),"After i.v. administration the AUC(0-120 min) values of monoHER in plasma and heart tissue were 20.5+/-5.3 micromol.min.ml(-1) and 4.9+/-1.3 micromol.min.g(-1) wet tissue, respectively.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),[min·μM] / [ml],20.5,249937,DB00997,Doxorubicin
,12898182,AUC(0-120 min),"After i.v. administration the AUC(0-120 min) values of monoHER in plasma and heart tissue were 20.5+/-5.3 micromol.min.ml(-1) and 4.9+/-1.3 micromol.min.g(-1) wet tissue, respectively.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),[min·μM] / [g],4.9,249938,DB00997,Doxorubicin
,12898182,peak plasma concentration,"After i.p. administration, a mean peak plasma concentration of about 130 microM monoHER was maintained from 5 to 15 min after administration.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),μM,130,249939,DB00997,Doxorubicin
,12898182,AUC(0-120 min),"The AUC(0-120 min) values of monoHER were 6.1+/-1.1 micromol.min.ml(-1) and 1.6+/-0.4 micromol.min.g(-1) wet tissue in plasma and heart tissue, respectively.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),[min·μM] / [ml],6.1,249940,DB00997,Doxorubicin
,12898182,AUC(0-120 min),"The AUC(0-120 min) values of monoHER were 6.1+/-1.1 micromol.min.ml(-1) and 1.6+/-0.4 micromol.min.g(-1) wet tissue in plasma and heart tissue, respectively.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),[min·μM] / [g],1.6,249941,DB00997,Doxorubicin
,12898182,AUC(0-120 min),"The AUC(0-120 min) values of monoHER in plasma, heart, liver and kidney tissues were 8.0+/-0.6 micromol.min.ml(-1), 2.0+/-0.1, 22.4+/-2.0 and 20.5+/-5.7 micromol.min.g(-1), respectively.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),[min·μM] / [ml],8.0,249942,DB00997,Doxorubicin
,12898182,AUC(0-120 min),"The AUC(0-120 min) values of monoHER in plasma, heart, liver and kidney tissues were 8.0+/-0.6 micromol.min.ml(-1), 2.0+/-0.1, 22.4+/-2.0 and 20.5+/-5.7 micromol.min.g(-1), respectively.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),[min·μM] / [g],2.0,249943,DB00997,Doxorubicin
,12898182,AUC(0-120 min),"The AUC(0-120 min) values of monoHER in plasma, heart, liver and kidney tissues were 8.0+/-0.6 micromol.min.ml(-1), 2.0+/-0.1, 22.4+/-2.0 and 20.5+/-5.7 micromol.min.g(-1), respectively.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),[min·μM] / [g],22.4,249944,DB00997,Doxorubicin
,12898182,AUC(0-120 min),"The AUC(0-120 min) values of monoHER in plasma, heart, liver and kidney tissues were 8.0+/-0.6 micromol.min.ml(-1), 2.0+/-0.1, 22.4+/-2.0 and 20.5+/-5.7 micromol.min.g(-1), respectively.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),[min·μM] / [g],20.5,249945,DB00997,Doxorubicin
,12898182,bioavailabilities,"The i.p. and s.c. bioavailabilities were about 30% and 40%, respectively.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),%,30,249946,DB00997,Doxorubicin
,12898182,bioavailabilities,"The i.p. and s.c. bioavailabilities were about 30% and 40%, respectively.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),%,40,249947,DB00997,Doxorubicin
,12898182,Cmax,"Under cardioprotective conditions (500 mg/kg, i.p.), the Cmax was 131 microM and the AUC(infinity) was 6.3 microM.min.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),μM,131,249948,DB00997,Doxorubicin
,12898182,AUC(infinity),"Under cardioprotective conditions (500 mg/kg, i.p.), the Cmax was 131 microM and the AUC(infinity) was 6.3 microM.min.",Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898182/),min·μM,6.3,249949,DB00997,Doxorubicin
,11051260,MTD,"The MTD in the sequence of doxorubicin after docetaxel was 40 and 50 mg/m2, respectively, with the dose-limiting toxicity of neutropenia.",Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11051260/),[mg] / [m2],40,250387,DB00997,Doxorubicin
,11051260,MTD,"The MTD in the sequence of doxorubicin after docetaxel was 40 and 50 mg/m2, respectively, with the dose-limiting toxicity of neutropenia.",Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11051260/),[mg] / [m2],50,250388,DB00997,Doxorubicin
,11051260,MTD,"On the other hand, the MTD of the sequence of docetaxel after doxorubicin was 70 and 50 mg/m2, respectively.",Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11051260/),[mg] / [m2],70,250389,DB00997,Doxorubicin
,11051260,MTD,"On the other hand, the MTD of the sequence of docetaxel after doxorubicin was 70 and 50 mg/m2, respectively.",Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11051260/),[mg] / [m2],50,250390,DB00997,Doxorubicin
,25769281,zeta potential,"Developed formulation revealed particle size, 235.3±15.12 nm, zeta potential, -27.5±0.7 mV and drug content (39.12±2.13 μg/mg), with spherical shape and smooth surface.","Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769281/),mv,-,250608,DB00997,Doxorubicin
,25769281,zeta potential,"Developed formulation revealed particle size, 235.3±15.12 nm, zeta potential, -27.5±0.7 mV and drug content (39.12±2.13 μg/mg), with spherical shape and smooth surface.","Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769281/),mv,27.5,250609,DB00997,Doxorubicin
,11157039,area under the curve,"rhuMAbVEGF, 3 mg/kg IV, was administered weekly for 8 weeks with (1) doxorubicin 50 mg/m(2) every 4 weeks; (2) carboplatin at area under the curve of 6 plus paclitaxel 175 mg/m(2) every 4 weeks; and (3) fluorouracil (5-FU) 500 mg/m(2) with leucovorin 20 mg/m(2) weekly, weeks 1 to 6 every 8 weeks.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),,6,250656,DB00997,Doxorubicin
,11157039,peak serum level,"The mean (+/- SD) peak serum level of rhuMAbVEGF was 167 +/- 46 microg/mL, and the mean terminal half-life was 13 days.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),[μg] / [ml],167,250657,DB00997,Doxorubicin
,11157039,terminal half-life,"The mean (+/- SD) peak serum level of rhuMAbVEGF was 167 +/- 46 microg/mL, and the mean terminal half-life was 13 days.",Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11157039/),d,13,250658,DB00997,Doxorubicin
,1551178,clearance,"For example, a 25-year-old man would display an average clearance of 95 l/h, whereas a 70-year-old woman would exhibit an average clearance of 64 l/h.",Variability in the pharmacokinetics of epirubicin: a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551178/),[l] / [h],95,250957,DB00997,Doxorubicin
,1551178,clearance,"For example, a 25-year-old man would display an average clearance of 95 l/h, whereas a 70-year-old woman would exhibit an average clearance of 64 l/h.",Variability in the pharmacokinetics of epirubicin: a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551178/),[l] / [h],64,250958,DB00997,Doxorubicin
,16818699,maximum tolerated dose,The maximum tolerated dose was 0.93 mg/kg.,Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16818699/),[mg] / [kg],0.93,251196,DB00997,Doxorubicin
,16818699,Tumor drug concentrations,Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue.,Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16818699/),[ng] / [mg·tissue],9.12,251197,DB00997,Doxorubicin
,31830661,limit of,Validation data confirmed that the limit of detection and limit of quantification was 0.25 ng/mL and 0.5 ng/mL in both matrices.,"Development and validation of a high-performance liquid chromatographic method with a fluorescence detector for the analysis of epirubicin in human urine and plasma, and its application in drug monitoring. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31830661/),[ng] / [ml],0.25,251785,DB00997,Doxorubicin
,31830661,limit of quantification,Validation data confirmed that the limit of detection and limit of quantification was 0.25 ng/mL and 0.5 ng/mL in both matrices.,"Development and validation of a high-performance liquid chromatographic method with a fluorescence detector for the analysis of epirubicin in human urine and plasma, and its application in drug monitoring. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31830661/),[ng] / [ml],0.5,251786,DB00997,Doxorubicin
,33861419,Peak concentration (CMAX,"Peak concentration (CMAX, µg/mL) for plasma, tumor tissue, and liver were 0.666, 4.232, and 0.270 for c-TACE versus 0.103, 8.988, and 0.610 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [ml],0.666,252179,DB00997,Doxorubicin
,33861419,Peak concentration (CMAX,"Peak concentration (CMAX, µg/mL) for plasma, tumor tissue, and liver were 0.666, 4.232, and 0.270 for c-TACE versus 0.103, 8.988, and 0.610 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [ml],4.232,252180,DB00997,Doxorubicin
,33861419,Peak concentration (CMAX,"Peak concentration (CMAX, µg/mL) for plasma, tumor tissue, and liver were 0.666, 4.232, and 0.270 for c-TACE versus 0.103, 8.988, and 0.610 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [ml],0.270,252181,DB00997,Doxorubicin
,33861419,Peak concentration (CMAX,"Peak concentration (CMAX, µg/mL) for plasma, tumor tissue, and liver were 0.666, 4.232, and 0.270 for c-TACE versus 0.103, 8.988, and 0.610 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [ml],0.103,252182,DB00997,Doxorubicin
,33861419,Peak concentration (CMAX,"Peak concentration (CMAX, µg/mL) for plasma, tumor tissue, and liver were 0.666, 4.232, and 0.270 for c-TACE versus 0.103, 8.988, and 0.610 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [ml],8.988,252183,DB00997,Doxorubicin
,33861419,Peak concentration (CMAX,"Peak concentration (CMAX, µg/mL) for plasma, tumor tissue, and liver were 0.666, 4.232, and 0.270 for c-TACE versus 0.103, 8.988, and 0.610 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [ml],0.610,252184,DB00997,Doxorubicin
,33861419,Area under the concentration versus time curve (AUC,"Area under the concentration versus time curve (AUC, µg/mL ∗ min) for plasma, tumor tissue, and liver were 18.3, 27,078.8, and 1339.1 for c-TACE versus 16.4, 26,204.8, and 1969.6 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [min·ml·∗],18.3,252185,DB00997,Doxorubicin
,33861419,Area under the concentration versus time curve (AUC,"Area under the concentration versus time curve (AUC, µg/mL ∗ min) for plasma, tumor tissue, and liver were 18.3, 27,078.8, and 1339.1 for c-TACE versus 16.4, 26,204.8, and 1969.6 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [min·ml·∗],"27,078.8",252186,DB00997,Doxorubicin
,33861419,Area under the concentration versus time curve (AUC,"Area under the concentration versus time curve (AUC, µg/mL ∗ min) for plasma, tumor tissue, and liver were 18.3, 27,078.8, and 1339.1 for c-TACE versus 16.4, 26,204.8, and 1969.6 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [min·ml·∗],1339.1,252187,DB00997,Doxorubicin
,33861419,Area under the concentration versus time curve (AUC,"Area under the concentration versus time curve (AUC, µg/mL ∗ min) for plasma, tumor tissue, and liver were 18.3, 27,078.8, and 1339.1 for c-TACE versus 16.4, 26,204.8, and 1969.6 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [min·ml·∗],16.4,252188,DB00997,Doxorubicin
,33861419,Area under the concentration versus time curve (AUC,"Area under the concentration versus time curve (AUC, µg/mL ∗ min) for plasma, tumor tissue, and liver were 18.3, 27,078.8, and 1339.1 for c-TACE versus 16.4, 26,204.8, and 1969.6 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [min·ml·∗],26,252189,DB00997,Doxorubicin
,33861419,Area under the concentration versus time curve (AUC,"Area under the concentration versus time curve (AUC, µg/mL ∗ min) for plasma, tumor tissue, and liver were 18.3, 27,078.8, and 1339.1 for c-TACE versus 16.4, 26,204.8, and 1969.6 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [min·ml·∗],204.8,252190,DB00997,Doxorubicin
,33861419,Area under the concentration versus time curve (AUC,"Area under the concentration versus time curve (AUC, µg/mL ∗ min) for plasma, tumor tissue, and liver were 18.3, 27,078.8, and 1339.1 for c-TACE versus 16.4, 26,204.8, and 1969.6 for DEE-TACE.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),[μg] / [min·ml·∗],1969.6,252191,DB00997,Doxorubicin
,33861419,half-life,"A single dose of intra-tumoral DOX maintained cytotoxic levels through 7-day post-procedure for both TACE varieties, with a half-life of 1.8 (c-TACE) and 0.8 (DEE-TACE) days.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),d,1.8,252192,DB00997,Doxorubicin
,33861419,half-life,"A single dose of intra-tumoral DOX maintained cytotoxic levels through 7-day post-procedure for both TACE varieties, with a half-life of 1.8 (c-TACE) and 0.8 (DEE-TACE) days.","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),d,0.8,252193,DB00997,Doxorubicin
,33861419,Tumor-to-normal liver DOX ratio,"Tumor-to-normal liver DOX ratio was high (c-TACE, 20.2; DEE-TACE, 13.3).","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),,20.2,252194,DB00997,Doxorubicin
,33861419,Tumor-to-normal liver DOX ratio,"Tumor-to-normal liver DOX ratio was high (c-TACE, 20.2; DEE-TACE, 13.3).","Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),,13.3,252195,DB00997,Doxorubicin
,33861419,Percent tumor necrosis,Percent tumor necrosis was similar (39% vs. 37%; P = 0.806).,"Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),%,39,252196,DB00997,Doxorubicin
,33861419,Percent tumor necrosis,Percent tumor necrosis was similar (39% vs. 37%; P = 0.806).,"Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33861419/),%,37,252197,DB00997,Doxorubicin
,24521993,Ctrough,"Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab.",Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521993/),[μg] / [ml],83·13,253189,DB00997,Doxorubicin
,24521993,Ctrough,"Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab.",Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521993/),[μg] / [ml],134·58,253190,DB00997,Doxorubicin
,16357174,t(1/2),Pharmacokinetic and biodistribution studies confirmed long circulation times (t(1/2) = 21 hours) and efficient accumulation in tumors (up to 15% ID/g) irrespective of the presence of the targeting ligand.,Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16357174/),h,21,253278,DB00997,Doxorubicin
,19407979,recovery rates,The limit of quantification was 25 ng/mL in plasma and 0.1 to 0.4 microg/mg in other tissues with recovery rates ranging from 52.4 to 95.2%.,A simple HPLC method for doxorubicin in plasma and tissues of nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19407979/),%,52.4 to 95.2,253333,DB00997,Doxorubicin
,23337906,extraction recoveries,"The SPE extraction recoveries ranged from 72.3 to 77.3% and 75.5 to 98.4% for doxorubicin and doxorubicinol, respectively.",Simultaneous measurement of doxorubicin and reduced metabolite doxorubicinol by UHPLC-MS/MS in human plasma of HCC patients treated with TACE. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337906/),%,72.3 to 77.3,253993,DB00997,Doxorubicin
,23337906,extraction recoveries,"The SPE extraction recoveries ranged from 72.3 to 77.3% and 75.5 to 98.4% for doxorubicin and doxorubicinol, respectively.",Simultaneous measurement of doxorubicin and reduced metabolite doxorubicinol by UHPLC-MS/MS in human plasma of HCC patients treated with TACE. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23337906/),%,75.5 to 98.4,253994,DB00997,Doxorubicin
,10623492,total recovery of radioactivity,"The mean total recovery of radioactivity in 96 h (urine plus faeces) was approximately 74 and 60% dose in male and female rats, respectively, while in female dogs approximately 72% dose was recovered in 336 h.","Species-differences in disposition and reductive metabolism of methoxymorpholinodoxorubicin (PNU 152243), a new potential anticancer agent. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623492/),%,74,254232,DB00997,Doxorubicin
,10623492,total recovery of radioactivity,"The mean total recovery of radioactivity in 96 h (urine plus faeces) was approximately 74 and 60% dose in male and female rats, respectively, while in female dogs approximately 72% dose was recovered in 336 h.","Species-differences in disposition and reductive metabolism of methoxymorpholinodoxorubicin (PNU 152243), a new potential anticancer agent. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623492/),%,60,254233,DB00997,Doxorubicin
,10623492,total recovery of radioactivity,"The mean total recovery of radioactivity in 96 h (urine plus faeces) was approximately 74 and 60% dose in male and female rats, respectively, while in female dogs approximately 72% dose was recovered in 336 h.","Species-differences in disposition and reductive metabolism of methoxymorpholinodoxorubicin (PNU 152243), a new potential anticancer agent. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10623492/),%,72,254234,DB00997,Doxorubicin
,17063712,half-lives,The pharmacokinetics of low-dose suramin followed a 2-compartment model with half-lives of 2 h and 6 days.,Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),h,2,254374,DB00997,Doxorubicin
,17063712,half-lives,The pharmacokinetics of low-dose suramin followed a 2-compartment model with half-lives of 2 h and 6 days.,Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),d,6,254375,DB00997,Doxorubicin
,17063712,distribution volume,"The distribution volume was a 0.34 +/- 0.12 L/kg, and clearance was 1.86 +/- 0.76 mL/kg/h.",Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),[l] / [kg],0.34,254376,DB00997,Doxorubicin
,17063712,clearance,"The distribution volume was a 0.34 +/- 0.12 L/kg, and clearance was 1.86 +/- 0.76 mL/kg/h.",Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),[ml] / [h·kg],1.86,254377,DB00997,Doxorubicin
,25517904,survival span,The DOX/ES-PEG-MWCNTs has also shown significantly longer survival span (43 days) than free DOX (18 days) and control group (12 days).,One platform comparison of estrone and folic acid anchored surface engineered MWCNTs for doxorubicin delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25517904/),d,43,254671,DB00997,Doxorubicin
,25517904,survival span,The DOX/ES-PEG-MWCNTs has also shown significantly longer survival span (43 days) than free DOX (18 days) and control group (12 days).,One platform comparison of estrone and folic acid anchored surface engineered MWCNTs for doxorubicin delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25517904/),d,18,254672,DB00997,Doxorubicin
,25517904,survival span,The DOX/ES-PEG-MWCNTs has also shown significantly longer survival span (43 days) than free DOX (18 days) and control group (12 days).,One platform comparison of estrone and folic acid anchored surface engineered MWCNTs for doxorubicin delivery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25517904/),d,12,254673,DB00997,Doxorubicin
,11012554,clearance (CL),Dox clearance (CL) and volume of distribution (Vd) were 32.0 l h-1 and 9.3 l (Inter-individual variability: 17.2% and 19.2%).,"Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012554/),[l] / [h],32.0,255043,DB00997,Doxorubicin
,11012554,volume of distribution (Vd),Dox clearance (CL) and volume of distribution (Vd) were 32.0 l h-1 and 9.3 l (Inter-individual variability: 17.2% and 19.2%).,"Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012554/),l,9.3,255044,DB00997,Doxorubicin
,11012554,Vd,"Eto CL (l h-1) and Vd were, respectively, 3.34-0.0083* serum creatinine (micromol l-1) and 6.38 l (interindividual variability: 15.6% and 18.7%).","Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012554/),l,6.38,255045,DB00997,Doxorubicin
,11012554,CL,"Ifo CL and Vd at day 1 were 5.6 l h-1 and 26.0 l (interindividual variability: 10.1% and 17.2%, respectively).","Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012554/),[l] / [h],5.6,255046,DB00997,Doxorubicin
,11012554,Vd,"Ifo CL and Vd at day 1 were 5.6 l h-1 and 26.0 l (interindividual variability: 10.1% and 17.2%, respectively).","Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11012554/),l,26.0,255047,DB00997,Doxorubicin
,18027989,objective response rate,"In 50 patients with measurable disease, the objective response rate was 60%, with complete responses in 6% of patients.",Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027989/),%,60,255193,DB00997,Doxorubicin
,18027989,AUC,"Cyclophosphamide exposure (the AUC) was significantly higher in patients with at least stable disease (n = 44) than in patients with progressive disease (n = 6; 945 micromol . h/L [95% CI 889, 1001] vs 602 micromol . h/L [95% CI 379, 825], p = 0.0002).",Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027989/),[h·μM] / [l],;,255194,DB00997,Doxorubicin
,18027989,AUC,"Cyclophosphamide exposure (the AUC) was significantly higher in patients with at least stable disease (n = 44) than in patients with progressive disease (n = 6; 945 micromol . h/L [95% CI 889, 1001] vs 602 micromol . h/L [95% CI 379, 825], p = 0.0002).",Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027989/),[h·μM] / [l],945,255195,DB00997,Doxorubicin
,18027989,AUC,"Cyclophosphamide exposure (the AUC) was significantly higher in patients with at least stable disease (n = 44) than in patients with progressive disease (n = 6; 945 micromol . h/L [95% CI 889, 1001] vs 602 micromol . h/L [95% CI 379, 825], p = 0.0002).",Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027989/),[h·μM] / [l],602,255196,DB00997,Doxorubicin
,1936069,terminal half-life,"In theory, however, with a terminal half-life of 30 h, the plasma levels of adriamycin and adriamycinol should be close to 0.1 pcg/ml.","New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936069/),h,30,255592,DB00997,Doxorubicin
,1936069,terminal half-lives of elimination,The terminal half-lives of elimination estimated in 8 patients were respectively 110 +/- 52 h for adriamycin and 92 h 50 min +/- 43 h for adriamycinol.,"New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936069/),h,110,255593,DB00997,Doxorubicin
,1936069,terminal half-lives of elimination,The terminal half-lives of elimination estimated in 8 patients were respectively 110 +/- 52 h for adriamycin and 92 h 50 min +/- 43 h for adriamycinol.,"New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936069/),h,92,255594,DB00997,Doxorubicin
,1936069,terminal half-lives of elimination,The terminal half-lives of elimination estimated in 8 patients were respectively 110 +/- 52 h for adriamycin and 92 h 50 min +/- 43 h for adriamycinol.,"New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936069/),min,50,255595,DB00997,Doxorubicin
,1936069,Surface ratios,Surface ratios under adriamycinol curves against calculated adriamycin was 1.10 +/- 0.26.,"New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936069/),,1.10,255596,DB00997,Doxorubicin
,1936069,half-life,It is difficult with a half-life to 110 h to predict the effects of residual concentrations of adriamycin and adriamycinol.,"New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936069/),h,110,255597,DB00997,Doxorubicin
,28222073,area under the curve,Maximum tolerated dose for the combination was 240 mg per day oral rucaparib and carboplatin area under the curve 5 mg ml-1 min-1.,A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),[mg] / [min·ml],5,255887,DB00997,Doxorubicin
≈,28222073,half-life,"Oral rucaparib demonstrated dose-proportional kinetics, a long half-life (≈17 h), and good bioavailability (36%).",A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),h,17,255888,DB00997,Doxorubicin
,28222073,bioavailability,"Oral rucaparib demonstrated dose-proportional kinetics, a long half-life (≈17 h), and good bioavailability (36%).",A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),%,36,255889,DB00997,Doxorubicin
,16842379,clearance,"Patient weight, age and serum glutamic-oxaloacetic transaminase level were determinants of paclitaxel clearance (clearance increased 0.437 l h-1 kg-1; decreased 0.223 l h-1 year-1 and 0.105 l h-1 IU-1).",Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842379/),[l] / [h·kg],0.437,256423,DB00997,Doxorubicin
,16842379,clearance,"Patient weight, age and serum glutamic-oxaloacetic transaminase level were determinants of paclitaxel clearance (clearance increased 0.437 l h-1 kg-1; decreased 0.223 l h-1 year-1 and 0.105 l h-1 IU-1).",Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842379/),[l] / [h·year],0.223,256424,DB00997,Doxorubicin
,16842379,clearance,"Patient weight, age and serum glutamic-oxaloacetic transaminase level were determinants of paclitaxel clearance (clearance increased 0.437 l h-1 kg-1; decreased 0.223 l h-1 year-1 and 0.105 l h-1 IU-1).",Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842379/),[l] / [h·iu],0.105,256425,DB00997,Doxorubicin
,16842379,AU,"In different measures of paclitaxel exposure, AUC was most predictive of toxicity, with higher AUC associated with granulocytopenia [probability of 1% at AUC=1 to 22% at AUC=4 microg l-1 h-1 for performance status (PS)=0].",Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842379/),,1,256426,DB00997,Doxorubicin
,16842379,AUC,"In different measures of paclitaxel exposure, AUC was most predictive of toxicity, with higher AUC associated with granulocytopenia [probability of 1% at AUC=1 to 22% at AUC=4 microg l-1 h-1 for performance status (PS)=0].",Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842379/),[μg] / [h·l],4,256427,DB00997,Doxorubicin
,8599871,T1/2,"Following the administration of AD 202 (20 mg/kg, i.v.) to anesthetized rats, rapid drug distribution (T1/2 5 min) was followed by more gradual elimination (T1/2 3.6h).","Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599871/),min,5,256448,DB00997,Doxorubicin
,8599871,T1/2,"Following the administration of AD 202 (20 mg/kg, i.v.) to anesthetized rats, rapid drug distribution (T1/2 5 min) was followed by more gradual elimination (T1/2 3.6h).","Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599871/),h,3.6,256449,DB00997,Doxorubicin
,8599871,Plasma clearance,Plasma clearance of AD 202 (224 +/- 63.6 ml/min per kg) and steady state volume of distribution (25.7 +/- 11.1 l/kg) were indicative of extensive tissue sequestration and/or a large degree of extra-hepatic metabolism.,"Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599871/),[ml] / [kg·min],224,256450,DB00997,Doxorubicin
,8599871,steady state volume of distribution,Plasma clearance of AD 202 (224 +/- 63.6 ml/min per kg) and steady state volume of distribution (25.7 +/- 11.1 l/kg) were indicative of extensive tissue sequestration and/or a large degree of extra-hepatic metabolism.,"Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599871/),[l] / [kg],25.7,256451,DB00997,Doxorubicin
,8599871,area under the plasma concentration-time curve from time zero to 480 min AUC(0-480),"The systemic exposure to this biotransformation product (area under the plasma concentration-time curve from time zero to 480 min AUC(0-480) 28 1672 ng.min/ml) was > tenfold higher than for the other detected plasma products (N-butyladriamycin-14-valerate, N-butyladriamycin, and three unidentified fluorescent signals; P1-3).","Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599871/),[min·ng] / [ml],28 1672,256452,DB00997,Doxorubicin
,8599871,elimination T1/2,"The relatively poor mass balance in these studies is attributed to prolonged intracellular retention (elimination T1/2 24.2h) of N,N-di(n-butyl)adriamycin.","Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599871/),h,24.2,256453,DB00997,Doxorubicin
,6268277,Objective response frequency,Objective response frequency was 14% with all responses occurring in patients with normal pretreatment bilirubin levels.,Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6268277/),%,14,256565,DB00997,Doxorubicin
,6268277,survival,Median survival of all patients was 87 days.,Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6268277/),d,87,256566,DB00997,Doxorubicin
,6268277,terminal half-life,"Despite moderately elevated transaminase levels (all cases) and bilirubin levels (three cases), plasma Adriamycin profiles in hepatoma patients were not elevated (terminal half-life of 30 hours) and were indistinguishable from that of non-hepatoma patients with normal liver functions.",Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6268277/),h,30,256567,DB00997,Doxorubicin
,6268277,CXT (concentration X time) ratio,"This resulted ina significant increase in the CXT (concentration X time) ratio of adriamycinol/Adriamycin in hepatoma patients compared with nonhepatoma patients (2.36 +/- 2.12 vs 0.76 +/- 0.31, (P less than 0.05).",Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6268277/),,2.36,256568,DB00997,Doxorubicin
,6268277,CXT (concentration X time) ratio,"This resulted ina significant increase in the CXT (concentration X time) ratio of adriamycinol/Adriamycin in hepatoma patients compared with nonhepatoma patients (2.36 +/- 2.12 vs 0.76 +/- 0.31, (P less than 0.05).",Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6268277/),,0.76,256569,DB00997,Doxorubicin
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],73.6,256672,DB00997,Doxorubicin
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],88.3,256673,DB00997,Doxorubicin
,28800509,zeta potential,"PEGCDSIR820 nanoparticles had an average diameter of 58.2±3.1nm, zeta potential of -6.9±0.1mV in cell culture media and stability against aggregation in physiological buffers.",Polyethylene glycol modified ORMOSIL theranostic nanoparticles for triggered doxorubicin release and deep drug delivery into ovarian cancer spheroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28800509/),mv,-6.9,256903,DB00997,Doxorubicin
,28800509,encapsulation efficiency,"The encapsulation efficiency of DOX was 65.0±3.0%, and that of IR820 was 76.0±2.1%.",Polyethylene glycol modified ORMOSIL theranostic nanoparticles for triggered doxorubicin release and deep drug delivery into ovarian cancer spheroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28800509/),%,65.0,256904,DB00997,Doxorubicin
,28800509,encapsulation efficiency,"The encapsulation efficiency of DOX was 65.0±3.0%, and that of IR820 was 76.0±2.1%.",Polyethylene glycol modified ORMOSIL theranostic nanoparticles for triggered doxorubicin release and deep drug delivery into ovarian cancer spheroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28800509/),%,76.0,256905,DB00997,Doxorubicin
,28800509,elimination half-life,Encapsulation of IR820 in PEGCDSIR820 increased the in-vivo elimination half-life to 41.0±7.2h from 30.5±0.5h of free IR820.,Polyethylene glycol modified ORMOSIL theranostic nanoparticles for triggered doxorubicin release and deep drug delivery into ovarian cancer spheroids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28800509/),h,41.0,256906,DB00997,Doxorubicin
,28800509,elimination half-life,Encapsulation of IR820 in PEGCDSIR820 increased the in-vivo elimination half-life to 41.0±7.2h from 30.5±0.5h of free IR820.,Polyethylene glycol modified ORMOSIL theranostic nanoparticles for triggered doxorubicin release and deep drug delivery into ovarian cancer spheroids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28800509/),h,30.5,256907,DB00997,Doxorubicin
,31179244,clinical benefit rate,"The clinical benefit rate was 33.3 and 50.0% in the platinum-resistant and the partially platinum-sensitive group, respectively.","A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31179244/),%,33.3,257588,DB00997,Doxorubicin
,31179244,clinical benefit rate,"The clinical benefit rate was 33.3 and 50.0% in the platinum-resistant and the partially platinum-sensitive group, respectively.","A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31179244/),%,50.0,257589,DB00997,Doxorubicin
,11350887,MTD,The MTD of DP without PSC 833 was 35 mg/m(2) doxorubicin and 150 mg/m(2) paclitaxel.,"A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350887/),mg,35,257766,DB00997,Doxorubicin
,11350887,MTD,The MTD of DPV without G-CSF was 12.5 mg/m(2) doxorubicin and 70 mg/m(2) paclitaxel.,"A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350887/),mg,12.5,257767,DB00997,Doxorubicin
,3409170,Peak plasma levels,Peak plasma levels are lower (16 ng/ml versus 135 ng/ml) compared with treatment by a doxorubicin solution.,Target organ disposition and plasma pharmacokinetics of doxorubicin incorporated into albumin microspheres after intrarenal arterial administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409170/),[ng] / [ml],16,257801,DB00997,Doxorubicin
,3409170,Peak plasma levels,Peak plasma levels are lower (16 ng/ml versus 135 ng/ml) compared with treatment by a doxorubicin solution.,Target organ disposition and plasma pharmacokinetics of doxorubicin incorporated into albumin microspheres after intrarenal arterial administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3409170/),[ng] / [ml],135,257802,DB00997,Doxorubicin
,2149998,mean residence time,The mean residence time was 3.9 h in patients without liver metastasis and 10.4 h in patients with liver metastasis.,"Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2149998/),h,3.9,258561,DB00997,Doxorubicin
,2149998,mean residence time,The mean residence time was 3.9 h in patients without liver metastasis and 10.4 h in patients with liver metastasis.,"Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2149998/),h,10.4,258562,DB00997,Doxorubicin
,15648940,Cmax,During the infusion the mean +/- SD for the Cmax of doxorubicin was 4037 +/- 2577 ng/mL.,Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15648940/),[ng] / [ml],4037,258700,DB00997,Doxorubicin
,15648940,terminal (beta-phase) half-life,"The terminal (beta-phase) half-life was 41.4 +/- 18.5 min, the systemic clearance (CI) was 45.7 +/- 18.0 mL/min/kg, the mean residence time (MRT) was 4.8 +/- 1.4 min, and the volume of distribution at steady state (V(SS)) was 238 +/- 131 mL/kg.",Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15648940/),min,41.4,258701,DB00997,Doxorubicin
,15648940,systemic clearance (CI),"The terminal (beta-phase) half-life was 41.4 +/- 18.5 min, the systemic clearance (CI) was 45.7 +/- 18.0 mL/min/kg, the mean residence time (MRT) was 4.8 +/- 1.4 min, and the volume of distribution at steady state (V(SS)) was 238 +/- 131 mL/kg.",Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15648940/),[ml] / [kg·min],45.7,258702,DB00997,Doxorubicin
,15648940,mean residence time (MRT),"The terminal (beta-phase) half-life was 41.4 +/- 18.5 min, the systemic clearance (CI) was 45.7 +/- 18.0 mL/min/kg, the mean residence time (MRT) was 4.8 +/- 1.4 min, and the volume of distribution at steady state (V(SS)) was 238 +/- 131 mL/kg.",Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15648940/),min,4.8,258703,DB00997,Doxorubicin
,15648940,volume of distribution at steady state (V(SS)),"The terminal (beta-phase) half-life was 41.4 +/- 18.5 min, the systemic clearance (CI) was 45.7 +/- 18.0 mL/min/kg, the mean residence time (MRT) was 4.8 +/- 1.4 min, and the volume of distribution at steady state (V(SS)) was 238 +/- 131 mL/kg.",Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15648940/),[ml] / [kg],238,258704,DB00997,Doxorubicin
,15648940,area under the curve (AUC(0-infinity)),The extrapolated area under the curve (AUC(0-infinity)) was 950 +/- 677 ng/mL x h.,Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15648940/),[ng] / [h·ml],950,258705,DB00997,Doxorubicin
,3370741,area under the curve,High-dose ranitidine increased the total exposure to doxorubicin (area under the curve of doxorubicin alone = 1.44 +/- 0.88 microM.h/ml vs 4.49 +/- 2.35 microM.hr/ml for doxorubicin given with high-dose ranitidine; P = 0.06).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),[h·μM] / [ml],1.44,259895,DB00997,Doxorubicin
,3370741,area under the curve,High-dose ranitidine increased the total exposure to doxorubicin (area under the curve of doxorubicin alone = 1.44 +/- 0.88 microM.h/ml vs 4.49 +/- 2.35 microM.hr/ml for doxorubicin given with high-dose ranitidine; P = 0.06).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),[h·μM] / [ml],4.49,259896,DB00997,Doxorubicin
,3370741,half-life,14C-Aminopyrine half-life was altered by a ranitidine dose of 25 mg/kg (aminopyrine half-life after placebo control = 97 +/- 6 min as against aminopyrine half-life after ranitidine = 121 +/- 7 min; mean +/- SEM; P less than 0.02).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),min,97,259897,DB00997,Doxorubicin
,3370741,half-life,14C-Aminopyrine half-life was altered by a ranitidine dose of 25 mg/kg (aminopyrine half-life after placebo control = 97 +/- 6 min as against aminopyrine half-life after ranitidine = 121 +/- 7 min; mean +/- SEM; P less than 0.02).,The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370741/),min,121,259898,DB00997,Doxorubicin
,17075050,half-life,"Upon i.v. administration to BALB/c mice with s.c. C-26 tumors, dendrimer-DOX was eliminated from the serum with a half-life of 16 +/- 1 h, and its tumor uptake was ninefold higher than i.v. administered free DOX at 48 h.",A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17075050/),h,16,260098,DB00997,Doxorubicin
> or =,9469355,serum peak,"After multivariate analysis, performed on patients with localized disease only, MTX serum peak (> or = 700 micromol/L) and histologic subtype were proven to be significant predictive factors of histologic response.","Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469355/),[μM] / [l],700,260230,DB00997,Doxorubicin
,9469355,serum peak,A dose adaptation of MTX is recommended to obtain a serum peak of 700 micromol/L or greater when MTX is infused in 6 hours.,"Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469355/),[μM] / [l],700,260231,DB00997,Doxorubicin
,11707655,plasma concentration ratio,"The median plasma concentration ratio capillary/venous was 1.13 (95% confidence interval: 1.06-1.20) and not affected either by plasma drug concentration, age or the body mass index of the patient.",Quantification of doxorubicin in plasma--a comparative study of capillary and venous blood sampling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707655/),,1.13,261167,DB00997,Doxorubicin
,27750088,encapsulation efficiency,"After DOX loading, the drug loading content and encapsulation efficiency were calculated to be 9.3±0.1% and 92.8±0.6%, respectively.",A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27750088/),%,92.8,261224,DB00997,Doxorubicin
,21040218,maximal tolerated doses,"The maximal tolerated doses in mice of NC-6300 and native epirubicin were 25 and 9 mg/kg, respectively, when administered three times with a 4-day interval between each dose.","Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040218/),[mg] / [kg],25,261786,DB00997,Doxorubicin
,21040218,maximal tolerated doses,"The maximal tolerated doses in mice of NC-6300 and native epirubicin were 25 and 9 mg/kg, respectively, when administered three times with a 4-day interval between each dose.","Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040218/),[mg] / [kg],9,261787,DB00997,Doxorubicin
,28028795,entrapment efficiency,"In addition, the entrapment efficiency and drug loading content of DOX reached 6.4 ± 0.05 and 99.29 ± 0.3%, respectively.",Membrane-Loaded Doxorubicin Liposomes Based on Ion-Pairing Technology with High Drug Loading and pH-Responsive Property. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28028795/),%,6.4,261938,DB00997,Doxorubicin
,28028795,drug loading content,"In addition, the entrapment efficiency and drug loading content of DOX reached 6.4 ± 0.05 and 99.29 ± 0.3%, respectively.",Membrane-Loaded Doxorubicin Liposomes Based on Ion-Pairing Technology with High Drug Loading and pH-Responsive Property. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28028795/),%,99.29,261939,DB00997,Doxorubicin
,12647011,clearance (CL),"Doxorubicin clearance (CL), peripheral volume of distribution (V2) and doxorubicinol apparent clearance (CLm/fm) and apparent volume of distribution (Vm/fm) were 62.3 l/h, 2360 l, 143 l/h and 3150 l, respectively, in the absence or presence of low doses of zosuquidar.3HCl (<500 mg).","A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12647011/),[l] / [h],62.3,263333,DB00997,Doxorubicin
,12647011,peripheral volume of distribution (V2),"Doxorubicin clearance (CL), peripheral volume of distribution (V2) and doxorubicinol apparent clearance (CLm/fm) and apparent volume of distribution (Vm/fm) were 62.3 l/h, 2360 l, 143 l/h and 3150 l, respectively, in the absence or presence of low doses of zosuquidar.3HCl (<500 mg).","A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12647011/),l,2360,263334,DB00997,Doxorubicin
,12647011,peripheral volume of distribution (V2),"Doxorubicin clearance (CL), peripheral volume of distribution (V2) and doxorubicinol apparent clearance (CLm/fm) and apparent volume of distribution (Vm/fm) were 62.3 l/h, 2360 l, 143 l/h and 3150 l, respectively, in the absence or presence of low doses of zosuquidar.3HCl (<500 mg).","A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12647011/),[l] / [h],143,263335,DB00997,Doxorubicin
,12647011,apparent clearance (CLm/fm),"Doxorubicin clearance (CL), peripheral volume of distribution (V2) and doxorubicinol apparent clearance (CLm/fm) and apparent volume of distribution (Vm/fm) were 62.3 l/h, 2360 l, 143 l/h and 3150 l, respectively, in the absence or presence of low doses of zosuquidar.3HCl (<500 mg).","A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12647011/),l,2360,263336,DB00997,Doxorubicin
,12647011,apparent clearance (CLm/fm),"Doxorubicin clearance (CL), peripheral volume of distribution (V2) and doxorubicinol apparent clearance (CLm/fm) and apparent volume of distribution (Vm/fm) were 62.3 l/h, 2360 l, 143 l/h and 3150 l, respectively, in the absence or presence of low doses of zosuquidar.3HCl (<500 mg).","A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12647011/),[l] / [h],143,263337,DB00997,Doxorubicin
,12647011,apparent volume of distribution (Vm/fm),"Doxorubicin clearance (CL), peripheral volume of distribution (V2) and doxorubicinol apparent clearance (CLm/fm) and apparent volume of distribution (Vm/fm) were 62.3 l/h, 2360 l, 143 l/h and 3150 l, respectively, in the absence or presence of low doses of zosuquidar.3HCl (<500 mg).","A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12647011/),l,3150,263338,DB00997,Doxorubicin
,12647011,t(max),"3HCl (>or=500 mg), these values decreased by 25%, 26%, 48% and 73%, respectively, and doxorubicinol pharmacokinetics were characterized by a delayed t(max) (24 h versus 4 h), which led to the inclusion of the parallel pathways.","A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12647011/),h,24,263339,DB00997,Doxorubicin
,12647011,t(max),"3HCl (>or=500 mg), these values decreased by 25%, 26%, 48% and 73%, respectively, and doxorubicinol pharmacokinetics were characterized by a delayed t(max) (24 h versus 4 h), which led to the inclusion of the parallel pathways.","A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12647011/),h,4,263340,DB00997,Doxorubicin
,9074848,overall response rates,Liposomal doxorubicin monotherapy in patients with AIDS-related Kaposi's sarcoma produced overall response rates (complete plus partial) of 43 and 59% in large comparative studies and 67 to 100% in noncomparative studies which included > or = 20 patients.,"Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,43,263580,DB00997,Doxorubicin
,9074848,overall response rates,Liposomal doxorubicin monotherapy in patients with AIDS-related Kaposi's sarcoma produced overall response rates (complete plus partial) of 43 and 59% in large comparative studies and 67 to 100% in noncomparative studies which included > or = 20 patients.,"Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,59,263581,DB00997,Doxorubicin
,9074848,overall response rates,Liposomal doxorubicin monotherapy in patients with AIDS-related Kaposi's sarcoma produced overall response rates (complete plus partial) of 43 and 59% in large comparative studies and 67 to 100% in noncomparative studies which included > or = 20 patients.,"Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,67,263582,DB00997,Doxorubicin
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,43,263583,DB00997,Doxorubicin
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,25,263584,DB00997,Doxorubicin
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,59,263585,DB00997,Doxorubicin
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,23,263586,DB00997,Doxorubicin
,15668288,overall response rate,"In 30 patients evaluated for response and toxicity, the overall response rate was 37% and 10% of patients achieved stable disease.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),%,37,263607,DB00997,Doxorubicin
,15668288,time to progression,"Median time to progression and overall survival were 5.5 months (range 1-10) and 9 months (range 2-16), respectively.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),month,5.5,263608,DB00997,Doxorubicin
,15668288,overall survival,"Median time to progression and overall survival were 5.5 months (range 1-10) and 9 months (range 2-16), respectively.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),month,9,263609,DB00997,Doxorubicin
,6690742,peak concentration,"After intra-arterial application, the mean peak concentration in renal interstitial fluid was approximately 30 times higher than that after intravenous infusion (66.49 and 2.38 nanograms per milliliter respectively).",Concentrations of doxorubicin in renal interstitial fluid after peripheral intravenous and intrarenal artery infusion in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690742/),[nanograms] / [milliliter],66.49,264183,DB00997,Doxorubicin
,6690742,peak concentration,"After intra-arterial application, the mean peak concentration in renal interstitial fluid was approximately 30 times higher than that after intravenous infusion (66.49 and 2.38 nanograms per milliliter respectively).",Concentrations of doxorubicin in renal interstitial fluid after peripheral intravenous and intrarenal artery infusion in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690742/),[nanograms] / [milliliter],2.38,264184,DB00997,Doxorubicin
,8261569,MTD,The MTD with this schedule was 30 mg/m2 per week x 3.,Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261569/),[mg] / [m],30,264216,DB00997,Doxorubicin
,8261569,AUC,"At the dose of 30 mg/m2 per week, the total doxorubicin AUC and peak total doxorubicin concentrations in plasma were 8.75 +/- 8.80 microM h (mean +/- SD) and 3.07 +/- 1.45 microM, respectively, after LED administration.",Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261569/),h·μM,8.75,264217,DB00997,Doxorubicin
,8261569,peak total doxorubicin concentrations,"At the dose of 30 mg/m2 per week, the total doxorubicin AUC and peak total doxorubicin concentrations in plasma were 8.75 +/- 8.80 microM h (mean +/- SD) and 3.07 +/- 1.45 microM, respectively, after LED administration.",Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261569/),μM,3.07,264218,DB00997,Doxorubicin
,8261569,AUC,"The total doxorubicin AUC and peak total doxorubicin concentrations in plasma were 3.92 +/- 2.47 microM h and 2.75 +/- 2.70 microM, respectively, after the infusion of standard-formulation doxorubicin.",Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261569/),h·μM,3.92,264219,DB00997,Doxorubicin
,8261569,peak total doxorubicin concentrations,"The total doxorubicin AUC and peak total doxorubicin concentrations in plasma were 3.92 +/- 2.47 microM h and 2.75 +/- 2.70 microM, respectively, after the infusion of standard-formulation doxorubicin.",Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261569/),μM,2.75,264220,DB00997,Doxorubicin
,8261569,total body clearance,The total body clearance of doxorubicin was 18.42 +/- 11.23 l/h after the infusion of LED and 31.21 +/- 15.48 l/h after the infusion of standard-formulation doxorubicin.,Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261569/),[l] / [h],18.42,264221,DB00997,Doxorubicin
,8261569,total body clearance,The total body clearance of doxorubicin was 18.42 +/- 11.23 l/h after the infusion of LED and 31.21 +/- 15.48 l/h after the infusion of standard-formulation doxorubicin.,Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261569/),[l] / [h],31.21,264222,DB00997,Doxorubicin
,8261569,elimination half-lives,The mean elimination half-lives of doxorubicin were similar: 8.65 +/- 5.16 h for LED and 7.46 +/- 5.16 h for standard-formulation doxorubicin.,Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261569/),h,8.65,264223,DB00997,Doxorubicin
,8261569,elimination half-lives,The mean elimination half-lives of doxorubicin were similar: 8.65 +/- 5.16 h for LED and 7.46 +/- 5.16 h for standard-formulation doxorubicin.,Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261569/),h,7.46,264224,DB00997,Doxorubicin
,3458430,t1/2 alpha,"The mean t1/2 alpha, beta, and gamma were 4.67 min, 1.15 h, and 36.5 h, respectively, which were characterized by a short distribution phase (alpha) and a prolonged elimination phase (gamma).",[Pharmacokinetics of epirubicin in cancer patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),min,4.67,264601,DB00997,Doxorubicin
,3458430,beta,"The mean t1/2 alpha, beta, and gamma were 4.67 min, 1.15 h, and 36.5 h, respectively, which were characterized by a short distribution phase (alpha) and a prolonged elimination phase (gamma).",[Pharmacokinetics of epirubicin in cancer patients]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),h,1.15,264602,DB00997,Doxorubicin
,3458430,beta,"The mean t1/2 alpha, beta, and gamma were 4.67 min, 1.15 h, and 36.5 h, respectively, which were characterized by a short distribution phase (alpha) and a prolonged elimination phase (gamma).",[Pharmacokinetics of epirubicin in cancer patients]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),h,36.5,264603,DB00997,Doxorubicin
,3458430,gamma,"The mean t1/2 alpha, beta, and gamma were 4.67 min, 1.15 h, and 36.5 h, respectively, which were characterized by a short distribution phase (alpha) and a prolonged elimination phase (gamma).",[Pharmacokinetics of epirubicin in cancer patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),h,36.5,264604,DB00997,Doxorubicin
,3458430,V1,"The distribution volume of the central compartment (V1 = 0.351 l/kg) was small, while that of the tissue compartment (V2 = 0.254, V3 = 45.8 l/kg) was large, which could be explained by the binding of the drug to cellular components.",[Pharmacokinetics of epirubicin in cancer patients]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),[l] / [kg],0.351,264605,DB00997,Doxorubicin
,3458430,V2,"The distribution volume of the central compartment (V1 = 0.351 l/kg) was small, while that of the tissue compartment (V2 = 0.254, V3 = 45.8 l/kg) was large, which could be explained by the binding of the drug to cellular components.",[Pharmacokinetics of epirubicin in cancer patients]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),,0.254,264606,DB00997,Doxorubicin
,3458430,V3,"The distribution volume of the central compartment (V1 = 0.351 l/kg) was small, while that of the tissue compartment (V2 = 0.254, V3 = 45.8 l/kg) was large, which could be explained by the binding of the drug to cellular components.",[Pharmacokinetics of epirubicin in cancer patients]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),[l] / [kg],45.8,264607,DB00997,Doxorubicin
,6585367,detection limit,The detection limit is 0.5 ng/ml for all compounds.,Rapid quantitative determination of seven anthracyclines and their hydroxy metabolites in body fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6585367/),[ng] / [ml],0.5,265267,DB00997,Doxorubicin
higher,25446512,critical micelle concentration,The critical micelle concentration of the amphiphilic copolymer was higher than 10(-6).,Nanomicelles based on X-shaped four-armed peglyated distearylglycerol as long circulating system for doxorubicin delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25446512/),,10(-6),265667,DB00997,Doxorubicin
,25446512,particle size,"Mean particle size and zeta potential of DOX-encapsulated Gemini-PEG2K-GCDS nanomicelles (DOX-GNMs) was 20.4nm and+3.91mv, respectively.",Nanomicelles based on X-shaped four-armed peglyated distearylglycerol as long circulating system for doxorubicin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25446512/),nm,20.4,265668,DB00997,Doxorubicin
,25446512,zeta potential,"Mean particle size and zeta potential of DOX-encapsulated Gemini-PEG2K-GCDS nanomicelles (DOX-GNMs) was 20.4nm and+3.91mv, respectively.",Nanomicelles based on X-shaped four-armed peglyated distearylglycerol as long circulating system for doxorubicin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25446512/),mv,+,265669,DB00997,Doxorubicin
,25446512,zeta potential,"Mean particle size and zeta potential of DOX-encapsulated Gemini-PEG2K-GCDS nanomicelles (DOX-GNMs) was 20.4nm and+3.91mv, respectively.",Nanomicelles based on X-shaped four-armed peglyated distearylglycerol as long circulating system for doxorubicin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25446512/),mv,3.91,265670,DB00997,Doxorubicin
,3116947,half-life period of the beta-phase,A dual-phase attenuation curve was obtained after the completion of infusion and the half-life period of the beta-phase was around 200 hours.,[The pharmacokinetics of cisplatin and its influence on renal functions based on different infusion methods]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3116947/),h,200,265946,DB00997,Doxorubicin
,22337718,Total clearance,Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],9.43,266008,DB00997,Doxorubicin
,22337718,Vd(ss),Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),l,9.61,266009,DB00997,Doxorubicin
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],8.21,266010,DB00997,Doxorubicin
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],12.68,266011,DB00997,Doxorubicin
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,30.7,266012,DB00997,Doxorubicin
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,24.7,266013,DB00997,Doxorubicin
,24621591,AUC,"The liposomal EPI formulation is eliminated slowly with an AUC of 7.6487, while the free drug has an AUC of only 0.0097.",Efficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24621591/),,7.6487,266106,DB00997,Doxorubicin
,24621591,AUC,"The liposomal EPI formulation is eliminated slowly with an AUC of 7.6487, while the free drug has an AUC of only 0.0097.",Efficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24621591/),,0.0097,266107,DB00997,Doxorubicin
,26685728,bioavailability,"The chemotherapeutic drug substance doxorubicin has been reported to be a substrate of P-gp, which induces a barrier for oral administration and leads to a bioavailability of 3% in male Sprague Dawley rats.",Tween 20 increases intestinal transport of doxorubicin in vitro but not in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26685728/),%,3,267266,DB00997,Doxorubicin
,26685728,a,200 μM (0.025%) tween 20 increased the intestinal absorptive permeability of doxorubicin in vitro by 48 ± 4% from 8.8 × 10(-6)cm/s to 13.0 × 10(-6)cm/s.,Tween 20 increases intestinal transport of doxorubicin in vitro but not in vivo. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26685728/),[cm] / [s],8.8 × 10(-6),267267,DB00997,Doxorubicin
,26685728,efflux ratio,"Further, the efflux ratio was reduced from 2.2 ± 0.06 to 1.2 ± 0.03 (n=3-7).",Tween 20 increases intestinal transport of doxorubicin in vitro but not in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26685728/),,2.2,267268,DB00997,Doxorubicin
,26685728,efflux ratio,"Further, the efflux ratio was reduced from 2.2 ± 0.06 to 1.2 ± 0.03 (n=3-7).",Tween 20 increases intestinal transport of doxorubicin in vitro but not in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26685728/),,1.2,267269,DB00997,Doxorubicin
,6590531,initial,"The data obtained were consistent with a two compartment model of drug disposition with initial and terminal half-life values of 6.6 min and 13.3 h, respectively.",Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6590531/),min,6.6,267716,DB00997,Doxorubicin
,6590531,terminal half-life,"The data obtained were consistent with a two compartment model of drug disposition with initial and terminal half-life values of 6.6 min and 13.3 h, respectively.",Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6590531/),h,13.3,267717,DB00997,Doxorubicin
,6590531,terminal half-life,The major fluorescent metabolite was eliminated with a terminal half-life of 25 h.,Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6590531/),h,25,267718,DB00997,Doxorubicin
,23203544,peak concentration,"The peak concentration of epirubicin in the MP group and the ID group were 21.84±18.85 ng/mL and 294.80±225.54 ng/mL, respectively.",Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203544/),[ng] / [ml],21.84,268477,DB00997,Doxorubicin
,23203544,peak concentration,"The peak concentration of epirubicin in the MP group and the ID group were 21.84±18.85 ng/mL and 294.80±225.54 ng/mL, respectively.",Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203544/),[ng] / [ml],294.80,268478,DB00997,Doxorubicin
,21787818,loading capacity,"PEG(2k)-CA(4) micelles, compared to PEG(5k)-CA(8) micelles, were found to have higher DOX loading capacity (14.8% vs. 8.2%, w/w), superior stability in physiological condition, and more sustained release profile.",PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21787818/),%,14.8,269180,DB00997,Doxorubicin
,21787818,loading capacity,"PEG(2k)-CA(4) micelles, compared to PEG(5k)-CA(8) micelles, were found to have higher DOX loading capacity (14.8% vs. 8.2%, w/w), superior stability in physiological condition, and more sustained release profile.",PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21787818/),%,8.2,269181,DB00997,Doxorubicin
,21787818,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) of DOX-loaded PEG(2k)-CA(4) micelles in mice was approximately 15 mg/kg, which was 1.5-fold higher of the MTD of free DOX.",PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21787818/),[mg] / [kg],15,269182,DB00997,Doxorubicin
,24036845,AUC,Only small variations were observed in the corresponding plasma AUC (2.9-5 μM h).,"Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24036845/),h·μM,2.9-5,269421,DB00997,Doxorubicin
,8622075,maximal rate of elimination (Vmax),"The data for 5-FU were best described by a one-compartment model with nonlinear elimination, where the maximal rate of elimination (Vmax) and the concentration at which the elimination was half-maximal (Km) were 105 mg/L.h and 27 mg/L, respectively.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),[mg] / [h·l],105,269720,DB00997,Doxorubicin
,8622075,concentration at which the elimination was half-maximal (Km),"The data for 5-FU were best described by a one-compartment model with nonlinear elimination, where the maximal rate of elimination (Vmax) and the concentration at which the elimination was half-maximal (Km) were 105 mg/L.h and 27 mg/L, respectively.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),[mg] / [l],27,269721,DB00997,Doxorubicin
,8622075,terminal half-life,"EPI concentration-time profiles showed a triexponential decline, with a mean terminal half-life of 24 hours and a clearance (CL) of 59 L/h.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),h,24,269722,DB00997,Doxorubicin
,8622075,clearance (CL),"EPI concentration-time profiles showed a triexponential decline, with a mean terminal half-life of 24 hours and a clearance (CL) of 59 L/h.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),[l] / [h],59,269723,DB00997,Doxorubicin
,8622075,half-life,"The elimination of 4-OHCP was monoexponential, with a mean half-life of 7 hours.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),h,7,269724,DB00997,Doxorubicin
,7743508,area under the plasma concentration-time curve,The area under the plasma concentration-time curve ranged from 30 to 80 ng/h/ml; plasma data suggested linear kinetics in the range of tested doses (although there was considerable interpatient variability).,Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743508/),[ng] / [h·ml],30 to 80,270687,DB00997,Doxorubicin
,7743508,maximum tolerated dose,The maximum tolerated dose defined in this study using this schedule is 1500 micrograms/m2.,Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743508/),[μg] / [m2],1500,270688,DB00997,Doxorubicin
,1350631,pulmonary concentration,The pulmonary concentration of THP-DXR reached 0.032 +/- 0.01 mumol g-1 60 min after the beginning of a perfusion of 1 microM of the drug.,Comparative pharmacokinetics of tetrahydropyranyl-doxorubicin and doxorubicin in rat isolated lung. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350631/),[μM] / [g],0.032,270780,DB00997,Doxorubicin
,1350631,lung concentrations,"Corresponding lung concentrations for DXR were 0.013 +/- 0.001 and 0.150 +/- 0.04 mumol g-1, respectively (P less than 0.05).",Comparative pharmacokinetics of tetrahydropyranyl-doxorubicin and doxorubicin in rat isolated lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350631/),[μM] / [g],0.013,270781,DB00997,Doxorubicin
,1350631,lung concentrations,"Corresponding lung concentrations for DXR were 0.013 +/- 0.001 and 0.150 +/- 0.04 mumol g-1, respectively (P less than 0.05).",Comparative pharmacokinetics of tetrahydropyranyl-doxorubicin and doxorubicin in rat isolated lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1350631/),[μM] / [g],0.150,270782,DB00997,Doxorubicin
up to,7902206,steady-state levels,Conclusions from the initial phase I trial with the use of CsA as a modulator of etoposide are: (1) Serum CsA steady-state levels of up to 4800 ng/ml (4 microM) could be achieved with acceptable toxicity.,Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902206/),[ng] / [ml],4800,270936,DB00997,Doxorubicin
above,7902206,steady-state plasma CsA levels,"Renal toxicity was uncommon, but severe in two patients with steady-state plasma CsA levels above 6000 ng/ml.",Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902206/),[ng] / [ml],6000,270937,DB00997,Doxorubicin
,7902206,steady-state serum levels,(4) The recommended dose of CsA is a 6-7 mg/kg loading dose administered as a 2-hour intravenous infusion followed by a continuous infusion of 18-21 mg/kg/day for 60 hours with adjustments in the infusion rate to maintain steady-state serum levels of 3000-4800 ng/ml (2.5-4.0 M).,Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902206/),[ng] / [ml],3000-4800,270938,DB00997,Doxorubicin
,1767983,area under curve concentrations,"On the basis of the kinetic variables calculated with the 2 administration schedules, area under curve concentrations of plasma doxorubicin were 136 micrograms.h/L (free infusion) and 734 micrograms.h/L (erythrocyte-encapsulated drug).",Pharmacokinetic properties of doxorubicin encapsulated in glutaraldehyde-treated canine erythrocytes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767983/),[h·μg] / [l],136,271936,DB00997,Doxorubicin
,1767983,area under curve concentrations,"On the basis of the kinetic variables calculated with the 2 administration schedules, area under curve concentrations of plasma doxorubicin were 136 micrograms.h/L (free infusion) and 734 micrograms.h/L (erythrocyte-encapsulated drug).",Pharmacokinetic properties of doxorubicin encapsulated in glutaraldehyde-treated canine erythrocytes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767983/),[h·μg] / [l],734,271937,DB00997,Doxorubicin
,1995359,initial plasma clearance,"Thus the initial plasma clearance after six perfusions was 39 +/- 9, and 36 +/- 11 ml/min/kg in the epirubicin and saline groups respectively.",Effect of repeated intraperitoneal chemotherapy with epirubicin on the hepatic transport of bile acids and their enterohepatic circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1995359/),[ml] / [kg·min],39,273508,DB00997,Doxorubicin
,1995359,initial plasma clearance,"Thus the initial plasma clearance after six perfusions was 39 +/- 9, and 36 +/- 11 ml/min/kg in the epirubicin and saline groups respectively.",Effect of repeated intraperitoneal chemotherapy with epirubicin on the hepatic transport of bile acids and their enterohepatic circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1995359/),[ml] / [kg·min],36,273509,DB00997,Doxorubicin
,1995359,excretory efficiency,The excretory efficiency of the liver at this stage was identical: 67 +/- 10% in the epirubicin treated animals and 67 +/- 6% in the saline controls.,Effect of repeated intraperitoneal chemotherapy with epirubicin on the hepatic transport of bile acids and their enterohepatic circulation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1995359/),%,67,273510,DB00997,Doxorubicin
,1995359,excretory efficiency,The excretory efficiency of the liver at this stage was identical: 67 +/- 10% in the epirubicin treated animals and 67 +/- 6% in the saline controls.,Effect of repeated intraperitoneal chemotherapy with epirubicin on the hepatic transport of bile acids and their enterohepatic circulation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1995359/),%,67,273511,DB00997,Doxorubicin
,7599068,Extraction ratios,Extraction ratios varied from 0.75 to 0.91 during hepatic artery infusion and from 0.50 to 0.72 during systemic infusion.,An evaluation of hepatic extraction and clearance of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599068/),,0.75 to 0.91,273521,DB00997,Doxorubicin
,7599068,Extraction ratios,Extraction ratios varied from 0.75 to 0.91 during hepatic artery infusion and from 0.50 to 0.72 during systemic infusion.,An evaluation of hepatic extraction and clearance of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599068/),,0.50 to 0.72,273522,DB00997,Doxorubicin
,2702792,maximum steady-state doxorubicin concentration,The mean maximum steady-state doxorubicin concentration was 6.04 ng/ml at a mean maximum infusion rate of 3.92 mg/m2/day.,Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702792/),[ng] / [ml],6.04,274088,DB00997,Doxorubicin
,2702792,maximum infusion rate,The mean maximum steady-state doxorubicin concentration was 6.04 ng/ml at a mean maximum infusion rate of 3.92 mg/m2/day.,Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702792/),[mg] / [d·m2],3.92,274089,DB00997,Doxorubicin
,8339389,Peak plasma DOX levels,"Peak plasma DOX levels were higher after the bolus injection than after continuous administration (1509 +/- 80 ng/ml vs 11.6 +/- 1.8 ng/ml, respectively), whereas the plasma area under the curve (AUC) levels were similar.",Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [ml],1509,274180,DB00997,Doxorubicin
,8339389,Peak plasma DOX levels,"Peak plasma DOX levels were higher after the bolus injection than after continuous administration (1509 +/- 80 ng/ml vs 11.6 +/- 1.8 ng/ml, respectively), whereas the plasma area under the curve (AUC) levels were similar.",Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [ml],11.6,274181,DB00997,Doxorubicin
,8339389,Maximum DOX cellular concentrations,Maximum DOX cellular concentrations were 8629 +/- 2902 ng/10(9) cells (bolus injection) and 2745 +/- 673 ng/10(9) cells (96 h infusion).,Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [10(9)·cells],8629,274182,DB00997,Doxorubicin
,8339389,Maximum DOX cellular concentrations,Maximum DOX cellular concentrations were 8629 +/- 2902 ng/10(9) cells (bolus injection) and 2745 +/- 673 ng/10(9) cells (96 h infusion).,Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [10(9)·cells],2745,274183,DB00997,Doxorubicin
